WorldWideScience

Sample records for iodine-131 labelled lipiodol

  1. Experimental dosimetry and kinetics of radioactive tracers for human applications: example of therapeutic injection of Lipiodol labelled with Iodine 131

    International Nuclear Information System (INIS)

    Ahmed Mahidi, N.

    1992-10-01

    We have evaluated the radiation dose received by the liver and lungs for 10 patients with a hepatic carcinoma after surgical operation followed by a therapeutic dose of Lipiodol labelled with iodine 131. The cumulated activities have been obtained by using a calibrated gamma camera. Fixation and kinetics of the I 131 Lipiodol in normal and cancers livers have been measured with the determination of the effective and biological half-lives. The calculated doses are based on the MIRD method. Results confirm that Lipiodol fixation is important in the liver at J1 (about 74% of the injected activity). Its elimination is essentially urinary, pulmonary fixation remained low, the dose received by the healthy part of liver is acceptable. These values have been compared with those obtained by another method using a thermoluminescent dosimeter (LiF) installed on the skin over the liver. Comparison between results obtained by the 2 methods shows a good correlation

  2. Intra-arterial injection of iodine-131-labeled lipiodol for treatment of hepatocellular carcinoma

    International Nuclear Information System (INIS)

    Boucher, Eveline; Garin, Etienne; Guylligomarc'h, Anne; Olivie, Damien; Boudjema, Karim; Raoul, Jean-Luc

    2007-01-01

    Background/Aim: The therapeutic effect of intra-arterial injection of 131-iodine-labeled lipiodol for treatment of hepatocellular carcinoma in palliative or adjuvant settings has been promising. We report, the results of an open study of this therapy in cirrhotic patients with small hepatocellular carcinoma. Patients and method: Forty patients with hepatocellular carcinoma were given intra-arterial injections of 131-iodine-labeled lipiodol. These injections were repeated if necessary every 3 months. Tumor response (WHO criteria) was determined on CT scans performed after each treatment and every 3 months during the follow-up. Side effects and the cause of death were recorded. Therapeutic response and survival were analyzed. Results: The median number of treatment was 2 (1-4). There was one complete response, 18 partial responses (47.5% response rate); 19 had stable disease and 2 progressions. Overall survival rates (±CI 95%) at 1, 2 and 3 years were: 90 ± 4.7%, 60.3 ± 8%, and 39 ± 8.3%, respectively. Median survival was 27 months; 25 patients have died (4-56 months), 8 of tumor progression with a multifocal spread in the liver. Tolerance was good except for 2 patients who develop a fatal drug-related pulmonary insufficiency. Conclusion: These data suggest that intra-arterial therapeutic injection of 131-iodine-labeled lipiodol for treatment of hepatocellular carcinoma can provide high rate response and long survival for individuals not eligible for surgery or local treatment

  3. Radiation exposure and radiation protection of the physician in iodine-131 Lipiodol therapy of liver tumours

    International Nuclear Information System (INIS)

    Risse, J.H.; Ponath, C.; Palmedo, H.; Biersack, H.J.; Menzel, C.; Gruenwald, F.

    2001-01-01

    Intra-arterial iodine-131 labelled Lipiodol therapy for liver cancer has been investigated for safety and efficacy over a number of years, but data on radiation exposure of personnel have remained unavailable to date. The aim of this study was to assess the radiation exposure of the physician during intra-arterial 131 I-Lipiodol therapy for liver malignancies and to develop appropriate radiation protection measures and equipment. During 20 intra-arterial administrations of 131 I-Lipiodol (1110-1924 MBq), radiation dose equivalents (RDE) to the whole body, fingers and eyes of the physician were determined for (a) conventional manual administration through a shielded syringe, (b) administration with an automatic injector and (c) administration with a lead container developed in-house. Administration by syringe resulted in a finger RDE of 19.5 mSv, an eye RDE of 130-140 μSv, and a whole-body RDE of 108-119 μSv. The injector reduced the finger RDE to 5 mSv. With both technique (a) and technique (b), contamination of angiography materials was observed. The container allowed safe transport and administration of the radiopharmaceutical from 4 m distance and reduced the finger RDE to 131 I-Lipiodol was administered by syringe or injector, but was significantly reduced with the lead container. (orig.)

  4. Do the benefits of iodine-131 lipiodol therapy for HCC outweigh the radiation safety issues?

    International Nuclear Information System (INIS)

    Kitchener, M.I.; Barnden, L.R.

    2005-01-01

    Introduction: lodine-131 Lipiodol is a well recognised palliative treatment option for Hepatocellular carcinoma (HCC) unsuitable for surgical resection/transplantation. However, the biological and physical half-life of lodine-131 Lipiodol in this situation has significant implications for radiation protection. Methods: A retrospective study was performed to evaluate the practical radiation issues and treatment efficacy. 22 patients were referred for assessment and 12 received Lipiodol therapy, 5 having multiple doses. Administered doses ranged from 1.0-2.2 GBq. Results: Patients were hospitalised between 4 and 8 days, with discharge rates ranging between 16 and 61uSv/hr at 1 metre. The shorter hospital stays and highest discharge rates related to 2 patients (multiple doses) who had difficulty tolerating the in-hospital isolation. Only 4 patients had discharge rates < 25uSv/hr at 1 metre. 2 with reduced doses. Special exemption was required from the State Radiation Protection Branch (RPB) to allow early discharge. Patients were given a radiation precaution sheet on discharge (as per the FMC program) and asked to observe the restrictions including not returning to work for 14-24 days and avoiding close contact with young children for 25-44 days post-discharge. The measured radiation dose for a patient's spouse/carer was < lOOuSv on 2 occasions. The mean exposure for nurses per patient admission was 9.1 uSv. The TLD readings for the Interventional Radiologist and treating Nuclear Physician remained well within acceptable levels. 4 of the 12 patients have died at a mean of 16.25 months (range 13-20 months) after their first dose of lodine-131 Lipiodol. Of the other 7, 3 now have progressive disease but are alive 18, 36 and 41 months following their first dose. 4 are less than 12 months post-therapy. With the co-operation of the State RPB. the issues relating to radiation protection are manageable and these patients do receive a therapeutic benefit

  5. The method of obtaining of sodium orthoiodohippurate labelled with iodine-131

    International Nuclear Information System (INIS)

    Aripov, D.; Abdukayumov, M.; Shukurov, A.Sh.

    1994-01-01

    The method of labelling of sodium orthoiodohippurate was elaborated with the purpose of increasing the preparation quality. Method includes the reaction of isotopic exchange between orthoiodhippur acid and sodium iodide solution labelled with iodine-131 with volume activity 150-200 mCu/mL and pH=6,5-7,0. Reaction occurs at temperature 120-130 C during 1,1-1,3 hours and the compound obtained is dissolved in 1% sodium bicarbonate solution. (author)

  6. Meta-iodobenzylguanidine synthesis and labelling with iodine-131

    International Nuclear Information System (INIS)

    Miranda, J.; Herrera, J.; Robles, A.; Caballero, J.; Portilla, A.; Ticona, L.

    1997-01-01

    Meta-iodo-benzylguanidine (MIBG) synthesis is carried out through m-iodo benzylamine condensation and subsequent formation of the hemisulfate salt. The synthesized product is characterized and identified by IR spectroscopy and m.p. determination. Acute toxicity tests conducted in mice demonstrated that the synthesized product is not toxic. MIBG hemisulfate labelling methods with I-131 is carried out by nucleophilic isotopic exchange; the reaction is catalyzed with cooper sulfate in the presence of ammonium sulfate at temperatures ranging between 140 and 150 o C . Biological distribution tests in wistar rats present an average value of 1,54% of injected dose/organ gram in suprarenal glands. These values show promise for the application of this radiopharmaceutical in radiodiagnosis of suprarenal tumors and procurement of adrenal medulla, myocardium and salivary gland images

  7. Labeling of Salmonella typhimurium with iodine-131 to study phagocytic function in rats

    International Nuclear Information System (INIS)

    Sato, M.K.; Rodrigues Junior, A.J.; Camargo, E.E.

    1989-01-01

    The present study descibes a method for labeling Salmonella tyhymurium with iodine-131 to evaluate both the morphological and the functional characteristics of the reticulo-endothelial system. A suspension containing 2 x 10 9 bacteria per ml was labeled with carrier-free Na 131 I without reductor, with a labeling yield of 46.5 +- 3% and 3.5 +- 1.3% of free Iodine-131. The biodistribution of the labeled bacteria in rats was studied with a large-field-of-view scintillation camera equiped with a pinhole collimator. Whole body images were obtained 15 and 30 minutes after intravenous injection of the labeled microorganisms. Images showed accumulation of bacteria in the liver and both normal and transplanted spleens of the animals. Autoradiographs of liver and spleen demonstrated labeled bacteria within the cells of the reticulo-endothelial system. The method described is easy to perform, has a good labeling yield and allows the function of the reticulo-monophagocytic system, including transplanted spleens. (author) [pt

  8. A Study on Labelling of Linolenic Acid as A Model of Isolated Benalu Teh for Cancer Diagnosis with Iodine-131

    International Nuclear Information System (INIS)

    Isti Daruwati; Eva Maria Widyasari; Nanny Kartini Oekar

    2009-01-01

    A study on active fraction of benalu teh has been carried out at Center for Application of Isotope and Radiation Technology - BATAN. This benalu teh active fraction has inhibition capability about 99% to the cancer cell. The isolated fraction is octadeca-8,10,12-triyonic acid compound which have long chain unsaturated fatty acid compound with three triple bonds. The Benalu teh active fraction has similar structure with linolenic acid which is a long chain unsaturated fatty acid with three triple bonds. Based on this similarity, the study of labelling of linolenic acid with iodine-131 has been conducted. The research was focused on optimum conditions for labelling of linolenic acid using Iodine-131 radionuclide. Labelling with iodine-131 was conducted using KIO 3 as an oxidizing agent, which can additionated linolenic acid and sodium metabisulfite for ending the reaction. Labelling efficiency determination was conducted using paper chromatography technique. The result showed that the optimum condition achieved by using KIO 3 as an oxidizing agent that gave radiochemical purity of 99,44% in virgin coconut oil, and labelling efficiency of about 69,9%. The labelled compound has high radiochemical purity i.e 96,85% in chloroform and 98,33% virgin coconut oil that was stable until 10 days in refrigerator. (author)

  9. Scintigraphic imaging and turnover studies with iodine-131 labelled serum amyloid P component in systemic amyloidosis

    International Nuclear Information System (INIS)

    Hawkins, P.N.; Pepys, M.B.; Aprile, C.; Capri, G.; Vigano, L.; Munzone, E.; Gianni, L.; Merlini, G.

    1998-01-01

    Radiolabelled serum amyloid P component (SAP) is a specific tracer for amyloid. Iodine-123 has ideal physical characteristics for scintigraphy but is expensive and not widely available. Here we report serial imaging and turnover studies in which we labelled SAP with iodine-131, a cheap alternative isotope which would be expected to yield poorer images but permit more prolonged turnover measurements. Imaging and plasma clearance and whole body retention (WBR) of tracer were studied for up to 7 days in ten patients with proven systemic AL amyloidosis and two patients in whom the diagnosis was suspected, after i.v. administration of about 37 MBq of 131 I-SAP. Normal blood pool images were obtained in the latter two subjects and amyloidosis was subsequently refuted histologically. WBR at 48 h was 65% of the injected dose (i.d.). Among the other ten patients, amyloid deposits were identified in the spleen in eight cases, liver in five and kidneys in four; other sites that gave positive results included bone, joints and soft tissues, and the myocardium in one case. Up to 95% of the tracer localised into amyloid within 6-h, and the values for WBR became progressively more discriminating during the study period, exceeding the normal reference value ( 131 I-SAP produced diagnostic scans in every patient in this series and, coupled with the detailed turnover information, is adequate for monitoring disease progress. (orig.)

  10. Iodine-131 labelled octreotide: not an option for somatostatin receptor therapy

    International Nuclear Information System (INIS)

    Bakker, W.H.; Breeman, W.A.P.; Pluijm, M.E. van der; Jong, M. de; Visser, T.J.; Krenning, E.P.

    1996-01-01

    This study deals with the radioiodination of very small amounts of peptide on a therapeutic scale, the required purification procedures after radioiodination, and the influence of high beta fluxes from 131 I on a peptide during radioiodination and purification. Based on the regularly used therapeutic doses of 131 I in cancer treatment and out previous experience with [ 111 In-DTPA-D-Phe 1 ]-octreotide, it was assumed that a minimal effective therapeutic dose of 3.7 GBq 131 I has to be coupled to a maximum of ∼100 μg peptide, representing only a slight excess of peptide over 131 I. This contrasts with non-peptide radiopharmaceuticals in which high compound to radionuclide ratios are usually used. Labelling at low peptide to radionuclide ratios (low labelling yields) results in the formation of di-iodinated compounds, whereas at high peptide to radionuclide ratios mono-iodinated products of low specific activity are formed. Thus, after radioiodination the desired mono-iodinated peptide has to be separated form unreacted iodide, and from di-iodinated and unreacted peptide, as both compounds compete for the receptors. Possible radiolysis of the peptide during labelling and separation steps were investigated by irradiating 30 μg unlabelled peptide with 370 MBq 131 I in a small volume. The peptide composition of the incubation mixtures was investigated by high-performance liquid chromatography after irradiation for 30 min to 24 h. The results showed that the peptide was degraded with a half-life of less than 1 h. During the preparation of a real therapeutic dose (at much higher β-flux) the peptide will be degraded even faster during the various steps required. In conclusion, intact mono-iodinated 131 I-labelled somatostatin analogues for peptide receptor therapy will be difficult to obtain. (orig./VHE)

  11. Labelling of human serum albumin with iodine-131 for diagnosis in nuclear medicine

    International Nuclear Information System (INIS)

    Silva Valente Goncalves, R. da.

    1979-01-01

    Labelling of 131 I-human serum albumin with I-131 from a solution of 131 I-sodium iodide using chloramine T as an oxidant agent is studied. Parameters which can influence on the labelling yield like mass of human serum albumin, and chloramine T, pH of the reaction, reaction time and activity of 131 I are also studied. The purification of the labeled product by means of IRA-410 Amberlite ion-exchange resin in chloride form and the sterilization of the 131 I-human serum albumin by its passage through a 0,22μ millipore filter are carried out. The radiochemistry control of the final product by paper chromatography and the microbiological control by cultivation of microorganisms in fluid medium: nutrient broth, sodium thioglycollate broth and Sabouraud, are performed. The stability of the radiopharmaceutical until ten days after its preparation is analysed by means of radiochemical control. (Author) [pt

  12. New bisphosphonate labeled with Iodine-131 for the palliative therapy for bone metastases pain

    International Nuclear Information System (INIS)

    Prats Capote, Anaís; Perera Pintado, Alejandro; León, Mariela; Hernández González, Ignacio; Leyva Montaña, René; Mocelo Castell, Raúl; O'Reilly, Beatriz; Calderón, Osmar; Griffith Pérez, Yoel; García Batle, Marisé; Rodríguez Tanty, Chryslaine

    2016-01-01

    The aim of this work was to obtain new bisphosphonate marked with 131I suitable for palliative treatment of bone metastases pain characteristics. Materials and Methods: It started with aromatic amino acids and the synthesis consisted of three stages: 1) Protection of amino groups by acetylation; 2) phosphonation protected amino acids with a mixture of phosphorous acid and phosphorus pentachloride; 3) Lack of protection of the amino groups by basic hydrolysis. The compounds obtained were characterized by IR, 1H NMR, RMN13-C mass. Los spectrometry bisphosphonic acids obtained were labeled with 131I using chloramine T and iodogen as oxidants. Stability of labeled compounds in aqueous solution was studied serum. 3 mg of 2-amino-3- (4-hydroxyphenyl) -1-hydroxypropyl-1,1-bisphosphonic acid labeled of 131I were administered to male wistar rats (170-190 g) through a lateral tail vein. The scintigraphic study was conducted at 2, 6 and 12 hours. Results: The yield of the reactions of the amino group protection four compounds ranged from 75 to 80%, while the phosphonation was between 50 and 60%. The radiochemical purity of 2-amino-3- (4-hydroxyphenyl) -1-hydroxypropyl-1,1- bisphosphonic acid labeled with 131I was (91.5 ± 1.4)% and its stability was satisfactory for 72h. Scintigraphic images suggest excretion by the kidneys of the compound and from 12 h post-administration begin to visualize bone structures of the animal, suggesting that the compound exhibits affinity for these tissues. Conclusions: A novel synthesis method with modifications that yielded the sodium salts of bisphosphonic acids starting from the respective aromatic amino acids was developed. 2-amino-3- (4-hydroxyphenyl) -1-hydroxypropyl-1,1-bisphosphonic acid 131I labeled was stable up to 72h and showed affinity for bone tissue. (author)

  13. Synthesis and Bioevaluation of Iodine-131 Directly Labeled Cyclic RGD-PEGylated Gold Nanorods for Tumor-Targeted Imaging

    Directory of Open Access Journals (Sweden)

    Yingying Zhang

    2017-01-01

    Full Text Available Introduction. Radiolabeled gold nanoparticles play an important role in biomedical application. The aim of this study was to prepare iodine-131 (131I-labeled gold nanorods (GNRs conjugated with cyclic RGD and evaluate its biological characteristics for targeted imaging of integrin αvβ3-expressing tumors. Methods. HS-PEG(5000-COOH molecules were applied to replace CTAB covering the surface of bare GNRs for better biocompatibility, and c(RGDfK peptides were conjugated onto the carboxyl terminal of GNR-PEG-COOH via EDC/NHS coupling reactions. The nanoconjugate was characterized, and 131I was directly tagged on the surface of GNRs via AuI bonds for SPECT/CT imaging. We preliminarily studied the characteristics of the probe and its feasibility for tumor-targeting SPECT/CT imaging. Results. The [131I]GNR-PEG-cRGD probe was prepared in a simple and rapid manner and was stable in both PBS and fetal bovine serum. It targeted selectively and could be taken up by tumor cells mainly via integrin αvβ3-receptor-mediated endocytosis. In vivo imaging, biodistribution, and autoradiography results showed evident tumor uptake in integrin αvβ3-expressing tumors. Conclusions. These promising results showed that this smart nanoprobe can be used for angiogenesis-targeted SPECT/CT imaging. Furthermore, the nanoprobe possesses a remarkable capacity for highly efficient photothermal conversion in the near-infrared region, suggesting its potential as a multifunctional theranostic agent.

  14. Evaluation of pancreatic lipase activity by simple urine analysis after oral administration of a new iodine-131-labeled triglyceride

    International Nuclear Information System (INIS)

    Kropp, J.; Knapp, F.F. Jr.; Weyenberg, A.; McPherson, D.W.; Ambrose, K.R.; Callahan, A.P.; Bergmann, K. von; Biersack, H.J.

    1994-01-01

    A new iodine-131-labeled triglyceride analogue called ''MIPAG'' [1,2-dipalmitoyl-3-[(15-p-iodophenyl) pentadecan-1-oyl]rac-glycerol] has been prepared in which 15-(p-iodophenyl)pentadecanoic acid (IPPA) is attached to position-3. MIPAG has been developed for the evaluation of pancreatic exocrine function by simple urine analysis and has been evaluated in rats and humans. After oral administration, IPPA is released from the triglyceride by the action of pancreatic lipases followed by intestinal absorption and the principal IPPA metabolite (p-iodobenzoic acid. IBA) is primarily excreted in the urine. Excretion in the urine and feces was evaluated in rats, as well as the biodistribution in various organs over 21 days. Twenty patients without pancreatic disease (normals) and four patients with pancreatic insufficiency were also investigated. Following oral administration of 30 μCi of MIPAG, urine was collected for two successive 24-h periods. Blood samples were drawn and thin-layer chromatographic (TLC) analysis was performed on the serum lipid extracts. Urine from normals contained 44.9%±7.7% and 61.8%±8.4% of the administered activity after 24 and 48 h, respectively. The patients with pancreatic insufficiency excreted 13.1%±5.6% and 18.9%±6.2%, respectively, which was significantly decreased (P<0.001) compared with normals. The TLC profiles showed an increasing proportion of IBA with time. Urine analysis after oral administration of MIPAG thus appears to be an attractive new technique for the evaluation of pancreatic lipase activity by a simple urine analysis. (orig.)

  15. Iodine-131 labeled anti-CEA polyclonal antibody detection of gastrointestinal cancer

    International Nuclear Information System (INIS)

    Nabi, H.A.; Hinkle, G.H.; Olsen, J.O.; Haagensen, D.A.; Thurston, M.O.; Mojzisik, C.; Houchens, D.; Martin, E.W. Jr.

    1984-01-01

    To localize gastrointestinal tumor, 31 patients were injected with 1.7-2.1 mCi I-131 anti-CEA baboon polyclonal antibody. Whole body imaging at 48, 72, and occasionally 96 hrs was performed with a Signa Camera (Technicare) peaked at 364 keV with 20% window. Additional spot views were usually obtained. No subtraction methods were used. All patients had surgical and pathological confirmation of the nuclear medicine studies. Labeled antibody images were positive in 15 (8 recurrent or metastatic colorectal, 2 gastric, 1 pancreatic, 1 primary colon, and 1 breast metastatic to chest wall). In 1, antibody images were positive for metastatic deposits in para-aortic lymph nodes, but negative for primary rectal tumor. True negative images were observed in 6; false negative images in 9 (4 liver metastases, 2 rectal, 1 pancreatic, 1 mesenteric lymph node metastasis, 1 bone metastasis). In all cases, no correlation existed between preoperative CEA serum levels and imaging. I-131 labeled anti-CEA polyclonal antibody imaging proved highly efficient in detecting gastric cancer (2/2) and moderately efficient in detecting recurrent colorectal cancer (8/15). On the other hand, the I-131 labeled polyclonal anti-CEA antibody imaging was of limited value in detecting colon cancer (1/9), pancreatic cancer (1/4) and metastatic liver disease

  16. Chloridrate of N-isopropyl-p-iodoamphetamine labeled with Iodine-131. Biological distribution in laboratory animals

    International Nuclear Information System (INIS)

    Colturato, Maria Tereza; Muramoto, Emiko; Carvalho, Olga Goncalves de

    2000-01-01

    The development of this work was based on a great interest from the medical class in the utilization of chloridrate of N-isopropyl-p-iodoamphetamine (IMP) labeled with 123 I, for brain perfusion evaluation. Studies were performed to optimize the labeling parameters of IMP with 131 I using nucleophilic substitution: temperature and, time reaction, ascorbic acid mass, pH and relation IMP mass/radioiodo activity, and stability of the final product. Radiochemistry purity method used showed to be efficient, quick and of easily handling for routine production. Biological distribution studies were performed in mice to determine the percent administered dose in the blood, different organs and whole body after intravenous administration of the radiopharmaceutical. The product crossed the intact blood brain barrier, allowing a follow up of further studies after the intravenous administration of the radiopharmaceutical. The principal elimination route 131 I-IMP was the urinary. Based on the results from radiochemical purity, stability and biological behavior in laboratory animals, we concluded that the studied radiopharmaceutical presents all ideal characteristics for clinical use in brain studies in nuclear medicine. (author)

  17. Effects of Glycosylation on Biodistribution and Imaging Quality of Necrotic Myocardium of Iodine-131-Labeled Sennidins.

    Science.gov (United States)

    Li, Ling; Zhang, Dongjian; Yang, Shengwei; Song, Shaoli; Li, Jindian; Wang, Qin; Wang, Cong; Feng, Yuanbo; Ni, Yicheng; Zhang, Jian; Liu, Wei; Yin, Zhiqi

    2016-12-01

    Sennidins are necrosis-avid agents for noninvasive assessment of myocardial viability which is important for patients with myocardial infarction (MI). However, high accumulation of radioactivity in the liver interferes with the assessment of myocardial viability. In this study, we compared sennidins with sennosides to investigate the effects of glycosylation on biodistribution and imaging quality of sennidins. Sennidin A (SA), sennidin B (SB), sennoside A (SSA), and sennoside B (SSB) were labeled with I-131. In vitro binding to necrotic cells and hepatic cells and in vivo biodistribution in rats with muscular necrosis were evaluated by gamma counting, autoradiography, and histopathology. Single photon emission computed tomography/computed tomography (SPECT/CT) images were acquired in rats with acute MI. The uptake of [ 131 I]SA, [ 131 I]SSA, [ 131 I]SB, and [ 131 I]SSB in necrotic cells was significantly higher than that in viable cells (p sennosides than those with [ 131 I]sennidins (p < 0.01). Autoradiography showed preferential accumulation of these four radiotracers in necrotic areas of muscle, confirmed by histopathology. SPECT/CT imaging studies showed better image quality with [ 131 I]SSB than with [ 131 I]SB due to less liver interference. Glycosylation significantly decreased the liver uptake and improved the quality of cardiac imaging. [ 131 I]SSB may serve as a promising necrosis-avid agent for noninvasive assessment of myocardial viability.

  18. Vasoactive intestinal peptide (VIP) labelling with iodine-131 by direct method

    International Nuclear Information System (INIS)

    Colturato, M.T.; Silva, C.P.G. da; Araujo, E.B.

    2002-01-01

    The Vasoactive Intestinal Peptide (VIP) is a 28-amino acid polypeptide with a great numbers of receptors in tumoral cells, including adenocarcinomas and pancreatic and colon carcinomas. The VIP molecule contains two tyrosine residues, in positions 10 and 22, that are theoretically equally susceptible to iodination, The VIP was labeled with 131-iodine by direct method using Iodogen as oxidant agent: 15.03 mmol VIP + 0.10 nmol KI + [ 131 I]NaI + 13.9 mmol Iodogen; the final volume was adjust to 100 μL using 0.2 M phosphate buffer, pH 7.5 and the reaction proceed with stirring for 30 minutes at room temperature. The radiochemical purity was determined by electrophoresis (Whatman 1MM paper; 0.05 M barbital buffer; pH 8.6; 150 V; 40 minutes) that indicates low percent of free 131-iodine. The high performance liquid chromatography (HPLC) system using RPC 18 , 10 μm, 4 x 250mm column, was able to separate the different radiochemical species, only when an isocratic mixture of acetonitrile: 0.1% trifluoroacetic acid (27:73) was used, with 0.5 mL/min. flux. (author)

  19. Biodistribution and tolerance of intravenous iodine-131-labelled hypericin in healthy dogs.

    Science.gov (United States)

    Abma, E; Peremans, K; De Vos, F; Bosmans, T; Kitshoff, A M; Daminet, S; Ni, Y; Dockx, R; de Rooster, H

    2018-01-04

    Hypericin (Hyp) is a necrosis-avid compound that can be efficiently labelled with radioiodine for both diagnostic and therapeutic purposes. Before 131 I-Hyp can be considered as a clinically useful drug in a combination therapy for canine cancer patients, evaluation of its toxicity is necessary. The aim of this study was to investigate the biodistribution and tolerance of a single dose administration of 131 I-Hyp. Three healthy dogs were included. 131 I-Hyp at a dose of 0.2 mg/kg and an activity of 185 MBq was intravenously injected. The effects on physical, haematological and biochemical parameters were characterized and the biodistribution and elimination pattern, the effective half-life and dose rate were assessed. Drug-related adverse events were limited to mild gastrointestinal signs, resolving within 48 hours. No significant differences were found in blood haematology and serum biochemistry before and after treatment. Following administration, highest percentage of injected dose (%ID ± SD) was found in the liver (5.5 ± 0.33), the lungs (4.17 ± 0.14) and the heart (3.11 ± 0.78). After 24 hours, highest %ID was found in colon (4.25 ± 1.45) and liver (3.45 ± 0.60). Clearance from all organs was effective within 7 days. Effective half-life was established at 80 hours, and the dose rate fell below <20 μSv/h at 1 m within 1 day. The current study reveals that single dose treatment with 131 I-Hyp at the described dose is well tolerated by healthy dogs and supports the use of radioiodinated hypericin in a combination therapy for canine cancer patients. © 2018 John Wiley & Sons Ltd.

  20. Renal excretion of iodine-131 labelled meta-iodobenzylguanidine and metabolites after therapeutic doses in patients suffering from different neural crest-derived tumours

    International Nuclear Information System (INIS)

    Wafelman, A.R.; Hoefnagel, C.A.; Maessen, H.J.M.; Maes, R.A.A.; Beijnen, J.H.

    1997-01-01

    Iodine-131 labelled meta-iodobenzylguanidine ([ 131 I[MIBG) is used for diagnostic scintigraphy and radionuclide therapy of neural crest-derived tumours. After administration of therapeutic doses of [ 131 I[MIBG (3.1-7.5 GBq) to 17 patients (n=32 courses), aged 2-73 years, 56%±10%, 73%±11%, 80%±10% and 83%±10% of the dose was cumulatively excreted as total radioactivity in urine at t=24 h, 48 h, 72 h and 96 h, respectively. Except for two adult patients, who showed excretion of 14%-18% of [ 131 I[meta-iodohippuric acid ([ 131 I[MIHA), the cumulatively excreted radioactivity consisted of >85% [ 131 I[MIBG, with 6% of the dose excreted as free [ 131 I[iodide, 4% as [ 131 I[MIHA and 2.5% as an unknown iodine-131 labelled metabolite. Cumulative renal excretion rates of total radioactivity and of [ 131 I[MIBG appeared to be higher in neuroblastoma and phaeochromocytoma patients than in carcinoid patients. Based on the excretion of small amounts of [ 131 I[meta-iodobenzoic acid in two patients, a possible metabolic pathway for [ 131 I[MIBG is suggested. The degree of metabolism was not related to the extent of liver uptake of radioactivity. (orig.). With 2 figs., 5 tabs

  1. The study of labeling with iodine-131 of monoclonal antibody anti-CD20 used for the treatment of non-Hodgkin lymphoma

    International Nuclear Information System (INIS)

    Akanji, Akinkunmi Ganiyu

    2006-01-01

    Lymphomas are malignancies of the lymphatic system, described by Thomas Hodgkin in 1932. Traditionally, lymphomas are classified in two basic groups: Hodgkin disease and non-Hodgkin lymphoma (NHL). Patients with NHL were earlier treated with radiotherapy alone or in combination with immunotherapy using monoclonal antibody anti-CD20 (ex., Rituximab-Mabthera, Roche). However, Radioimmunotherapy is a new modality of treatment for patients with NHL, in which cytotoxic radiation from therapeutic radioisotopes is delivered to tumors through monoclonal antibodies. This study focused on labeling conditions of monoclonal anti-CD20 (ex., Rituximab-Mabthera, Roche) with iodine-131, by direct radioiodination method using Chloramine-T as oxidizing agent. Labeling parameters investigated were: Radiochemical purity (RP), method of purification, incubation time, antibody mass, oxidative agent mass, stability in vitro, immunoreactivity and biological distribution performed in normal Swiss mouse. Product of high radiochemical purity was obtained with no notable difference between the methods applied. No clear evidence of direct influence of incubation time on radiochemical purity of the labeled antibody was observed. Whereas, a clear evidence of direct influence of activity on radiochemical purity of the labeled antibody was varied. After purification the labeled product presented radiochemical purity of approximately 100 %. Product of superior radiochemical yield was observed when standard condition of labeling was used. The labeled product presented variation in radiochemical purity using five different stabilizer conditions. The condition in which gentisic acid combined with freeze appears more suitable and capable of minimizing autoradiolysis of the antibody labeled with freeze appears more suitable and capable of minimizing autoradiolysis of the antibody labeled with high therapeutic activity of iodine-131. The labeled product presented low immunoreactivity when compared to the

  2. The study of labeling with Iodine-131 of monoclonal antibody anti-CD20 used for the treatment of non-Hodgkin lymphoma

    International Nuclear Information System (INIS)

    Akanji, Akinkunmi Ganiyu

    2006-01-01

    Lymphomas are malignancies of the lymphatic system, described by Thomas Hodgkin in 1932. Traditionally, lymphomas are classified in two basic groups: Hodgkin disease and non-Hodgkin lymphoma (NHL). Patients with NHL were earlier treated with radiotherapy alone or in combination with immunotherapy using monoclonal antibody anti-CD20 (ex., Rituximab-Mabthera, Roche). However, Radioimmunotherapy is a new modality of treatment for patients with NHL, in which cytotoxic radiation from therapeutic radioisotopes is delivered to tumors through monoclonal antibodies. This study focused on labeling conditions of monoclonal antibody anti-CD20 (Rituximab-Mabthera, Roche) with iodine-131, by direct radioiodination method using Chloramine-T as oxidizing agent. Labeling parameters investigated were: Radiochemical purity (RP), method of purification, incubation time, antibody mass, oxidative agent mass, stability in vitro, stability in vivo, immunoreactivity and biological distribution performed in normal Swiss mouse. Product of high radiochemical purity was obtained with no notable difference between the methods applied. No clear evidence of direct influence of incubation time on radiochemical purity of the labeled antibody was observed. Whereas, a clear evidence of direct influence of activity on radiochemical purity of the labeled antibody was observed when antibody mass was varied. After purification, the labeled product presented radiochemical purity of approximately 100 %. Product of superior radiochemical yield was observed when standard condition of labeling was used. The labeled product presented variation in radiochemical purity using five different stabilizer conditions. The condition in which gentisic acid was combined with freeze appears more suitable and capable of minimizing autoradiolysis of the antibody labeled with high therapeutic activity of iodine-131. The labeled product presented low immunoreactivity when compared to the literature. Biological distribution in

  3. Radioimmunotherapy targeting the extra domain B of fibronectin in C6 rat gliomas: a preliminary study about the therapeutic efficacy of iodine-131-labeled SIP(L19)

    International Nuclear Information System (INIS)

    Spaeth, Nicolas; Wyss, Matthias T.; Pahnke, Jens; Biollaz, Gregoire; Trachsel, Eveline; Drandarov, Konstantin; Treyer, Valerie; Weber, Bruno; Neri, Dario; Buck, Alfred

    2006-01-01

    Despite aggressive treatment protocols, patients suffering from glioblastoma multiforme still experience poor outcome. Therefore, new adjuvant therapeutic options such as radioimmunotherapy (RIT) have been studied and have resulted in significant survival benefit. In this study, we assessed the efficacy of a novel radioimmunotherapeutic approach targeting the extra domain B (EDB) of fibronectin, a marker of angiogenesis, in glioma-bearing rats. Methods: C6 gliomas were induced intracerebrally in Wistar rats. Ten to 11 days later, 220-360 MBq of iodine-131-labeled anti-EDB SIP(L19) ('small immunoprotein') was administered intravenously into nine animals, yielding a radiation dose of 13-21 Gy. Another nine rats served as controls. Then the following parameters were compared: median survival time, tumor size and histology. Results: Histological examination of the tumors revealed typical glioblastoma characteristics. Eleven of 18 rats developed a tumor size bigger than 150 mm 3 . When these animals were used for survival analysis, median survival did significantly differ between groups [22 days (therapy; n=7) vs. 16 days (control; n=4); P 131 I-SIP(L19)-RIT showed promising potential in treating C6 gliomas, warranting further studies. However, larger trials with preferentially higher doses are needed to confirm this finding and, potentially, to further increase the efficacy of this treatment

  4. Necrosis targeted radiotherapy with iodine-131-labeled hypericin to improve anticancer efficacy of vascular disrupting treatment in rabbit VX2 tumor models.

    Science.gov (United States)

    Shao, Haibo; Zhang, Jian; Sun, Ziping; Chen, Feng; Dai, Xu; Li, Yaming; Ni, Yicheng; Xu, Ke

    2015-06-10

    A viable rim of tumor cells surrounding central necrosis always exists and leads to tumor recurrence after vascular disrupting treatment (VDT). A novel necrosis targeted radiotherapy (NTRT) using iodine-131-labeled hypericin (131I-Hyp) was specifically designed to treat viable tumor rim and improve tumor control after VDT in rabbit models of multifocal VX2 tumors. NTRT was administered 24 hours after VDT. Tumor growth was significantly slowed down by NTRT with a smaller tumor volume and a prolonged tumor doubling time (14.4 vs. 5.7 days), as followed by in vivo magnetic resonance imaging over 12 days. The viable tumor rims were well inhibited in NTRT group compared with single VDT control group, as showed on tumor cross sections at day 12 (1 vs. 3.7 in area). High targetability of 131I-Hyp to tumor necrosis was demonstrated by in vivo SPECT as high uptake in tumor regions lasting over 9 days with 4.26 to 98 times higher radioactivity for necrosis versus the viable tumor and other organs by gamma counting, and with ratios of 7.7-11.7 and 10.5-13.7 for necrosis over peri-tumor tissue by autoradiography and fluorescence microscopy, respectively. In conclusion, NTRT improved the anticancer efficacy of VDT in rabbits with VX2 tumors.

  5. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue

    International Nuclear Information System (INIS)

    Liu, S Y.; Eary, Janet F.; Petersdorf, S H.; Martin, P J.; Maloney, D G.; Applebaum, F. R.; Matthews, D. C.; Bush, S A.; Durack, L. D.; Fisher, Darrell R.; Gooley, T A.; Bernstein, I. D.; Press, O. W.

    1997-01-01

    Radioimmunotherapy (RIT) is a promising treatment approach for B-cell lymphomas. This is our first opportunity to report long-term follow-up data and late toxicities in 29 patients treated with myeloablative doses of iodine-131-anti-CD20 antibody (anti-B1) and autologous stem-cell rescue. PATIENTS AND METHODS: Trace-labeled biodistribution studies first determined the ability to deliver higher absorbed radiation doses to tumor sites than to lung, liver, or kidney at varying amounts of anti-B1 protein (0.35, 1.7, or 7 mg/kg). Twenty- nine patients received therapeutic infusions of single-agent (131)I- anti-B1, given at the protein dose found optimal in the biodistribution study, labeled with amounts of (131)I (280 to 785 mCi[10.4 to 29.0 GBq]) calculated to deliver specific absorbed radiation doses to the normal organs, followed by autologous stem-cell support. RESULTS: Major responses occurred in 25 patients (86%), with 23 complete responses (CRs; 79%). The nonhematopoietic do se-limiting toxicity was reversible cardiopulmonary insufficiency, which occurred in two patients at RIT doses that delivered > or = 27 Gy to the lungs. With a median follow-up time of 42 months, the estimated overall and progression-free survival rates are 68% and 42%, respectively. Currently, 14 of 29 patients remain in unmaintained remissions that range from 27+ to 87+ months after RIT. Late toxicities have been uncommon except for elevated thyroid-stimulating hormone (TSH) levels found in approximately 60% of the subjects. Two patients developed second malignancies, but none have developed myelodysplasia (MDS). CONCLUSION: Myeloablative (131)I-anti- B1 RIT is relatively well tolerated when given with autologous stem- cell support and often results in prolonged remission durations with few late toxicities

  6. Iodine-131-labelled CDR grafted monoclonal antibody huA33 metastatic colorectal carcinoma: A case study

    International Nuclear Information System (INIS)

    Thomas, D.L.; Lee, F.T.; Scott, A.M.

    1997-01-01

    Full text: A 58-year-old woman was diagnosed with metastatic colorectal carcinoma two years after initial surgery for sigmoid carcinoma. As part of the staging work-up she was initially referred for a 18 F-FDG PET scan at the PET Centre. FDG PET scans of the abdomen and pelvis demonstrated multiple hepatic lesions, but there was no evidence of disease outside the liver. On the basis of extensive hepatic disease, the patient was scheduled for a laparotomy for insertion of an hepatic artery catheter for chemotherapy. In view of her clinical presentation, the patient was eligible for a Phase 1 trial with 131 l-labelled huA33, and agreed to participate. HuA33 is a humanised CDR-grafted recombinant monoclonal antibody directed against an antigen found on >95 per cent of all colorectal carcinomas, and on small bowel and colonic mucosa. The phase 1 trial is a protein dose escalation study designed to examine the biodistribution, pharmacokinetics, dosimetry and safety profile of huA33, and sequential gamma camera images of the whole body were obtained daily until seven days post infusion. SPECT images were obtained on day 6. Excellent localisation of 131 l-huA33 was seen in hepatic lesions. Calculation of whole body retention and tumour uptake was performed, and pharmacokinetic analysis also undertaken. Biopsies of tumour obtained at surgery were used to quantitate tumour uptake and cellular trafficking of 131 l-huA33. On the basis of this phase 1 study, future therapeutic trials of 131 I-huA33 are planned

  7. Automation of labelling of Lipiodol with high-activity generator-produced 188Re

    International Nuclear Information System (INIS)

    Lepareur, Nicolas; Ardisson, Valerie; Noiret, Nicolas; Boucher, Eveline; Raoul, Jean-Luc; Clement, Bruno; Garin, Etienne

    2011-01-01

    This work describes optimisation of the kit formulation for labelling of Lipiodol with high-activity generator-produced rhenium-188. Radiochemical purity (RCP) was 92.52±2.3% and extraction yield was 98.56±1.2%. The synthesis has been automated with a TADDEO module (Comecer) giving a mean final yield of 52.68±9.6%, and reducing radiation burden to the radiochemist by 80%. Radiolabelled Lipiodol ( 188 Re-SSS/Lipiodol) is stable for at least 7 days (RCP=91.07±0.9%).

  8. A Comparison of Three Transarterial Lipiodol-Based Formulations for Hepatocellular Carcinoma: In Vivo Biodistribution Study in Humans

    International Nuclear Information System (INIS)

    Yu, Simon Chun Ho; Leung, Thomas Wai Tong; Lau, Wan Yee; Lee, Nelson; Hui, Edwin Pun; Yeo, Winnie; Lai, Paul Bo San; Mok, Tony Shu Kam

    2008-01-01

    This study aimed to evaluate and compare the biodistribution properties of three transarterial Lipiodol-based therapeutic regimens in human hepatocellular carcinoma (HCC). In this prospective study with 13 patients randomly allocated to one of three study groups, each of the patients received transcatheter intra-arterial administration into a solitary HCC with one of three different Lipiodol-based formulations: Lipiodol-ethanol mixture (LEM; Group A), Lipiodol alone (Group B), and Lipiodol and gelatin pledgets (Group C). With the use of radioactive iodine-131-labeled Lipiodol, each group was assessed for (1) pattern of Lipiodol accumulation in the lungs within the first 2 weeks as evaluated by single-photon emission computed tomography and (2) decomposition of Lipiodol formulation within the first 2 weeks as evaluated by radioactivity detected in peripheral blood and urine. The degree of Lipiodol retention in the tumor within the first 4 weeks was evaluated with CT. No statistically significant difference in Lipiodol accumulation in the lungs was detected among the three groups. However, the peak accumulation in the lungs was delayed 3 days for Group A compared to Groups B and C. The degree of Lipiodol retention within the tumor in Group A was significantly greater than that in Groups B and C on day 14 (p = 0.014) and day 28 (p = 0.013). This study showed that LEM is associated with a greater embolic effect in intrahepatic HCC at 4 weeks, and a comparable degree of lung shunting and decomposition rates, compared with ethanol-free Lipiodol formulations

  9. Management of patient with hepatocellular carcinomas by in situ injection of iodine-131 labelled lipiodol solution (Lipiocis) in the Biophysics and Timone APHM University Hospital Central Service

    International Nuclear Information System (INIS)

    Sigrist, S.

    2008-01-01

    The aim of this work was to determine what are the prognosis factors in term of global expectation of life at patient receiving a treatment by Lipiocis, to estimate the tolerance at this treatment in order to choose patient which will be the best candidates to this treatment and to define more precisely the criteria of patient inclusion and follow-up. A study including 35 patient having received one or several Lipiocis injections between May 2003 and May 2007 has been carried out. The results of this study are given. Lipiocis seems to be a well tolerated treatment which has proved its efficiency. (O.M.)

  10. Iodine 131 and 133 as Fission Indicators

    Energy Technology Data Exchange (ETDEWEB)

    Broda, E.

    1944-07-01

    This report was written by E. Broda at the Cavendish Laboratory (Cambridge) in September 1944 and is about the possible use of Iodine 131 and 133 as fission indicators. Additionally, the description of the chemical procedure for I 131 and I 133 and the corresponding results can be found in this report. (nowak)

  11. Thrombus imaging with indium-111 and iodine-131-labeled fibrin-specific monoclonal antibody and its F(ab')2 and Fab fragments

    International Nuclear Information System (INIS)

    Rosebrough, S.F.; Grossman, Z.D.; McAfee, J.G.

    1988-01-01

    We have previously reported successful imaging of fresh (2-4 hr old) and aged (1-5 days old) canine thrombi with 131 I-labeled intact monoclonal antibody (MAb) specific for fibrin. We now report thrombus imaging with 131 I-labeled F(ab')2 and Fab and 111 In-labeled intact MAb, F(ab')2, and Fab. Indium-111-labeled F(ab')2 proved to be the best imaging agent due to less nonspecific binding in the liver than whole IgG. Image quality was improved by the higher administered dose permissible with 111 In and its better physical characteristics for imaging, compared to 131 I. Immunofluorescence of fresh human histologic sections showed intact MAb and F(ab')2 binding to thrombi, pulmonary emboli, and atherosclerotic plaques, strengthening the feasibility of clinical thrombus imaging

  12. Radiosensitizers action on Iodine 131 therapeutical effect

    International Nuclear Information System (INIS)

    Agote, Marcos; Kreimann, Erica L.; Bocanera, Laura V.; Dagrosa, Maria A.; Juvenal, Guillermo J.; Pisarev, Mario A.

    1999-01-01

    Present studies were aimed to research the possible application of a radiosensitizer, nicotinamide, to increase the therapeutical effect of radioiodine. There were used goitrous and normal rats with growing dose of Iodine 131, with and without simultaneous treatment with nicotinamide. The obtained results show that the nicotinamide treatment importantly increases the thyroid radio destructive effect induced by radioiodine. Under these experimental conditions, nicotinamide induces to a significant increase of thyroid vascularisation, without changes in the proteins ADP-ribosylation activity. These results show, for the first time, the radiosensitizer effect of nicotinamide in front of Iodine 131 and give the possibility of using it in the treatment of hyperthyroid or thyroid difference cancer patients. (author)

  13. Vasoactive intestinal peptide (VIP) labelling with iodine-131 by direct method; Marcacao do peptideo intestinal vasoativo (VIP) com iodo-131 por metodo direto

    Energy Technology Data Exchange (ETDEWEB)

    Colturato, M.T.; Silva, C.P.G. da; Araujo, E.B. [Instituto de Pesquisas Energeticas e Nucleares (IPEN), Sao Paulo, SP (Brazil). Centro de Radiofarmacia

    2002-07-01

    The Vasoactive Intestinal Peptide (VIP) is a 28-amino acid polypeptide with a great numbers of receptors in tumoral cells, including adenocarcinomas and pancreatic and colon carcinomas. The VIP molecule contains two tyrosine residues, in positions 10 and 22, that are theoretically equally susceptible to iodination, The VIP was labeled with 131-iodine by direct method using Iodogen as oxidant agent: 15.03 mmol VIP + 0.10 nmol KI + [{sup 131} I]NaI + 13.9 mmol Iodogen; the final volume was adjust to 100 {mu}L using 0.2 M phosphate buffer, pH 7.5 and the reaction proceed with stirring for 30 minutes at room temperature. The radiochemical purity was determined by electrophoresis (Whatman 1MM paper; 0.05 M barbital buffer; pH 8.6; 150 V; 40 minutes) that indicates low percent of free 131-iodine. The high performance liquid chromatography (HPLC) system using RPC{sup 18}, 10 {mu}m, 4 x 250mm column, was able to separate the different radiochemical species, only when an isocratic mixture of acetonitrile: 0.1% trifluoroacetic acid (27:73) was used, with 0.5 mL/min. flux. (author)

  14. Study on stability of labeled yttrium-90 with lipiodol by chemical extraction for liver cancer

    International Nuclear Information System (INIS)

    Mu, P.Y.; Jiang, X.L.; Chen, J.; Zhu, Y.J.

    2005-01-01

    Liver cancer, particularly hepatocellular carcinoma, is one of the most common malignant diseases in many developed and developing countries. It is also one of the most common diseases endangering the people's lives and health heavily. Surgery is very effective in early-stage patients. Unfortunately, there is less than 10% of the patients with hepatocellular carcinoma fitting for surgical therapy. Instead of surgical therapy, other methods are considered for patients in whom surgery may not work well. Systemic administration of chemotherapeutic agents is not often considered in liver cancer patients, due to discouraging result and adverse side effects. Also, hepatocellular carcinoma is not keen on usual radioactive therapy. However, method of inner interventional radioactive nuclide is a potential way to cure liver tumors. Hepatocellular carcinoma would be cured with inner interventional radioactive nuclide, which is a hot topic in experimental research on hepatocellular carcinoma at home and abroad. The purpose of the study is to label Yttrium-90 with lipiodol by means of the chemical extraction method and research the stability of labeled Yttrium-90 ( 90 Y-P204-Lipiodol) in serum of a newly-born cattle and human's blood. We chose to label steady yttrium with lipiodol, because radioactive yttrium has great nuclear character for liver cancer, yttrium-90 can eradiate pure β radial, and it's half time is 64 hours. Average energy of it is 0.93 Mev, the highest energy is 2.27 Mev. Yttrium-90 can be labeled with lipiodol by means of the chemical extraction method, which is mature in chemical techniques, combined with method of radioactive nuclide labeled in. nuclear medicine. At first, yttrium-90 is extracted in certain condition(pH, temperature, whisk time, whisk frequency, etc ) after adding yttrium-90 solution. We use some distilled water to balance the labeled organic phase twice, and test the stability of labeled yttrium-90 in serum of a newly-born cattle and

  15. Iodine-131 monitoring in sewage plant outflow

    International Nuclear Information System (INIS)

    McGowan, D R; Crawley, M T; Pratt, B E; Hinton, P J; Peet, D J

    2014-01-01

    Three different hospital sites (Oxford, Sutton and Guildford) have performed sampling of their local sewage plant outflow to determine levels of radioactivity resulting from iodine-131 patients undergoing radionuclide therapies. It was found that a maximum of 20% of activity discharged from the hospitals was present in the sewage plant final effluent channel. This is significantly below the level predicted by mathematical models in current use. The results further show that abatement systems to reduce public exposure are unlikely to be warranted at hospital sites. (paper)

  16. A new technique for labeling of Lipiodol with 188Re in the treatment of hepatic tumor

    International Nuclear Information System (INIS)

    Shyh-Jen Wang; Wan-Yu Lin; Bor-Tsung Hsieh; Kai-Yuan Cheng; Lie-Hang Shen; Ming-Ja Su

    2004-01-01

    A new method for the synthesis of 188 Re-Lipiodol without using a chelating agent and to evaluate the stability and biodistribution of the new agent in rats with hepatic tumors was attempted. Eighteen male Sprague -Dawley rats with liver tumors were sacrificed at 1, 24, and 48 hours (six rats at each time) after injection of approximately 7.4 MBq (0.2 mCi) of 188 Re Lipiodol via the hepatic artery. Samples of tumor, liver and other organs were collected and tissue concentration (%ID/g) of the markers were calculated. A high level of radioactivity in the hepatic tumors was found at every time of the study. The ratios of tumor to normal liver tissue concentration (T/N ratio) were 7.62 at 1 hour, 8.03 at 24 hours, and 7.70 at 48 hours. Except for the liver, kidneys and lungs, concentrations in other organs were low. The new method for labeling Lipiodol with 188 Re is simple and has potential for the treatment of hepatic tumors. (author)

  17. Guidelines on the management of patients treated with iodine-131

    International Nuclear Information System (INIS)

    1993-03-01

    The purpose of these guidelines is to assist health care institutions establish protocols for the management of patients treated with iodine-131. These guidelines are written primarily for the use of Na 131 I in the treatment of benign and malignant thyroid disease. The principles have some application for the use of complex 131 I-labelled radiopharmaceuticals in that the treated patient will become a temporary radiation source and since contamination with body fluids of treated patients must be guarded against. The document outlines radiation protection and logistical concerns associated with the management of 131 I patients before, during and after therapy. These concerns include the safety of health care personnel, visitors, and any other persons who are at risk; and protection of the environment. (L.L.) 23 refs., 2 tabs

  18. Malignant disease after iodine-131 therapy

    International Nuclear Information System (INIS)

    Holm, L.E.; Hall, P.; Lundell, G.

    1991-01-01

    Iodine-131 therapy is one of the most common treatments for hyperthyroidism and thyroid cancer. Data on man exposed to 131-I are still scarce, and there is concern as to its possible genetic and carcinogenic effects. No overall increased cancer risk has been observed in patients receiving 131-I therapy for hyperthyroidism. Two studies have reported increased risks for leukemia after 131-I therapy for throid cancer. Different sites have been demonstrated to be at increased cancer risk in different record-linkage studies of thyroid cancer patients, e.g. bone-marrow, breast and kidney, nervous tissue, and connective tissue. However, the findings are not consistent. This article presents results from a Swedish multicenter cohort study analyzing risks of second primary tumors in patients treated with 131-I for hyperthyroidism or thyroid cancer. 10 refs

  19. Chapter 5: Measurements of iodine-131 in milk supplies

    International Nuclear Information System (INIS)

    Duggleby, J.C.; Kotler, L.H.; Wilks, M.J.; Wise, K.N.

    1974-01-01

    As with previous series of French nuclear tests in Polynesia, a program was instituted to monitor major milk supplies for iodine-131. This program extended from 25 July to 23 October 1973, and was terminated only after there was no further possibility of iodine-131 reaching the milk supplies. The program covered the nine major population centres and effectively monitored the milk consumed by 80 per cent of the entire Australian population. The method employed for iodine-131 assay of milk supplies is described, and the final results obtained are presented. (author)

  20. Nursing of patients with hyperthyroidism treated by using iodine-131

    International Nuclear Information System (INIS)

    Chen Dongju; Cao Guoxiang

    2002-01-01

    Hyperthyroidism was a common endocrine disease, its clinic treatment mainly include anti thyroid drug treatment, surgical operation and iodine-131 therapy. The latter have unique superiority, which was adapted by clinic doctors. The nursing method was distinguished from that of others because the principle of iodine-131 therapy was different from other therapy in course of the treatment of hyperthyroidism. Combining the nursing experiences with related documents, this article was about to sum up briefly the nursing and matters needing attention in course of treatment of iodine-131 in patients with hyperthyroidism

  1. Source of Iodine-131 in Europe Identified

    International Nuclear Information System (INIS)

    2011-01-01

    Full text: The IAEA has received information from the Hungarian Atomic Energy Authority (HAEA) that the source of the iodine-131 (I-131) detected in Europe was most probably a release to the atmosphere from the Institute of Isotopes Ltd., Budapest. The Institute of Isotopes Ltd. produces radioisotopes for healthcare, research and industrial applications. According to the HAEA, the release occurred from September 8 to November 16, 2011. The cause of the release is under investigation. As previously mentioned, the levels of I-131 that have been detected in Europe are extremely low. There is no health concern to the population. If any member of the public were to breathe iodine for a whole year at the levels measured in European countries, then they would receive a dose in the range of 0.01 microsieverts for the year. To put this into perspective, the average annual background is 2 400 microsieverts per year. The IAEA was first notified of the presence of trace levels of I-131 by authorities from the Czech Republic on 11 November. Since this notification, the IAEA contacted several member states throughout the region to determine the cause and origin. The IAEA also worked with the World Meteorological Organization (WMO) to conduct air dispersion modelling, as part of efforts to determine the source. (IAEA)

  2. The therapeutic threesome, Iodine 131, Lutetium-111 and Rhenium-188 Radionuclide Trifecta

    International Nuclear Information System (INIS)

    Turner, J.H.

    2007-01-01

    Full text: Affordable, available, cost-effective, safe, efficacious therapeutic radiopharmaceuticals are required for clinical application throughout the world. In-house preparation of non-proprietary therapeutic radiopharmaceuticals at tertiary referral hospitals in all countries following appropriate technology transfer and training at key research and development centres can potentially supply this need. Illustrative examples of novel therapeutic radiopharmaceuticals currently under development in physician sponsored phase II clinical trials and candidates for contemplation of translation to developing countries include: (1) I-131 Rituximab radioimmunotherapy of relapsed/refractory and first-line treatment of non- Hodgkin's lymphoma; (2) Lu-177 octreotate radiopeptide therapy of neuroendocrine malignancy with capecitabine tumour radiosensitization; (3) Re-188 lipiodol intrahepatic arterial therapy of hepatocellular carcinoma. In addition to presentation of preliminary clinical results, the logistics and techniques of preparation, quality control and administration of each of these therapeutic radiopharmaceuticals will be described and the calculation of individual patient dosimetry and issues of radiation safety will also be addressed. 1. Iodine-131 rituximab: I-131 rituximab may be prepared in a hospital department of nuclear medicine equipped with a shielded fume cupboard, using commercially available single-use sterile pyrogen-free labelling kits (Go Medical Industries Pty Ltd, Subiaco, Australia) (1). Individualized prospective dosimetry is performed on each patient by quantitative whole body gamma imaging, to determine the therapeutic administered activity, to provide a maximum safe whole body radiation absorbed dose of 0.75 Gy, which equates to less than 2 Gy to red marrow (2). More than 200 patients with relapsed/refractory non-Hodgkin's lymphoma have been treated at Fremantle Hospital without infection or haemorrhagic incident. Myelosuppression is self

  3. Genetic effects of iodine 131 incorporation in mammals

    International Nuclear Information System (INIS)

    Bajrakova, A.

    1988-01-01

    The translocation yield after single treatment of male mice with iodine 131 (55,5 - 222,0 kBq/g b.w.) was investigated. The results of the cytogenetic analysis of the gonad cells revealed the effectiveness only of the highest activity, distroying the thyroid gland. The so-called direct method was also used for determination of the risk coefficients for the expected new carriers of balanced and unbalanced translocations in the first generation - the genetic effects which could be expected from the use of iodine-131-diagnostics in a hypothetic population

  4. Merkel cell carcinoma and iodine-131 metaiodobenzylguanidine scan

    International Nuclear Information System (INIS)

    Castagnoli, A.; Biti, G.; De Cristofaro, M.T.R.; Papi, M.G.; Ferri, P.; Magrini, S.M.; Bianchi, S.

    1992-01-01

    Two cases of Merkel cell carcinoma, a neuroendocrine neoplasia of the skin, investigated with iodine, 131 metaiodobenzylguanidine ( 131 I-mIBG) scintigraphy, are reported. Uptake in the tumor was evident only in 1 case. The possible diagnostic and therapeutic role of 131 I-mIBG in patients with this rare neoplasm is discussed. (orig.)

  5. Introduction of iodine 131 and bromine 82 in antibiotics of tetracycline group

    International Nuclear Information System (INIS)

    Mironov, V.P.; Kudryashov, V.P.; Grushevich, L.E.; Kuz'mina, T.S.

    1983-01-01

    Chloline- and oxytetracycline reactions with iodide-131-and bromide-82-ions in methanol and acetone are studied. It is established that labelled compounds reveal tetracycline (TC) properties in pharmacokinetic experiments on laboratory animals for 20-25 hours after synthesis; the yield of purposeful preparations for radioactive isotopes is 90-95%. Kinetic dependences of iodine-131 and bromine-82-TC yield on acidity and temperature of medium are presented. TC radiation resistance in solutions and in solid state at different temperatures in the range of absorbed doses of 1-10 Mrad is investigated. The possibility of TC radiation sterilization is shown

  6. Transarterial Re-188 labeled Lipiodol therapy in cases of inoperable hepatocellular carcinoma

    International Nuclear Information System (INIS)

    Kumar, Ajay; Pant, G.S.; Bandopadhyaya, G.P.; Bal, C.S.; Srivastava, D.N.; Acharya, S.K.; Pandey, G.K.; DattaGupta, S.; Sundaram, K.R.; Zanzonicog, Pat; Sundaram, Felix X.; Padhy, A.K.

    2004-01-01

    -absorbed dose to the various organs (including that to tumor) was calculated according to MIRD scheme using specially developed software by IAEA. From this value, the MTA of Re-188, which could be safely injected to the patient, was calculated and injected through hepatic artery after femoral catheterisation. Mean age, height and weight of the patients were 47.4+8.6 years, 165.8+9.3 cm and 58.4+10.7 Kg, respectively (M:F=9:1). Mean radiation absorbed dose was calculated to be 0.37+0.18, 0.045+0.05, 0.00017+0.00006 and 1.61+0.93 cGy/MBq to the normal liver parenchyma, lungs, bone marrow and tumor, respectively. The mean MTA was calculated to be 9432+3650 MBq, with the normal liver parenchyma being the critical organ in 74% cases. With administered MTA, 115+39 Gy of radiation dose could be delivered to the tumor, which was much more than the desired tumoricidal dose. All patients tolerated therapy very well. We conclude that with individual dosimetry, one can safely administer the maximum possible amount of Re-188 labeled lipiodol to the patients with hepatocellular carcinoma; delivering the tumoricidal radiation dose to the tumor without jeopardizing the other organs. (author)

  7. Iodine-131 releases from the Hanford Site, 1944--1947

    International Nuclear Information System (INIS)

    Heeb, C.M.

    1992-10-01

    Detailed results of the Hanford Environmental Dose Reconstruction (HEDR) iodine-131 release reconstruction are presented in this volume. Included are daily data on B, D, and F Plant, reactor operations from the P-Department Daily Reports (General Electric Company 1947). Tables of B and T Plant material processed from the three principal sources on separations plant operations: The Jaech report (Jaech undated), the 200 Area Report (Acken and Bird 1945; Bird and Donihee 1945), and the Metal History Reports (General Electric Company 1946). A transcription of the Jaech report is also provided because it is computer-generated and is not readily readable in its original format. The iodine-131 release data are from the STRM model. Cut-by-cut release estimates are provided, along with daily, monthly, and yearly summations. These summations are based on the hourly release estimates. The hourly data are contained in a 28 megabyte electronic file. Interested individuals may request a copy

  8. Radiation doses by therapeutical practices with iodine 131

    International Nuclear Information System (INIS)

    Di Trano, J.L.; Rojo, A.M.; Gomez Parada, I.M.; Grassi, E.; Gatica, N.; Kunst, J.J.; Gonzalez, M.

    1998-01-01

    The aim of this document is to estimate the doses to workers and public due to therapeutical practices with iodine 131. Environmental and personal doses by external irradiation were determined using thermoluminescent dosimeters (TLD). The environmental dosimetry resulted in an equivalent dose H * (10) of approximately 0,1 mSv. The calculated personal equivalent dose Hp (10) was of the order of 0,1 mSv. The exposition rate was measured, being the values obtained in the range of 0,20 and 0,35 mSv/h. (1m from the abdominal wall). Concentrations of iodine 131 were determinate in the air of the room, during the first day in the hospital. Values obtained were between 0,04 Bq/l and 0,20 Bq/l. Surface samples were taken in the service, obtaining levels of contamination in the range of 0,001 and 0,4 Bq/cm 2 . The surface samples obtained in the hospital room were about 0,15 Bq/cm 2 . Urine samples were collected resulting in an eliminated activity of iodine 131, during the first 24 hours, of about 60 % of the administered activity. Samples of sweat of different cutaneous regions were obtained, the maximum values of the activity measured reached 200 Bq/cm 2 . According to the obtained results it is important to elaborate guides to be given to patients as an instrument to reduce the external exposure and to avoid internal contamination. (author)

  9. Some methods of detection of atmospheric contamination by iodine 131

    International Nuclear Information System (INIS)

    Billard, Francois; Chevalier, Gerard; Gaillard, Pierre; Pradel, Jacques

    1964-01-01

    Due to the extensive use of iodine, risks of contamination by iodine 131 are increasing. Moreover, the increase of reactor power requires venting installations equipped with efficient safety filters which must be tested. The authors thus report the study of iodine trapping in filters, and its atmospheric detection and measurement. They report studies and achievements in the field of measurement of atmospheric pollution, and tests performed on iodine trapping by activated coals. After having outlined key qualities of an apparatus for atmospheric control, the authors indicate the various sampling methods. They discuss the method and calibration for the measurement of radioactivity of filters and coal which have trapped iodine 131. They discuss measurement sensitivity. They report how the efficiency of coals has been checked. They describe the experimental installation, and report the tests of some detectors of atmospheric contamination: sampling cartridges full of activated coal, gas mask cartridge, continuous control apparatus ('coffee machine' type), and detector of gaseous iodine. Appendices indicate the calculation of error on a cartridge counting rate, iodine generation methods (discontinuous method, continuous method) [fr

  10. Chemical treatment of wastewaters produced during separation of iodine 131

    International Nuclear Information System (INIS)

    Cohen, P.; Marcaillou, J.; Amavis, R.

    1959-01-01

    The authors report the development and assessment of a chemical treatment of radioactive wastewaters by co-precipitation. This treatment is aimed at replacing a treatment based on the use of calcium phosphate which proved to be insufficient for wastewaters resulting from the production of iodine 131. After a presentation of the characteristics of the effluents to be processed, the authors report co-precipitation tests performed on effluents before release in the storage vessel (by using barium hydroxide, lead acetate or lead sulfate) and on effluents diluted on the storage vessel. They show that a co-precipitation method based on the use of lead sulfate in alkaline medium gives the best results

  11. Activity concentrations of iodine-131 and radiocesium in milk

    International Nuclear Information System (INIS)

    Rabitsch, H.; Kahr, G.; Oswald, K.

    1991-12-01

    We have measured the activity concentrations of iodine-131 and radiocesium in pasteurized fresh milk following the Chernobyl accident. Average monthly concentrations of radiocesium are given until December 1991. Samples originated from the local dairy (Milchhof Graz, Austria) and the measured activities in milk represent a large part of the total intake in the population of Graz. Observed activities are also compared with the activity levels obtained after the earlier nuclear contaminations. From the data of our measurements for radiocesium we have estimated the internal effective dose equivalent due to the intake of contaminated milk during the first year after the fallout. Results indicate that the averaged consumer rates for milk, usually used for predictions of dose, were too high. We have also observed great differences in the activity levels of raw milk and the activities in milk consumed by the population. (authors)

  12. Immunotoxic effects of iodine-131 in prenatally exposed rats

    International Nuclear Information System (INIS)

    Cole, D.A.; Stevens, R.H.; Lindholm, P.A.; Cheng, H.F.

    1985-01-01

    Present results suggest that offspring exposed in utero to radioactive iodine-131 develop a measureable cell-mediated immune (CMI) response. Regnant Fischer F344 inbred rats were exposed to 370 kBg to 3.7 MBg (10 to 100 μCi) Na 131I on 16 to 18 days of gestation and evaluated for CMI responsiveness 2 to 3 months post exposure using an 125I radiolabeled membrane release assay. Current data suggest that not only the F1, but also the F2 pups develop a measureable CMI response. In order to determine whether other immune functions are altered studies have been initiated to evaluate the immunotoxic effect of prenatal exposure to 131I. These studies include the evaluation of the delayed hypersensitivity response and the blastogenic responses to phytoheemagglutinin, concanavalin A, and lipopolysaccharide

  13. Treatment of hyperthyroidism with fixed dose form Iodine 131

    International Nuclear Information System (INIS)

    Pacheco Torres, P.; Cerquera, A.M.; Acosta, F.; Sierra, M.

    2007-01-01

    Full text: Objective: Evaluation of the response to therapy with fixed dose of Iodine-131 in patients with hyperthyroidism. One hundred seventeen patients with hyperthyroidism were tested and sent for treatment with Iodine-131. The dose of the therapy was calculated according to the pathology (Diffuser goiter (DG): Multinodular goiter (MNG) and Single toxic nodule (NST). Values of TSH confirmed hyperthyroidism by laboratory methods. The thyroid-blocking agents were discontinued: methimazole for five days and propylthiouracil two days prior to therapy. The pregnancy tests were routinely conducted in females of reproductive age group. Patients reported fasting for therapy. The doses were administered in capsule form after obtaining informed consent from the patients. The patients were normally instructed to eat only after two hours after administration of iodine to promote gastric absorption of the radionuclide. Normally a post therapy thyroid scan is performed four days after treatment. Patients are usually followed up by the endocrinologists. A three- month post therapy evaluation is done by the nuclear medicine physician by telephone. The demographic data of our patients treated are as follows: Total number of patients: 117 Female: 88 (75.21%) Male: 29 (24.79%) Age average: 45 years. Diffuse Goiter= 94 (80.34%), Multinodular Goiter= 17 (14.52%) and Toxic Adenoma (NST) = 6 (5.12%). The average administered dose was 22.5 mCi to DG, 41.8 mCi to MNG and 37.5 mCi to NST. 102 (87.14%) patients at the control at 2 years after treatment presented stable response to therapy, 15 (12.86%) required a second therapy, 11 (11.70%) with BD and 4 (23.52%) with BMN; and any patient with NST required a second therapy. 83 (88.29%) of the patients with BD; 13 (76.48%) with BMN and 6 (100%) with NST the therapy was successful. Conclusion: Fixed dose of I-131 in hyperthyroidism is useful in patients with DG (11.70%). In patients with MNG whom a fixed dose is supplied, 23.52% require a

  14. Radiochemical studies on the separation of iodine-131 and radioiodination of some organic compounds

    International Nuclear Information System (INIS)

    Mohamed, M.A.I.

    2010-01-01

    This thesis is constituted of three chapters:Chapter I: It deals with the theoretical consideration of the subject. The chapter deals with the importance of radioisotopes in medical applications, and the physical and biological properties of these isotopes. Also, this part deals with the chemical and physical properties of both tellurium and iodine and the methods of the production of radioiodine from tellurium targets especially dry distillation method and ion exchange method. It deals with general methods of labeling, chemistry of iodine especially the most frequently used in nuclear medicine, their methods of production and applications. It includes also the techniques used for the preparation of the radioiodinated compounds, especially the electrophilic technique or the oxidative radioiodination technique. In this technique, oxidizing agents are used to oxidize iodide ions to iodonium ions capable of electrophilic attack on the aryl group of the organic compound. This chapter deals also with the receptor tracers, their types and the effects that can occur due to the binding of these receptors to the cell membrane. Since these radiopharmaceuticals are used for diagnosis and therapeutic treatment of human diseases, quality control tests such as chemical purity, radionuclidic purity, radiochemical purity, sterility, apyrogenicity and biodistribution are performed to ensure the purity, the safety and efficiency of these products for the intended nuclear medicine application.Chapter II:It contains detailed information concerning the chemicals, reagents, the radionuclides, the equipment and the counting systems used in the study. It describes production technique of iodine-131 using dry distillation method. It describes also the electrophilic radioiodination for each of Y-indole and epidepride. Analysis of the labeled products was performed using two chromatographic techniques. The first technique is thin layer chromatography in which the compound was identified by

  15. [Thyroid cancer after Chernobyl: is iodine 131 the only culprit ? Impact on clinical practice].

    Science.gov (United States)

    Guiraud-Vitaux, Françoise; Elbast, Mouhamad; Colas-Linhart, Nicole; Hindie, Elif

    2008-02-01

    The large increase in the incidence of thyroid cancer among children who were mainly less than five years old at the time of the Chernobyl accident is still a major preoccupation for endocrinologists and nuclear physicians. Epidemiological studies have focused solely on iodine 131. However, past knowledge on thyroid irradiation (medical use of iodine 131, radioactive fallout on Marshall islands and the Nevada, and Hanford site releases) as well as number of recent works (about low-dose irradiation), raise question on the role of other factors. It is here shown that post-Chernobyl thyroid irradiation is complex and that all factors (iodine 131, but also short lived isotopes of iodine and external irradiation) should be considered. Finally, one need to think about some of the present medical uses of iodine 131, and especially to the treatment of hyperthyroidism in young subjects.

  16. Radiation safety considerations for post-iodine-131 hyperthyroid therapy

    International Nuclear Information System (INIS)

    Culver, C.M.; Dworkin, H.J.

    1991-01-01

    The purpose of this study was to develop guidelines based on patient measurements as to when iodine-131- (131I) treated hyperthyroid patients may resume close personal contact. External exposure rates were measured on 59 patients using an ionization survey meter in the upright position. The initial measurement was recorded within 20 min post-dose administration at one meter. Exposure rates were measured 2-11 days post-dose administration at 1, 0.6, and 0.3 meters from the patient's thyroid. In the administered dose range of 3 to less than 12 mCi of 131I, all 40 patients measured less than or equal to 2.0 mR/hr at one meter on Day 0, and 25 patients (25/29) were less than or equal to 2.0 mR/hr at 0.6 meter on Days 2-4. Guidelines can be prepared based on the administered dose that are rational and in conformity with existing radiologic health standards

  17. Iodine-131: optimal therapy for hyperthyrodism in children and adolescents

    International Nuclear Information System (INIS)

    Freitas, J.E.; Swanson, D.P.; Gross, M.D.; Sisson, J.C.

    1979-01-01

    To assess the medium- to long-term effects of I-131 therapy of hyperthyroidism in children and adolescents, we studied 51 patients (age range 6 to 18; 8 boys, 43 girls) treated with I-131 for Graves' disease with hyperthyroidism at the University of Michigan Medical Center (1951 to 1972). Patients received total doses ranging from 3 to 81.6 mCi. The mean followup period was 14.6 +- 7.9 yr. Hyperthyroidism was effectively treated in 49 within 1 to 12 months. One patient failed to respond to three treatment doses, and hyperthyroidism recurred in two patients: 2 and 11 yr after initial therapy. Of these three patients, two were treated by thyroidectomy and was retreated successfully with I-131. There were no cases of thyroid cancer, other malignancies or leukemia. The patients' reproductive histories and the health of their offspring were as in the general population. At the time of study, the prevalence of hypothyroidism was 92%, with no recurrent goiters or thyroid nodules. Iodine-131 is found to be safe and effective treatment of hyperthyroidism in children and adolescents and should be the preferred mode of therapy

  18. Radiation protection data sheets for the use of iodine 131 in unsealed sources

    International Nuclear Information System (INIS)

    Anon.

    1993-01-01

    This radiation protection data sheet is intended for supervisors and staff in the different medical, hospital, pharmaceutical, university and industrial laboratories and departments where Iodine 131 is handled, and also for all those involved in risk prevention in this field. It provides essential data on radiation protection measures during the use of Iodine 131 in unsealed sources: physical characteristics, risk assessment, administrative procedures, recommendations, regulations and bibliography

  19. Hyperthyroidism treatment by iodine 131: about a study on 270 patients

    International Nuclear Information System (INIS)

    Leroux, M.A.

    2005-01-01

    This study constitutes a starting point for a thought about the use of iodine 131 in the treatment of hyperthyroidism. The therapies are different depending on the teams, for the iodine 131 activities to deliver and their calculation modes; The use of synthesis anti-thyroid drugs before therapy is discussed. The radiation protection is an important factor in the decision of a metabolic radiotherapy. The indications of the treatment by radioactive iodine are different in Europe and in Usa. (N.C.)

  20. Experimental results concerning the metabolism of ingested iodine-131 in adult sheep under lactation

    International Nuclear Information System (INIS)

    Daburon, F.; Capelle, A.; Tricaud, Y.; Nizza, P.

    1967-01-01

    The authors give the results of a series of experiments on metabolism of ingested iodine-131 in adult sheep under lactation; the measurement were carried out over a number of years from 1961 to 1966. The work was concerned initially with the fixation of iodine 131 in the thyroid gland, with the calculation of radiation doses absorbed and with ways of showing up any possible radiation damage in the gland. The modes of absorption of iodine 131 and its elimination through milk, urine and the faeces were then considered. Finally, a last chapter is devoted to changes in the radioactivity of the blood and of the milk, to variations of the PBI level of the blood serum as to different methods for measuring this level. (authors) [fr

  1. Putting to point the production process of iodine-131 by dry distillation (Preoperational tests)

    International Nuclear Information System (INIS)

    Alanis M, J.

    2002-12-01

    With the purpose of putting to point the process of production of 131 I, one of the objectives of carrying out the realization of operational tests of the production process of iodine-131, it was of verifying the operation of each one of the following components: heating systems, vacuum system, mechanical system and peripheral equipment that are part of the production process of iodine-131, another of the objectives, was settling down the optimal parameters that were applied in each process during the obtaining of iodine-131, it is necessary to point out that this objective is very important, since the components of the equipment are new and its behavior during the process is different to the equipment where its were carried out the experimental studies. (Author)

  2. Uptake of Iodine-131 in mussel (Mytilus smaragdinns) and algae (caulerpa racemosa)

    International Nuclear Information System (INIS)

    Sombrito, E.Z.; Banzon, R.B.; de la Mines, A.S.; Bautista, E.Rb.

    1982-01-01

    The behavior of radionuclides in the environment has been the subject of research. Iodine-131, a beta emitter as one of the radionuclides has been studied. This study describes Iodine-131 uptake in mussel and algae. The bioaccumulation factor C was determined which gave the relationship between the concentration of radioactivity in biota relative to the water environment. Results of the experiments showed that the mussels steadily accumulated I-131 from radioactive medium. Much higher bioaccumulation factor was obtained in algae than in mussel. No attempt was made to measure activity in the soft parts. (ELC)

  3. Effect of a 188 Re-SSS lipiodol/131I-lipiodol mixture, 188 Re-SSS lipiodol alone or 131I-lipiodol alone on the survival of rats with hepatocellular carcinoma.

    Science.gov (United States)

    Garin, Elienne; Rakotonirina, Hervé; Lejeune, Florence; Denizot, Benoit; Roux, Jerome; Noiret, Nicolas; Mesbah, Habiba; Herry, Jean-Yues; Bourguet, Patrick; Lejeune, Jean-Jacques

    2006-04-01

    It has been shown that the use of a cocktail of isotopes of different ranges of action leads to an increase in the effectiveness of metabolic radiotherapy. The purpose of the present study was to compare with a control group the effectiveness of three different treatments in rats bearing hepatocellular carcinoma (HCC), using (1) a mixture of lipiodol labelled with both I and Re, (2) lipiodol labelled with I alone and (3) lipiodol labelled with Re alone. Four groups were made up, each containing 14 rats with the N1-S1 tumour cell line. Group 1 received a mixture composed of 22 MBq of Re-SSS lipiodol and 7 MBq I-lipiodol. Group 2 received 14 MBq I-lipiodol. Group 3 received 44 MBq of Re-SSS lipiodol and group 4 acted as the control. The survival of the various groups was compared by a non-parametric test of log-rank, after a follow-up of 60, 180 and 273 days. Compared with the controls, the rats treated with a mixture of Re-SSS lipiodol and I-lipiodol show an increase in survival, but only from day 60 onwards (P=0.05 at day 60 and 0.13 at days 180 and 273). For the rats treated with I-lipiodol, there was a highly significant increase in survival compared with the controls at day 60, day 180 and day 273 (P=0.03, 0.04 and 0.04, respectively). There is no significant increase in survival for the rats treated with Re-SSS lipiodol, irrespective of the follow-up duration (P=0.53 at day 60, 0.48 at day 180, and 0.59 at day 273). In this study, I-lipiodol is the most effective treatment in HCC-bearing rats, because this is the only method that leads to a prolonged improvement of survival. These results cannot necessarily be extrapolated to humans because of the relatively small size and unifocal nature of the lesions in this study. It appears necessary to carry out a study in humans with larger tumours in order to compare these three treatments, particularly with a view to replacing I-labelled lipiodol by Re-labelled lipiodol. However, this study clearly demonstrated that

  4. Comparison of short-term effects between interventional embolization treatment and iodine-131 therapy for graves'hyperthyroidism

    International Nuclear Information System (INIS)

    Zhu Gaohong; Zhao Wei; Yuan Weihong; Wang Bailing; Yi Gengfa; Yang Shumin

    2010-01-01

    Objective: To compare the short-term effects between interventional arterial embolization and iodine-131 therapy in treating Graves' disease. Methods: A total of 84 patients with Graves' disease (GD), confirmed by clinical data and laboratory tests, were divided into two groups: interventional group (n = 42) receiving arterial embolization and iodine-131 group (n = 42)receiving iodine-131 therapy. Before and after the treatment thyroid angiography and SPECT / CT imaging were performed to determine the shape and size of the thyroid, and radioimmunoassay method was used to measure serum levels of FT3, FT4, TSH and TRAb at 3, 6 and 12 months after the therapy. The results were compared and statistically analyzed. The occurrence of complications was observed. Results: No statistically significant difference in short-term therapeutic effects was found between interventional group and iodine-131 group. The occurrence of early severe complication was much higher in interventional group than that in iodine-131 group, while the occurrence of hypothyroidism was obviously higher in iodine-131 group than that in interventional group. Conclusion: Both interventional embolization and iodine-131 therapy have reliable effect for the treatment of Graves' disease. Iodine-131 therapy may be used in patients who plan to receive initial treatment or in patients who failed to effectively respond to other kinds of therapies, while interventional embolization may be employed in patients who are not able to receive surgery or in patients who have failed to respond to anti-thyroid drug treatment, or in patients whose iodine-131 intake rate is too low to undergo iodine-131 therapy, especially in patients with refractory and intractable hyperthyroidism. Interventional embolization can be regarded as an alternative treatment for Graves' disease. (authors)

  5. A review of best practice in relation to iodine-131 ablation discharges to sewer

    International Nuclear Information System (INIS)

    Punt, A.; Kruse, P.; Smith, K

    2010-03-01

    This report was produced by Enviros Consulting Ltd under contract to the RPII. It presents a review of best practice in relation to the management of iodine-131 ablation discharges to sewer and recommends a waste management strategy that could be adopted in the Republic of Ireland

  6. Production of fusion radionuclides: Molybdenum-99/ Iodine - 131 and Xenon-133

    International Nuclear Information System (INIS)

    Barrachina, M.; Carrillo, D.

    1982-01-01

    This report presents a new radiochemical method for industrial production of the radionuclides: molybdenum-99, iodine-131 and xenon-133. The above mentioned method based on the alkaline metathesis reaction of irradiated uranium (IV) fluoride, presents the best characteristics for the proposed objective. The study deals with the analysis of that reaction and the separation and purification processes. (Author) 71 refs

  7. Incidence of thyroid carcinoma in patients who had diagnostic iodine-131 tests during childhood and adolescence

    International Nuclear Information System (INIS)

    Hahn, K.; Schnell-Inderst, P.; Haenseler, G.J.; Kandziora, C.; Meyer, G.

    1999-01-01

    To determine the carcinogenic effects of diagnostic amounts of radioactive iodine-131 on the infantile thyroid gland a multi-center retrospective cohort study was conducted which included data of 4973 subjects who had either been referred to diagnostic iodine-131 uptake tests (2262 subjects) or had had a diagnostic procedure of the thyroid without 131-iodine (2711 subjects) until the age of 18 years. Follow-up examinations of 35 percent of the subjects in the iodine-131 group and 41 percent of the subjects in the control group took place after a mean time period of 20 years after the first examination. Dosimetry of the thyroid burden of iodine-131 was carried out according to ICRP 53. The median of the thyroid organ dose was 1012 mGy. The report compares prevalences or incidences of thyroid disorders resp. occurring in both groups and gives a stratified analysis of primary diagnosis, age at exposure, and organ dose. A total number of five carcinomas of the thyroid was found. In the radioiodine group two carcinomas were assessed in a period of 16500 person-years. The control group yielded three carcinomas over 21000 person-years (Relative rate: 0,89, 95% confidence interval: 0,14-5,13). (orig.) [de

  8. Manual on therapeutic uses of iodine-131. Incorporating: Applications guide, procedures guide, basics guide

    International Nuclear Information System (INIS)

    1992-01-01

    This booklet contains information about procedures to protect hospital staff and visitors and families of patients treated with iodine 131 from exposure to radiation from I-131. It also includes a basic guide to the principles of the production of ionizing radiation and to methods of radiation protection and dosimetry

  9. Chromosomal damage after Iodine-131 treatment for differentiated thyroid cancer: in vivo dose-effect relationship

    International Nuclear Information System (INIS)

    Nguyen, V.K.; Nguyen, X.P.; Truong, Q.X.

    2007-01-01

    Full text: Although it is well known that radiation induces chromosomal aberrations, there is a lack of information on the in- vivo dose-effect relationship in patients receiving Iodine-131 treatment and the results of previous studies are controversial. In this study, the dicentric chromosomal aberrations (DCA) analysis method was employed to investigate acute and late chromosomal damage (CD) in the peripheral lymphocytes of 58 differentiated thyroid cancer patients who received dose 1,1 GBq of Iodine-131 (group A), and 34 patients who received dose 3,7 GBq of Iodine- 131 (group B). The mean 100 metaphase spreads were scored for each subject. The DCA frequencies in cultured peripheral lymphocytes were determined before treatment to assess basal DCA frequencies, on the 3rd day to assess acute DCA frequencies and 6 months later to assess late DCA frequencies. The basal, acute and late DCA frequencies were divided into two groups: 0,18%, 2,14% and 0,53% (group A) and 0,18%, 2,12 % and 0,89% (group B), respectively, and these values differed significantly at various time after treatment (p 2 = 0,987), and group B as Y= 32,71 + 0,189 X. (r = 0,9381, R 2 = 0,880). However, there was an interesting difference in comparison with in- vitro studies, in that we found the coefficient β to have a negative value, suggesting the disappearance of damaged lymphocytes from peripheral circulation in a dose- dependent manner following Iodine-131 treatment. Further studies are therefore needed to clarify the effect of the negative β value on biological dosimetry approach in continuous internal low LET radiation, as in the case of Iodine-131 treatment. (author)

  10. Evaluation of radiation exposure from patients with thyroid disease by iodine-131 therapy

    International Nuclear Information System (INIS)

    Li Xianfeng; Lu Keyi; Duan Lian

    2004-01-01

    Purpose: To evaluate the radiation exposure to the individuals other than patients with thyroid disease, who had received radioiodine (iodine-131) therapy and had turned into a specific 'radiant point'. Methods: 107 outpatients or inpatients, with iodine-131 therapy had been investigated and followed up by telephone and outpatients. There were 117 times treatment (68 females, 49 males, mean age 41 years old), including the patients with hyperthyroidism (39 females, 40 males), thyroid cancer (27 females, 8 males), toxic thyroid adenoma (1 female and 1 male) and nontoxic nodular goiter(1 female). According to the personal condition of the patients, we attained the percentage of thyroid iodine-131 uptake (U), the iodine-131 dose (Q), the duration of constrained social activity, and the occupancy factor (OF) for the 3 periods (the preequilibrium, OFp; the constrained, OFc; and the unconstrained, OFuc), and the time of exposure to individuals other than patients, and to calculate the exposure dose (mSv) to the individuals. The formula is E (mSv) = Q[OFP(0.0173)+ OFC(0.537)U(1-e-0.095C)+0.023(1-U)(1-e-2.08C ) +OFUC (0.537) Ue-0.095C +0.0236(1-U)e-2.08C]. In accordance with the new recommendations of the national criteria from GB18871-2002, we evaluated the radiation safety to the individuals other than patients Results: Based on the national criteria the total effective dose equivalent to the individuals other than patients may not exceed 5 mSv. For all patients, including 79 hyperthyroidism, 2 toxic thyroid adenoma and 16 times treatment of thyroid cancer, the exposure doses to the individuals were not likely to exceed 5 mSv, but the others, including 19 times treatment of thyroid cancer and 1 nontoxic nodular goiter, the exposure doses were higher than 5 mSv. There were no difference between the part of hyperthyroidism and thyroid cancer of inpatients were compared with outpatients (P>0.05, respectively). we found that occupancy factor during the preequilibrium period

  11. Scintigraphic disagreement in the study of thyroid nodules using technetium 99m and iodine 131

    International Nuclear Information System (INIS)

    Planchon, C.A.

    1977-01-01

    116 patients with thyroid nodules, iso or hyperfixing, heterogeneous or scintigraphically indistinct after administration of pertechnetate 99mTc, were systematically re-examined with iodine 131. The results of this study are as follows: 1) 99mTc, while its advantages justify its extensive application, is an imperfect tracer and cannot replace iodine 131 altogether. In fact in 12% of the cases the results were conflicting. 2) The technological conditions may sometimes be to blame but the hypothesis of a special metabolic behavior of the nodule examined seems plausible in certain cases of disagreement (blocking of hormone synthesis and escape of non-hormonal iodine). 3) These observations correspond to no particular anatomo-clinical factors. The legitimate conclusion therefore is that the exclusive use of 99mTc could result in failure to recognise a non-functional nodule (1 case in about 10), a possibility not to be neglected because of the risk of cancer [fr

  12. Treatment by iodine 131 and thyroid pathologies 14 Nfs iatrogenic 'Around France of that particular medical treatment'

    International Nuclear Information System (INIS)

    Baldet, L.

    2000-01-01

    In the case of hyperthyroidism bound to amiodarone, the iodine 131 prescription appears able to cure this disease in 84% of cases; the use of iodine 131 before amiodarone to prevent a hyperthyroidism, in case of goiter or thyroid nodules is little used (17% of practitioners) when it is more used in case of past history of induced hyperthyroidism (34% of physicians). This prescription is nevertheless efficient in the both cases. The use of iodine 131 is little used in the case of hyperthyroidism appeared during the use of cytokines (22% of physicians). The induction of hypothyroidism by iodine 131 in the case of severe cardiopathies is becoming little frequent (9% of physicians). (N.C.)

  13. Manual on therapeutic uses of iodine-131. Incorporating: Applications guide, procedures guide, basics guide

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    1996-03-01

    This publication is part of practical radiation safety manual series for different fields of application aimed primarily at persons handling radiation sources on a daily routine basis, which could at same time be used by the competent authorities, supporting their efforts in the radiation protection training of workers or medical assistance personnel or helping on-site management to set up local radiation protection rules. It is dedicated to therapeutic uses of Iodine-131: its application and procedures guides.

  14. Implementation of the protocol on treatment of outpatients and hospitalized patients with iodine 131r

    International Nuclear Information System (INIS)

    Mildred De Mendoza, L.

    1996-01-01

    In Nuclear medicine different working protocols are used which are adequate for the treatment of patients with radioactive materials and which at the same time prevent the contamination of the occupationally exposed workers In Guatemala (the implementation of these protocols aims at keeping a records all the personal and centers that make use of iodine 131, improving the quality of diagnostic information; utilizing the necessary amount of radionuclide activity so as to ensure a good diagnosis and effectively utilizing economic resources

  15. Manual on therapeutic uses of iodine-131. Incorporating: Applications guide, procedures guide, basics guide

    International Nuclear Information System (INIS)

    1996-01-01

    This publication is part of practical radiation safety manual series for different fields of application aimed primarily at persons handling radiation sources on a daily routine basis, which could at same time be used by the competent authorities, supporting their efforts in the radiation protection training of workers or medical assistance personnel or helping on-site management to set up local radiation protection rules. It is dedicated to therapeutic uses of Iodine-131: its application and procedures guides

  16. Internal contamination of nurses as a result of the therapeutic use of iodine-131

    Energy Technology Data Exchange (ETDEWEB)

    Termorshuizen, W; Gerritsen, A J.M.

    1988-02-01

    The internal contamination of nurses with sodium iodide-131 is studied in two different housing situations. Before moving, the therapy unit was an unventilated double room with a lock. In the new building, the unit consists of three single rooms and one double room with a lock and air conditioning. Also the concentration of iodine-131 in the air is measured. 2 figs.; 1 table.

  17. Iodine-125 and Iodine-131 in the Thames Valley and other areas

    International Nuclear Information System (INIS)

    Howe, J.R.; Lloyd, M.K.; Bowlt, C.

    1985-01-01

    Part of the Iodine-125 and Iodine-131 waste from hospitals and research centres is discarded down drains and passes through sewage and water reclamation works into the river system. Relatively high concentration of radioiodine occur in outfalls that discharge into the river Thames, lower levels are found in the mainstream river and less still in the reservoirs and tap water supplies abstracted from the river. The pathway from waste to drinking water could account for the low levels of Iodine-125 found in the thyroid glands of some farm animals and human beings in the Thames valley

  18. Evaluation of radiation safety from patients with thyroid disease undergoing iodine-131 therapy

    International Nuclear Information System (INIS)

    Lu, K.-Y.; Li, X.F.; Liu, J.-Z.; Li, S.-J.; Hu, G.

    2007-01-01

    Full text: Objective: By calculating the dose equivalent of patients with thyroid disease who had received iodine-131 therapy, based on the China national criteria, we evaluate the radiation safety of the individuals other than the patients who had turned into a specific 'radiant source'. Methods: 152 outpatients and inpatients, with iodine-131 therapy had been investigated and followed-up. There were 162 treatments which included patients with hyperthyroidism (HT)-124, 35 thyroid cancers (TC), 2 toxic thyroid adenomas and 1 nontoxic nodular goiter. In addition, we had achieved the practical measures and contact instance with household members and the general public, including 37 HT (contact with 37 adults and 8 infants) and 3 TC. According to the personal condition of the patients and the time of exposure to individuals other than patients, and to calculate the exposure dose (mSv) to the individuals with formulae. Results: Based on the national criteria the total dose equivalent to the individuals other than patients may not exceed 5 mSv. For most patients, including 124 HT, 2 toxic thyroid adenomas and 16 times treatment of TC, the exposure doses to the individuals were not likely to exceed 5 mSv, but the others, including 19 treatments of TC and 1 nontoxic nodular goiter, the exposure doses were higher than 5 mSv. There was no difference between the part of HT and TC of inpatients when compared with outpatients (P>0.05, respectively). We found that occupancy factor during the preequilibrium period play an important role on the exposure doses to the individuals, especially TC patients. With the dose equivalent to the same HT patient, practical measures for accumulating doses is higher and more practical than the simplistic formula calculating ones (P 0.05). Conclusions: Most of the outpatients with iodine- 131 therapy were safe to the individuals surrounding them within 1 meter, but the part of TC patients needed to be treated in the hospital and took a dose

  19. Test of irradiation of tellurium oxide for obtaining iodine-131 by dry distillation

    International Nuclear Information System (INIS)

    Alanis M, J.

    2003-07-01

    With the purpose of optimizing to the maximum independently the work of the reactor of those mathematical calculations of irradiation that are already optimized, now it corresponds to carry out irradiation tests in the different positions with their respective neutron fluxes that it counts the reactor for samples irradiation. Then, it is necessary to carry out the irradiation of the tellurium dioxide through cycles, with the purpose of observing the activity that it goes accumulating in each cycle and this way to obtain an activity of the Iodine-131 obtained when finishing the last cycle. (Author)

  20. Considerations of food hygiene in the case of mussels accidentally contaminated by iodine 131

    International Nuclear Information System (INIS)

    Battani, N.; Chambost, Marie-Daniel; Leandri, Marcel

    1969-09-01

    As the transfer to mankind of radioactive pollution by food chains is a matter of concern, the authors report the study of the use of mussels contaminated by iodine 131 in a food preparation in order to follow the evolution of this radionuclide. After their contamination in seawater, mussels are prepared either with or without their shell. Counting is performed after cooking. Results are discussed in terms of presence of the radionuclide in the different parts of the crude or cooked mussels (shell, body, liquid) [fr

  1. Iodine-131 distribution on the territory of the Republic of Belarus during the first period of the Chernobyl NPP catastrophe

    International Nuclear Information System (INIS)

    Germenchuk, M.G.; Zhukova, O.M.; Shagalova, E.D.; Matveenko, I.I.

    1998-01-01

    To reconstruct space distribution of iodine-131 on the territory of Belarus we used the following data: (i) contents of iodine-131 in soil measured by gamma spectrometry method in May-July, 1986; (ii) contents of iodine-131 in samples of radioactive atmospheric fall-outs measured by gamma spectrometry method in May, 1986; (iii) daily measurements of exposure dose power levels on the territory of Belarus obtained in April-July, 1986; (iv) results of aerial gamma radiation mapping, obtained in May, 1986; (v) daily measurements of radioactive contamination of milk on the territory of Belarus obtained in May-July, 1986; (vi) measurements of iodine-131 content in links of biological chain 'soil-grass-milk' sampled from 15 reference farms; (vii) maps of specific activity of natural hayfields grass on the territory of Belarus (for every district) obtained on June 2 and 5, on July 3, 1986. Dose commitments on thyroid gland caused by iodine isotopes were formed mainly during the first 2.5 months after the accident. Local irradiation of this organ was stipulated by high accumulation factor of iodine isotopes in thyroid gland that caused increasing of malignant thyroid tumors incidences, including children, on all over the territory of Belarus. Comparison of iodine-131 distribution map and malignant thyroid gland tumor incidences among children on the territory of Belarus map shows that the more level of iodine contamination the more malignant thyroid gland tumor incidence

  2. Scoping calculation for components of the cow-milk dose pathway for evaluating the dose contribution from iodine-131

    International Nuclear Information System (INIS)

    Ikenberry, T.A.; Napier, B.A.

    1992-12-01

    A series of scoping calculations have been undertaken to evaluate The absolute and relative contribution of different exposure pathways to doses that may have been received by individuals living in the vicinity of the Hanford site. This scoping calculation (Calculation 001) examined the contributions of the various exposure pathways associated with environmental transport and accumulation of iodine-131 in the pasture-cow-milk pathway. Addressed in this calculation were the contributions to thyroid dose of infants and adult from (1) the ingestion by dairy cattle of various feedstuffs (pasturage, silage, alfalfa hay, and grass hay) in four different feeding regimes; (2) ingestion of soil by dairy cattle; (3) ingestion of stared feed on which airborne iodine-131 had been deposited; and (4) inhalation of airborne iodine-131 by dairy cows

  3. Conversion and correction factors for historical measurements of iodine-131 in Hanford-area vegetation 1948--1951

    International Nuclear Information System (INIS)

    Denham, D.H.; Mart, E.I.; Thiede, M.E.

    1993-09-01

    This report is a part of the Hanford Environmental Dose Reconstruction (HEDR) Project, whose goal is to estimate the radiation dose that individuals could have received from emissions since 1944 at the US Department of Energy's (DOE) Hanford Site near Richland, Washington. The key radionuclide emitted that would affect the radiation dose was iodine-131 (Napier 1992). Because the early methods of measuring iodine-131 were not comparable to later techniques, conversion and correction factors are needed to convert the historical measurement data into concentration values that would be determined using today's knowledge and technologies. This report describes the conversion and correction factors developed for reconstructing historical measurements of iodine-131 in Hanford-area vegetation, which was collected from 1948 through the end of December 1951

  4. Iodine-131 induced hepatotoxicity in previously healthy patients with Grave's disease.

    Science.gov (United States)

    Jhummon, Navina Priya; Tohooloo, Bhavna; Qu, Shen

    2013-01-01

    To describe the association of the rare and serious complication of liver toxicity in previously healthy Grave's disease (GD) patients after the treatment with radioactive iodine (131)I (RAI). We report the clinical, laboratory and pathologic findings of 2 cases of severe liver toxicity associated with the treatment with RAI in previously healthy patients with GD. Clinical examination and laboratory investigations excluded viral hepatitis, autoimmune hepatitis, granulomatous disease, primary biliary disease, extrahepatic biliary obstruction, and heart failure. Case 1: A previously healthy 52-years old man reportedly having a typical GD but following RAI treatment, concomitantly developed severe liver toxicity that required 1 week of treatment in hospital. Case 2: A previously healthy 34-years old woman is reported as having a typical GD but developed jaundice following RAI treatment that required several weeks of in hospital treatment in the hepato-biliary department. In both cases, the liver dysfunction resolved after intensive treatment with hepato-protective agents. In this report the therapeutic considerations as well as the pathogenetic possibilities are reviewed. To the best of our knowledge, this is the first description of the association observed, which is rare but may be severe and should be considered in any case of thyrotoxicosis where a liver dysfunction develops after the treatment with radioactive iodine (131)I.

  5. Iodine-131 induced hepatotoxicity in previously healthy patients with Grave’s disease

    Science.gov (United States)

    2013-01-01

    Objective To describe the association of the rare and serious complication of liver toxicity in previously healthy Grave’s disease (GD) patients after the treatment with radioactive iodine 131I (RAI). Case presentation We report the clinical, laboratory and pathologic findings of 2 cases of severe liver toxicity associated with the treatment with RAI in previously healthy patients with GD. Clinical examination and laboratory investigations excluded viral hepatitis, autoimmune hepatitis, granulomatous disease, primary biliary disease, extrahepatic biliary obstruction, and heart failure. Case 1: A previously healthy 52-years old man reportedly having a typical GD but following RAI treatment, concomitantly developed severe liver toxicity that required 1 week of treatment in hospital. Case 2: A previously healthy 34-years old woman is reported as having a typical GD but developed jaundice following RAI treatment that required several weeks of in hospital treatment in the hepato-biliary department. In both cases, the liver dysfunction resolved after intensive treatment with hepato-protective agents. In this report the therapeutic considerations as well as the pathogenetic possibilities are reviewed. Conclusion To the best of our knowledge, this is the first description of the association observed, which is rare but may be severe and should be considered in any case of thyrotoxicosis where a liver dysfunction develops after the treatment with radioactive iodine 131I. PMID:23497434

  6. Conversion and correction factors for historical measurements of iodine-131 in Hanford-area vegetation, 1945--1947

    International Nuclear Information System (INIS)

    Mart, E.I.; Denham, D.H.; Thiede, M.E.

    1993-12-01

    This report is a result of the Hanford Environmental Dose Reconstruction (HEDR) Project whose goal is to estimate the radiation dose that individuals could have received from emissions since 1944 at the U.S. Department of Energy's (DOE) Hanford Site near Richland, Washington. The HEDR Project is conducted by Battelle, Pacific Northwest Laboratories (BNW). One of the radionuclides emitted that would affect the radiation dose was iodine-131. This report describes in detail the reconstructed conversion and correction factors for historical measurements of iodine-131 in Hanford-area vegetation which was collected from the beginning of October 1945 through the end of December 1947

  7. Management of patient with hepatocellular carcinomas by in situ injection of iodine-131 labelled lipiodol solution (Lipiocis) in the Biophysics and Timone APHM University Hospital Central Service; Prise en charge des patients atteints d'hepatocarcinome par injection in situ d'une solution de lipiodol radiomarque a l'iode 131 (Lipiocis) au sein du service central de biophysique et de medecine nucleaire du CHU Timone APHM

    Energy Technology Data Exchange (ETDEWEB)

    Sigrist, S

    2008-07-01

    The aim of this work was to determine what are the prognosis factors in term of global expectation of life at patient receiving a treatment by Lipiocis, to estimate the tolerance at this treatment in order to choose patient which will be the best candidates to this treatment and to define more precisely the criteria of patient inclusion and follow-up. A study including 35 patient having received one or several Lipiocis injections between May 2003 and May 2007 has been carried out. The results of this study are given. Lipiocis seems to be a well tolerated treatment which has proved its efficiency. (O.M.)

  8. Quality of life assessment in radionuclide therapy: a feasibility study of the EORTC QLQ-C30 questionnaire in palliative 131I-lipiodol therapy

    International Nuclear Information System (INIS)

    Brans, B.; Lambert, B.; De Beule, E.; De Winter, F.; Dierckx, R.A.; Van Belle, S.; Van Vlierberghe, H.; De Hemptinne, B.

    2002-01-01

    The good tolerance of radionuclide therapy has frequently been proposed as a major advantage. This study explored the feasibility of using the EORTC QLQ-C30 questionnaire in palliative iodine-131 lipiodol therapy for hepatocellular carcinoma. Questionnaires were completed during interviews in which all symptoms, co-morbidity and medication were assessed at baseline within 1 week before 131 I-lipiodol therapy, and subsequently after 1 and 3 months, in 20 patients treated with locoregional, intra-arterial 131 I-lipiodol therapy with or without cisplatin. Principal observations were that (1) a number of important scales, i.e. overall quality of life, physical functioning and pain, worsened between 0 and 3 months after 131 I-lipiodol therapy, irrespective of tumour response, and (2) the occurrence of clinical side-effects was associated with a negative impact on quality of life and physical functioning 1 and 3 months after 131 I-lipiodol. The QLQ-C30 can be regarded as a feasible method for quality of life assessment in 131 I-lipiodol therapy for hepatocellular carcinoma and possibly in other radionuclide therapies. These observations should be related to the impact of other treatment modalities on quality of life. (orig.)

  9. Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: Clinical Phase I/II trials

    International Nuclear Information System (INIS)

    Chen Zhinan; Mi Li; Xu Jing

    2006-01-01

    Purpose: HAb18G/CD147 is a hepatocellular carcinoma (HCC)-associated antigen. We developed iodine ( 131 I) metuximab injection (Licartin), a novel 131 I-labeled HAb18G/CD147-specific monoclonal antibody F(ab') 2 fragment, and evaluated its safety, pharmacokinetics, and clinical efficacy on HCC in Phase I/II trials. Methods and Materials: In a Phase I trial, 28 patients were randomly assigned to receive the injection in 9.25-, 18.5-, 27.75-, or 37-MBq/kg doses by hepatic artery infusion. In a multicenter Phase II trial, 106 patients received the injection (27.75 MBq/kg) on Day 1 of a 28-day cycle. Response rate and survival rate were the endpoints. Results: No life-threatening toxic effects were found. The safe dosage was 27.75 MBq/kg. The blood clearance fitted a biphasic model, and its half-life was 90.56-63.93 h. In the Phase II trial, the injection was found to be targeted and concentrated to tumor tissues. Of the 73 patients completing two cycles, 6 (8.22%) had a partial response, 14 (19.18%) minor response, and 43 (58.90%) stable disease. The 21-month survival rate was 44.54%. The survival rate of progression-free patients was significantly higher than that of patients with progressive disease after either one or two cycles (p 131 I) metuximab injection is safe and active for HCC patients

  10. Guide-line of the radio-iodine (131I) therapy in Graves' disease and thyroid cancer

    International Nuclear Information System (INIS)

    Mori, Yutaka; Ikekubo, Katsuji

    2005-01-01

    Radio-iodine ( 131 I) therapy has been using in Graves' disease and well differentiated thyroid cancer. The rules of control in the discharge from radio-isotope hospital were notified in 1999 in Japan. Guideline of the 131 I therapy in Graves' disease and thyroid cancer were prepared by sub-group of Japanese Society of Nuclear Medicine. (author)

  11. Long-term follow-up study of the therapeutic effect after iodine-131 therapy for hyperthyroidism

    International Nuclear Information System (INIS)

    Liu Changjiang; Li Long; Gao Jianqing; Xu Sumei; Chen Linna; Zhou Jianming

    2006-01-01

    To investigate the therapeutic effect through long-term visit and analyze the affecting factors of cure rate after iodine-131 therapy for hyperthyroidism, a long-term follow-up has been undertaken for the patients with hyperthyroidism after iodine-131 treatment. The following results have been obtained. (1) The cure rate of iodine-131 therapy for hyperthyroidism is 74.4%, and the incidence of permanent hypothyroidism is 7.5%. (2) There is no significant difference in the cure rate and incidence of hypothyroidism between the groups of male and female or 'not take ATD' and 'ATD withdrawn longer than 2 weeks' (P>0.05). (3) The difference of the cure rate among the groups of the courses of disease 3 a are significant (P 55 g are significant (P 0.05). The course of disease, age and thyroid mass are the major factors which influence the cure rate. Meanwhile, age and thyroid mass are the major factors which influence the incidence of hypothyroidism. To get high cure rate, the patients with hyperthyroidism should be treated with iodine-131 as early as possible. In the meantime, the incidence of permanent hypothyroidism must be paid attention to. (authors)

  12. Retrospective reconstruction of Iodine-131 distribution through the analysis of Iodine-129

    Science.gov (United States)

    Matsuzaki, Hiroyuki; Muramatsu, Yasuyuki; Ohno, Takeshi; Mao, Wei

    2017-09-01

    Iodine-131 distribution released from the Fukushima Dai-ichi Nuclear Power Plant accident was reconstructed through the iodine-129 measurements. From nearly 1,000 surface soil samples iodine was extracted by the pyro hydrolysis method. Extracted iodine was then mixed with carrier, purified and finally collected as silver iodide. Silver iodide sample was pressed into the cathode holder and set at the ion source of the MALT facility, The University of Tokyo. The isotopic ratio 129I/127I was measured by means of Accelerator Mass Spectrometry. From 129I data obtained, 131I deposition map was constructed. There observed various fine structures in the map which could not estimated neither by the simulation nor 137Cs distribution.

  13. [Iodine 131 joint radio frequency ablation treatment for child with hyperthyroidism goiter: one case report].

    Science.gov (United States)

    Chen, Yonghua; Liang, Li; Fang, Yanlan; Wang, Chunlin; Li, Linfa; Jiang, Tian'an

    2017-01-25

    A 12-year-old girl presented with a history of cervical mass, and one week of throat discomfort and dyspnea. Five years ago, the patient was diagnosed as Hashimoto's thyroiditis and hyperthyroidism; she received antithyroid drug treatment, but the result was not satisfactory. B-ultrasonic showed that the size of thyroid gland was 8.1 cm×3.2 cm in the left and 8.2 cm×4.8 cm in the right. After iodine 131 combined with radiofrequency ablation (RFA) treatment, throat discomfort and recumbent breathing difficulties disappeared, and B-ultrasonic showed that the size of thyroid reduced to 2.3 cm×1.7 cm (left) and 2.8 cm×2.0 cm (right). No recurrence was observed during the two and a half years of follow-up.

  14. Gold-198 and rose bengal marked with iodine-131 in the diagnostic of hepatic vesicular affections

    International Nuclear Information System (INIS)

    Manambelona Razafimalaza, J.

    1961-06-01

    Colloidal gold-198 makes it possible to obtain clear images of hepatic parenchyma; the examination can be repeated from different angles thus demonstrating the presence of pathologically inert regions, whether they be hydatic cysts, abscesses or neoplasia. The study of the disappearance curve for the colloid, together with a measurement of the blood volume, makes it possible also to calculate the hepatic flow. Using Rose Bengal marked with iodine-131, it is possible to obtain images of the liver and of the bile ducts, and to follow the elimination of the dye in the intestines. The simultaneous recording of the disappearance curves for the blood and of the appearance of the dye in the intestines constitutes an useful working test which is particularly sensible for evaluating the permeability of the bile ducts and, to a certain degree, the site of an obstruction. (author) [fr

  15. Iodine-131 MIBG scintigraphy of the extremities in metastatic pheochromocytoma and neuroblastoma

    International Nuclear Information System (INIS)

    Shulkin, B.L.; Shen, S.W.; Sisson, J.C.; Shapiro, B.

    1987-01-01

    Iodine-131 MIBG scintigraphy may be used to determine the presence or absence of metastases to the appendicular skeleton in malignant pheochromocytoma and neuroblastoma. Normal bones show no uptake of [ 131 I]MIBG and the joints are seen as photon-deficient areas surrounded by background muscle activity. Discrete concentrations of radioactivity in bone are often seen in patients with malignant pheochromocytoma and neuroblastoma. Bone marrow involvement in neuroblastoma may be indicated by diffuse uptake of [ 131 I]MIBG or focal accumulation at the metaphyses. Uncommonly, bone involvement may not be displayed by the [ 131 I]MIBG images. Since conventional bone scanning agents may also fail to detect these tumors, skeletal scintigraphy with both [ 131 I]MIBG and [/sup 99m/Tc]MDP is necessary to reliably stage malignant pheochromocytoma and neuroblastoma

  16. Identifying best practice in relation to Iodine-131 ablation discharges to sewers in Ireland

    International Nuclear Information System (INIS)

    Ryan, Thomas P.; Fennell, Stepehn; McGarry, Ann; Punt, Adrian

    2008-01-01

    Full text: In line with a commitment in Ireland's strategy on the implementation of the Oslo-Paris Convention (OSPAR) as well as recent developments in the provision of national oncology services, best practice in relation to Iodine-131 (I-131) ablation discharges to sewers in Ireland is under review. Preparatory to this review the Radiological Protection Institute of Ireland (RPII) commissioned a study of current practices in Ireland and associated doses as well as a review of international best practice and advice. Currently, there are three hospitals in Ireland at which thyroid ablation therapy procedures (large therapeutic administrations of I-131 for thyroid cancer treatment) are carried out. Only one facility has a limited capacity for delay and decay storage prior to discharge. Based on current administrations and discharges, the potentially most exposed workers comprises hospital plumbers dealing with specific incidents with estimated doses in the order of 50 to 70 μSv per incident. Doses to sewage workers and fishing communities are estimated at less than 4 μSv y -1 and 0.4 μSv y -1 respectively. Based on anticipated future service requirements in Ireland, a marginal increase in doses to some of these groups is estimated. Iodine-131 discharges to the environment and associated doses to workers and members of the public may be significantly reduced by the introduction of state-of-the-art delay and decay tanks using multi-tank vacuum systems. The justification for the introduction of a regulatory requirement to install such systems is examined taking account of: discharges to the environment, concentrations in the environment, doses to workers and members of the public, best available techniques (BAT), international best practice and advice as well as the financial implications for medical facilities. The case for retrofitting delay and decay tanks to existing medical facilities is also examined as well as the option of including such tanks in the

  17. The influence of physical parameters on the adsorption of iodine 131 by activated charcoals

    International Nuclear Information System (INIS)

    Billard, F.; Chevalier, G.; Caron, J.; Van Der Meersch, J.

    1966-01-01

    Following an outline of the means of generating iodine 131 in the gas phase and a brief description of the apparatus used, the authors analyse the experimental results obtained on the trapping of iodine 131 by activated charcoal. The efficiency depends concurrently on the relative humidity and the iodine concentration of the air. While it is independent of this concentration in dry air, it does not exceed 50 in moist air, whatever the bed depth, when the concentration is less than 1 mCi/m 3 , then it increases with the concentrations to reach values close to those obtained in dry air for concentrations of around 1000 Ci/m 3 . At the same time the efficiency of a dust filter with respect to iodine remains very low in dry air whatever the iodine concentration; in moist air this efficiency, which is high at low concentrations, decreases when the latter increases. In addition if a charcoal bed is divided into several beds, separated by an amount corresponding to a passage time of about a second, it is found that the efficiency of the whole is appreciably higher than that of the initial bed. These results appear to establish the existence of at least two forms of iodine, one molecular form and one particulate form probably formed by clusters, the forms equilibrium being functions of the relative concentrations of iodine and water vapour in the air. The third form evidence, a gaseous form compound, remains hypothetical; the experimental curves can be explained either by the molecular and particular forms reversibility or by the increase of clusters size with the relative humidity of the air. (authors) [fr

  18. Diagnosis of Intracranial Lesions by Gamma-Encephalography using Human Serum Albumin Labelled with Iodine-131; Diagnostic des lesions intracraniennes par la gamma-encephalographie a l'aide de la serumalbumine humaine marquee a l'iode 131; Diagnoz vnutricherepnykh povrezhdenij putem gamma-ehntsefalografii pri pomoshchi mechenoj iodom-131 albuminovoj syvorotki cheloveka; Diagnostico de las lesiones intracraneanas por gammaencefalografia mediante sero- albumina humana marcada con yodo-131

    Energy Technology Data Exchange (ETDEWEB)

    Planiol, Therese [Institut National d' Hygiene, Paris (France)

    1959-07-01

    Six hundred patients were examined by means of serum albumin labelled with iodine-131. Radioactivity was read twice with an scintillation counter in contact with the skull, two hours and twenty-four hours after the radioactive injection. Of 175 intracranial tumours, 150 were accompanied by a focus of persistent gamma hyperactivity. Of those not detected by the examination, half were tumours of the hemispheres and half of the posterior fossa and pineal body. Abscesses, haematomata and cirsoid aneurisms were detected. In one-third of the cases acute cerebro-vascular lesions produced abnormal readings, half of which had the peculiar appearance pathognomonic of softening (or thrombosis); the others resembled tumour graphs, the only difference being that the abnormal readings associated with acute vascular lesions disappeared in a few weeks. Two-thirds of these acute lesions were associated with a negative gamma-encephalogram. Arterial aneurisms, non-tumourous epileptogenic foci, and various purely neurological conditions gave normal results in 96 per cent of cases. Brain investigation by radioalbumin can provide valuable information not only on the presence and exact location of a neurosurgical injury but also on its nature. In particular, it seems very likely to detect a meningioma, glioblastoma or metastatic growth. These properties, together with information on positive diagnosis and location, make it a specially useful neurodiagnostic method. Gamma-encephalography also seems likely to be one of the most reliable ways of detecting relapses and of following-up the effects of medical treatment or radiotherapy. (author) [French] 600 malades ont ete examines a l'aide de la serumalbumine marquee a l'iode 131, les mesures de radioactivite etant faites par un compteur a scintillations place au contact du crane, en deux seances, deux heures et vingt-quatre heures apres l'injection radioactive. Sur 175 tumeurs intracraniennes, 150 se sont accompagnees d'un foyer d

  19. Iodine-131 in sewage sludge from a small water pollution control plant serving a thyroid cancer treatment facility.

    Science.gov (United States)

    Rose, Paula S; Swanson, R Lawrence

    2013-08-01

    Iodine-131 (half-life = 8.04 d) is the most widely used radionuclide in medicine for therapeutic purposes. It is excreted by patients and is discharged directly to sewer systems. Despite considerable dilution in waste water and the relatively short half-life of I, it is readily measured in sewage. This work presents I concentrations in sewage sludge from three water pollution control plants (WPCPs) on Long Island, NY. Iodine-131 concentrations ranged from 0.027 ± 0.002 to 148 ± 4 Bq g dry weight. The highest concentrations were measured in the Stony Brook WPCP, a relatively small plant (average flow = 6.8 × 10 L d) serving a regional thyroid cancer treatment facility in Stony Brook, NY. Preliminary radiation dose calculations suggested further evaluation of dose to treatment plant workers in the Stony Brook WPCP based on the recommendations of the Interagency Steering Committee on Radiation Standards.

  20. The evaluation of functioning thyroid nodules using sodium pertechnetate TC-99m scan in comparison with iodine-131

    Directory of Open Access Journals (Sweden)

    Saghari M

    1993-04-01

    Full Text Available Thyroid scintigraphy has been helpful in detecting and evaluation of thyroid nodules. Sodium pertechnetate Tc-99m is the most commonly used radionuclide for thyroid imaging because of its general availability, favorable dosimetric characteristics and low cost. But, there are reports of occasional disparity in isotope uptake in lesions compared with radioiodide. In order to determine percentage and clinical significance of this disparity, we screened 101 patients with solitary functioning nodules using sodium pertechnetate TC-99m in comparison with subsequent Iodine-131 scan in research institute for nuclear medicine. We conclude that sodium pertechnetate TC-99m is a reliable radiotracer for the detection and evaluation of thyroid nodules and there is no need for the subsequent Iodine-131 scan.

  1. Kinetics of Iodine 131 labelled fibrinogen in cancerous patients. Pharmacological study

    International Nuclear Information System (INIS)

    Boneu-Valmalette, Andree; Bugat, Roland; David, J.-F.; Combes, P.-F.

    1977-01-01

    The results obtained in a previous study using 131 I fibrinogen in cancerous patients suggested a local intravascular clotting process. In order to elucidate the mechanism of fibrinogen kinetic abnormalities different drugs including heparin, prednisone, ticlopidin, aspirin and indomethacin were administred in 68 patients and their effects evaluated by change in the 131 I fibrinogen disappearance rate. The results suggest that these drugs may counteract with the early stages of coagulation (kinin-forming system, factor XII) and that abnormal 131 I fibrinogen kinetic in cancer would be a non specific phenomenon [fr

  2. Iodine 131 labeled GD2 monoclonal antibody in the diagnosis and therapy of human neuroblastoma

    International Nuclear Information System (INIS)

    Cheung, N.K.V.; Miraldi, F.D.

    1988-01-01

    High dose marrow ablative therapy followed by autologous bone marrow transplantation (ABMT) has prolonged survival in patients with neuroblastoma. Total body and focal irradiation play an integral role in the overall treatment of this disease. The biological basis for radiation is the radiosensitivity and the lack of sublethal repair in neuroblastoma cells. However, radiation therapy has not by itself been adequate because of the usual widespread nature of neuroblastoma and the inability to achieve selective tumor versus normal tissue delivery, especially at multiple tumor sites. Monoclonal antibodies are agents selected for their specificity for human tumors. In vivo they have the ability of targeting selectively to occult metastases. This paper discusses how the availability of radioisotopes and the development of conjugation chemistries have greatly expanded the potentials of these antibodies

  3. Liquid dynamic in the retroperitoneum: study of albumin labelled with iodine-131

    International Nuclear Information System (INIS)

    Steinman, E.

    1990-01-01

    The retroperitoneal region in not very well-known, specially what concerns its behavior and dynamics, when there is presence of blood and other collections. Therefore, we decided to study the dissemination of the absorption of liquids, using for that a radioactive indicator deposited in different areas of the retroperitoneum. The chosen indicator was iodinated albumin (RIHSA). This study was performed in patients submitted to different types of surgical procedures, but in those who did not present retroperitoneum affections or previous surgeries. In all patients, the blood concentration rate of the indicator in determined times was determined and also the scintilografic image with 24, 48 and 72 hours after finished the surgical procedure was undertaken. It was observed that in the retroperitoneum, the indicator tend to be concentrated in the same place as it was injected at least up to 72 hours and that in the peritoneum the indicator migrates earlier to the abdominal cavity. Besides, the blood transference in retroperitoneum is performed on a slower manner when compared to the peritoneum, except for the anterior para renal area. Radioactive iodine injected in the retroperitoneum was earlier captured by the thyroid. The adopted technique is inocuous, simple, reproductible and quantified. (author)

  4. A comparison of the radiochemical stability of different iodine-131 labelled metaiodobenzylguanidine formulations for therapeutic use

    International Nuclear Information System (INIS)

    Wafelman, A.R.; Beijnen, J.H.; Hoefnagel, C.A.; Maes, R.A.A.

    1994-01-01

    The results of a stability study of three commercially available formulations of [ 131 I]MIBG for therapeutic use and an unstabilized formulation, stored under various conditions, are presented. The stability was followed for 20 days. In all formulations tested, free [ 131 I]iodide, formed by radiolysis, was the most important radiochemical impurity. The pharmaceutical formulation with the largest amount of stabilizer was radiochemically - but not chemically -most stable. (author)

  5. Impact of iodine 131 release from an anti cancerous center on the activity present in the channel of waste water treatment

    International Nuclear Information System (INIS)

    Desjardins, E.; Laugle, S.; Houy, J.C.

    2002-01-01

    Iodine 131 has been detected in the incineration waste. This iodine 131 would come from the muds of the water treatment by plant of Beaurade. This plant treats the waste water of Rennes. This radioactivity is caused by iodine 131 used in the medical medium for the diagnosis and the treatment of liver and thyroid neoplasms. The urines are stocked in tanks until a decrease of activity to 7 Bq/l and the waste waters used to wash the clothes are at delayed evacuation. The iodine comes from the patients feces. This study consists in defining the activity levels of iodine 131 in the channel of waste water treatment, from the purification station of Beaurade to the incinerator of Villejean. (N.C.)

  6. Destruction of post-surgery thyroid remnants by 19 mCi (703 MBq) of iodine 131

    International Nuclear Information System (INIS)

    Tassy, D.; Lonchampt, M.F.; Minebois, A.; Antigny, J.F.

    1997-01-01

    The adjuvant treatment by iodine 131 in good prognostic forms of differentiated thyroid cancers (DTC) makes not the object of a general consensus. There is no study demonstrating the benefit from such a treatment. Administration of an elevated iodine 131 activity and the constraint of a supplementary hospitalization are in these conditions questionable. In 6 patients, presenting the criteria of good prognostic and in post-operation, ambulatory conditions, administration of 19 mCi (703 MBc) of iodine 131 was done without previous administration of tracing dosage, followed after 72 hours by a whole-body scintigraphy, in the usual pause conditions. This administration was repeated 6 to 12 months later and followed by a new scintigraphic examination. The cervical fixation of iodine 131 was established qualitatively and quantitatively (as compared with a control zone). Five/six patients presented initially a cervical intense fixation with the star-like usual image and 1/6 patient a moderated fixation. Beginning with the second administration no cervical fixation was noted in 4/6 patients and a very low fixation in 2/6 patients. The concomitantly measured thyroglobulin, under simulation by TSH endogenous, was 131 I after quasi-total thyroidectomy in good-prognostic forms of DTC, without administration of previous tracing dosage to avoid possible phenomena of thyroid tissue blocking, allows probably, in overwhelming majority of cases, both a full or quasi-full destruction of the thyroid remnants and a severe reduction in the thyroglobulin rate measured in the conditions of pause of hormone-therapy

  7. Lymphocyte proliferative responses to mitogens in rats having an ancestry of a perinatal iodine-131 insult

    International Nuclear Information System (INIS)

    Stevens, R.H.; Cheng, H.F.

    1987-01-01

    The possible existence of a genealogical memory consisting of altered lymphocyte proliferative responses to a perinatal iodine-131 insult has been investigated in two generations of inbred Fischer F344 rat offspring. The studies which involved exposure to the radioiodine during late pregnancy with concentrations ranging from 1.85 MBq (50 μCi) to 7.4 MBq (200 μCi) revealed that only the peripheral blood T lymphocytes of the first generation male animals were significantly affected. These animals were found to possess T lymphocytes which exhibited increased proliferative responses expressed toward the mitogens concanavalin A and phytohemagglutin; however, no significant changes were noticeable in their B cell population following exposure to lipopolysaccharide. Neither the first generation females nor the male and female offspring of the second generation developed through sibling interbreeding seemed to be affected, this was unlike the cellular, humoral, and natural immunity which had previously been observed to be changed in both the second and third generation animals. These observations suggest that the effects of the radiation insult upon immunocompetency as measured by lymphocyte proliferation do not appear to be inherited

  8. Iodine-131 Therapy and Nasolacrimal Duct Obstructions: What We Know and What We Need to Know.

    Science.gov (United States)

    Ali, Mohammad Javed

    2016-01-01

    The aims of the current review are to summarize the etiopathogenesis, symptomatology, management, complications, and outcomes of iodine-131-induced nasolacrimal duct obstructions, to propose a screening protocol and elucidate the potential avenues of future research. The authors performed an electronic database (PubMed, MEDLINE, EMBASE, and Cochrane Library) search of all articles published in English on nasolacrimal duct obstructions following radioiodine therapy. These articles were reviewed along with their relevant cross references. Data reviewed included demographics, presentations, investigations, management, complications, and outcomes. In addition, based on relevant unanswered questions and current lacunae in literature, potential avenues for further research have been elucidated. The frequency of nasolacrimal duct obstruction is reported to range from 2.2% to 18% following I-131 therapy. They are mostly bilateral and noted in patients who receive more than 150 mCi radioiodine. Exact etiopathogenesis is unknown but radiotoxicity to lacrimal sac and nasolacrimal duct is believed to be mediated through a sodium-iodine symporter protein. Although uncommon, it is important to increase awareness among treating physicians and patients receiving radioiodine therapy about the potential side effect of nasolacrimal duct obstruction. Imaging modalities are useful adjuncts in the diagnosis. Dacryocystorhinostomy is the most common modality of management with good outcomes. Nasolacrimal duct obstruction following radioiodine treatment is a distinct clinical entity. Increased awareness would facilitate timely diagnosis, management, and an enhanced quality of life for the patients.

  9. Using ion-selective electrode for determining iodine-131 preparation specific activity

    International Nuclear Information System (INIS)

    Melnik, M.I.; Nazirova, T.E.

    2002-01-01

    A pilot facility was developed in 2000 for the production of iodine-131. The parameters of the preparation are as follows: chemical form: sodium iodide solution (NaI-131) in a carbonate-bicarbonate buffer (or in 0.001M NaOH); specific activity: carrier free (> 5 Ci/mg); solution pH: 7-10; radionuclide purity: > 99.9%; radiochemical purity: > 97%; bulk activity: 0.15 Ci/ml. The experimental results of investigation aimed at the determination of the specific activity of the I-131 preparation using a iodine-selective electrode are described. The method enables the analytical concentration of iodide ions in the carbonate-bicarbonate buffer (pH = 8-11) and NaOH solution (0.01 mol/l, pH = 8-11) to be determined. A micro-cell has been developed for the analysis of the I-131 solution allowing the sample volume to be reduced to below 0.3 ml. The relative error of determination of the analytical concentration of iodide (10 -6 to 10 -1 mol/l) does not exceed 1%

  10. Management of fear of radiation exposure in carers of outpatients treated with iodine-131

    International Nuclear Information System (INIS)

    Calais, P.J.; Turner, J.H.

    2012-01-01

    The objective of this study was to characterise potential fear of radiation exposure in a normal population of individuals who have volunteered to care for a radioactive family member or friend after outpatient radioimmunotherapy (RIT) treatment for cancer, and obtain their knowing and willing acceptance of the risk. Over 750 carers of 300 patients confined to their homes for 1 week following outpatient iodine-131 rituximab RIT of lymphoma were interviewed by a nuclear medicine physicist according to a multi-visit integrated protocol designed to minimise radiation exposure, define risk and gain informed consent. Median radiation exposure of carers was 0.49 mSv (range 0.01-3.7 mSv) which is below the Western Australian regulatory limit of 5 mSv for consenting adult carers of radioactive patients. After signing a declaration of consent, only 2 carers of 750 abrogated their responsibility and none of those who carried out their duties expressed residual concerns at the end of the exit interview with respect to their radiation exposure. Fear of radiation exposure in a normal population may be characterised as a normal emotional response. In the special case of carers of radioactive patients, this fear may be successfully managed by rational, authoritative and empathic explanation to define the risk and gain willing acceptance within the context of domiciliary patient care. (author)

  11. Effect of decicurie doses of radioactive iodine 131 on parathyroid function

    International Nuclear Information System (INIS)

    Glazebrook, G.A.

    1987-01-01

    Although parathyroid deficiency has been reported after administration of relatively small doses of iodine 131, reports of such deficiency after the much larger doses given in the management of thyroid cancer are notable by their absence in the literature. We observed one such patient, then instituted a prospective study. We observed a 58 percent incidence of apparently diminished parathyroid reserve among 53 patients given high doses of I 131. Susceptibility does not appear to be related to age, sex, extent of thyroid operation, operative technique, the amount of thyroidal I 131 uptake, the use of external radiation to the neck, or to the presence of parathyroid glands or of Hashimoto's disease in the operative specimen; however, susceptibility may be related to the anatomic location of the parathyroid glands in relation to the thyroid gland. The administered dose of I 131 almost reached significant levels (p = 0.1) in the present study. The initial pretreatment serum calcium levels were consistently lower among affected patients (p = 0.01), suggesting the presence of a preexisting latent impairment of parathyroid reserve which was subsequently unmasked after the administration of I 131. Thyroid cancer is compatible with very long-term survival, and therefore, there is a considerable risk of delayed chronic hypocalcemia among patients who have received large doses of I 131, particularly female patients in the premenopausal age group. These patients deserve special management surveillance

  12. [Metabolic therapy with iodine 131 in patients with chronic renal failure. Clinical case].

    Science.gov (United States)

    Vázquez-Rodríguez Barbero, Inmaculada; Espadas-Maeso, María José; Muñoz-Morales, Ana; Flores-Gómez, Pilar; Serrano-Carretero, María Belén; Castedo-Sal, Juan José; Sánchez Rey-Castro, Elena; Zamorano-Córdoba, Antonio

    2015-01-01

    62 year-old male with CKD stage 5 in dialysis program since 2012 who underwent surgery for papillary thyroid carcinoma with lymph node metastasis. Subsequently, the patient was admitted to the Unit of Metabolic Therapy at his reference hospital, where he is administered 80 millicuries of iodine-131 as a treatment associated with the surgery, unable to have his conventional dialysis, nursing interventions required in various stages of implementation of the continuous extrarenal clearance techniques (TCDE) were performed. The following care values were addressed targeted to patients undergoing treatment with I(131): specific equipment, personal protective measures and major diagnoses and nursing interventions. TCDE, despite being attributed to very critical patients, they can be extrapolated to other patients in a given time. TCDE allowed these patients to undergo dialysis in a safe environment for staff, ensuring proper disposal of contaminated liquids. TCDE were an effective treatment for the removal of I131, a single ssesion being necessary to normalize the levels of radioactivity. Coordination between services allewed ensure proper and effective treatment for the patient. Copyright © 2015 Elsevier España, S.L.U. All rights reserved.

  13. Metastatic phaeochromocytoma with a long-term response after iodine-131 metaiodobenzylguanidine therapy

    International Nuclear Information System (INIS)

    Pujol, P.; Bringer, J.; Faurous, P.; Jaffiol, C.

    1995-01-01

    Iodine-131 metaiodobenzylguanidine ([ 131 I] MIBG), a radiopharmaceutical agent, is used for treating malignant phaeochromocytoma. [ 131 I]MIBG therapy results in a hormone response rate of approximately 50%, but generally it yields only a partial or no tumour response. We present a case of a 46-year-old woman with a familial history of von Hippel-Lindau disease, who was treated with [ 131 I]MIBG for a metastatic phaeochromocytoma involving the lungs, liver and bones. The patient received a cumulative dose of 33.3 GBq (900 mCi) and a complete hormone response was observed, as evaluated on the basis of catecholamine and metanephrine levels. Conventional radiography, computerized tomography and [ 131 I]MIBG scintigraphy indicated that a near-complete tumour regression was achieved, with no evidence of relapse during a 4-year follow-up period. This case thus demonstrates that treatment with [ 131 I]MIBG may lead to a dramatic tumour response in malignant phaeochromocytoma presenting both soft tissue and bone metastases. (orig.)

  14. Colon transit scintiraphy in health and constipation using oral iodine-131-cellulose

    International Nuclear Information System (INIS)

    McLean, R.G.; Smart, R.C.; Gaston-Parry, D.; Barbagallo, S.; Baker, J.; Lyons, N.R.; Bruck, C.E.; King, D.W.; Lubowski, D.Z.; Talley, N.A.

    1990-01-01

    The purpose of the study was to assess if a new scintigraphic method for noninvasive assessment of colonic transit could differentiate between subjects with normal bowel transit and those with constipation. Eleven normal subjects and 29 constipated patients were given 4 MBq iodine-131-cellulose ( 131 I-cellulose) orally and sequential abdominal scans were performed at 6, 24, 48, 72, and 96 hr from which total and segmental percent retentions were calculated. There were clear differences between the normal subjects and the constipated patients for the total percent retention at all time intervals, on a segmental basis in the right colon at 24 hr, and in all segments at 48 and 72 hr. Three-day urinary excretion of radioiodine was minimal; 2.4% +/- 1.2% (mean +/- s.d.) in constipated patients and 3.1% +/- 0.8% in normals, with approximately 75% occurring in the first day. The use of oral radiotracers in the investigation of constipation appears promising

  15. Iodine-131 Metaiodobenzylguanidine Therapy for Neuroblastoma: Reports So Far and Future Perspective

    Directory of Open Access Journals (Sweden)

    Daiki Kayano

    2015-01-01

    Full Text Available Neuroblastoma, which derives from neural crest, is the most common extracranial solid cancer in childhood. The tumors express the norepinephrine (NE transporters on their cell membrane and take in metaiodobenzylguanidine (MIBG via a NE transporter. Since iodine-131 (I-131 MIBG therapy was firstly reported, many trails of MIBG therapy in patients with neuroblastoma were performed. Though monotherapy with a low dose of I-131 MIBG could achieve high-probability pain reduction, the objective response was poor. In contrast, more than 12 mCi/kg I-131 MIBG administrations with or without hematopoietic cell transplantation (HCT obtain relatively good responses in patients with refractory or relapsed neuroblastoma. The combination therapy with I-131 MIBG and other modalities such as nonmyeloablative chemotherapy and myeloablative chemotherapy with HCT improved the therapeutic response in patients with refractory or relapsed neuroblastoma. In addition, I-131 MIBG therapy incorporated in the induction therapy was proved to be feasible in patients with newly diagnosed neuroblastoma. To expand more the use of MIBG therapy for neuroblastoma, further studies will be needed especially in the use at an earlier stage from diagnosis, in the use with other radionuclide formations of MIBG, and in combined use with other therapeutic agents.

  16. Management of fear of radiation exposure in carers of outpatients treated with iodine-131.

    Science.gov (United States)

    Calais, Phillipe J; Page, Andrew C; Turner, J Harvey

    2012-07-01

    To characterise potential fear of radiation exposure in a normal population of individuals who have volunteered to care for a radioactive family member or friend after outpatient radioimmunotherapy (RIT) treatment for cancer, and obtain their knowing and willing acceptance of the risk. Over 750 carers of 300 patients confined to their homes for 1 week following outpatient iodine-131 rituximab RIT of lymphoma were interviewed by a nuclear medicine physicist according to a multi-visit integrated protocol designed to minimise radiation exposure, define risk and gain informed consent. Median radiation exposure of carers was 0.49 mSv (range 0.01-3.7 mSv) which is below the Western Australian regulatory limit of 5 mSv for consenting adult carers of radioactive patients. After signing a declaration of consent, only 2 carers of 750 abrogated their responsibility and none of those who carried out their duties expressed residual concerns at the end of the exit interview with respect to their radiation exposure. Fear of radiation exposure in a normal population may be characterised as a normal emotional response. In the special case of carers of radioactive patients, this fear may be successfully managed by rational, authoritative and empathic explanation to define the risk and gain willing acceptance within the context of domiciliary patient care.

  17. Prostaglandins as biochemical markers of radiation injury to the salivary glands after iodine-131 therapy?

    Energy Technology Data Exchange (ETDEWEB)

    Rodrigues, M.; Havlik, E.; Sinzinger, H. [Univ. Hospital of Vienna (Austria). Dept. of Nuclear Medicine; Peskar, B. [Graz Univ. (Austria). Abt. Pharmakologie

    1998-03-01

    Because salivary glands, as well as thyroid tissue, are able to concentrate radioiodine, the treatment of thyroid diseases with iodine-131 may have secondary effects on salivary gland function which seriously impair the quality of life. Such effects include sialoadenitis and xerostomia. Salivary secretion is stimulated by prostaglandins (PGs). In this study we evaluate whether {sup 131}I therapy influences the levels of PGs in saliva. Patients who had previously received {sup 131}I for treatment of hyperthyroidism or differentiated thyroid cancer and healthy volunters were studied. Levels of PGs [6-oxo-PGF{sub 1{alpha}}, bicyclo-PGEm, thromboxane B{sub 2} (TXB{sub 2}), PGF{sub 2{alpha}}], in unstimulated saliva were measured using enzyme immunoassay. Significantly lower levels of 6-oxo-PGF{sub 1} {sub {alpha}}, bicyclo-PGEm and PGF{sub 2{alpha}} and higher levels of TXB{sub 2} were found in the group of patients in comparison with the controls. Differences between patients and controls were more pronounced in smokers. This study demonstrates that salivary gland uptake of {sup 131}I significantly affects PG levels in saliva. (orig.)

  18. Alteration of radioactive iodine uptake after treatment of hyperthyroidism with iodine 131

    International Nuclear Information System (INIS)

    Heath, R.C.; Gossain, V.V.; Rovner, D.R.

    1988-01-01

    To determine whether a therapeutic dose of iodine 131 affects the results of 24-hour radioactive iodine uptake (RAIU) testing, we reviewed records of hyperthyroid patients previously treated with 131 I at Michigan State University and its affiliated hospitals. We identified 26 patients who had had clinical evaluation and determination of the serum thyroxine (T4) level, triiodothyronine resin uptake (T3RU), and RAIU (using 131 I) within two weeks before and several months after the therapeutic dose of 131 I. Before treatment, all patients had clinical hyperthyroidism, with an elevated T4 level and increased T3RU and RAIU. After treatment with 131 I, eight patients (31%) had an RAIU that was discordant with their clinical and biochemical (T4 and T3RU) assessment. In six patients (23%) of the RAIU was inappropriately high, and in two patients (8%) it was inappropriately low. Since we did not identify any other factors known to interfere with the results of RAIU testing, we conclude that a therapeutic dose of 131 I, may by itself increase or decrease a subsequent RAIU determination; therefore, after treatment with 131 I, RAIU is not a good diagnostic index of thyroid activity

  19. Prostaglandins as biochemical markers of radiation injury to the salivary glands after iodine-131 therapy?

    International Nuclear Information System (INIS)

    Rodrigues, M.; Havlik, E.; Sinzinger, H.; Peskar, B.

    1998-01-01

    Because salivary glands, as well as thyroid tissue, are able to concentrate radioiodine, the treatment of thyroid diseases with iodine-131 may have secondary effects on salivary gland function which seriously impair the quality of life. Such effects include sialoadenitis and xerostomia. Salivary secretion is stimulated by prostaglandins (PGs). In this study we evaluate whether 131 I therapy influences the levels of PGs in saliva. Patients who had previously received 131 I for treatment of hyperthyroidism or differentiated thyroid cancer and healthy volunters were studied. Levels of PGs [6-oxo-PGF 1α , bicyclo-PGEm, thromboxane B 2 (TXB 2 ), PGF 2α ], in unstimulated saliva were measured using enzyme immunoassay. Significantly lower levels of 6-oxo-PGF 1 α , bicyclo-PGEm and PGF 2α and higher levels of TXB 2 were found in the group of patients in comparison with the controls. Differences between patients and controls were more pronounced in smokers. This study demonstrates that salivary gland uptake of 131 I significantly affects PG levels in saliva. (orig.)

  20. Iodine-131 treatment and chromosomal damage: in vivo dose-effect relationship.

    Science.gov (United States)

    Erselcan, Taner; Sungu, Selma; Ozdemir, Semra; Turgut, Bulent; Dogan, Derya; Ozdemir, Ozturk

    2004-05-01

    Although it is well known that radiation induces chromosomal aberrations, there is a lack of information on the in vivo dose-effect relationship in patients receiving iodine-131 treatment, and the results of previous studies are controversial. In this study, the sister chromatid exchange (SCE) method was employed to investigate acute and late chromosomal damage (CD) in the peripheral lymphocytes of 15 patients who received various doses of (131)I (259-3,700 MBq), either for thyrotoxicosis (TTX) or for ablation treatment in differentiated thyroid cancer (DTC). The SCE frequencies in cultured peripheral lymphocytes were determined before treatment (to assess basal SCE frequencies), on the 3rd day (to assess acute SCE frequencies) and 6 months later (to assess late SCE frequencies). The basal, acute and late SCE frequencies (mean+/-SD) were 3.19+/-0.93, 10.83+/-1.72 and 5.75+/-2.06, respectively, in the whole group, and these values differed significantly from each other ( Pdisappearance of damaged lymphocytes from the peripheral circulation in a dose-dependent manner following (131)I treatment. Further studies are therefore needed to clarify the effect of the negative beta value on the biological dosimetry approach in continuous internal low LET radiation, as in the case of (131)I treatment.

  1. Practical recommendations for outpatients after differentiated thyroid carcinoma treatment with iodine-131

    International Nuclear Information System (INIS)

    Carlier, T.; Kraeber-Bodere, F.; Ansquer, C.; Couturier, O.; Lisbona, A.; Kraeber-Bodere, F.; Couturier, O.

    2004-01-01

    Few studies on radiation protection recommendation for patients leaving hospitalization area after thyroid carcinoma treatment with iodine-131 are based on experimental determination of effective half life. The aim of this work was to calculate times of adhesion to restrictions for patients using one dose rate measurement at 30 cm the last day, just before leaving hospital. Dose rate measurements were achieved every day at two localizations (abdomen mid trunk and neck) during hospitalization. Data were fitted by a monoexponential or a biexponential model in order to derive the effective half life. We considered 7 exposure states between patient and neighboring. We showed, according to our realistic scatter state, a dose rate variation inversely proportional to the distance from patient. Effective half life is equal to 16 ± 6 h whatever the measurement localization. Thus the times of adhesion to restrictions is never greater than 2 days after 3 days of hospitalization. A simple table is given to allow the computation of restrictions times according to the dose rate measurement before the patient is discharged. This protocol is applied in our institution and gives whole satisfaction as far as the ALARA principle and the patient information are concerned. (author)

  2. Iodine-131 treatment strategy in papillary and follicular thyroid cancers at Centre Antoine Lacassagne (Nice)

    International Nuclear Information System (INIS)

    Bussiere, F.

    2003-01-01

    We report on iodine-131 treatment strategy in 1207 papillary and 250 follicular thyroid cancers admitted at our institution between 1976 and 2001. At the time of diagnosis, 51 patients (3.5%) had already metastases. The rest were 155 (11 %) pT4, 619 (44.6 %) pT1 588 (42,6 %) pT2, 26 pT3, 5 pT0 and 4 pTx. All patients underwent quasi-total thyroidectomy. Lymph node dissection was performed in most patients except in 49.7 %n of pT1 and 33% of pT2. Lastly, multifocal thyroid lesions were found in 28.5% of pT1 and 27,6 % of pT2. 80 patients did not receive radio-iodine (among them 60 were pT1 pN0 or pNx). 1114 patients received one therapeutic dose of 3.7 GBq of 131-iodine 6 to 8 weeks post surgery. 181 patients were treated twice (89 for remnants and 92 for disease progression). 82 patients received at least 3 doses and 5 up to 7 doses. 116 deaths were recorded, 59 (4 %) were related to thyroid cancer. The relatively poor prognosis of the follicular form is confirmed with 15.2 % deaths. This study needs to be further analysed focusing oil the follow-up of pT1 patients in order to redefine the indications of iodine therapy in that group. (author)

  3. Evaluation of the uncertainties associated to the in vivo monitoring of iodine-131 in the thyroid

    Energy Technology Data Exchange (ETDEWEB)

    Gontijo, Rodrigo Modesto Gadelha; Lucena, Eder Augusto; Dantas, Ana Leticia A.; Dantas, Bernardo Maranhao [Instituto de Radioprotecao e Dosimetria (IRD/CNEN-RJ), Rio de Janeiro, RJ (Brazil)

    2011-07-01

    The internal dose from the incorporation of radionuclides by humans can be estimated by in vivo direct measurements in the human body and in vitro analysis of biological indicators. In vivo techniques consist on the identification and quantification of radionuclides present in the whole body and in specific organs and tissues. The results obtained in measurements may present small uncertainties which are within pre-set limits in monitoring programs for occupationally exposed individuals. This study aims to evaluate the sources of uncertainty associated with the results of in vivo monitoring of iodine 131 in the thyroid. The benchmarks adopted in this study are based on the criteria suggested by the General Guide for Estimating Effective Doses from Monitoring Data (Project IDEAS/European Community). The reference values used were the ones for high-energy photons (>100 keV). Besides the parameters suggested by the IDEAS Guide, it has also been evaluated the fluctuation of the counting due to the phantom repositioning, which represents the reproducibility of the counting geometry. Measurements were performed at the Whole Body Counter Unit of the IRD using a scintillation detector NaI (Tl) 3'' x 3'' and a neck-thyroid phantom developed at the In Vivo Monitoring Laboratory of IRD. This phantom contains a standard source of barium-133 added to a piece of filter paper with the dimension and shape of a thyroid gland. Scattering factors were calculated and compared in different counting geometries. The results show that the technique studied presents reproducibility equivalent to the values suggested in the IDEAS Guide and measurement uncertainties compatible to international quality standards for this type of in vivo monitoring. (author)

  4. Phaeochromocytoma and functioning paraganglioma in childhood and adolescence: Role of iodine 131 metaiodobenzylguanidine

    International Nuclear Information System (INIS)

    Khafagi, F.A.; Shapiro, B.; Fischer, M.; Sisson, J.C.; Beierwaltes, W.H.; Hutchinson, R.

    1991-01-01

    Phaeochromocytomas and functioning paragangliomas are rare tumours in childhood and adolescence. We review our experience of 43 cases (24 men, 19 women) who were first diagnosed at the age of ≤ 18 years. All patients were evaluated at some point in their illness, with iodine 131 metaiodobenzylguanidine ( 131 I-mIBG) scintigraphy. Eight patients (19%) had bilateral adrenal tumours, 12 (28%) had solitary extraadrenal tumours, and 8 (19%) had multiple tumours. In 10 patients (23%), the tumours were associated with a familial neurocristopathic syndrome. Thirteen of 24 (54%) unifocal tumours which were initially considered to be benign ultimately proved to be multi-focal and/or malignant. The final prevalence of malignancy was 60% - 26 patients, of whom only 15 (57%) had obviously malignant tumours at the time of diagnosis. Primary tumour size ≥ 5 cm was more commonly associated with a malignant course in adrenal but not extra-adrenal tumours. No other clinical, biochemical or morphological characteristic was significantly associated with malignancy. Although the high prevalence of malignancy in this series at least partly reflects referral bias, the need for lifelong follow-up of these patients is underscored. 131 I-mIBG scintigraphy was positive in 36 patients (84%), with a somewhat lower false-negative rate (12%) than X-ray computed tomography (20%). Eight patients with malignant tumours received therapeutic doses of 131 I-mIBG, with partial tumour responses in 3. Thus, 131 I-mIBG is an efficacious, non-invasive, localising agent and may be considered as a palliative therapeutic agent when alternatives have failed. (orig.)

  5. Factors Predicting Treatment Failure in Patients Treated with Iodine-131 for Graves’ Disease

    International Nuclear Information System (INIS)

    Manohar, Kuruva; Mittal, Bhagwant Rai; Bhoil, Amit; Bhattacharya, Anish; Dutta, Pinaki; Bhansali, Anil

    2013-01-01

    Treatment of Graves' disease with iodine-131 ( 131 I) is well-known; however, all patients do not respond to a single dose of 131 I and may require higher and repeated doses. This study was carried out to identify the factors, which can predict treatment failure to a single dose of 131 I treatment in these patients. Data of 150 patients with Graves' disease treated with 259-370 MBq of 131 I followed-up for at least 1-year were retrospectively analyzed. Logistic regression analysis was used to predict factors which can predict treatment failure, such as age, sex, duration of disease, grade of goiter, duration of treatment with anti-thyroid drugs, mean dosage of anti-thyroid drugs used, 99m Tc-pertechnetate ( 99m TcO 4 - ) uptake at 20 min, dose of 131 I administered, total triiodothyronine and thyroxine levels. Of the 150 patients, 25 patients required retreatment within 1 year of initial treatment with 131 I. Logistic regression analysis revealed that male sex and 99m TcO 4 - uptake were associated with treatment failure. On receiver operating characteristic (ROC) curve analysis, area under the curve (AUC) was significant for 99m TcO 4 - uptake predicting treatment failure (AUC = 0.623; P = 0.039). Optimum cutoff for 99m TcO 4 - uptake was 17.75 with a sensitivity of 68% and specificity of 66% to predict treatment failure. Patients with >17.75% 99m TcO 4 - uptake had odds ratio of 3.14 (P = 0.014) for treatment failure and male patients had odds ratio of 1.783 for treatment failure. Our results suggest that male patients and patients with high pre-treatment 99m TcO 4 - uptake are more likely to require repeated doses of 131 I to achieve complete remission

  6. Pregnancy after high therapeutic doses of iodine-131 in differentiated thyroid cancer: potential risks and recommendations

    International Nuclear Information System (INIS)

    Casara, D.; Rubello, D.; Saladini, G.; Piotto, A.; Pelizzo, M.R.; Girelli, M.E.; Busnardo, B.

    1993-01-01

    Seventy female patients who had been treated with high doses of iodine-131 for differented thyroid cancer (DTC) and who had a subsequent pregnancy were evaluated. The global 131 I dose ranged from 1.85 to 16.55 GBq (mean±SD=4.39±25.20 GBq). Age at first therapy ranged from 15 to 36 years (mean±SD=24.3±5.0 years) and the interval from 131 I therapy to pregnancy varied from 2 to 10 years (mean±SD=5.3±2.8 years). The estimated radiation dose to the gonads ranged from 10 to 63 cGy (mean±SD=24.0±13.5 cGy). All patients were treated with L-thyroxine at doses capable of suppressing thyroid-stimulating hormone. Seventy-three children were followed-up and seven pregnancies are still in progress. One child was affected by Fallot's trilogy and three had a low birth weight though with subsequent regular growth; the others were healthy with subsequent regular growth. No newborn with clinical or biochemical thyroid dysfunctions was found. Two spontaneous abortions during the second month of pregnancy were recorded. One of two patients in question subsequently had two healthy children. On the basis of these data, previous administration of high 131 I doses does not appear to be a valid reason for dissuading young female DTC patients from considering pregnancy. However, patients should be advised to avoid pregnancy after 131 I administration for a period sufficient to ensure complete elimination of the radionuclide and to permit confirmation of complete disease remission, i.e. at least 1 year in our opinion. (orig.)

  7. Managing Terrorism or Accidental Nuclear Errors, Preparing for Iodine-131 Emergencies: A Comprehensive Review

    Directory of Open Access Journals (Sweden)

    Eric R. Braverman

    2014-04-01

    Full Text Available Chernobyl demonstrated that iodine-131 (131I released in a nuclear accident can cause malignant thyroid nodules to develop in children within a 300 mile radius of the incident. Timely potassium iodide (KI administration can prevent the development of thyroid cancer and the American Thyroid Association (ATA and a number of United States governmental agencies recommend KI prophylaxis. Current pre-distribution of KI by the United States government and other governments with nuclear reactors is probably ineffective. Thus we undertook a thorough scientific review, regarding emergency response to 131I exposures. We propose: (1 pre-distribution of KI to at risk populations; (2 prompt administration, within 2 hours of the incident; (3 utilization of a lowest effective KI dose; (4 distribution extension to at least 300 miles from the epicenter of a potential nuclear incident; (5 education of the public about dietary iodide sources; (6 continued post-hoc analysis of the long-term impact of nuclear accidents; and (7 support for global iodine sufficiency programs. Approximately two billion people are at risk for iodine deficiency disorder (IDD, the world’s leading cause of preventable brain damage. Iodide deficient individuals are at greater risk of developing thyroid cancer after 131I exposure. There are virtually no studies of KI prophylaxis in infants, children and adolescents, our target population. Because of their sensitivity to these side effects, we have suggested that we should extrapolate from the lowest effective adult dose, 15–30 mg or 1–2 mg per 10 pounds for children. We encourage global health agencies (private and governmental to consider these critical recommendations.

  8. Preparation of [[sup 131]I]lipiodol as a hepatoma therapeutic agent

    Energy Technology Data Exchange (ETDEWEB)

    Jiunnguang Lo; Aiyih Wang; Yuanyaw Wei (National Tsinghua Univ., Hsinchu (Taiwan). Inst. of Nuclear Science); Wingyiu Lui; Chinwen Chi (Taipei Veterans General Hospital, Taipei (Taiwan)); Wingkai Chan (Academia Sinica, Taipei (Taiwan). Inst. of Biomedical Sciences)

    1992-12-01

    An isotopic exchange method was used to label lipiodol with [sup 131]I. The labelling efficiency was > 92.5%, and the radiochemical purity of [[sup 131]I]lipiodol was above 98% as determined by ITLC. The influencing factors e.g. the heating temperature, reaction, pH and storage conditions were studied and the optimum conditions were determined. In a pilot study injecting [[sup 131]I]lipiodol for the treatment of hepatoma, about 70% of hepatoma patients had a response to the treatment with a reduction of [alpha]-fetoprotein and decrease of hepatoma sizes. The overall median survival was 9 months (range 2-17 months). (author).

  9. Rapid clearance of iodine-131 MIBG from the heart and liver of patients with adrenergic dysfunction and pheochromocytoma

    International Nuclear Information System (INIS)

    Nakajo, M.; Shimabukuro, K.; Miyaji, N.; Shimada, J.; Shirono, K.; Sakata, H.; Yoshimura, H.; Yonekura, R.; Shinohara, S.

    1985-01-01

    Iodine-131 MIBG, a radiolabeled adrenergic neuron-blocking agent, decreased rapidly from the heart and liver of patients with adrenergic dysfunction and pheochromocytoma when compared with eight controls. However, there was no significant difference in the rate of [ 131 I]MIBG decrease in these organs between controls and patients in the intervals subsequent to 4 hr. These findings suggest that adrenergic neuronal uptake of [ 131 I]MIBG in these organs is smaller in the patients than in the controls. Measurements of time-activity relationships of radioiodinated MIBG may be useful for assessment of adrenergic function of these organs and thus of generalized disorders of adrenergic innervation

  10. Intrathoracic stomach mimicking bone metastasis from thyroid cancer in whole-body iodine-131 scan diagnosed by SPECT/CT

    Energy Technology Data Exchange (ETDEWEB)

    Garcia-Gomez, Francisco Javier; Riva-Perez, Pablo Antonio de la; Calvo-Moron, Cinta; Bujan-Lloret, Cristina; Cambil-Molina, Teresa; Castro-Montano, Juan [Dept. of Nuclear Medicine, Virgen Macarena University Hospital, Sevilla (Spain)

    2017-05-15

    The whole-body iodine-131 scintigraphy is an imaging technique in monitoring patients with a history of thyroid cancer. Although the rate of false positives is negligible, it is not nonexistent. We report the case of an intervened and treated patient for thyroid cancer with good clinical and biochemical response. Scintigraphic findings were consistent with unsuspected bone metastasis. Fused SPECT/CT data allowed accurate diagnosis of giant diaphragmatic hernia associated with intrathoracic stomach, a very rare pathology that can lead to false positive results. (author)

  11. Using medically-derived iodine-131 to track sewage effluent in the Laurentian Great Lakes.

    Science.gov (United States)

    Montenero, Michael P; Dilbone, Elizabeth K; Waples, James T

    2017-10-15

    Tracking sewage wastewater in a large lake is difficult. Concentrations of pharmaceuticals that can be used as indicator compounds are quickly diluted and not easy to measure. In this study, we examined the potential of using medically-derived iodine-131 ( 131 I, t ½  = 8.02 d) as a tracer for Milwaukee sewage effluent in Lake Michigan. 131 I activities in sewage effluent from two Milwaukee wastewater treatment plants (WWTPs) were measured in conjunction with 131 I activities in water, sediment and biota in the Milwaukee Outer Harbor and Lake Michigan. 131 I discharge rates from both WWTPS ranged from 34 ± 15 to 1807 ± 24 MBq d -1 , with average and median 131 I discharges of 278 and 129 MBq d -1 . A budget of 131 I in the Milwaukee Outer Harbor - based on measured sediment and water column inventories - showed that ∼11% of the 131 I discharged to the harbor was scavenged to bottom sediments, ∼19% decayed in the harbor water column, and ∼70% was flushed out of the harbor to Lake Michigan. From this budget, we derived a harbor flushing rate of 3.1 days. In Lake Michigan, 131 I activity was found in Cladophora algae (undetected to 91 ± 2 Bq kg -1 ) along ∼40 km of shoreline. Benthic trawl samples showed 131 I activity up to 8 km from shore. Calculated 131 I length scales were 30 km alongshore and 3.4 km offshore and corresponded to sewage effluent dispersion rates of ∼2.6 km d -1 and ∼0.3 km d -1 in along- and offshore directions. Using 131 I as a tracer of sewage effluent from other coastal municipalities to the Laurentian Great Lakes appears feasible, particularly for larger (>10 5 ) population centers. Copyright © 2017 Elsevier Ltd. All rights reserved.

  12. Iodine-131 treatment and chromosomal damage: in vivo dose-effect relationship

    International Nuclear Information System (INIS)

    Erselcan, Taner; Ozdemir, Semra; Turgut, Bulent; Dogan, Derya; Sungu, Selma; Ozdemir, Ozturk

    2004-01-01

    Although it is well known that radiation induces chromosomal aberrations, there is a lack of information on the in vivo dose-effect relationship in patients receiving iodine-131 treatment, and the results of previous studies are controversial. In this study, the sister chromatid exchange (SCE) method was employed to investigate acute and late chromosomal damage (CD) in the peripheral lymphocytes of 15 patients who received various doses of 131 I (259-3,700 MBq), either for thyrotoxicosis (TTX) or for ablation treatment in differentiated thyroid cancer (DTC). The SCE frequencies in cultured peripheral lymphocytes were determined before treatment (to assess basal SCE frequencies), on the 3rd day (to assess acute SCE frequencies) and 6 months later (to assess late SCE frequencies). The basal, acute and late SCE frequencies (mean±SD) were 3.19±0.93, 10.83±1.72 and 5.75±2.06, respectively, in the whole group, and these values differed significantly from each other (P 131 I dose in the whole group, but a negative correlation was found between the 131 I dose and the RR at the 6th month (r=-0.60, P=0.04). The best fit for this relationship was obtained by a linear-quadratic model, as y=104.89x-28.4x 2 +38.1 (R 2 =0.51, P=0.04). On the other hand, comparative analysis with the results of previous studies with comparable sampling times revealed that the best fit for the relationships between the administered dose of 131 I and DR and RR were obtained with a linear-quadratic model (Y=αD+βD 2 ) rather than a linear one. However, there was an interesting difference in comparison with in vitro studies, in that we found the coefficient β to have a negative value, suggesting the disappearance of damaged lymphocytes from the peripheral circulation in a dose-dependent manner following 131 I treatment. Further studies are therefore needed to clarify the effect of the negative β value on the biological dosimetry approach in continuous internal low LET radiation, as in the case

  13. Radiation exposure of the families of outpatients treated with radioiodine (iodine-131) for hyperthyroidism

    Energy Technology Data Exchange (ETDEWEB)

    Barrington, S.F.; O`Doherty, M.J.; Seed, P. [Guy`s, King`s and St. Thomas` Schools of Medicine, London (United Kingdom); Kettle, A.G. [Kent and Canterbury NHS Trust, Canterbury (United Kingdom); Thomson, W.H.; Harding, L.K. [City Hospitals NHS Trust, Birmingham (United Kingdom); Mountford, P.J.; Farrell, R.J. [North Staffordshire Hospital NHS Trust, Stoke-on-Trent (United Kingdom); Burrell, D.N. [University Hospital, Birmingham NHS Trust, Birmingham (United Kingdom); Batchelor, S. [Guy`s and St. Thomas` Hospitals NHS Trust, London (United Kingdom)

    1999-07-01

    Patients who receive radioiodine (iodine-131) treatment for hyperthyroidism (195-800 MBq) emit radiation and represent a potential hazard to other individuals. Critical groups amongst the public are fellow travellers on the patient`s journey home from hospital and members of the patient`s family, particularly young children. The dose which members of the public are allowed to receive as a result of a patient`s treatment has been reduced in Europe following recently revised recommendations from ICRP. The annual public dose limit is 1 mSv, though adult members of the patient`s family are allowed to receive higher doses, with the proviso that a limit of 5 mSv should not be exceeded over 5 years. Unless the doses received during out-patient administration of radioiodine can be demonstrated to comply with these new limits, hospitalisation of patients will be necessary. The radiation doses received by family members (35 adults and 87 children) of patients treated with radioiodine at five UK hospitals were measured using thermoluminescent dosimeters mounted in wrist bands. Families were given advice (according to current practice) from their treatment centre about limiting close contact with the patient for a period of time after treatment. Doses measured over 3-6 weeks were adjusted to give an estimate of values which might have been expected if the dosimeters had been worn indefinitely. Thirty-five passengers accompanying patients home after treatment also recorded the dose received during the journey using electronic (digital) personal dosimeters. For the ``adjusted`` doses to infinity, 97% of adults complied with a 5-mSv dose limit (range:0.2-5.8 mSv) and 89% of children with a 1-mSv limit (range: 0.2-7.2 mSv). However 6 of 17 children aged 3 years or less had an adjusted dose which exceeded this 1 mSv limit. The dose received by adults during travel was small in comparison with the total dose received. The median travel dose was 0.03 mSv for 1 h travel (range: 2 {mu

  14. Radiation exposure of the families of outpatients treated with radioiodine (iodine-131) for hyperthyroidism

    International Nuclear Information System (INIS)

    Barrington, S.F.; O'Doherty, M.J.; Seed, P.; Kettle, A.G.; Thomson, W.H.; Harding, L.K.; Mountford, P.J.; Farrell, R.J.; Burrell, D.N.; Batchelor, S.

    1999-01-01

    Patients who receive radioiodine (iodine-131) treatment for hyperthyroidism (195-800 MBq) emit radiation and represent a potential hazard to other individuals. Critical groups amongst the public are fellow travellers on the patient's journey home from hospital and members of the patient's family, particularly young children. The dose which members of the public are allowed to receive as a result of a patient's treatment has been reduced in Europe following recently revised recommendations from ICRP. The annual public dose limit is 1 mSv, though adult members of the patient's family are allowed to receive higher doses, with the proviso that a limit of 5 mSv should not be exceeded over 5 years. Unless the doses received during out-patient administration of radioiodine can be demonstrated to comply with these new limits, hospitalisation of patients will be necessary. The radiation doses received by family members (35 adults and 87 children) of patients treated with radioiodine at five UK hospitals were measured using thermoluminescent dosimeters mounted in wrist bands. Families were given advice (according to current practice) from their treatment centre about limiting close contact with the patient for a period of time after treatment. Doses measured over 3-6 weeks were adjusted to give an estimate of values which might have been expected if the dosimeters had been worn indefinitely. Thirty-five passengers accompanying patients home after treatment also recorded the dose received during the journey using electronic (digital) personal dosimeters. For the ''adjusted'' doses to infinity, 97% of adults complied with a 5-mSv dose limit (range:0.2-5.8 mSv) and 89% of children with a 1-mSv limit (range: 0.2-7.2 mSv). However 6 of 17 children aged 3 years or less had an adjusted dose which exceeded this 1 mSv limit. The dose received by adults during travel was small in comparison with the total dose received. The median travel dose was 0.03 mSv for 1 h travel (range: 2

  15. Radiation protection measures for reduction of incorporations of iodine-131 by the staff of a radionuclide therapy ward

    International Nuclear Information System (INIS)

    Petzold, J.; Meyer, K.; Lincke, T.; Sabri, O.; Alborzi, H.; Lorenz, J.; Schoenmuth, T.; Keller, A.

    2009-01-01

    The air in patient's rooms with thyroid therapies is loaded with iodine 131, which is to be seen as a cause for the incorporation of iodine 131 by the staff. The patients exhale a part of the iodine applied for their intended radionuclide therapy. The activity is concentrated in the saliva and, thereby, the breath air is moistened and iodine reaches the exhaled and compartment air. The detection of iodine in the form of contaminations and/or incorporations with the staff succeeds only after a longer stay in the patient's room. With this, a clear relation between the particular type of work performed in the room and therapy of malignant thyroid disease with high amounts of radioactivity can be found. The measured values of incorporations, obtained with an whole-body counter, are in the range of up to 400Bq. The activity concentration in the compartment air some hours after application of the therapeutic activity reaches a maximum and then decreases with a half-life of about 15 hours. As a protection measure we asked the patients wearing a mask up to 30 hours after application to (orig.)

  16. Effects of hemodialysis on iodine-131 biokinetics in thyroid carcinoma patients with end-stage chronic renal failure.

    Science.gov (United States)

    Yeyin, Nami; Cavdar, Iffet; Uslu, Lebriz; Abuqbeitah, Mohammad; Demir, Mustafa

    2016-03-01

    Radioiodine therapy could be challenging in chronic renal failure patients requiring hemodialysis. The aim of this study was to establish the effects of hemodialysis on elimination of radioiodine from the body in thyroid carcinoma patients with end-stage chronic renal failure and to determine its effects on environmental radiation dose. Three end-stage chronic renal failure patients (four cases) diagnosed with differentiated thyroid carcinoma requiring radioiodine therapy were included in our study. Each patient was given 50-75 mCi (1850-2775 MBq) iodine-131 with 50% dose reduction. Dose rate measurement was performed at the 2nd, 24th, and 48th hour (immediately before and after hemodialysis) after radioiodine administration. The Geiger-Müller probe was held at 1 m distance at the level of the midpoint of the thorax for the dose rate measurement. The effective half-life of iodine-131 for three patients was found to be 44 h. In conclusion, the amount of radioiodine excreted per hemodialysis session was calculated to be 51.25%.

  17. Targeting cancer chemotherapeutic agents by use of lipiodol contrast medium

    International Nuclear Information System (INIS)

    Konno, T.

    1990-01-01

    Arterially administered Lipiodol Ultrafluid contrast medium selectively remained in various malignant solid tumors because of the difference in time required for the removal of Lipiodol contrast medium from normal capillaries and tumor neovasculature. Although blood flow was maintained in the tumor, even immediately after injection Lipiodol contrast medium remained in the neovasculature of the tumor. To target anti-cancer agents to tumors by using Lipiodol contrast medium as a carrier, the characteristics of the agents were examined. Anti-cancer agents had to be soluble in Lipiodol, be stable in it, and separate gradually from it so that the anti-cancer agents would selectively remain in the tumor. These conditions were found to be necessary on the basis of the measurement of radioactivity in VX2 tumors implanted in the liver of 16 rabbits that received arterial injections of 14C-labeled doxorubicin. Antitumor activities and side effects of arterial injections of two types of anti-cancer agents were compared in 76 rabbits with VX2 tumors. Oily anti-cancer agents that had characteristics essential for targeting were compared with simple mixtures of anti-cancer agents with Lipiodol contrast medium that did not have these essential characteristics. Groups of rabbits that received oily anti-cancer agents responded significantly better than groups that received simple mixtures, and side effects were observed more frequently in the groups that received the simple mixtures. These results suggest that targeting of the anti-cancer agent to the tumor is important for treatment of solid malignant tumors

  18. Conversion and correction factors for historical measurements of iodine-131 in Hanford-area vegetation, 1945--1947. Hanford Environmental Dose Reconstruction Project

    Energy Technology Data Exchange (ETDEWEB)

    Mart, E.I.; Denham, D.H.; Thiede, M.E.

    1993-12-01

    This report is a result of the Hanford Environmental Dose Reconstruction (HEDR) Project whose goal is to estimate the radiation dose that individuals could have received from emissions since 1944 at the U.S. Department of Energy`s (DOE) Hanford Site near Richland, Washington. The HEDR Project is conducted by Battelle, Pacific Northwest Laboratories (BNW). One of the radionuclides emitted that would affect the radiation dose was iodine-131. This report describes in detail the reconstructed conversion and correction factors for historical measurements of iodine-131 in Hanford-area vegetation which was collected from the beginning of October 1945 through the end of December 1947.

  19. Treatment of liver cancer with Rhenium-188 Lipiodol: Colombian experience

    International Nuclear Information System (INIS)

    Bernal, P.; Osorio, M.; Mendoza, M.; Esguerra, R.; Ucros, G.; Gutierrez, C.; Velez, O.; Cerquera, A.M.; Padhy, A.K.

    2002-01-01

    Aim:Trans-arterial Radio-conjugate therapy plays an important role in the palliative treatment of inoperable liver cancer. It also helps in reduction of the tumor to an operable state from an inoperable one. As a part of an IAEA sponsored coordinated research project, a new radiopharmaceutical, Rhenium-188 Lipiodol has been developed. The aim of this study was to establish the safety of the radiopharmaceutical and to find out the efficacy of treatment. Materials and Methods: Eight patients suffering from various forms of liver cancer (Hepatocellular carcinoma-4, Metastases from carcinoma of colon-3 and Carcinoid- 1) were treated with Rhenium -188 Lipiodol. Seven out of the eight patients were classified as ECOG- 1 and one as ECOG- 3. Labelling of Rhenium-188 with Lipiodol was carried out according to a protocol developed under the CRP and standardized in our service. Rhenium-188 Lipiodol was administered through the trans-arterial route by either selective (75%) or ultra selective (25%) hepatic arteriography. Administered therapeutic doses ranged between 170 MBq and 4181 MBq. Dosimetric evaluations were made using the IAEA developed dosimetry spreadsheet. All patients were followed up (1-5 months, average = 2 months) after treatment by clinical examination, liver function tests, haematological examinations and CT scans of liver to determine the size of hepatic tumor. Results: Rhenium-188 Lipiodol treatment was well tolerated by all patients. No immediate systemic complications were noted in any of the patients within 72 hrs. following therapy. Only two patients had mild rise in temperature in the immediate post-therapy period, which subsided subsequently. One patient who was classified as Child B and ECOG 3, developed encephalopathy on the seventh day after treatment. He died of hepatic failure. Another one present depressive syndrome, didn't accept food and died Follow-up CT scans in all the surviving (6/8) patients revealed significant reduction of the tumours

  20. RETROSPECTIVE RECONSTRUCTION OF INTEGRAL IODINE-131 FALLOUT FOR THE SETTLEMENTS OF THE BRYANSK REGION OF RUSSIA ON THE BASIS OF RESULTS OF IODINE-129 CONTENT IN THE SOIL DETERMINATION IN 2008

    Directory of Open Access Journals (Sweden)

    Yu. I. Gavrilin

    2009-01-01

    Full Text Available The article briefly describes the procedure of reconstruction of integral iodine-131 fallouts using fragmentary data on iodine-131 fallouts in May-June 1986, as well as results of determination (in the late period after the accident of iodine-129 concentration in the soil and values of integral fallouts of cesium-137 in the settlements of the Bryansk region of Russia. Results of estimation of integral iodine-131 fallouts (in the area of 32 soil sampling points are presented in the table form. Regularities of ratio (131I/137CsII change in the integral radionuclide fallouts are being determined and values of integral iodine-131 fallouts are being estimatedfor the other settlements of the region with the known values of integral cesium-137 fallouts. It is shown that variability of the average for settlements values of integral iodine-131 fallouts is 70 times less then variability of corresponding integral cesium-137 fallouts.

  1. Use of Iodine-131 to Tellurium-132 Ratios for Assessing the Relationships between Human Inhaled Radioactivity and Environmental Monitoring after the Accident in Fukushima

    Directory of Open Access Journals (Sweden)

    Koji Uchiyama

    2018-03-01

    Full Text Available Significant differences in findings were seen between the intake amounts of iodine-131 that were derived from direct measurements and the estimated intake from environmental monitoring data at the Fukushima accident. To clarify these discrepancies, we have investigated the iodine-131 and tellurium-132 body burdens of five human subjects, who after being exposed to a radioactive plume, underwent 21.5 h whole body counter measurements at Fukui Prefectural Hospital, so clear intake scenario and thyroid counter measurement data were available. To determine the iodine-131 and tellurium-132 body burdens, we introduced a new method of whole body counter calibration composed of a self-consistent approach with the time-dependent correction efficiency factors concept. The ratios of iodine-131 to tellurium-132, ranging from 0.96 ± 0.05 to 2.29 ± 0.38, were consistent with results of the environmental measurements. The 24 h iodine uptake values ranging from 12.1–16.0% were within euthyroid range in Japanese people. These results suggest, even if the relatively low thyroid iodine uptake in the Japanese population was taken into consideration, that there is no doubt about the consistency between direct measurements and environmental monitoring data. Adequate intake scenario is suggested to be principally important to estimate the inhaled radioactivity in areas in or around nuclear accidents.

  2. Production of fusion radionuclides: Molybdenum-99/ Iodine - 131 and Xenon-133; Produccion de los radionucleidos de fision: Molibdeno-99, Yodo-131 y Xenon-133

    Energy Technology Data Exchange (ETDEWEB)

    Barrachina, M; Carrillo, D

    1982-07-01

    This report presents a new radiochemical method for industrial production of the radionuclides: molybdenum-99, iodine-131 and xenon-133. The above mentioned method based on the alkaline metathesis reaction of irradiated uranium (IV) fluoride, presents the best characteristics for the proposed objective. The study deals with the analysis of that reaction and the separation and purification processes. (Author) 71 refs.

  3. Thyroid uptake and imaging with iodine-123 at 4-5 hours: replacement of the 24-hour iodine-131 standard

    International Nuclear Information System (INIS)

    Floyd, J.L.; Rosen, P.R.; Borchert, R.D.; Jackson, D.E.; Weiland, F.L.

    1985-01-01

    A study was carried out to determine the suitability of utilizing a 4 to 5 hr interval from administration of Iodine-123 to imaging and uptake measurement as a replacement for the 24-hr standard originally established with Iodine-131. In 55 patients who underwent scintigraphy at 4 and 24 hr, there was no discrepancy between paired images. In 55 patients who had uptake measured at 4 and 24 hr and in 191 patients who had uptake measured at 5 and 24 hr, the early measurements proved equal or better discriminants of euthyroid from hyperthyroid patients. In our institutions, these findings and the logistical advantages of completing the exam in 4-5 hr led us to abandon the 24-hr study in the majority of patients

  4. A comparison of physical and cytogenetic estimates of radiation dose in patients treated with iodine-131 for thyroid carcinoma

    International Nuclear Information System (INIS)

    Lloyd, D.C.; Purrott, R.J.; Dolphin, G.W.; Horton, P.W.; Halnan, K.E.; Scott, J.S.; Mair, G.

    1976-01-01

    Physical and cytogenetic estimates of the whole-body radiation doses have been compared in 11 patients receiving large doses of iodine-131 for the treatment of thyroid carcinoma. The physical estimate was based on the measurement of thyroid uptake, of the plasma activity variation, and of urinary activity. The cytogenetic estimate was obtained from the analysis of chromosome aberrations in peripheral blood lymphocytes. Good agreement between the estimates was observed in patients whose thyroid glands had previously be ablated by radioiodine. In patients who had varying degrees of thyroid function, there were considerable differences between the estimates with the cytogenetic value always being higher. It is suggested that these differences might be due in part to non-uniform irradiation of lymphocytes by local sources of activity in the thyroid and in the liver. (author)

  5. Accidental release of iodine 131 by the IRE of the Fleurus site: return on experience by the Belgian safety authority

    International Nuclear Information System (INIS)

    Vandecasteele, C.M.; Sonck, M.; Degueldre, D.

    2010-01-01

    After a presentation of the activities of the IRE, the Belgian National Institute of Radio-elements, i.e. the production of radionuclides used in nuclear medicine, this report describes the process and chemical reaction which caused an accidental release of iodine 131. It analyzes the causes of this incident, and how the incident has been managed by the Belgian safety authority. It discusses the first assessment of radiological consequences, describes how the incident has been managed at the federal level, and how population and media have been informed. It discusses the actual radiological consequences through measurements performed on grass and vegetables (graphs and maps indicate contamination levels and contaminated areas), and through the assessment of exposure of adults and children by different ways. Lessons learned are then discussed

  6. A model for determination of human foetus irradiation during intrauterine development when the mother incorporates iodine 131

    International Nuclear Information System (INIS)

    Vasilev, V.; Doncheva, B.

    1989-01-01

    A model is presented for irradiation calculation of human foetus during weeks 8-15 of the intrauterine development, when the mother chronically incorporates iodine 131. This period is critical for the nervous system of the foetus. Compared to some other author's models, the method proposed eliminates some uncertainties and takes into account the changes in the activity of mother's thyroid in time. The model is built on the base of data from 131 I-kinetics of pregnant women and experimental mice. A formula is proposed for total foetus irradiation calculation including: the internal γ and β irradiation; the external γ and β irradiation from the mother as a whole; and the external γ irradiation from the mother's thyroid

  7. Patient release criteria following radioactive iodine-131 treatment in the light of international practice: where does South Africa fit in?

    Science.gov (United States)

    Mongane, Modisenyane S; Rae, William I D

    2017-10-01

    The release from hospital of patients treated with radioactive iodine-131 (I) remains a controversial issue as a result of the range of guidelines implemented by national regulatory bodies responsible for radiation protection in various countries worldwide. The aim of this study was to review and analyse the literature on patient release criteria (PRC) applied internationally in an attempt to achieve a justifiable approach to setting equivalent criteria in South Africa. In 2016, the South African Department of Health, Directorate: Radiation Control added conditions (numbers 50 and 90), to licences to use radioactive nuclides. These conditions state that patients must be hospitalized when the dose rate at 1 m is above 25 μSv/h, or more than 555 MBq of iodine-131 was administered to the patient. However, these criteria do not consider patients' socioeconomic conditions. A literature survey was carried out of articles detailing PRC from high-income countries as well as those in the middle-income and lower-income groups. Socioeconomic conditions within countries were determined using the International Monetary Fund lists of gross domestic product. The results from the literature have shown that in setting PRC, several countries have considered the socioeconomic conditions prevailing in their countries to achieve harmony between public protection and cost associated with hospitalization. The South African authority conditions must be seen in the context of the approach followed by other countries. Considering the international context, a justifiable, and potentially implementable, guideline or policy for improving individualized and more caring patient management is advocated.

  8. 188Re-SSS lipiodol: radiolabelling and biodistribution following injection into the hepatic artery of rats bearing hepatoma.

    Science.gov (United States)

    Garin, Etienne; Denizot, Benoit; Noiret, Nicolas; Lepareur, Nicolas; Roux, Jerome; Moreau, Myriam; Herry, Jean-Yves; Bourguet, Patrick; Benoit, Jean-Pierre; Lejeune, Jean-Jacques

    2004-10-01

    Although intra-arterial radiation therapy with 131I-lipiodol is a useful therapeutic approach to the treatment of hepatocellular carcinoma, various disadvantages limit its use. To describe the development of a method for the labelling of lipiodol with 188Re-SSS (188Re (S2CPh)(S3CPh)2 complex) and to investigate its biodistribution after injection into the hepatic artery of rats with hepatoma. 188Re-SSS lipiodol was obtained after dissolving a chelating agent, previously labelled with 188Re, in cold lipiodol. The radiochemical purity (RCP) of labelling was checked immediately. The 188Re-SSS lipiodol was injected into the hepatic artery of nine rats with a Novikoff hepatoma. They were sacrificed 1, 24 and 48 h after injection, and used for ex vivo counting. Labelling of 188Re-SSS lipiodol was achieved with a yield of 97.3+/-2.1%. The immediate RCP was 94.1+/-1.7%. Ex vivo counting confirmed a predominantly hepatic uptake, with a good tumoral retention of 188Re-SSS lipiodol, a weak pulmonary uptake and a very faint digestive uptake. The 'tumour/non-tumoral liver' ratio was high at 1, 24 and 48 h after injection (2.9+/-1.5, 4.1+/-/4.1 and 4.1+/-0.7, respectively). Using the method described here, 188Re-SSS lipiodol can be obtained with a very high yield and a satisfactory RCP. The biodistribution in rats with hepatoma indicates a good tumoral retention of 188Re-SSS lipiodol associated with a predominant hepatic uptake, a weak pulmonary uptake and a very faint digestive uptake. This product should be considered for intra-arterial radiation therapy in human hepatoma.

  9. Evaluation of the Basedow disease treatment by a iodine 131 fixed dose; Evaluation du traitement de la maladie de Basedow par une dose fixe d'iode 131

    Energy Technology Data Exchange (ETDEWEB)

    El Ajmi, W.; Slim, I; Rmadi, S.; Yeddes, I.; Krimi, S.; Ltaief, B.; Mhiri, A.; Ben Slimene, M.F. [Service de medecine nucleaire, institut Salah Azeiz, Tunis, (Tunisia)

    2009-05-15

    The treatment of the basedow disease by iodine 131 is more and more used. however, the doses used stay variable. In order to reduce the treatment failure, we chose a protocol with strong fix doses of iodine 131. We give our preliminary results for 63 patients. The treatment by strong fix dose of iodine 131 is simple, safe and efficient for the control of hyperthyroidism in the Basedow disease. This protocol has for advantage to be simpler comparatively to these ones using adjusted doses according the weight of the thyroid and its fixation rate. (N.C.)

  10. Estimation of the activity and doses to personnel which intake Iodine 131 by coffee consumption in a cabinet of Nuclear Medicine

    International Nuclear Information System (INIS)

    Ruiz C, M.A.; Alfaro L, M.; Salinas, J.A.; Molina, G.

    2003-01-01

    Soon after an incident in a cabinet of nuclear medicine, its were carried out in the National Institute of Nuclear Research of Mexico (ININ), a series of bio essays measurements by whole-body counting to six people attributed to this cabinet. Of six people, five are classified as Occupational Exposed Personnel (POE), and the other one that works as secretary, according to the General Regulation of Radiological Safety, is classified as public member. Six people that were involved in this incident, the one which presumably it took place among November 15 and 18, 2002 and that it consisted on the effusion of a vial containing an unknown quantity of Iodine-131 to a coffeepot, they ingested coffee in diverse quantities. The Iodine-131 is used in nuclear medicine, so much for the illnesses diagnostic like in the treatment of thyroid cancer and of hyperthyroidism. (Author)

  11. Place of synthesis anti thyroids in the hyperthyroidism treatment by iodine 131; Place des antithyroidiens de synthese dans le traitement par iode 131 des hyperthyroidies

    Energy Technology Data Exchange (ETDEWEB)

    Clerc, J. [Hopital Necker, 75 - Paris (France)

    2000-01-01

    The prescription of synthesis anti thyroids allows to get a fast control of hyperthyroidism when the average time of curing after iodine 131 varies from 6 to 12 weeks, according to the level of radiation doses. It allows to treat the patients in euthyroidism and to avoid aggravation of thyrotoxicosis in the following of the iodine and is particularly useful for the old patients with a cardio vascular risk.

  12. Image findings of a false positive radioactive iodine-131 uptake mimicking metastasis in pulmonary aspergillosis identified on single photon emission computed tomography-computed tomography

    Directory of Open Access Journals (Sweden)

    Kamaleshwaran Koramadai Karuppusamy

    2015-01-01

    Full Text Available High doses of iodine-131 are commonly used in patients with differentiated thyroid cancer after total or subtotal thyroidectomy, in order to ablate the remaining cancer or normal thyroid tissue. Multiple different false-positive scans can occur in the absence of residual thyroid tissue or metastases. The authors present a case of abnormal uptake of radioactive iodine in the aspergilloma, potentially masquerading as pulmonary metastases.

  13. (188)Re-SSS/Lipiodol: Development of a Potential Treatment for HCC from Bench to Bedside.

    Science.gov (United States)

    Lepareur, Nicolas; Ardisson, Valérie; Noiret, Nicolas; Garin, Etienne

    2012-01-01

    Hepatocellular carcinoma (HCC) is the 5th most common tumour worldwide and has a dark prognosis. For nonoperable cases, metabolic radiotherapy with Lipiodol labelled with β-emitters is a promising therapeutic option. The Comprehensive Cancer Centre Eugène Marquis and the National Graduate School of Chemistry of Rennes (ENSCR) have jointly developed a stable and efficient labelling of Lipiodol with rhenium-188 (E(βmax) = 2.1 MeV) for the treatment of HCC. The major "milestones" of this development, from the first syntheses to the recent first injection in man, are described.

  14. Skin eruptions following treatment with Iodine-131 for hyperthyroidism. A rare and un-reported early/intermediate side effect

    International Nuclear Information System (INIS)

    Paul, A. K.; AL-Nahhas, A.; Ansari, S. M.; Islam, N.

    2005-01-01

    Iodine-131 ( 131I ) is a well-established method for the treatment of hyperthyroidism. Following such therapy, patients may experience symptoms relating to early or delayed side effects that can be prevented or minimized if necessary measures are taken. We have noticed an unusual side effect of 131I therapy in the form of a skin eruption (iododerma) and aimed at assessing the frequency and severity of this side effect. Retrospective review of 141 patients treated with 131I between January 1994 to December 2000 (86 F, 55 M; mean age 41.35±11.02 years) was performed. The dose of 131I ranged from 250.500 MBq. Post therapy clinical and biochemical evaluation of thyroid function was done at 6 weeks, 3, 6, and 9 months then annually. Of the 141 treated patients, 3 patients (2.1%) presented with iododerma 4.6 weeks after 131I therapy administration. Lesions were observed at both ankles and lower legs in all 3 cases. All lesions disappeared within 6 months with no residual effect. No other skin lesions were seen thereafter during the follow-up period. Iododerma is a rare complication of 131I therapy that has not been reported before. It appears within 4.6 weeks after therapy and is a self-limiting condition. (author)

  15. Effect on thyroid function and serum PTH, BGP, CT of small dose of iodine 131 combined with Methimazole in patients with hyperthyroidism

    Directory of Open Access Journals (Sweden)

    Jia-Yin Qiu

    2016-03-01

    Full Text Available Objective: To observe the effect on thyroid function and serum PTH, BGP, CT of small dose of iodine 131 combined with Methimazole in patients with hyperthyroidism. Methods: A total of 104 patients with hyperthyroidism willing be incorporated into the study were randomly divided into the observation group (54 cases and the control group (50 cases. The control group was treated with Methimazole, and the observation group was given a small dose of iodine 131 the basised on the control group. For 2 months, to observe the changes of thyroid function (TT3, TT4, FT3, FT4 and TSH and bone metabolism related indexes (PTH, BGP and CT of the two groups. Results: (1 After treatment, TT3, FT3, TT4 and FT4 of the two groups decreased with before, and the observation group improved more significantly than the control group, with statistical difference; TSH of the two groups had no significant change. (2 After treatment, BGP and CT of the two groups decreased and PTH increased, the observation group improved more significantly than the control group, with statistical difference. Conclusion: small dose of iodine 131 combined with Methimazole can correct thyroid function and bone metabolism quickly in patients with hyperthyroidism.

  16. Hyperthyroidism treatment by iodine 131: about a study on 270 patients; Traitement de l'hyperthyroidie par l'iode 131: a propos d'une etude sur 270 patients

    Energy Technology Data Exchange (ETDEWEB)

    Leroux, M.A

    2005-07-01

    This study constitutes a starting point for a thought about the use of iodine 131 in the treatment of hyperthyroidism. The therapies are different depending on the teams, for the iodine 131 activities to deliver and their calculation modes; The use of synthesis anti-thyroid drugs before therapy is discussed. The radiation protection is an important factor in the decision of a metabolic radiotherapy. The indications of the treatment by radioactive iodine are different in Europe and in Usa. (N.C.)

  17. Synthesis and In Vitro and In Vivo Evaluation of Iodine-131-Labeled Folates: Potential Molecular Diagnostic and Therapeutic Radiopharmaceuticals

    International Nuclear Information System (INIS)

    Al Jammaz, I.

    2009-01-01

    Molecular targeting imaging has a great potential to be able to image molecular changes that are currently defined as predisease states which facilitate earlier detection of cancer and consequently, the greatest chance of cure. Advancement of scintigraphic imaging and radiotherapy is highly determined by development of more specific radiotracers. The Membrane-associated-folic acid receptor is a glycosylphospstidylinositol protein that overexpressed in approximately 100% of serious ovarian adenocarcinomas and various epithelial cancers including cervical, colorectal and renal cancers. Meanwhile, this receptor is highly restricted in most normal tissues which make these tumors as an excellent candidates for molecular targeting imaging and therapy through the folate receptor system. As part of our on-going research effort to develop prosthetic precursors for radiohalogenation of bioactive molecules, we have previously reported the synthesis and biological characterization of [ 18 F]- fluorobenzene and pyridine carbohydrazide-folate conjugates ([ 18 F]-SFB and [ 18 F]-SFP-folates). We here report the synthesis and biological characterization of [ 131 I]-iodobenzenecarbohydrazide-folate conjugate ([ 131 I]-SIB-folate) as a potential therapeutic radiopharmaceutical. The synthetic approaches for preparation of [ 131 I]iodobenzene carbohydrazide-folates ([ 131 I]-SIB-folate) entailed sequence of reactions. Hydrazide-folate was reacted with N-succinimidyl-m-[131I]-iodobenzoate-carboxylate ([ 131 I]-SIB) to give [ 131 I]-SIB-folate conjugate. Radiochemical yield was greater than 80% and synthesis times were ranging between 40-45 min. Radiochemical purity was also greater than 97% without HPLC purification. These synthetic approaches hold considerable promise as rapid and simple method for the radiohalogenation of folate in high radiochemical yield in short time. In vitro tests on KB cell line has shown that significant amount of the radioconjugate associated with cell fractions and in vivo characterization in normal CBA/J mice revealed rapid blood clearance of this radioconjugate with excretion predominantly by the hepatobiliary system. In vivo tumor targeting capacity of this radioconjugate in athymic mice with folate-receptor-positive human KB cell tumor xenografts is currently in progress. (author)

  18. Biodistribution and scintigraphy of iodine-131-iododeoxyadenosine in rats bearing breast cancer

    International Nuclear Information System (INIS)

    Kim, Seon Gu; Kim, Chang Guhn; Lee, Kang Mo

    1998-01-01

    I-131 labeled (2'-deoxy-2'-iodo-β-D-arabinofuranosyl) adenine (IAD) may be involved in DNA synthesis during active proliferation of tumor cells. We conducted this study to find out the biodistribution of IAD and it's feasibility for scintigraphic tumor imaging. Tosyl acetyl-adenosine was dissolved in acetonitrile, and I-131-NaI was added and heated to synthesize IAD. Female Fisher 344 rats inoculated with breast tumor cells were injected with 0.27 MBq of IAD. Rats were sacrificed at 0.5, 1, 2, 4, 24h and the % of injected dose per gram of tissue (%ID/g) was determined. For scintigraphy, rats bearing breast cancer were administered with 1.11 MBq of IAD and imaging was performed after 2 and 24h. Then, rat body was fixed and microtomized slice was placed on radiographic film for autoradiography. %ID/g of tumor was 0.74 (0.5h), 0.73 (1h), 0.55 (2h), 0.38 (4h), and 0.05 (24h), respectively. At 1h after injection, %ID/g of tumor was higher than that of heart (0.51). However, %ID/g of tumor was lower than blood (1.06), lung (0.77), and thyroid (177.71). At 4h, %ID/g of tumor in comparison with other tissue did not change. Tumor contrast expressed by tumor to blood ratio was 0.69 and tumor to muscle ratio was 5.11 at 1h. However, these ratios did not improve through 24h. On autoradiogram and scintigraphy at 2 and 24 hour, the tumor was well visualized. This results suggest that IAD may have a potential for tumor scintigraphy. However, further work is needed to improve localization in tumor tissue

  19. Exposure rates (versus time after administration), in relation with clinical factors, for thyroid carcinoma patients treated with Iodine-131

    International Nuclear Information System (INIS)

    Papadimitriou, D.; Oros, L.; Manetou, A.; Perris, A.; Molfetas, M.; Kottou, S.

    2002-01-01

    While the therapeutic use of iodine-131 for thyroid carcinoma patients offers enormous benefit to them, it contributes also significantly to the radiation exposure of individuals and population. A critical quantity for decisions relating radiation protection system based on restrictions recommended by authorities is the residual I-131 activity in patient's body. When this value is larger than a threshold level, it may keep the patient hospitalised for a short period of usually 2 to 3 days with an additional period of 7 days at home, where he must sleep separately and avoid close contact with other people. Essential for radiation protection issues is the careful collection of radioactive urine, radioactive waste and avoidance of any contaminations by perspiration and saliva. Longer hospital stay would increase the total cost of the treatment and limit the availability of the isolation room. So the patient has then to return home, having always in mind that in spite of the fast washout of the I-131 from his body, even the second week still contributes significantly to the total radiation burden to relatives and friends. Radiation hazards concerning relatives and friends can be kept to a truly negligible level (a small fraction of the annual dose limit of only 1mSv), only if it is provided that: a) reasonable standards of personal hygiene and cleanliness are followed, b) urine or saliva contaminations are avoided and c) patient's close contact with relatives or friends is kept to a minimum. These measures should be followed for a time period of 2-8 days after hospital discharge, a period that depends on administered and retained I-131 activity. This work tries to estimate the correlation between several clinical factors and the residual activity of I-131 in patient's body and proposes a method for a more simple measurement of the total body activity during patient's stay in the treatment centre - hospital

  20. Three-dimensional noninvasive monitoring iodine-131 uptake in the thyroid using a modified Cerenkov luminescence tomography approach.

    Science.gov (United States)

    Hu, Zhenhua; Ma, Xiaowei; Qu, Xiaochao; Yang, Weidong; Liang, Jimin; Wang, Jing; Tian, Jie

    2012-01-01

    Cerenkov luminescence tomography (CLT) provides the three-dimensional (3D) radiopharmaceutical biodistribution in small living animals, which is vital to biomedical imaging. However, existing single-spectral and multispectral methods are not very efficient and effective at reconstructing the distribution of the radionuclide tracer. In this paper, we present a semi-quantitative Cerenkov radiation spectral characteristic-based source reconstruction method named the hybrid spectral CLT, to efficiently reconstruct the radionuclide tracer with both encouraging reconstruction results and less acquisition and image reconstruction time. We constructed the implantation mouse model implanted with a 400 µCi Na(131)I radioactive source and the physiological mouse model received an intravenous tail injection of 400 µCi radiopharmaceutical Iodine-131 (I-131) to validate the performance of the hybrid spectral CLT and compared the reconstruction results, acquisition, and image reconstruction time with that of single-spectral and multispectral CLT. Furthermore, we performed 3D noninvasive monitoring of I-131 uptake in the thyroid and quantified I-131 uptake in vivo using hybrid spectral CLT. Results showed that the reconstruction based on the hybrid spectral CLT was more accurate in localization and quantification than using single-spectral CLT, and was more efficient in the in vivo experiment compared with multispectral CLT. Additionally, 3D visualization of longitudinal observations suggested that the reconstructed energy of I-131 uptake in the thyroid increased with acquisition time and there was a robust correlation between the reconstructed energy versus the gamma ray counts of I-131 (r(2) = 0.8240). The ex vivo biodistribution experiment further confirmed the I-131 uptake in the thyroid for hybrid spectral CLT. Results indicated that hybrid spectral CLT could be potentially used for thyroid imaging to evaluate its function and monitor its treatment for thyroid cancer.

  1. Iodine-131 dose dependent gene expression in thyroid cancers and corresponding normal tissues following the Chernobyl accident.

    Directory of Open Access Journals (Sweden)

    Michael Abend

    Full Text Available The strong and consistent relationship between irradiation at a young age and subsequent thyroid cancer provides an excellent model for studying radiation carcinogenesis in humans. We thus evaluated differential gene expression in thyroid tissue in relation to iodine-131 (I-131 doses received from the Chernobyl accident. Sixty three of 104 papillary thyroid cancers diagnosed between 1998 and 2008 in the Ukrainian-American cohort with individual I-131 thyroid dose estimates had paired RNA specimens from fresh frozen tumor (T and normal (N tissue provided by the Chernobyl Tissue Bank and satisfied quality control criteria. We first hybridized 32 randomly allocated RNA specimen pairs (T/N on 64 whole genome microarrays (Agilent, 4×44 K. Associations of differential gene expression (log(2(T/N with dose were assessed using Kruskall-Wallis and trend tests in linear mixed regression models. While none of the genes withstood correction for the false discovery rate, we selected 75 genes with a priori evidence or P kruskall/P trend <0.0005 for validation by qRT-PCR on the remaining 31 RNA specimen pairs (T/N. The qRT-PCR data were analyzed using linear mixed regression models that included radiation dose as a categorical or ordinal variable. Eleven of 75 qRT-PCR assayed genes (ACVR2A, AJAP1, CA12, CDK12, FAM38A, GALNT7, LMO3, MTA1, SLC19A1, SLC43A3, ZNF493 were confirmed to have a statistically significant differential dose-expression relationship. Our study is among the first to provide direct human data on long term differential gene expression in relation to individual I-131 doses and to identify a set of genes potentially important in radiation carcinogenesis.

  2. Test of irradiation of tellurium oxide for obtaining iodine-131 by dry distillation; Prueba de irradiacion de dioxido de telurio para obtener yodo-131 por destilacion seca

    Energy Technology Data Exchange (ETDEWEB)

    Alanis M, J. [ININ, Departamento de Materiales Radiactivos, 52045 Ocoyoacac, Estado de Mexico (Mexico)

    2003-07-15

    With the purpose of optimizing to the maximum independently the work of the reactor of those mathematical calculations of irradiation that are already optimized, now it corresponds to carry out irradiation tests in the different positions with their respective neutron fluxes that it counts the reactor for samples irradiation. Then, it is necessary to carry out the irradiation of the tellurium dioxide through cycles, with the purpose of observing the activity that it goes accumulating in each cycle and this way to obtain an activity of the Iodine-131 obtained when finishing the last cycle. (Author)

  3. Evaluation the sources of uncertainty associated to the measurement results of in vivo monitoring of iodine 131 in the thyroid

    International Nuclear Information System (INIS)

    Gontijo, Rodrigo Modesto Gadelha

    2011-01-01

    In vivo monitoring techniques consist of identification and quantification of radionuclides present in the whole body and specific organs and tissues. In Vivo monitoring requires the use of detedors which are sensitive to the radiation emitted by radionuclides present in the monitored individual. The results obtained in measurements may present small uncertainties which are within pre-set limits in monitoring programs for occupationally exposed individuais. However, any device used to determine physical quantities present uncertainties in the measured values. The total uncertainty of a measurement result is estimated from the propagation of the uncertainties associated to each parameter of the calculation. This study aims to evaluate the sources of uncertainty associated to the measurement results of in vivo monitoring of iodine 131 in the thyroid, in comparison to the suggested in the General Guide for Estimating Effective Doses from Monitoring Data (Project IDEAS/European Community). The reference values used were the ones for high-energy photons (>100 keV). The measurement uncertainties were divided into two categories: type A and type B. The component of type A represents the statistical fluctuation in the counting of the standard source. Regarding type B, the following variations were presented: detector positioning over the phantom; variation of background radiation; thickness of the overlay tissue over the monitored organ, distribution of the activity in the organ. Besides the parameters suggested by the IDEAS Guide, it has also been evaluated the fluctuation of the counting due to the phantom repositioning, which represents the reproducibility of the measurement geometry. Measurements were performed at the Whole Body Counter Unit of IRD using a scintillation detector Nal (Tl) 3 x3 and a neck-thyroid phantom developed at LABMIVIRD. Scattering factors were calculated and compared in different counting geometries. The results of this study show that the

  4. Putting to point the production process of iodine-131 by dry distillation (Preoperational tests); Puesta a punto el proceso de produccion de yodo-131 por destilacion seca (Pruebas preoperacionales)

    Energy Technology Data Exchange (ETDEWEB)

    Alanis M, J. [ININ, Departamento de Materiales Radiactivos, 52045 Ocoyoacac, Estado de Mexico (Mexico)

    2002-12-15

    With the purpose of putting to point the process of production of {sup 131}I, one of the objectives of carrying out the realization of operational tests of the production process of iodine-131, it was of verifying the operation of each one of the following components: heating systems, vacuum system, mechanical system and peripheral equipment that are part of the production process of iodine-131, another of the objectives, was settling down the optimal parameters that were applied in each process during the obtaining of iodine-131, it is necessary to point out that this objective is very important, since the components of the equipment are new and its behavior during the process is different to the equipment where its were carried out the experimental studies. (Author)

  5. 18F-FDG SPECT/CT in the diagnosis of differentiated thyroid carcinoma with elevated thyroglobulin and negative iodine-131 scans

    International Nuclear Information System (INIS)

    Ma, C.; Wu, Z.; Wang, H.; Wang, X.; Shao, M.; Zhao, L.; Jiawei, X.

    2015-01-01

    Aim of the present study was to investigate the usefulness of 18 F-FDG SPECT/CT in differentiated thyroid cancer (DTC) with elevated serum thyroglobulin (Tg) but negative iodine-131 scan. This retrospective review of patients with DTC recurrence who had 18 F-FDG SPECT/CT and 18 F-FDG PET/CT for elevated serum Tg but negative iodine-131 scan (March 2007-October 2012). After total thyroidectomy followed by radioiodine ablation, 86 consecutive patients with elevated Tg levels underwent 18 F-FDG SPECT/CT or 18 F-FDG PET/CT. Of these, 45 patients had 18 F-FDG SPECT/CT, the other 41 patients had 18 F-FDG PET/CT 3-4 weeks after thyroid hormone withdrawal. The results of 18 F-FDG PET/CT and SPECT/CT were correlated with patient follow-up information, which included the results from subsequent imaging modalities such as neck ultrasound, MRI and CT, Tg levels, and histologic examination of surgical specimens. The diagnostic accuracy of the two imaging modalities was evaluated. In 18 F-FDG SPECT/CT scans, 24 (24/45) patients had positive findings, 22 true positive in 24 patients, false positive in 2 patients, true-negative and false-negative in 6, 15 patients, respectively. The overall sensitivity, specificity, and accuracy of 18F-FDG SPECT/CT were 59.5%, 75% and 62.2%, respectively. Twenty six patients had positive findings on 18 F-FDG PET/CT scans, 23 true positive in 26 (26/41) patients, false positive in 3 patients, true-negative and false-negative in 9, 6 patients, respectively. The overall sensitivity, specificity, and accuracy of 18F-FDG PET/CT were 79.3%, 81.8% and 78.1%, respectively. Clinical management changed for 13 (29%) of 45 patients by 18 F-FDG SPECT/CT, 14 (34%) of 41 patients by 18F-FDG PET/CT including surgery, radiation therapy, or multi kinase inhibitor. Based on the retrospective analysis of 86 patients, 18F-FDG SPECT/CT has lower sensitivity in the diagnosis of DTC recurrence with elevated Tg and negative iodine-131scan to 18F-FDG PET/CT. The clinical

  6. A cause of false positive of the whole body scanning with iodine 131: obstructive hydronephrosis; Une cause de faux-positif du balayage corps entier a l'iode 131: l'hydronephrose obstructive

    Energy Technology Data Exchange (ETDEWEB)

    Sellem, A.; Elbez, I.; Rejeb, O.; Elkadri, N.; Hammami, H. [Service de medecine nucleaire, hopital Militaire, Tunis, (Tunisia)

    2009-05-15

    The objective is to report the case of a differentiated carcinoma of the thyroid with a false positive aspect to the whole-body scanning with iodine 131 in relation with an accumulation of the tracer at the level of an obstructive appearance hydronephrosis. (N.C.)

  7. Chemical treatment of wastewaters produced during separation of iodine 131; Traitement chimique des eaux residuaires provenant de la preparation d'iode-131

    Energy Technology Data Exchange (ETDEWEB)

    Cohen, P.; Marcaillou, J.; Amavis, R.

    1959-06-22

    The authors report the development and assessment of a chemical treatment of radioactive wastewaters by co-precipitation. This treatment is aimed at replacing a treatment based on the use of calcium phosphate which proved to be insufficient for wastewaters resulting from the production of iodine 131. After a presentation of the characteristics of the effluents to be processed, the authors report co-precipitation tests performed on effluents before release in the storage vessel (by using barium hydroxide, lead acetate or lead sulfate) and on effluents diluted on the storage vessel. They show that a co-precipitation method based on the use of lead sulfate in alkaline medium gives the best results.

  8. Radioablative therapy with Iodine-131 on a patient with thyroid cancer and chronic renal failure in hemodialysis first experience in Peru

    International Nuclear Information System (INIS)

    Apaza Veliz, D. G.; Herrera Vera, R. D.; Cardenas Abarca, C. A.; Oporto Gonzales, C. A.; Aguilar Ramírez, C.; Urquizo Baldomero, R. M.; Vega Ramírez, J. L.

    2016-01-01

    The Iodine-131 (I-131) is a radioisotope used as a standard treatment for radioablation of thyroid remnants. Among thyroid cancer patients, the ones undergoing hemodialysis represent a specific group. The dose of I-131 is given orally to these patients, part of it is absorbed by the thyroid remnants and the rest of it, largely not incorporated, is excreted primarily by renal excretion. The use of a high dose of radioactivity in the process, and the inability of excretion, represents a high risk of exposure to the patient, medical staff and hemodialysis equipment. This work describes the procedure applied on the radioablation therapy for thyroid cancer while receiving hemodialysis, minimizing the risks for the patient and the staff involved. This clinical procedure will establish the dosimetric measures, a plan on radiation protection and a treatment protocol for this specific type of patients.

  9. Radioablative therapy with Iodine-131 on a patient with thyroid cancer and chronic renal failure in hemodialysis first experience in Peru

    Energy Technology Data Exchange (ETDEWEB)

    Apaza Veliz, D. G., E-mail: dgav02@gmail.com [Hospital Nacional Carlos Alberto Seguin Escobedo, Servicio de Medicina Nuclear, Arequipa, Perú, Universidad Nacional de San Agustín de Arequipa, Escuela de Física, Arequipa (Peru); Herrera Vera, R. D.; Cardenas Abarca, C. A.; Oporto Gonzales, C. A.; Aguilar Ramírez, C.; Urquizo Baldomero, R. M. [Hospital Nacional Carlos Alberto Seguin Escobedo, Servicio de Medicina Nuclear, Arequipa (Peru); Vega Ramírez, J. L. [Universidad Nacional de San Agustín de Arequipa, Escuela de Física, Arequipa (Peru)

    2016-07-07

    The Iodine-131 (I-131) is a radioisotope used as a standard treatment for radioablation of thyroid remnants. Among thyroid cancer patients, the ones undergoing hemodialysis represent a specific group. The dose of I-131 is given orally to these patients, part of it is absorbed by the thyroid remnants and the rest of it, largely not incorporated, is excreted primarily by renal excretion. The use of a high dose of radioactivity in the process, and the inability of excretion, represents a high risk of exposure to the patient, medical staff and hemodialysis equipment. This work describes the procedure applied on the radioablation therapy for thyroid cancer while receiving hemodialysis, minimizing the risks for the patient and the staff involved. This clinical procedure will establish the dosimetric measures, a plan on radiation protection and a treatment protocol for this specific type of patients.

  10. Experience in the patients management which received treatments with radioactive iodine (131I). Measurements and dosimetry pertaining to the personnel related

    International Nuclear Information System (INIS)

    Ruiz J, A.

    1999-01-01

    In the INNSZ there are administering ablative doses of radioactive iodine to patients with problems of the thyroid gland from 40 years ago. Starting from 1992 was initiated the restlessness to inform to the patients verbally and in writing over the measurements of radiological safety that must be followed for the protection of their families. In this work it is commented, the benefits obtained with the patients and the teachings to give to the personnel what attend the patients which receive treatments with iodine-131 and must be hospitalized. It is commented too over the standardization standing of the patients discharged whom received radioactive material and lastly, it was make a dosimetric study of the nurses, radiotherapeutic and control area. (Author)

  11. Radioablative therapy with Iodine-131 on a patient with thyroid cancer and chronic renal failure in hemodialysis first experience in Peru

    Science.gov (United States)

    Apaza Veliz, D. G.; Herrera Vera, R. D.; Cardenas Abarca, C. A.; Oporto Gonzales, C. A.; Aguilar Ramírez, C.; Vega Ramírez, J. L.; Urquizo Baldomero, R. M.

    2016-07-01

    The Iodine-131 (I-131) is a radioisotope used as a standard treatment for radioablation of thyroid remnants. Among thyroid cancer patients, the ones undergoing hemodialysis represent a specific group. The dose of I-131 is given orally to these patients, part of it is absorbed by the thyroid remnants and the rest of it, largely not incorporated, is excreted primarily by renal excretion. The use of a high dose of radioactivity in the process, and the inability of excretion, represents a high risk of exposure to the patient, medical staff and hemodialysis equipment. This work describes the procedure applied on the radioablation therapy for thyroid cancer while receiving hemodialysis, minimizing the risks for the patient and the staff involved. This clinical procedure will establish the dosimetric measures, a plan on radiation protection and a treatment protocol for this specific type of patients.

  12. Preliminary study of the distribution of dose in patients with Graves disease undergoing examination of uptake of iodine-131 using Monte Carlo simulation

    International Nuclear Information System (INIS)

    Schwarcke, Marcelo; Marques, Tatiana; Alva, Mirko; Baffa, Oswaldo; Nicolucci, Patricia

    2009-01-01

    Patients with Graves' disease have a high hormonal disorder, which causes the change of behavior in society. One way to treat this disease is the use of doses of Iodine-131, requiring that the patient carries out the examination of uptake of 131 I estimates for completion of the activity to be administered. Using these data capture and compared with the simulated data using the Monte Carlo code Penelope is possible to determine a distribution of dose to the region surrounding the thyroid. As noted the difference between the simulated values and the experimentally obtained were 10.36%, thus showing the code of simulation for accurate determination of absorbed dose in tissue near the thyroid. (author)

  13. Psychological and behavioral intervention improves the quality of life and mental health of patients suffering from differentiated thyroid cancer treated with postoperative radioactive iodine-131

    Directory of Open Access Journals (Sweden)

    Wu HX

    2016-05-01

    Full Text Available Hong-Xia Wu,1,* Hua Zhong,2,3,* Yue-Dong Xu,1 Cui-Ping Xu,4 Ying Zhang,5 Wei Zhang1 1Department of Endocrinology, Shandong Provincial Qianfoshan Hospital, Shandong University, 2Department of Oncology, Shandong University of Traditional Chinese Medicine, 3Department of Traditional Chinese Medicine, Shandong Provincial Qianfoshan Hospital, Shandong University, 4Department of Nursing, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong, 5Department of Nursing, Tianjin Chest Hospital, Tianjing, People’s Republic of China *These authors contributed equally to this work Background: We examined the effects of psychological and behavioral intervention on health-related quality of life and mental health among patients suffering from differentiated thyroid cancer (DTC treated with postoperative radioactive iodine-131 (RAI.Methods: Sixty patients with DTC, undergoing RAI, were randomly assigned to receive either conventional nursing (n=30 or a 1-year psychological and behavioral intervention based on conventional nursing (n=30. Health-related quality of life and mental health issues, depression, and anxiety were measured using the Quality of Life Core Questionnaire, Self-rating Depression Scale, and Self-rating Anxiety Score, respectively.Results: After RAI treatment, patients in both groups showed improved functional capacities (ie, physical, role, cognitive, emotional, and social and global quality of life, along with reduced depression and anxiety (P<0.05. At 1-year follow-up, compared with patients in the routine nursing group, those in the psychological and behavioral intervention group demonstrated greater improvements in functional capacities, global quality of life, and depression and anxiety symptoms (P<0.05.Conclusion: Psychological and behavioral interventions for patients with DTC undergoing RAI facilitated positive outcomes, suggesting that nursing care models that include psychological and behavioral interventions

  14. Radioecology application to electronuclear site studies. Experimental data on uptake and desorption of iodine 131 and molybdenum 99 by Cyprinus carpio (L.)

    International Nuclear Information System (INIS)

    Bourdeau, F.; Baudin, J.P.; Foulquier, L.; Lambrechts, A.

    1980-01-01

    The contamination of the carps by the iodine 131 is characterized by a very swift build-up followed by a slight radioactive decay which tends to an equilibrium state; 16 days later, the concentration factor, in terms of the wet weight, is in the order of 6. 37,5% of the fixed radionuclide is concentrated in the muscles and the skeleton and 43% in the viscera. The decontamination study shows a biological half-life of about 33 days and an effective half-life of 6 days. Because of the difficult radioactivity measurements pertaining to the separation of the molybdenum 99, and of its by-product the technetium 99m, the study, then, relates to the mixing of the two elements. The build-up of the two radionuclides essentially takes place in the first hours after introducing the contaminating solution into the medium. 14 days later, the concentration factor, in terms of the wet weight, is about 0,20. The highest 99 Mo+sup(99m)Tc abundance is to be found in the viscera which hold up 50% of the whole radioactivity for fishes. The elimination of the mixing by the carps occurs very fast. The desorption process corresponds to two biological half-lives: Tb 1 approximately 8 hours and Tb 2 approximately 180 hours. The effective half-lives are: Te 1 approximately 8 hours and Te 2 approximately 50 hours. This preliminary data shows a low transfer rate of the iodine 131 and of the mixing molybdenum 99 + technetium 99m between water and fishes. This data must be completed as follows: by knowing the role of the food chain and the influence of the physico-chemical form of these radionuclides [fr

  15. Analysis of changes in the percentage of B (CD19) and T (CD3) lymphocytes, nk cells, subsets CD4, CD8 in differentiated thyroid cancer patients treated with iodine-131

    International Nuclear Information System (INIS)

    Luo Quanyong; Yu Yongli; Chen Libo; Lu Hankui; Zhu Ruisen

    2004-01-01

    Objective: To evaluate the changes in the percentage of B (CD19) and T (CD3) lymphocytes, NK cells, subsets CD4, CD8 in patients with differentiated thyroid carcinoma (DTC) who received iodine-131 for therapeutic purposes. Methods: In this study, 102 DTC patients were divided into three groups. Group A, 8 cases received 1850 MBq of iodine-131 for the remnant thyroid ablation. Group B, 43 cases received 3700 MBq of iodine-131 for the treatment of cervical lymph node metastasis. Group C, 51 cases received 7400 MBq of iodine-131 for remote metastasis. All patients were in a hypothyroid state at the time of administration of iodine-131 and resumed L-thyroxine (2μg/Kg/day) 5 days after iodine-131 administration. The percentage of B and T lymphocytes, NK cells, subsets CD4, CD8 in peripheral blood were serially analyzed at baseline and at days 7, 30 and 90 after iodine-131 administration using a Coulter EPICS XL cytometer. Ten healthy individuals were used as a control group for lymphocyte subset values. Results: Comparing the basal lymphocyte subset levels in groups A, B and C with the control group, only NK cells showed significantly higher levels in patients than in controls (P=0.043). In group A, only the percentage of NK cells (P=0.031) and B cells (P =0.024) were reduced at day 7. In group B, a decrease in the percentage of NK cells at days 7(P=0.005), 30 (P=0.021) was observed, while a significant decrease in the percentage of B cells was only observed at day 7(P=0.006). Among T cells, only CD4+ was obviously affected, resulting in a reduction in the CD4+/CD8+ ratio at day 30 (P=0.034). In group C, patients showed a decrease in the percentage of NK cells at days 7 (P=0.023), 30 (P=0.006). A decrease in the percentage of both B and T lymphocytes was observed at days 7(P=0.020, 0.018 respectively), 30(P=0.041, 0.025 respectively). Among T cells, a decrease in the percentage of CD4+ and an increase in the percentage of CD8+ were observed, resulting in a marked

  16. Intravascular Lipiodol Presenting as an Atrial Mass

    NARCIS (Netherlands)

    Kootte, Ruud S.; Haeck, Joost D. E.; van Lienden, Krijn P.; van Boven, Wim J. P.; van der Wal, Allard C.; de Boer, Hans H.

    2017-01-01

    A 68-year-old woman, previously treated with embolization of the thoracic duct with Lipiodol (an ethiodized oil injection) and cyanoacrylate glue (a topical tissue adhesive), was admitted with an asymptomatic mass in the inferior vena cava (IVC) and right atrium. The mass was surgically removed, and

  17. An estimation of Iodine 131 intakes for occupational workers of nuclear medicine group at the Instituto Nacional de Cancerologia, Bogota, Colombia

    International Nuclear Information System (INIS)

    Nino, Nelcy Yasmin; Lagares, Luis Carlos; Veloza, Luz Stella; Martinez, Maria Cristina; Reyes, Amelia de los

    2008-01-01

    Full text: In nuclear medicine, unsealed radioactive substances are administered to patients for diagnosis, treatment or research. The manipulation of these radionuclides, particularly those volatile, like iodine 131 (I-131), generates a risk of internal contamination by ingestion and inhalation. The inhaled radioactive particles are retained in the lungs or uptake by the thyroid tissue and could produce health effects. The IAEA provides regulatory practices in handling radioactive material to reduce internal contamination in the staff, based on the radiation protection principle to achieve occupational doses as low as reasonably achievable (ALARA). A quality assurance program in radioprotection should include the monitoring of occupational intakes. This paper describes a pilot study which determined quantitative methods to monitoring the nuclear medicine staff. The estimates of intakes and doses of I-131 were derived from the review and interpretation of urine monitoring data, using a Ludlum model 203 Shielded Well Scintillator (2 inches diameter x 1.8 inches thick), with a ratemeter model 2200. This study included workers occupationally exposed to I-131: physicians, technicians, radio pharmacists and physicists. The initial tests of the activity levels of I-131 in urine showed an average MPBB (Maximum Permissible Body Burden) of 0.035%, i.e. 0.025 μCi. Comparing with the maximum value of whole body 0.7μCi, the percentages of I-131 MPBB indicate the presence of small activities of I-131 in the urine, suggesting low-level chronic exposures from occupational workers in Nuclear Medicine. The higher values are the medical personnel who perform treatments for thyroid disorders. Conclusion: To do statistically significant the sampling and to protect individuals in each area it should be considered the daily urinary excretion, which is due to implement a protocol for regular assessment of the levels of incorporation of iodine 131 for jobs and activities, personnel in

  18. Quantitative mRNA expression analysis of selected genes in patients with early-stage hypothyroidism induced by treatment with iodine-131.

    Science.gov (United States)

    Guo, Kun; Gao, Rui; Yu, Yan; Zhang, Weixiao; Yang, Yuxuan; Yang, Aimin

    2015-11-01

    The present study aimed to investigate the molecular markers indicative of early-stage hypothyroidism induced by treatment with iodine-131, in order to assist in further investigations of radio iodine‑induced hypothyroidism. A total of 59 patients diagnosed with hyperthyroidism (male/female, 16/43; median age, 46.4 years) and 27 healthy subjects (male/female, 7/21; median age, 44.6 years) were included in the present study. All patients were treated with appropriate doses of iodine‑131 and, three months following treatment, the patients were subdivided into two groups: A group with early‑stage hypothyroidism symptoms, and a group with non‑early‑stage hypothyroidism, including euthyroid patients and patients remaining with hyperthyroidism. Tissue samples from the patients and healthy subjects were collected by fine needle biopsies, and the mRNA expression levels of B-cell lymphoma 2 (Bcl‑2), nuclear factor (NF)‑κB, Ku70, epidermal growth factor receptor (EGFR), early growth response 1 (Egr‑1), TP53 and ataxia telangiectasia mutated were analyzed using reverse transcription‑quantitative polymerase chain reaction prior to iodine‑131 treatment. The association of the variation of target genes with susceptibility to early‑stage hypothyroidism was analyzed. Compared with normal subjects, the mRNA expression levels of Ku70 (0.768, vs. 3.304, respectively; Ptreatment with iodine‑131, 30 of the 59 (50.8%) patients with hyperthyroidism were diagnosed with early‑stage hypothyroidism, and in the early‑stage hypothyroidism group, the mRNA expression levels of Bcl‑2 were significantly decreased (Phypothyroidism group. The association between the changes in the expression levles of Bcl‑2 and Egr‑1 and susceptibility to early‑stage hypothyroidism was supported by multivariate regression analysis. No significant changes in the expression levels of the other target genes were detected. The opposing changes in the mRNA expression levels of Bcl‑2

  19. Preparation of Labelled I131 Rose-Bengal

    International Nuclear Information System (INIS)

    Mayani, Mbutyabo; Chabouri, Galaal.

    1978-01-01

    Rose bengal purified on a Sephadex G-25 column has been labelled with iodine-131. The exchange reaction has been undertaken in an ether - alcohol medium. The influence of different factors (iodine concentration, Psup(h), purity and chemical form of the substratum, reaction rate) on the labelling yield has been studied. Radiochemical yield of 90% have been obtained in some conditions instead of the normal 80% reported in the literature

  20. Prognostication of the radioactive contamination with iodine 131, strontium 90 and cesium 137 of the air and soil after commissioning the ''Kozloduj'' nuclear power plant

    Energy Technology Data Exchange (ETDEWEB)

    Khristova, M; Paskalev, Z [Nauchno-Izsledovatelski Inst. po Radiologiya i Radiatsionna Khigiena, Sofia (Bulgaria)

    1975-01-01

    The content of iodine 131, strontium 90 and cesium 137 in the air (curie/l) and soil (curie/m/sup 2/ sec) in the area of the Kozloduj atomic power station (at a distance from 3 to 75 km from the chimney-stack of the power station) was determined. The concentrations of these radionuclides are determined under different meteorologic conditions: air temperature from -20/sup 0/C to +20/sup 0/C and a wind speed from 2 m/sec to 30 m/sec. The data show that at -20/sup 0/C radionuclide concentrations in the air decrease with increasing distance from the chimney-stack, regardless of the speed of the wind. At +20/sup 0/C radionuclide concentrations in the air increase with the distance from the chimney-stack, peak at a definite distance and then decrease. At 2 m/sec and speed this maximum is at a distance of 50 km from station. As the speed of the air increases, the peak moves nearer and remains about 30 km from the power station. Results on ground surface concentrations show that a trend is observed toward persistent decrease with distance from the power station. In rainy weather they are almost four times higher than in dry weather. The radionuclide concentrations on the ground surface will be comparable to their global deposits.

  1. Real-life radiation burden to relatives of patients treated with iodine-131: a study in eight centres in Flanders (Belgium)

    International Nuclear Information System (INIS)

    Monsieurs, M.; Thierens, H.; Dierckx, R.A.; Casier, K.; Simons, M.; Baere, E. de; Ridder, L. de; Saedeleer, C. de; Winter, H. de; Lippens, M.; Imschoot, S. van; Wulfrank, D.

    1998-01-01

    In view of the EURATOM 96/29 regulations, a prospective multicentre study was performed to evaluate the present guidelines given to relatives of patients treated with iodine-131 for both thyroid carcinoma and thyrotoxicosis, based on the real-life radiation burden. This study comprised 166 measurements carried out on a group of 94 relatives of 65 patients. All relatives wore a thermoluminescent dosemeter (TLD) on the wrist for 7 days. Sixty-one relatives agreed to wear another TLD for an additional 7 days. TLD were placed on nine patients' bedside tables. The eight participating centres were arbitrarily divided into three groups according to the period of time they advised their patients to sleep separately. Groups I, II and III respectively advised their patients to sleep separately for 0, 7-10 and 14-21 days. The median dose received by in-living relatives of thyroid carcinoma patients during the 14 days following hospital discharge was 281 μSv (doses to infinity not calculated); the median dose to infinity received by in-living relatives of ambulatory treated thyrotoxicosis patients was 596 μSv, as compared with 802 μSv for in-living relatives of hospitalised thyrotoxicosis patients. In general the children of patients received a significantly (P 131 I, while still following the ALARA principle. (orig.)

  2. Iodine metabolism and thyroid functions in various species of domestic animals and poultry birds. II - Distribution of iodine-131 in developing ova in poultry birds

    International Nuclear Information System (INIS)

    Parshad, Omkar; Setia, M.S.; Rattan, P.J.S.; Sodhi, S.P.S.; Varman, P.N.

    1974-01-01

    To study the distribution of iodine in different stages of developing ova in relation to iodine metabolism, twentyfour healthy laying birds were randomly distributed into four groups of 6 birds each. Each bird was injected with 25.26 μCi. of carrier-free iodine-131. Afterwards, birds of group I, II, III and IV were sacrificed at 24, 48, 72 and 96 hours respectively. The results have revealed that : (i) the state of development of ovum may be an important factor in controlling the distribution of iodine in ova; (ii) the iodine may be found distributed in both the lipid as well as non-lipid fractions of the ova; (iii) most of the iodine in the ova may be present in the form of inorganic iodine whereas very minor amount of the iodine may be as butanol-extractable iodine and (iv) the changes in iodine content in different stages of development of ova observed during the present study may be considered to have a direct effect on the overall metabolism of iodine in the poultry birds. (author)

  3. The biodistribution and effect on hepatic parenchyma with intraarterial injected I-131 lipiodol into hepatic artery

    International Nuclear Information System (INIS)

    Kim, Dong Ik; Suh, Jung Ho; Yoo, Hyung Sik; Lee, Jong Tae; Kim, Ki Whang; Park, Chan Il; Kim, Byung Ro

    1989-01-01

    Iodized oil has been used as a contrast agent in lymphangiography. One of the commercially available compounds is Lipidol Ultra-fluid(LUF) which contains 38% iodine by weight. Nakakuma et al(1979) reported that LUF was selectively retained in the hypervascular hepatocellular carcinoma when injected directly into the ligated hepatic artery. Since that time, it has been widely utilized in the detection as well as the therapeutic attempts of hepatocellular carcinoma, where it has been mixed with chemotherapeutic agents or labeled with radioactive I-131. Like all significant advances, the mechanism of lipid retention within the hepatocellular carcinoma is not clearly understood, and also there is a lack of information about the biodistribution and kinetics of I-131 Lipiodol. The apparent safety of this technique require confirmation. The present study was aimed to assess the biodistribution and kinetics of intraarterially injected I-131 Lipiodol and the histologic changes in canine livers. It was also to verify the safety of this technique in clinical applications. Radioactive iodized oil was obtained by simple exchange method . 518 ± 19 MBq(14 mCi, about 1 mCi/kg body weight) of I-131 Lipiodol was injected intraarterially in 12 dogs as a experimental group. Serial count rates over the livers under gamma camera were measured, and then it was compared with quantitative analysis of radioactivities distributed in liver, lung, spleen, kidney, thyroid, bile and circulating blood using dose calibrator after sacrifice at various time intervals. Cumulative radiation doses were calculated by Quimby method. The effect of I-131 lipiodol on hepatic function were analysed by serial liver function tests after intrahepatic injection of I-131 Lipiodol and compared with preinjection values. Liver tissue obtained after sacrifice were stained with hematoxylin-eosin, Oil red-O, and also election microscopic examinations were performed. The results were summarized as follows; 1

  4. Evaluation of cardiac adrenergic neuronal damage in rats with doxorubicin-induced cardiomyopathy using iodine-131 MIBG autoradiography and PGP 9.5 immunohistochemistry

    International Nuclear Information System (INIS)

    Jeon, T.J.; Lee, J.D.; Ha, J.-W.; Yang, W.I.; Cho, S.H.

    2000-01-01

    Doxorubicin is one of the most useful anticancer agents, but its repeated administration can induce irreversible cardiomyopathy as a major complication. The purpose of this study was to investigate doxorubicin toxicity on cardiac sympathetic neurons using iodine-131-metaiodobenzylguanidine (MIBG) and protein gene product (PGP) 9.5 immunohistochemistry, which is a marker of cardiac innervation. Wistar rats were treated with doxorubicin (2 mg/kg, i.v.) once a week for 4 (n=5), 6 (n=6) or 8 (n=7) weeks consecutively. Left ventricular ejection fraction (LVEF), calculated by M-mode echocardiography, was used as an indicator of cardiac function. Plasma noradrenaline (NA) concentration was measured by high-performance liquid chromatography (HPLC). 131 I-MIBG uptake of the left ventricular wall (24 ROIs) was measured by autoradiography. 131 I-MIBG uptake pattern was compared with histopathological results, the neuronal population on PGP 9.5 immunohistochemistry and the degree of myocyte damage assessed using a visual scoring system on haematoxylin and eosin and Masson's trichrome staining. LVEF was significantly decreased in the 8-week group (P 131 I-MIBG uptake ratio of subepicardium to subendocardium were significantly increased (P<0.05) in the 8-week group as compared with the control group. It may be concluded that radioiodinated MIBG is a reliable marker for the detection of cardiac adrenergic neuronal damage in doxorubicin-induced cardiomyopathy; it detects such damage earlier than do other clinical parameters and in this study showed a good correlation with the reduction in the neuronal population on PGP 9.5 stain. The subendocardial layer appeared to be more vulnerable to doxorubicin than the subepicardium. (orig.)

  5. [Proposals for the revision of radiation protection measures for doses up to 222 MBq iodine-131 for whole body scintiscan for the detection of metastatic lesions].

    Science.gov (United States)

    Karaveli, Maria; Hatzigiannaki, Anastasia; Dedousi, Eleni

    2006-01-01

    The goal of this study was to estimate the necessary period of time, required for radiation protection instructions to be followed by patients with differentiated thyroid carcinoma (DTC) after total thyroidectomy who are given iodine-131 ((131)I) for a whole body scintiscan (WBS) in relation to the instructions of the European Commission and the ICRP. In order to estimate and evaluate the dose received by the family members and the general public, we have studied 30 patients and were given a dose of 92-222 MBq of (131)I for a diagnostic WBS. The patients studied were four men with mean age+/-standard deviation (M+/-SD)=55+/-6 y and 26 women with: M+/-SD=47+/-14 y. Dose rate measurements were carried out at the Nuclear Medicine Department of the AHEPA University Hospital; 1 h after the patients had received the (131)I dose and 48 h later when they returned to the hospital for the WBS. The calculated doses received by the in-living relatives of the patients and by the general public, assuming that radiation protection measures were applied for 2d, ranged between 76-640 microSv and 22-171 microSv respectively. In conclusion, the results of this study, compared to the dose constraints suggested by the European Commission, indicate that the duration of radiation protection guidelines for patients receiving (131)I for diagnostic purposes could be reduced to only two days without any potential risk to family members or to members of the public. The case of children of the immediate family environment, aged less than 3 y, was not investigated in this study.

  6. Role of single photon emission computed tomography/computed tomography in diagnostic iodine-131 scintigraphy before initial radioiodine ablation in differentiated thyroid cancer

    International Nuclear Information System (INIS)

    Agrawal, Kanhaiyalal; Bhattacharya, Anish; Mittal, Bhagwant Rai

    2005-01-01

    The study was performed to evaluate the incremental value of single photon emission computed tomography/computed tomography (SPECT/CT) over planar radioiodine imaging before radioiodine ablation in the staging, management and stratification of risk of recurrence (ROR) in differentiated thyroid cancer (DTC) patients. Totally, 83 patients (21 male, 62 female) aged 17–75 (mean 39.9) years with DTC were included consecutively in this prospective study. They underwent postthyroidectomy planar and SPECT/CT scans after oral administration of 37–114 MBq iodine-131 (I-131). The scans were interpreted as positive, negative or suspicious for tracer uptake in the thyroid bed, cervical lymph nodes and sites outside the neck. In each case, the findings on planar images were recorded first, without knowledge of SPECT/CT findings. Operative and pathological findings were used for postsurgical tumor–node–metastasis staging. The tumor staging was reassessed after each of these two scans. Single photon emission computed tomography/computed tomography localized radioiodine uptake in the thyroid bed in 9/83 (10.8%) patients, neck nodes in 24/83 (28.9%) patients and distant metastases in 8/83 (9.6%) patients in addition to the planar study. Staging was changed in 8/83 (9.6%), ROR in 11/83 (13.2%) and management in 26/83 (31.3%) patients by the pretherapy SPECT/CT in comparison to planar imaging. SPECT/CT had incremental value in 32/83 patients (38.5%) over the planar scan. Single photon emission computed tomography/computed tomography is feasible during a diagnostic I-131 scan with a low amount of radiotracer. It improved the interpretation of pretherapy I-131 scintigraphy and changed the staging and subsequent patient management

  7. Comparison of computational models for estimation of whole body and organ radiation dose in rainbow trout from uptake of iodine-131 - Comparison of rainbow trout phantoms for estimation of whole body and organ radiation dose rates from uptake of iodine-131 in freshwater systems

    Energy Technology Data Exchange (ETDEWEB)

    Martinez, Nicole E. [Department of Environmental and Engineering Sciences, Clemson University, Clemson, South Carolina, 29634 (United States); Johnson, Thomas E.; Ruedig, Elizabeth; Pinder, John E. III [Department of Environmental and Radiological Health Sciences, Colorado State University, 1681 Campus Delivery, Fort Collins, Colorado, 80523 (United States)

    2014-07-01

    Internal radiation dose rates to biota are typically calculated utilizing dose conversion factors (DCF), which are values for absorbed dose rate per activity concentration (i.e. mGy d{sup -1} per Bq g{sup -1}). The current methodology employed by both the ICRP and within the ERICA Integrated Approach for calculating dose conversion coefficients is to use Monte Carlo modeling of a homogeneously distributed radionuclide within an ellipsoidal phantom chosen to represent a particular organism. It has been shown that for whole-body DCF, homogenous distribution is a reasonable assumption for electrons, and is associated with an uncertainty of less than 30% for photons. However, if a radionuclide has a specific tissue tropism (e.g. iodine-131 in thyroid) a much higher dose will be received by the organ or tissue than by the whole body. Internal organs are modeled generically as spheres within the ellipsoid phantom, due to the complex and variable nature of organ structure and arrangement within different types of organisms. Ratios of whole-body to organ mass offer conservative conversions of whole-body to organ specific DCF (Gomez-Ros et al 2008), but may considerably overestimate the organ dose; more accurate estimates can be made based on specific absorbed fractions and activity concentrations. Establishment of appropriate screening levels in the regulatory paradigm requires incorporation of sufficient knowledge of dose effects; the ICRP currently lists no derived consideration reference levels for organs, meaning that specific risks associated with organ dose rates are unavailable (ICRP 108). Model comparison and refinement is important in the process of determining both dose rates and dose effects, and here we develop and compare three models for rainbow trout (Oncorhynchus mykiss): the simple geometry described above, a more specific geometry employing anatomically relevant organ size and location, and voxel reconstruction of internal anatomy obtained from CT imaging

  8. Experimental results concerning the metabolism of ingested iodine-131 in adult sheep under lactation; Resultats experimentaux relatifs au metabolisme de l'iode 131 ingere chez la brebis adulte en lactation

    Energy Technology Data Exchange (ETDEWEB)

    Daburon, F.; Capelle, A.; Tricaud, Y.; Nizza, P. [Commissariat a l' Energie Atomique, 92 - Fontenay-aux-Roses (France). Centre d' Etudes Nucleaires. Departement de la Protection Sanitaire, Laboratoire-etable de Radiobiologie Appliquee

    1967-07-01

    The authors give the results of a series of experiments on metabolism of ingested iodine-131 in adult sheep under lactation; the measurement were carried out over a number of years from 1961 to 1966. The work was concerned initially with the fixation of iodine 131 in the thyroid gland, with the calculation of radiation doses absorbed and with ways of showing up any possible radiation damage in the gland. The modes of absorption of iodine 131 and its elimination through milk, urine and the faeces were then considered. Finally, a last chapter is devoted to changes in the radioactivity of the blood and of the milk, to variations of the PBI level of the blood serum as to different methods for measuring this level. (authors) [French] Les auteurs rapportent les resultats d'une serie d'experimentations relatives au metabolisme de l'iode 131 ingere chez la brebis adulte en lactation, et qui se sont etalees sur plusieurs annees, de 1961 a 1966. Les etudes ont porte d'abord sur les aspects de la fixation de l'iode 131 dans la thyroide, avec le calcul des doses de rayonnements absorbees et les moyens de mettre en evidence les radiolesions eventuelles de la glande. Ensuite ont ete traitees les modalites de l'absorption de l'iode 131 et de son elimination par le lait, les urines et les feces. Enfin un dernier chapitre a ete consacre a l'evolution de la radioactivite du sang et du lait, aux variations ainsi qu'aux divers moyens d'evaluation du taux de PBI du serum sanguin. (auteurs)

  9. Experimental results concerning the metabolism of ingested iodine-131 in adult sheep under lactation; Resultats experimentaux relatifs au metabolisme de l'iode 131 ingere chez la brebis adulte en lactation

    Energy Technology Data Exchange (ETDEWEB)

    Daburon, F; Capelle, A; Tricaud, Y; Nizza, P [Commissariat a l' Energie Atomique, 92 - Fontenay-aux-Roses (France). Centre d' Etudes Nucleaires. Departement de la Protection Sanitaire, Laboratoire-etable de Radiobiologie Appliquee

    1967-07-01

    The authors give the results of a series of experiments on metabolism of ingested iodine-131 in adult sheep under lactation; the measurement were carried out over a number of years from 1961 to 1966. The work was concerned initially with the fixation of iodine 131 in the thyroid gland, with the calculation of radiation doses absorbed and with ways of showing up any possible radiation damage in the gland. The modes of absorption of iodine 131 and its elimination through milk, urine and the faeces were then considered. Finally, a last chapter is devoted to changes in the radioactivity of the blood and of the milk, to variations of the PBI level of the blood serum as to different methods for measuring this level. (authors) [French] Les auteurs rapportent les resultats d'une serie d'experimentations relatives au metabolisme de l'iode 131 ingere chez la brebis adulte en lactation, et qui se sont etalees sur plusieurs annees, de 1961 a 1966. Les etudes ont porte d'abord sur les aspects de la fixation de l'iode 131 dans la thyroide, avec le calcul des doses de rayonnements absorbees et les moyens de mettre en evidence les radiolesions eventuelles de la glande. Ensuite ont ete traitees les modalites de l'absorption de l'iode 131 et de son elimination par le lait, les urines et les feces. Enfin un dernier chapitre a ete consacre a l'evolution de la radioactivite du sang et du lait, aux variations ainsi qu'aux divers moyens d'evaluation du taux de PBI du serum sanguin. (auteurs)

  10. National intercomparison on in vivo measurement of Iodine-131 in the thyroid within a Brazilian Internal Dosimetry Laboratory Network - IAEA PROJECT BRA9055; Intercomparacao nacional de medicao in vivo de Iodo-131 na tireoide - Projeto TC IAEA BRA 9055

    Energy Technology Data Exchange (ETDEWEB)

    Dantas, B.M.; Dantas, A.L.A.; Lucena, E.A., E-mail: bmdantas@ird.gov.br [Instituto de Radioprotecao e Dosimetria (IRD/CNEN-RJ), Rio de Janeiro (Brazil); Cardoso, J.S. [Instituto de Pesquisas Energeticas e Nucleares (IPEN/CNEN-SP), Sao Paulo, SP (Brazil); Ramos, M.A.P.; Sa, M.S. [Eletrobras Eletronuclear, Angra dos Reis, RJ (Brazil); Alonso, T.C.; Silva, T.V.; Oliveira, C.M. [Centro de Desenvolvimento da Tecnologia Nuclear (CDTN/CNEN-MG), Belo Horizonte, MG (Brazil); Lima, F.F.; Oliveira, M.L.; Lacerda, I.V.B. [Centro Regional de Ciencias Nucleares (CRCN-NE/CNEN-PE), Recife, PE (Brazil); Fajgelj, A. [International Atomic Energy Agency (IAEA), Vienna (Austria)

    2013-08-15

    In 2011, in Brazil, a National Intercalibration and Intercomparison exercise on in vivo measurement of iodine-131 in the thyroid was carried out in the scope of the Project IAEABRA9055 'Establishing a National Laboratory Network for Internal Individual Monitoring'. The exercise was conducted by the Institute for Radiation Protection and Dosimetry (IRD) and the Institute for Nuclear and Energetic Research (IPEN), from National Nuclear Energy Commission (CNEN). The objectives of the exercise were to (i) update information on current instrumentation resources available in the in vivo monitoring laboratories in operation in Brazil and to (ii) verify the reliability of the results of measurements of iodine-131 in thyroid provided by those laboratories. The procedure consisted on the measurement of a neck-thyroid anthropomorphic phantom provided by the In Vivo Monitoring Laboratory of IRD, containing two barium-133 standard sources certified by the National Laboratory for Metrology of Ionizing Radiation. Each participant should measure the phantom in a period of five days. The five laboratories are located in the States of Rio de Janeiro, Sao Paulo, Minas Gerais and Pernambuco, in the following Institutions: Institute for Radiation Protection and Dosimetry, Nuclear Power Station Almirante Alvaro Alberto, Center for the Development of Nuclear Technology, Institute for Nuclear and Energetic Research, and Regional Center for Nuclear Sciences. The results reported included: activity measured, minimum detectable activity, accuracy and precision. The performance of the laboratories was evaluated according to the criteria suggested by ANSI 13.30 indicating their capacity to provide reliable results of iodine-131 content in the thyroid. (author)

  11. Relative value of thallium-201 and iodine-131 scans in the detection of recurrence or distant metastasis of well differentiated thyroid carcinoma

    International Nuclear Information System (INIS)

    Lin Jen-Der; Weng Hsiao-Fen; Lu Wen-Tsoung; Kao Pan-Fu; Huang Miau-Ju

    1998-01-01

    Radioactive iodine ( 131 I) has been found to be more sensitive and more specific than thallium-201 for the detection of distant metastases and thyroid remnants in the neck in cases of well-differentiated thyroid carcinoma. 201 Tl has been deemed particularly useful in localizing metastases or recurrence in patients with a negative 131 I scan and abnormal levels of serum thyroglobulin (Tg). This study aimed to: (1) determine the value of 201 Tl imaging in localizing metastases or recurrence in patients with well-differentiated thyroid carcinoma, and (2) evaluate the false-positive and false-negative results of 131 I and 201 Tl scintigraphy. Sixty-two thyroid remnant ablated patients who underwent simultaneous postoperative 201 Tl and 131 I scans and and serum Tg determinations were evaluated. Fifty patients had papillary thyroid carcinomas and 12 had follicular thyroid carcinomas. 201 Tl imaging was performed before the 131 I studies. Of the 62 patients who underwent 201 Tl imaging studies, 24 were found to have positive results, with local recurrence or distant metastases. Patients with positive results in the 201 Tl imaging studies tended to be older, were mor often male, had higher Tg levels and had a higher recurrence rate. Of these 24 patients, ten had negative diagnostic or therapeutic 131 I scans. Concurrently, serum Tg levels were less than 5 ng/ml in five of these ten patients. Three patients were deemed false positive by 201 Tl scans; one had a parotid tumour, one a periodontal abscess and one lung metastasis. Among the 38 patients with negative 201 Tl scans, 11 had positive findings on 131 I scans. Three had distant metastases: two with lung metastases and one with bone metastases. Patients with false-positive results on 131 I scans included those with biliary tract stones, ovarian cysts, and breast secretion. Of the 27 patients with negative 201 Tl and 131 I scans, 15 had elevated serum Tg levels. Among these, local recurrence followed by lung

  12. Prediction of iodine-131 biokinetics and radiation doses from therapy on the basis of tracer studies: an important question for therapy planning in nuclear medicine.

    Science.gov (United States)

    Willegaignon, José; Pelissoni, Rogério A; Lima, Beatriz C G D; Sapienza, Marcelo T; Coura-Filho, George B; Buchpiguel, Carlos A

    2016-05-01

    This study aimed to present a comparison of iodine-131 (I) biokinetics and radiation doses to red-marrow (rm) and whole-body (wb), following the administration of tracer and therapeutic activities, as a means of confirming whether I clearance and radiation doses for therapy procedures can be predicted by tracer activities. Eleven differentiated thyroid cancer patients were followed after receiving tracer and therapeutic I activity. Whole-body I clearance was estimated using radiation detectors and OLINDA/EXM software was used to calculate radiation doses to rm and wb. Tracer I activity of 86 (±14) MBq and therapeutic activity of 8.04 (±1.18) GBq were administered to patients, thereby producing an average wb I effective half-time and residence time of, respectively, 13.51 (±4.05) and 23.13 (±5.98) h for tracer activities and 13.32 (±3.38) and 19.63 (±4.77) h for therapy. Radiation doses to rm and wb were, respectively, 0.0467 (±0.0208) and 0.0589 (±0.0207) mGy/MBq in tracer studies and 0.0396 (±0.0169) and 0.0500 (±0.0163) mGy/MBq in therapy. Although the differences were not considered statistically significant between averages, those between the values of effective half-times (P=0.906), residence times (P=0.145), and radiation doses to rm (P=0.393) and to wb (P=0.272), from tracer and therapy procedures, large differences of up to 80% in wb I clearance, and up to 50% in radiation doses were observed when patients were analyzed individually, thus impacting on the total amount of I activity calculated to be safe for application in individual therapy. I biokinetics and radiation doses to rm and wb in therapy procedures are well predicted by diagnostic activities when average values of a group of patients are compared. Nonetheless, when patients are analyzed individually, significant differences may be encountered, thus implying that nuclear medicine therapy-planning requires due consideration of changes in individual patient-body status from

  13. Iodine-131 imaging using 284 keV photons with a small animal CZT-SPECT system dedicated to low-medium-energy photon detection.

    Science.gov (United States)

    Kojima, Akihiro; Gotoh, Kumiko; Shimamoto, Masako; Hasegawa, Koki; Okada, Seiji

    2016-02-01

    Iodine-131 is widely used for radionuclide therapy because of its β-particle and for diagnostic imaging employing its principal gamma ray. Since that principal gamma ray has the relatively high energy of 364 keV, small animal single-photon emission computed tomography (SPECT) imaging systems may be required to possess the ability to image such higher energy photons. The aim of this study was to investigate the possibility of imaging I-131 using its 284 keV photons instead of its 364 keV photons in a small animal SPECT imaging system dedicated to the detection of low-medium-energy photons (below 300 keV). The imaging system used was a commercially available preclinical SPECT instrument with CZT detectors that was equipped with multi-pinhole collimators and was accompanied by a CT imager. An energy window for I-131 imaging was set to a photopeak of 284 keV with a low abundance compared with 364 keV photons. Small line sources and two mice, one of each of two types, that were injected with NaI-131 were scanned. Although higher counts occurred at the peripheral region of the reconstructed images due to the collimator penetration by the 364 keV photons, the shape of the small line sources could be well visualized. The measured spatial resolution was relatively poor (~1.9 mm for full width at half maximum and ~3.9 mm for full width at tenth maximum). However, a good linear correlation between SPECT values and the level of I-131 radioactivity was observed. Furthermore, the uptake of NaI-131 to the thyroid gland for the two mice was clearly identified in the 3D-SPECT image fused with the X-ray CT image. We conclude that the use of an energy window set on the photopeak of 284 keV and the multi-pinhole collimator may permit I-131 imaging for a preclinical CZT-SPECT system that does not have the ability to acquire images using the 364 keV photons.

  14. Fatty acids labelled in the. omega. -position with iodine isotopes

    Energy Technology Data Exchange (ETDEWEB)

    Mathieu, J.P.; Busquet, G.; Comet, M. (Universite Scientifique et Medicale de Grenoble, 38 - La Tronche (France)); Riche, F.; Vidal, M. (Laboratoire d' Etudes Dynamiques et Structurales de la Selectivite, 38 - Grenoble (France)); Coornaert, S.; Bardy, A. (CEA, Centre de Saclay, 91 - Gif-sur-Yvette (France)); Godart, J. (Institut des Sciences Nucleaires, 38 - Grenoble (France))

    1982-01-01

    The synthesis of saturated acetylenic and olefinic (Z or E) ..omega..-iodinated fatty acids has been carried out and their labelling with iodine-131 or 123 by exchange I/sup -/, *I/sup -/ has been studied. The influence of several parameters -water and fatty acid concentrations, specific activity, labelling solution acidity, iodine carrier presence- on this exchange reaction has been noted, enabling experimental conditions to be defined that produce labelling yields of greater than 95%. These results should lead to widespread clinical use of iodine labelled fatty acids.

  15. Conference on radionuclide labelled cellular blood elements

    International Nuclear Information System (INIS)

    1986-01-01

    The South African Medical Research Council presented this conference on radionuclide labelled cellular blood elements with application in atherosclerosis and thrombosis. The conference was held in Bloemfontein from 3-6 February 1986. This work only consists of the abstracts of the seminars that were delivered on the conference. The radioisotopes that occur most of the time in the abstracts include Indium 111, Indium 114, Chromium 51, Iodine 125, Iodine 131 and Carbon 14. Especially Indium 111 seems to be the method of choice for all labelling

  16. Iodine-131 Releases from Radioactive Lanthanum Processing at the X-10 Site in Oak Ridge, Tennessee (1944-1956)- An Assessment of Quantities released, Off-Site Radiation Doses, and Potential Excess Risks of Thyroid Cancer, Volume 1

    International Nuclear Information System (INIS)

    Apostoaei, A.I.; Burns, R.E.; Hoffman, F.O.; Ijaz, T.; Lewis, C.J.; Nair, S.K.; Widner, T.E.

    1999-01-01

    In the early 1990s, concern about the Oak Ridge Reservation's past releases of contaminants to the environment prompted Tennessee's public health officials to pursue an in-depth study of potential off-site health effects at Oak Ridge. This study, the Oak Ridge dose reconstruction, was supported by an agreement between the U.S. Department of Energy (DOE) and the State of Tennessee, and was overseen by a 12-member panel appointed by Tennessee's Commissioner of Health. One of the major contaminants studied in the dose reconstruction was radioactive iodine, which was released to the air by X-10 (now called Oak Ridge National Laboratory) as it processed spent nuclear reactor fuel from 1944 through 1956. The process recovered radioactive lanthanum for use in weapons development. Iodine concentrates in the thyroid gland so health concerns include various diseases of the thyroid, such as thyroid cancer. The large report, ''Iodine-131 Releases from Radioactive Lanthanum Processing at the X-10 Site in Oak Ridge, Tennessee (1944-1956) - An Assessment of Quantities Released, Off-site Radiation Doses, and Potential Excess Risks of Thyroid Cancer,'' is in two volumes. Volume 1 is the main body of the report, and Volume 1A, which has the same title, consists of 22 supporting appendices. Together, these reports serve the following purposes: (1) describe the methodologies used to estimate the amount of iodine-131 (I-131) released; (2) evaluate I-131's pathway from air to vegetation to food to humans; (3) estimate doses received by human thyroids; (4) estimate excess risk of acquiring a thyroid cancer during ones lifetime; and (5) provide equations, examples of historical documents used, and tables of calculated values. Results indicate that females born in 1952 who consumed milk from a goat pastured a few miles east of X-10 received the highest doses from I-131 and would have had the highest risks of contracting thyroid cancer. Doses from cow's milk are considerably less . Detailed

  17. Iodine-131 Releases from Radioactive Lanthanum Processing at the X-10 Site in Oak Ridge, Tennessee (1944-1956)- An Assessment of Quantities released, Off-Site Radiation Doses, and Potential Excess Risks of Thyroid Cancer, Volume 1

    Energy Technology Data Exchange (ETDEWEB)

    Apostoaei, A.I.; Burns, R.E.; Hoffman, F.O.; Ijaz, T.; Lewis, C.J.; Nair, S.K.; Widner, T.E.

    1999-07-01

    In the early 1990s, concern about the Oak Ridge Reservation's past releases of contaminants to the environment prompted Tennessee's public health officials to pursue an in-depth study of potential off-site health effects at Oak Ridge. This study, the Oak Ridge dose reconstruction, was supported by an agreement between the U.S. Department of Energy (DOE) and the State of Tennessee, and was overseen by a 12-member panel appointed by Tennessee's Commissioner of Health. One of the major contaminants studied in the dose reconstruction was radioactive iodine, which was released to the air by X-10 (now called Oak Ridge National Laboratory) as it processed spent nuclear reactor fuel from 1944 through 1956. The process recovered radioactive lanthanum for use in weapons development. Iodine concentrates in the thyroid gland so health concerns include various diseases of the thyroid, such as thyroid cancer. The large report, ''Iodine-131 Releases from Radioactive Lanthanum Processing at the X-10 Site in Oak Ridge, Tennessee (1944-1956) - An Assessment of Quantities Released, Off-site Radiation Doses, and Potential Excess Risks of Thyroid Cancer,'' is in two volumes. Volume 1 is the main body of the report, and Volume 1A, which has the same title, consists of 22 supporting appendices. Together, these reports serve the following purposes: (1) describe the methodologies used to estimate the amount of iodine-131 (I-131) released; (2) evaluate I-131's pathway from air to vegetation to food to humans; (3) estimate doses received by human thyroids; (4) estimate excess risk of acquiring a thyroid cancer during ones lifetime; and (5) provide equations, examples of historical documents used, and tables of calculated values. Results indicate that females born in 1952 who consumed milk from a goat pastured a few miles east of X-10 received the highest doses from I-131 and would have had the highest risks of contracting thyroid cancer. Doses from cow

  18. Synthesis and biodistribution of novel magnetic-poly(HEMA-APH) nanopolymer radiolabeled with iodine-131 and investigation its fate in vivo for cancer therapy

    Science.gov (United States)

    Avcıbaşı, Uğur; Avcıbaşı, Nesibe; Akalın, Hilmi Arkut; Ediz, Melis; Demiroğlu, Hasan; Gümüşer, Fikriye Gül; Özçalışkan, Emir; Türkcan, Ceren; Uygun, Deniz Aktaş; Akgöl, Sinan

    2013-10-01

    Herein, we investigated the biological uptake, distribution, and radiopharmaceutical potential of a novel molecule based on 2-hydroxyethyl methacrylate (HEMA) and anilinephtalein (APH) in the metabolism of Albino Wistar rats. In order to achieve this, we synthesized APH using organic synthesis methods and copolymerized APH with HEMA using a common polymerization method, surfactant-free emulsion polymerization. In the presence of Fe3O4 particles, we obtained a new generation magnetic-nano-scale polymer, magnetic-poly(HEMA-APH). This new molecule was chemically identified and approved by several characterization methods using Fourier transform infrared spectroscopy, scanning electron microscope, energy dispersive X-ray spectroscopy, electron spin resonance, atomic force microscope, and Zeta particle-size analysis. To evaluate the biological activity in live metabolism and anti-cancer potential of mag-poly(HEMA-APH), molecule was radioiodinated by a widely used labeling technique, iodogen method, with a gamma diffuser radionuclide, 131I. Thin-layer radiochromatography experiments demonstrated that 131I binded to nanopolymer with the labeling yield of 90 %. Lipophilicity and stability experiments were conducted to determine the condition of cold and labeled mag-poly(HEMA-APH) in rat blood and lipid medium. Results demonstrated that radioiodinated molecule stayed as an intact complex in rat metabolism for 24 h and experimental lipophilicity was determined as 0.12 ± 0.02. In vivo results obtained by imaging and biological distribution experiments indicated that mag-poly(HEMA-APH) labeled with 131I [131I-mag-poly(HEMA-APH)] highly incorporated into tissues of the uterus, the ovarian, the prostate, and the lungs in rat metabolism. Based on these results, it may be evaluated that novel mag-poly(HEMA-APH) molecule labeled with 131I is a compound which has a significant potential for being used as an anti-cancer agent. Certain results can only be obtained whether this

  19. Estimation of the activity and doses to personnel which intake Iodine 131 by coffee consumption in a cabinet of Nuclear Medicine; Estimacion de la actividad y dosis a personal que ingirio Yodo 131 por consumo de cafe en un gabinete de Medicina nuclear

    Energy Technology Data Exchange (ETDEWEB)

    Ruiz C, M.A.; Alfaro L, M.; Salinas, J.A.; Molina, G. [ININ, 52045 Ocoyoacac, Estado de Mexico (Mexico)

    2003-07-01

    Soon after an incident in a cabinet of nuclear medicine, its were carried out in the National Institute of Nuclear Research of Mexico (ININ), a series of bio essays measurements by whole-body counting to six people attributed to this cabinet. Of six people, five are classified as Occupational Exposed Personnel (POE), and the other one that works as secretary, according to the General Regulation of Radiological Safety, is classified as public member. Six people that were involved in this incident, the one which presumably it took place among November 15 and 18, 2002 and that it consisted on the effusion of a vial containing an unknown quantity of Iodine-131 to a coffeepot, they ingested coffee in diverse quantities. The Iodine-131 is used in nuclear medicine, so much for the illnesses diagnostic like in the treatment of thyroid cancer and of hyperthyroidism. (Author)

  20. Synthesis and biodistribution of novel magnetic-poly(HEMA-APH) nanopolymer radiolabeled with iodine-131 and investigation its fate in vivo for cancer therapy

    Energy Technology Data Exchange (ETDEWEB)

    Avc Latin-Small-Letter-Dotless-I bas Latin-Small-Letter-Dotless-I , Ugur, E-mail: uguravcibasi@yahoo.com [Celal Bayar University, Department of Chemistry, Faculty of Arts and Science (Turkey); Avc Latin-Small-Letter-Dotless-I bas Latin-Small-Letter-Dotless-I , Nesibe [Ege University, Ege Higher Vocational School (Turkey); Akal Latin-Small-Letter-Dotless-I n, Hilmi Arkut; Ediz, Melis; Demiroglu, Hasan [Celal Bayar University, Department of Chemistry, Faculty of Arts and Science (Turkey); Guemueser, Fikriye Guel [Celal Bayar University, Department of Nuclear Medicine, Faculty of Medicine (Turkey); Oezcal Latin-Small-Letter-Dotless-I skan, Emir; Tuerkcan, Ceren [Ege University, Department of Biochemistry, Faculty of Science (Turkey); Uygun, Deniz Aktas [Adnan Menderes University, Department of Chemistry, Faculty of Arts and Science (Turkey); Akgoel, Sinan [Ege University, Department of Biochemistry, Faculty of Science (Turkey)

    2013-10-15

    Herein, we investigated the biological uptake, distribution, and radiopharmaceutical potential of a novel molecule based on 2-hydroxyethyl methacrylate (HEMA) and anilinephtalein (APH) in the metabolism of Albino Wistar rats. In order to achieve this, we synthesized APH using organic synthesis methods and copolymerized APH with HEMA using a common polymerization method, surfactant-free emulsion polymerization. In the presence of Fe{sub 3}O{sub 4} particles, we obtained a new generation magnetic-nano-scale polymer, magnetic-poly(HEMA-APH). This new molecule was chemically identified and approved by several characterization methods using Fourier transform infrared spectroscopy, scanning electron microscope, energy dispersive X-ray spectroscopy, electron spin resonance, atomic force microscope, and Zeta particle-size analysis. To evaluate the biological activity in live metabolism and anti-cancer potential of mag-poly(HEMA-APH), molecule was radioiodinated by a widely used labeling technique, iodogen method, with a gamma diffuser radionuclide, {sup 131}I. Thin-layer radiochromatography experiments demonstrated that {sup 131}I binded to nanopolymer with the labeling yield of 90 %. Lipophilicity and stability experiments were conducted to determine the condition of cold and labeled mag-poly(HEMA-APH) in rat blood and lipid medium. Results demonstrated that radioiodinated molecule stayed as an intact complex in rat metabolism for 24 h and experimental lipophilicity was determined as 0.12 {+-} 0.02. In vivo results obtained by imaging and biological distribution experiments indicated that mag-poly(HEMA-APH) labeled with {sup 131}I [{sup 131}I-mag-poly(HEMA-APH)] highly incorporated into tissues of the uterus, the ovarian, the prostate, and the lungs in rat metabolism. Based on these results, it may be evaluated that novel mag-poly(HEMA-APH) molecule labeled with {sup 131}I is a compound which has a significant potential for being used as an anti-cancer agent. Certain

  1. Radioactive pollutions by iodine-131 in France, from November 1, 1961 to February 1, 1962; Les pollutions radioactives par l'iode 131 en France du 1er novembre 1961 au 1er fevrier 1962

    Energy Technology Data Exchange (ETDEWEB)

    Jeanmaire, L; Michon, G

    1962-07-01

    The report gives all the results of iodine-131 measurements on 450 milk samples, on 27 animal thyroids, and on 311 human thyroids between November 1, 1961 and February 1, 1962. All these results and their interpretation show that the iodine concentrations, even if they have not attained a critical level have nevertheless come close to it, and that if the Soviet series of explosions had continued it would perhaps have been necessary to take sanitary precautions. The discussion concerns the determination of the moment when such steps should be taken. (authors) [French] Le rapport fournit l'ensemble des dosages d'iode 131 effectues sur 450 echantillons de lait, sur 27 thyroides animales et sur 311 thyroides humaines entre le 1er novembre 1961 et le 1er fevrier 1962. L'ensemble des resultats et leur interpretation montrent que les teneurs en iode, si elles n'ont pas atteint les niveaux critiques, s'en sont toutefois approchees et que si la serie des explosions sovietiques s'etait poursuivie, la situation aurait pu necessiter la mise en place de mesures sanitaires. La discussion porte sur la determination du moment ou de telles mesures doivent etre prises. (auteurs)

  2. Oak Ridge Reservation Volume 3. Records relating to RaLa, iodine-131, and cesium-137 at the Oak Ridge National Laboratory and the Oak Ridge Operations Office: A guide to record series of the Department of Energy and its contractors

    International Nuclear Information System (INIS)

    1995-01-01

    The purpose of this guide is to describe each of the documents and record series pertaining to the production, release, and disposal of radioactive barium-lanthanum (RaLa), iodine-131, and cesium-137 at the Department of Energy's (DOE) Oak Ridge National Laboratory (ORNL) in Oak Ridge, Tennessee. History Associates Incorporated (HAI) prepared this guide as part of DOE's Epidemiologic Records Inventory Project, which seeks to verify and conduct inventories of epidemiologic and health-related records at various DOE and DOE contractor sites. This introduction briefly describes the Epidemiologic Records Inventory Project and HAI's role. It provides information on the history of the DOE-Oak Ridge Reservation (ORR), particularly ORNL. Specific attention is given to the production of RaLa and the fission products iodine-131 and cesium-137. This introduction also describes the methodologies HAI used in the selection and inventorying of documents and record series pertaining to RaLa, iodine-131, and cesium-137, and in the production of this guide. Concluding paragraphs describe the arrangement of the record series, explain the information contained in the record series descriptions, and indicate restrictions on access to the records

  3. Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion

    Energy Technology Data Exchange (ETDEWEB)

    Baere, Thierry de, E-mail: thierry.debaere@gustaveroussy.fr [Gustave Roussy, Department of Interventional Radiology (France); Arai, Yasuaki, E-mail: arai-y3111@mvh.biglobe.ne.jp [National Cancer Center, Department of Diagnostic Radiology (Japan); Lencioni, Riccardo, E-mail: riccardo.lencioni@med.unipi.it [Pisa University School of Medicine, Division of Diagnostic Imaging and Intervention (R.L.) (Italy); Geschwind, Jean-Francois, E-mail: jfg@jhmi.edu [The Johns Hopkins Hospital, Vascular and Interventional Radiology (United States); Rilling, William, E-mail: wrilling@mcw.edu [Medical College of Wisconsin, Division of Vascular and Interventional Radiology Rm2803 (United States); Salem, Riad, E-mail: r-salem@northwestern.edu [Northwestern University, Department of Radiology (United States); Matsui, Osamu, E-mail: matsuio@med.kanazawa-u.ac.jp [Kanazawa University Graduate School of Medical Sciences, Department of Advanced Medical Imaging (Japan); Soulen, Michael C., E-mail: michael.soulen@uphs.upenn.edu [University of Pennsylvania, Division of Interventional Radiology (MCS) (United States)

    2016-03-15

    Transarterial chemoembolization with Lipiodol (Lipiodol TACE), also called conventional TACE, was developed in the early 1980s and widely adopted worldwide after randomized control trials and meta-analysis demonstrated superiority of Lipiodol TACE to best supportive care. Presently, there is no level one evidence that other TACE techniques are superior to Lipiodol TACE for intermediate stage hepatocellular carcinoma (HCC), which includes patients with preserved liver function and nonsurgical large or multinodular HCC without distant metastases. In addition, TACE is part of the treatment for progressive or symptomatic liver metastases from gastroenteropancreatic neuroendocrine tumors. When injected into the hepatic artery, Lipiodol has the unique property of selective uptake and retention in hyperarterialyzed liver tumors. Lipiodol/drug emulsion followed by particle embolization has been demonstrated to improve the pharmacokinetic of the drug and tumor response. Radio opacity of Lipiodol helps to monitor treatment delivery, with retention of Lipiodol serving as an imaging biomarker for tumor response. For 30 years, Lipiodol TACE has been inconsistently referenced in many publications with various levels of details for the method of preparation and administration, with reported progressive outcomes following improvements in the technique and the devices used to deliver the treatment and better patient selection. Consequently, there is no consensus on the standard method of TACE regarding the use of anticancer agents, embolic material, technical details, and the treatment schedule. In order to develop an internationally validated technical recommendation to standardize the Lipiodol TACE procedure, a worldwide panel of experts participated in a consensus meeting held on May 10, 2014.

  4. Determination of behaviour of the corn weevil Sitophilus zeamais, Motschulsky, 1855 (Coleoptera, Curculionidae) in corn, rice and wheat grains by using radioactive tracer iodine-131

    International Nuclear Information System (INIS)

    Pacheco, I.A.

    1989-01-01

    The dispersion behaviour and distribution pattern of Sitophilus zeamais Motschulsky, 1855 through a bulk of corn, rice and wheat,leaving from a infestation focus, was investigated by means of tracer methodology. Adults insects were labeled with the gamma emitter 131 I, through bath in Na 131 I solution and released onto the top of grain mass deposited in cylinders each 430 mm height and 195 mm in diameter, filled to 20 mm of the top with grains. The cylinders were enclosed with lids. The insects were detected through the bulk of the grain by means of a crystal scintillator, in fourteen sites, zero 3, 6, 12, 24, 48, 72, 96 and 120 hours after releasing. (author)

  5. Gold-198 and rose bengal marked with iodine-131 in the diagnostic of hepatic vesicular affections; L'or{sup 198} et le rose bengale marque a l'iode{sup 131} dans le diagnostic des affections hepatovesiculaires

    Energy Technology Data Exchange (ETDEWEB)

    Manambelona Razafimalaza, J [Commissariat a l' Energie Atomique, Saclay (France). Centre d' Etudes Nucleaires

    1961-06-15

    Colloidal gold-198 makes it possible to obtain clear images of hepatic parenchyma; the examination can be repeated from different angles thus demonstrating the presence of pathologically inert regions, whether they be hydatic cysts, abscesses or neoplasia. The study of the disappearance curve for the colloid, together with a measurement of the blood volume, makes it possible also to calculate the hepatic flow. Using Rose Bengal marked with iodine-131, it is possible to obtain images of the liver and of the bile ducts, and to follow the elimination of the dye in the intestines. The simultaneous recording of the disappearance curves for the blood and of the appearance of the dye in the intestines constitutes an useful working test which is particularly sensible for evaluating the permeability of the bile ducts and, to a certain degree, the site of an obstruction. (author) [French] L'or colloidal-198 permet d'obtenir avec nettete des images du parenchyme hepatique; l'examen peut etre repete sous plusieurs incidences mettant ainsi en evidence les zones muettes pathologiques, qu'il s'agisse de kystes hydatiques, d'abces ou de neoplasies. L'etude de la courbe d'epuration du colloide completee par une mesure du volume sanguin offre en outre la possibilite de calculer le debit hepatique. A l'aide du rose bengale marque a l'iode-131, il est possible d'obtenir des images du foie et de la vesicule biliaire, et de suivre l'elimination intestinale du colorant. L'enregistrement simultane des courbes d'epuration sanguine et d'apparition intestinale constitue une epreuve fonctionnelle particulierement sensible pour apprecier la permeabilite des voies biliaires et dans une certaine mesure le site d'une obstruction. (auteur)

  6. Iodine-131 treatment of thyroid cancer cells leads to suppression of cell proliferation followed by induction of cell apoptosis and cell cycle arrest by regulation of B-cell translocation gene 2-mediated JNK/NF-κB pathways

    Energy Technology Data Exchange (ETDEWEB)

    Zhao, L.M.; Pang, A.X., E-mail: zhaoliming515@126.com [Department of Nuclear Medicine, Linyi People' s Hospital, Linyi (China); Department of Urology, Linyi People' s Hospital, Linyi (China)

    2017-10-01

    Iodine-131 ({sup 131}I) is widely used for the treatment of thyroid-related diseases. This study aimed to investigate the expression of p53 and BTG2 genes following {sup 131}I therapy in thyroid cancer cell line SW579 and the possible underlying mechanism. SW579 human thyroid squamous carcinoma cells were cultured and treated with {sup 131}I. They were then assessed for {sup 131}I uptake, cell viability, apoptosis, cell cycle arrest, p53 expression, and BTG2 gene expression. SW579 cells were transfected with BTG2 siRNA, p53 siRNA and siNC and were then examined for the same aforementioned parameters. When treated with a JNK inhibitor of SP600125 and {sup 131}I or with a NF-kB inhibitor of BMS-345541 and {sup 131}I, non-transfected SW579 cells were assessed in JNK/NFkB pathways. It was observed that {sup 131}I significantly inhibited cell proliferation, promoted cell apoptosis and cell cycle arrest. Both BTG2 and p53 expression were enhanced in a dose-dependent manner. An increase in cell viability by up-regulation in Bcl2 gene, a decrease in apoptosis by enhanced CDK2 gene expression and a decrease in cell cycle arrest at G{sub 0}/G{sub 1} phase were also observed in SW579 cell lines transfected with silenced BTG2 gene. When treated with SP600125 and {sup 131}I, the non transfected SW579 cell lines significantly inhibited JNK pathway, NF-kB pathway and the expression of BTG2. However, when treated with BMS-345541 and {sup 131}I, only the NF-kB pathway was suppressed. {sup 131}I suppressed cell proliferation, induced cell apoptosis, and promoted cell cycle arrest of thyroid cancer cells by up-regulating B-cell translocation gene 2-mediated activation of JNK/NF--κB pathways. (author)

  7. Partial splenic artery embolization with gelatin sponge or with lipiodol for hypersplenism: a comparative study

    International Nuclear Information System (INIS)

    Liu Yamin; Sun Gangqing; Qin Hao; Wang Chongbao

    2010-01-01

    Objective: To discuss the effects and the complications of partial splenic artery embolization with gelatin sponge or with lipiodol for hypersplenism, to provide scientific information helpful for the selection of embolization materials in clinical practice. Methods: Partial splenic artery embolization with gelatin sponge was performed in forty patients with hypersplenism due to cirrhosis (gelatin sponge group) and partial splenic artery embolization with lipiodol was carried out in another thirty-nine patients (lipiodol group). The clinical data were retrospectively analyzed. The laboratory studies, complications and recurrence were observed and compared between two groups. Results: No significant difference in the reduction of splenic size, in the hemoglobin levels and in the thrombocyte and leucocyte counts existed between two groups (P > 0.05). However, the platelet count in lipiodol group was obviously decreased three months after the treatment. The occurrence of complications in gelatin sponge group was much higher than that in lipiodol group (P < 0.05). The toxic reaction of the liver and gastrointestinal tract in lipiodol group was significantly slighter than that in gelatin sponge group. Conclusion: Partial splenic artery embolization with lipiodol should be employed for the treatment of hypersplenism when the patient is elder and the disease is accompanied by poor liver function, massive ascites, severe dysfunction of blood coagulation and serious portal hypertension. (authors)

  8. Lipiodol as a Fiducial Marker for Image-Guided Radiation Therapy for Bladder Cancer

    Energy Technology Data Exchange (ETDEWEB)

    Freilich, Jessica M.; Spiess, Philippe E.; Biagioli, Matthew C.; Fernandez, Daniel C.; Shi, Ellen J.; Hunt, Dylan C.; Gupta, Shilpa; Wilder, Richard B., E-mail: richard.wilder@moffitt.org [Moffitt Cancer Center, Tampa, FL (United States)

    2014-03-15

    Purpose: To evaluate Lipiodol as a liquid, radio-opaque fiducial marker for image-guided radiation therapy (IGRT) for bladder cancer; Materials and Methods: Between 2011 and 2012, 5 clinical T2a-T3b N0 M0 stage II-III bladder cancer patients were treated with maximal transurethral resection of a bladder tumor (TURBT) and image-guided radiation therapy (IGRT) to 64.8 Gy in 36 fractions ± concurrent weekly cisplatin-based or gemcitabine chemotherapy. Ten to 15mL Lipiodol, using 0.5mL per injection, was injected into bladder submucosa circumferentially around the entire periphery of the tumor bed immediately following maximal TURBT. The authors looked at inter-observer variability regarding the size and location of the tumor bed (CTVboost) on computed tomography scans with versus without Lipiodol. Results: Median follow-up was 18 months. Lipiodol was visible on every orthogonal two-dimensional kV portal image throughout the entire, 7-week course of IGRT. There was a trend towards improved inter-observer agreement on the CTVboost with Lipiodol (p = 0.06). In 2 of 5 patients, the tumor bed based upon Lipiodol extended outside a planning target volume that would have been treated with a radiation boost based upon a cystoscopy report and an enhanced computed tomography (CT) scan for staging. There was no toxicity attributable to Lipiodol: Conclusions: Lipiodol constitutes a safe and effective fiducial marker that an urologist can use to demarcate a tumor bed immediately following maximal TURBT. Lipiodol decreases inter-observer variability in the definition of the extent and location of a tumor bed on a treatment planning CT scan for a radiation boost. (author)

  9. Lipiodol as a Fiducial Marker for Image-Guided Radiation Therapy for Bladder Cancer

    Directory of Open Access Journals (Sweden)

    Jessica M. Freilich

    2014-04-01

    Full Text Available Purpose To evaluate Lipiodol as a liquid, radio-opaque fiducial marker for image-guided radiation therapy (IGRT for bladder cancer.Materials and Methods Between 2011 and 2012, 5 clinical T2a-T3b N0 M0 stage II-III bladder cancer patients were treated with maximal transurethral resection of a bladder tumor (TURBT and image-guided radiation therapy (IGRT to 64.8 Gy in 36 fractions ± concurrent weekly cisplatin-based or gemcitabine chemotherapy. Ten to 15mL Lipiodol, using 0.5mL per injection, was injected into bladder submucosa circumferentially around the entire periphery of the tumor bed immediately following maximal TURBT. The authors looked at inter-observer variability regarding the size and location of the tumor bed (CTVboost on computed tomography scans with versus without Lipiodol.Results Median follow-up was 18 months. Lipiodol was visible on every orthogonal two-dimensional kV portal image throughout the entire, 7-week course of IGRT. There was a trend towards improved inter-observer agreement on the CTVboost with Lipiodol (p = 0.06. In 2 of 5 patients, the tumor bed based upon Lipiodol extended outside a planning target volume that would have been treated with a radiation boost based upon a cystoscopy report and an enhanced computed tomography (CT scan for staging. There was no toxicity attributable to Lipiodol.Conclusions Lipiodol constitutes a safe and effective fiducial marker that an urologist can use to demarcate a tumor bed immediately following maximal TURBT. Lipiodol decreases inter-observer variability in the definition of the extent and location of a tumor bed on a treatment planning CT scan for a radiation boost.

  10. Baseline Tumor Lipiodol Uptake after Transarterial Chemoembolization for Hepatocellular Carcinoma: Identification of a Threshold Value Predicting Tumor Recurrence.

    Science.gov (United States)

    Matsui, Yusuke; Horikawa, Masahiro; Jahangiri Noudeh, Younes; Kaufman, John A; Kolbeck, Kenneth J; Farsad, Khashayar

    2017-12-01

    The aim of the study was to evaluate the association between baseline Lipiodol uptake in hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE) with early tumor recurrence, and to identify a threshold baseline uptake value predicting tumor response. A single-institution retrospective database of HCC treated with Lipiodol-TACE was reviewed. Forty-six tumors in 30 patients treated with a Lipiodol-chemotherapy emulsion and no additional particle embolization were included. Baseline Lipiodol uptake was measured as the mean Hounsfield units (HU) on a CT within one week after TACE. Washout rate was calculated dividing the difference in HU between the baseline CT and follow-up CT by time (HU/month). Cox proportional hazard models were used to correlate baseline Lipiodol uptake and other variables with tumor response. A receiver operating characteristic (ROC) curve was used to identify the optimal threshold for baseline Lipiodol uptake predicting tumor response. During the follow-up period (mean 5.6 months), 19 (41.3%) tumors recurred (mean time to recurrence = 3.6 months). In a multivariate model, low baseline Lipiodol uptake and higher washout rate were significant predictors of early tumor recurrence ( P = 0.001 and Baseline Lipiodol uptake and washout rate on follow-up were independent predictors of early tumor recurrence. A threshold value of baseline Lipiodol uptake > 270.2 HU was highly sensitive and specific for tumor response. These findings may prove useful for determining subsequent treatment strategies after Lipiodol TACE.

  11. 133Xe labelling of acrylate for catheter embolisation

    International Nuclear Information System (INIS)

    Endert, G.; Penzel, E.; Ritter, H.; Schumann, E.

    1983-01-01

    A method for radio-nucleide labelling of histo-acryl/lipiodol with 133 Xe gas is described. The method consists of disolving the gas in lipiodol under sterile conditions. After embolisation and angiography, the localisation of the embolising material can be determined by means of a scintillation camera. The labelling method was used in 15 patients. In all patients the position of the embolising material, as demonstrated by scintigraphy, corresponded with the radiological findings. It was not possible to demonstrate escape of the material by scintigraphy. (orig.) [de

  12. SU-D-BRB-07: Lipiodol Impact On Dose Distribution in Liver SBRT After TACE

    International Nuclear Information System (INIS)

    Kawahara, D; Ozawa, S; Hioki, K; Suzuki, T; Lin, Y; Okumura, T; Ochi, Y; Nakashima, T; Ohno, Y; Kimura, T; Murakami, Y; Nagata, Y

    2015-01-01

    Purpose: Stereotactic body radiotherapy (SBRT) combining transarterial chemoembolization (TACE) with Lipiodol is expected to improve local control. This study aims to evaluate the impact of Lipiodol on dose distribution by comparing the dosimetric performance of the Acuros XB (AXB) algorithm, anisotropic analytical algorithm (AAA), and Monte Carlo (MC) method using a virtual heterogeneous phantom and a treatment plan for liver SBRT after TACE. Methods: The dose distributions calculated using AAA and AXB algorithm, both in Eclipse (ver. 11; Varian Medical Systems, Palo Alto, CA), and EGSnrc-MC were compared. First, the inhomogeneity correction accuracy of the AXB algorithm and AAA was evaluated by comparing the percent depth dose (PDD) obtained from the algorithms with that from the MC calculations using a virtual inhomogeneity phantom, which included water and Lipiodol. Second, the dose distribution of a liver SBRT patient treatment plan was compared between the calculation algorithms. Results In the virtual phantom, compared with the MC calculations, AAA underestimated the doses just before and in the Lipiodol region by 5.1% and 9.5%, respectively, and overestimated the doses behind the region by 6.0%. Furthermore, compared with the MC calculations, the AXB algorithm underestimated the doses just before and in the Lipiodol region by 4.5% and 10.5%, respectively, and overestimated the doses behind the region by 4.2%. In the SBRT plan, the AAA and AXB algorithm underestimated the maximum doses in the Lipiodol region by 9.0% in comparison with the MC calculations. In clinical cases, the dose enhancement in the Lipiodol region can approximately 10% increases in tumor dose without increase of dose to normal tissue. Conclusion: The MC method demonstrated a larger increase in the dose in the Lipiodol region than the AAA and AXB algorithm. Notably, dose enhancement were observed in the tumor area; this may lead to a clinical benefit

  13. SU-D-BRB-07: Lipiodol Impact On Dose Distribution in Liver SBRT After TACE

    Energy Technology Data Exchange (ETDEWEB)

    Kawahara, D; Ozawa, S; Hioki, K; Suzuki, T; Lin, Y; Okumura, T; Ochi, Y; Nakashima, T; Ohno, Y; Kimura, T; Murakami, Y; Nagata, Y [Hiroshima University, Hiroshima, Hiroshima (Japan)

    2015-06-15

    Purpose: Stereotactic body radiotherapy (SBRT) combining transarterial chemoembolization (TACE) with Lipiodol is expected to improve local control. This study aims to evaluate the impact of Lipiodol on dose distribution by comparing the dosimetric performance of the Acuros XB (AXB) algorithm, anisotropic analytical algorithm (AAA), and Monte Carlo (MC) method using a virtual heterogeneous phantom and a treatment plan for liver SBRT after TACE. Methods: The dose distributions calculated using AAA and AXB algorithm, both in Eclipse (ver. 11; Varian Medical Systems, Palo Alto, CA), and EGSnrc-MC were compared. First, the inhomogeneity correction accuracy of the AXB algorithm and AAA was evaluated by comparing the percent depth dose (PDD) obtained from the algorithms with that from the MC calculations using a virtual inhomogeneity phantom, which included water and Lipiodol. Second, the dose distribution of a liver SBRT patient treatment plan was compared between the calculation algorithms. Results In the virtual phantom, compared with the MC calculations, AAA underestimated the doses just before and in the Lipiodol region by 5.1% and 9.5%, respectively, and overestimated the doses behind the region by 6.0%. Furthermore, compared with the MC calculations, the AXB algorithm underestimated the doses just before and in the Lipiodol region by 4.5% and 10.5%, respectively, and overestimated the doses behind the region by 4.2%. In the SBRT plan, the AAA and AXB algorithm underestimated the maximum doses in the Lipiodol region by 9.0% in comparison with the MC calculations. In clinical cases, the dose enhancement in the Lipiodol region can approximately 10% increases in tumor dose without increase of dose to normal tissue. Conclusion: The MC method demonstrated a larger increase in the dose in the Lipiodol region than the AAA and AXB algorithm. Notably, dose enhancement were observed in the tumor area; this may lead to a clinical benefit.

  14. Exposure to iodine 131 during the supply of capsules used for ira-therapy: comparative study of three measurement systems; Exposition a l'iode 131 lors de la dispensation des gelules utilisees pour l'iratherapie: etude comparative de trois systemes de mesure

    Energy Technology Data Exchange (ETDEWEB)

    Moubarik, C.; Giraud, F.; Bourrelly, M.; Guillet, B.; Pisano, P. [Service de medecine nucleaire, CHU de la Timone, Marseille, (France)

    2009-05-15

    The objective was to study the efficiency in the field of radiation protection of the new handle elaborated by the Covidien laboratories. In conclusions, this new handle seems to be the most efficient system in term of radiation protection of hands extremities. Indeed, it allows to reduce of 70% the exposure to extremities during the distribution of iodine 131 capsules. This supplementary protection comes from a better ergonomics and from the presence of a lead shield on the new prehension handle of Covidien laboratories. (N.C.)

  15. Phase III Randomized Study of Rituximab/Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) Compared With Iodine-131 Tositumomab/BEAM With Autologous Hematopoietic Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma: Results From the BMT CTN 0401 Trial

    Science.gov (United States)

    Vose, Julie M.; Carter, Shelly; Burns, Linda J.; Ayala, Ernesto; Press, Oliver W.; Moskowitz, Craig H.; Stadtmauer, Edward A.; Mineshi, Shin; Ambinder, Richard; Fenske, Timothy; Horowitz, Mary; Fisher, Richard; Tomblyn, Marcie

    2013-01-01

    Purpose This clinical trial evaluated standard-dose radioimmunotherapy with a chemotherapy-based transplantation regimen followed by autologous hematopoietic cell transplantation versus rituximab with the same regimen in patients with relapsed diffuse large B-cell lymphoma (DLBCL). Patients and Methods Patients with chemotherapy-sensitive persistent or relapsed DLBCL were randomly assigned to receive iodine-131 tositumomab (dosimetric dose of 5 mCi on day −19 and therapeutic dose of 0.75 Gy on day −12), carmustine 300 mg/m2 (day −6), etoposide 100 mg/m2 twice daily (days −5 to −2), cytarabine 100 mg/m2 twice daily (days −5 to −2), and melphalan 140 mg/m2 (day −1; B-BEAM) or rituximab 375 mg/m2 on days −19 and −12 and the same chemotherapy regimen (R-BEAM). Results Two hundred twenty-four patients were enrolled, with 113 patients randomly assigned to R-BEAM and 111 patients assigned to B-BEAM. Two-year progression-free survival (PFS) rates, the primary end point, were 48.6% (95% CI, 38.6% to 57.8%) for R-BEAM and 47.9% (95% CI, 38.2% to 57%; P = .94) for B-BEAM, and the 2-year overall survival (OS) rates were 65.6% (95% CI, 55.3% to 74.1%) for R-BEAM and 61% (95% CI, 50.9% to 69.9%; P = .38) for B-BEAM. The 100-day treatment-related mortality rates were 4.1% (95% CI, 0.2% to 8.0%) for R-BEAM and 4.9% (95% CI, 0.8% to 9.0%; P = .97) for B-BEAM. The maximum mucositis score was higher in the B-BEAM arm (0.72) compared with the R-BEAM arm (0.31; P < .001). Conclusion The B-BEAM and R-BEAM regimens produced similar 2-year PFS and OS rates for patients with chemotherapy-sensitive relapsed DLBCL. No differences in toxicities other than mucositis were noted. PMID:23478060

  16. Treatment of Thyrotoxicosis Using Radioactive Iodine 131

    International Nuclear Information System (INIS)

    JAJA, Salvador Bessarione

    1998-01-01

    Throtoxicosis is common in the Sudan, and its management constitute a significant health problem in terms of expenses, in addition to dilemma of best therapy between the physician's choice and the patients' reference. As the role of Radioactive lodine is becoming more acceptable. It is wise to evaluate our experience and compare it to the current literature, aiming to use the treatment more effectively in our setting. The objective is to evaluate the effectively of radioiodine and factors affecting them, and to find out the possible complications, and compare the cost of treatment to that of surgery and antithyroid drugs, as well as to find out the patient attitude and knowledge towards the treatment. 103 thyrotoxic patients referred to Radioisotope center and received Radioiodine therapy in the period between 1986-1997 were considered in the study. Those who received the treatment in 1997 were followed up prospectively for minimum of 12 months. Clinical feature, severity of the disease, size and type of goitre and complications were considered. Patients were treated as out patients and followed up in the referred clinic. 115 patients (88.5%) were female and 15(11.5%) were male. The mean age was (49±)10.7), the majority (43.9%) were fluocortolonum state and the least (1.5%) from Southern states. Most of the patients (58%) were referred from medical units in the hospitals, their mean thyroxine level (212.285±36.753) and mean weight (58.031±8.724)kg. (54.6%) had diffused goitre and 36% multinodular goitre and 9.2% had solitary nodule. 48.5% of the patients had moderate size goitre, 32.3% large size and 19.2% small size goitre. The main indication was replace after medical treatment (40%). Out of the 59 patients interviewed (77.9%) have no knowledge about the therapy, and (48.4%) accepted the treatment without difficulty. 22 patients presented with complications, and most of the complications were cardiac, heart failure with arrhythmia (50%) 15 patients had ophthalmopathy and they had variable response to treatment. (80.7%) of the patients showed clinical response within 6 months. 113 patients gained weight and all had reduction of thyroid size with (100%) disappearance among patients with solitary, and (91.7%) among those with diffused goitre. (23%) of the patients developed early complications. (50%) was transient worsening of the symptoms and (20%) was transient hypothyroidism. Recurrence was mainly seen among patients with diffused gotire (7.04%) and hypothyroidism was in (16.6%) among patients with diffused goitre, which from the highest percentage of hypothyroidism. There was no significant differences in treatment response in relation to initial thyroxine level and size of goitre, but the response was better among diffuse goitre and solitary nodule. Carcinoma of the thyroid and Leukaemia were not seen in our series, genetic effect and infertility were not considered in our study. Radioactive lodine is cheap, effective and safe with exception of hypothyroidism, there was not other significant complication. Excluding children and pregnant women, it can be used in all patients and as a first line in elderly and patients with complications.(Author)

  17. Nodular Hashitoxicosis - treatment with iodine-131

    International Nuclear Information System (INIS)

    Jara Yorg, J.A.; Ruiz Perez, V.; Acosta, N.

    2004-01-01

    Present case presents a patient of 58 years old of feminine sex with records of Tiroiditis of Hashimoto TSH of15 UI/ml (VN 0.5-4.0) who has been treated orally with sodium levotiroxina (100 ucg/dia) on a daily basis during 3 years with antibodies antimicrosomal or antitiroperoxidasa (TPO ab) with a value of 1/1550 UI/ml, with court 50 UI/ml and antitiroglobuliana (ATG ab) with values of 1/320 UI/ml with court 100 positive UI/ml [es

  18. Treatments of hyperthyroidism with iodine-131

    International Nuclear Information System (INIS)

    Kuniyasu, Yoshio

    1978-01-01

    The results of treatment 131 I were reported, and hypothyroidism as a late disturbance was described. The therapeutic results of a standard dose of 6000 rad and the incidence of hypothyroidism were discussed. Of the 117 patients followed up (80% were 21-50 years of age, and 30% were followed up for more than 10 years), 98 (83.8%) were euthyroid (cured), and 19 (16.2%) had hypothyroidism. Hypothyroidism occurred 6 months and 2 years later in one case each, 5 years later in 9, and more than 10 years later in 6; the onset increased with increasing years. Sixty patients (55%) were cured by the first treatment, and 36 were relieved by the second a total of 96 patients (87.2%) were relieved by two irradiations. Of all hypothyroidism was observed in 12 patients (10%). The incidence of hypothyroidism increased among the patients given more than 3 irradiations. There was no significant difference in the incidence of hypothyroidism between single 131 I treatment and 131 I treatment following the internal use of antithyroid drugs. Hypothyroidism did not occur in cases given less than 5000 rad, but occurred in 8.5% of those given 5000-10000 rad and 18.9% of those given 10000-15000 rad. With a standard dose of 6000 rad, 109 (82%) of the 133 patients followed up for less than 4 years were relieved or cured; hypothyroidism appeared in 13 cases (9.8%) including transient one immediately after recovery and this result is less satisfactory than that obtained with 9000 rad previously. (Chiba, M.)

  19. Axillary iodine-131 accumulation due to perspiration

    International Nuclear Information System (INIS)

    Camponovo, E.J.; Goyer, P.F.; Silverman, E.D.; Kistler, A.M.; Yudt, W.M.

    1989-01-01

    A case of spurious axillary uptake of I-131 proven to be caused by perspiration is presented. False-positive localizations of radioiodine, both pathologic and physiologic, are reviewed to avoid confusion of these entities with functioning thyroid carcinoma metastases

  20. Contamination with iodine-131 in metabolic therapy

    International Nuclear Information System (INIS)

    Garcia, R.; Luis, J.; Gomez, A.; Gonzalez, V.; Herrador, M.; Rogriguez, J.R.

    1997-01-01

    High-dose radioactive iodine therapy using 131 I is the treatment of choice for patients with thyroid cancer following thyroidectomy. Because of the large amount of activity which is excreted during hospitalization, contamination harzard from 131 I excretion via perspiration, saliva, breath and urine may arise. In twelve patients treated with doses of 131 I ranging from 1.85-7.4GBq activity levels were measured in room surface, the toilet, patients saliva and skin. Removable activity from skin reached a maximum at 24h post-therapy. Removable activity from room surfaces exceed the level of contamination which requires clean-up in a public area during patient's hospitalization. The relatively high activities present in the saliva and skin of these patients emphasizes the need for all individuals coming in contact with these patients to be made aware of the contamination hazard present. (author)

  1. Thyroid cancer following diagnostic iodine-131 administration

    International Nuclear Information System (INIS)

    Hall, P.; Holm, L.-E.; Boice, J.D.

    1996-01-01

    To provide quantitative data on the risk of thyroid cancer following 131 I exposure, 34104 patients administered 131 I for diagnostic purposes were followed for up to 40 years. Mean thyroid dose was estimated as 1.1 Gy, and 67 thyroid cancers occurred in contrast to 49.7 expected [standardized incidence ratio (SIR)=1.35; 95% confidence interval (CI) 1.05-1.71]. Excess cancers were apparent only among patients referred because of a suspected thyroid tumor and no increased risk was seen among those referred for other reasons. Further, risk was not related to radiation dose to the thyroid gland, time since exposure, or age at exposure. The slight excess of thyroid cancer, then appeared due to the underlying thyroid condition and not radiation exposure. Among those under age 20 years when 131 I was administered, a small excess risk (3 cancers vs 1.8 expected) was about 2-10 times lower than that predicted from A-bomb data. These data suggest that protraction of dose may result in a lower risk than acute x-ray exposure of the same total dose

  2. Uptake of iodine-131 in tropical crops

    International Nuclear Information System (INIS)

    Asprer, G.A.; Lansangan, L.M.

    1986-01-01

    Vegetable crops which include sweet potato tops (Ipomoea batatas), kangkong (Ipomoea repitans) and tomato plants were grown in dark-painted jars containing Hoagland-Arnon modified nutrient solution, utilizing the technique of hydroponics. The experiments for sweet potato tops and kangkong plants were duplicated for replicate studies and steady-state conditions were simulated throughout. Tomato plants were grown in the same manner but growth was observed to be hampered when starting from mature plants. Radioiodine was added to the nutrient medium containing 0.5% non-radioactive NaI solution. The solution in the jar was adjusted daily so as to maintain a constant concentration which would simulate routine releases that are essentially continuous. After incorporating the radioiodine to the solution, 10 ml aliquot was taken and counted for radioactivity by means of a 5'' x 5'' NaI(T1) detector connected to the multichannel gamma analyzer. Both plants and solution were counted for radioactivity at different time intervals using the same geometry. Results indicate that the activity in the plants were relatively higher than that of the solution. The activity tends to level off or decrease after a few days. The concentration factor which is the ratio of the activity in the plant (uCi/gm) over the activity in the medium (uCi/ml) varied for each time interval. 12 references, 2 figures, 3 tables

  3. Iodine-131 therapy for parotid oncocytoma

    Energy Technology Data Exchange (ETDEWEB)

    Kosuda, S.; Ishikawa, M.; Tamura, K.; Mukai, M.; Kubo, A.; Hashimoto, S.

    1988-06-01

    We present a rare case of a patient with coexisting parotid oncocytoma and chronic thyroiditis who received two therapeutic doses of (/sup 131/I)iodide for a recurrent oncocytoma (oxyphilic granular cell adenoma), resulting in a definite reduction in tumor volume. We suggest that radioiodine therapy for a recurrent oncocytoma is an effective form of tumor therapy.

  4. Contamination of pasture by iodine 131

    International Nuclear Information System (INIS)

    Angeletti, Livio

    1980-08-01

    The reassessment of the experimental data on the transfer of iodine to aerial parts of rye-gras leads to the following significant findings: 1 - Water content of herbage depending markedly on time and location, the contamination of the vegetals has to be expressed on a dry weight basis. 2 - The value of the geometrical mean of the deposition velocity of iodine vapour as derived from 19 experiments carried out over 4 years is 0.76 cm/s. This value agrees very well with the value of V(d)=0.80 obtained in the USA during experiments comparable as to the number of tests and their duration. Consequently we propose a value of V(d)=0.76 cm/s for the evaluation of pasture land contamination by iodine resulting from routine releases. For accidental releases, however, we propose a value of V(d)=2 cm/s, which was the upper limit in about 90% of our experimental results. 3 - The analysis of data on wet deposition of iodine on the aerial parts of rye-grass shows that the initial retention when expressed as percent of the total deposit decreases with aspersion intensities. If expressed as retention factor, the initial retention is constant, for all aspersion intensities. The average initial iodine retention being lower by a factor of 2.3 than water retention the value of the latter will therefore be the upper limit for this radionuclide [fr

  5. Therapeutic value of hysterosalpingography with Lipiodol ultra fluid

    International Nuclear Information System (INIS)

    Rasmussen, F.; Justesen, P.; Toenner Nielsen, D.

    1987-01-01

    Hysterosalpingography (HSG) with Lipiodol ultra fluid was performed in 294 infertile women with a normal ovulatory temperature curve and at least two years of infertility and a partner with normal sperm. In 21%, pregnancy occurred within 6 months after the examination, and about one third of the women with a normal finding or with intraperitoneal adhesions at HSG conceived. The pregnancy rate was especially high in the first two cycles after HSG. The spontaneous pregnancy rate was 8%, and the difference between this and the total number of pregnancies must be attributed to a therapeutic effect of the procedure. Previous pelvic inflammatory disease was present in 40% of those who did not become pregnant, while only 11% of those who conceived had previous inflammation. Of the women without previous gynecologic disease 30% conceived. (orig.)

  6. Study on blood supply of lung metastasis with trans-pulmonary arterial lipiodol infusion

    International Nuclear Information System (INIS)

    Zhou Jianqin; Dong Weihua; Dong Weihua; Ouyang Chang; Chang Heng; Xiao Xiangsheng

    2008-01-01

    Objective: To evaluate the blood supply of pulmonary metastases using small volume of lipiodol through pulmonary arterial infusion. Methods: 10 cases of lung metastasis were enroled including the primary tumors of liver cancer (n=5), renal carcinoma (n=3), chordoma (n=1) and malignant neurofibroma (n=1). Plain CT scan was performed to exclude calcification or ossification within metastasis and then pulmonary arterial DSA was undertaken to evaluate tumor vessels or staining. After pulmonary arteriovenous fistula or other anomalous circulation was excluded by lobar arterial DSA, small volume of lipiodol was infused under fluoroscopy (0.5-1.5 ml for each lobar artery, total volume less than 3.0 ml). CT scan was immediately performed. Blood supply of the pulmonary metastases was assessed according to the accumulation of lipiodol on CT scans. Results: No cases but one experienced cough, expectoration, suffocating or dyspnea. No complication of cerebral or visceral embolism occurred. Totally 27 nodules were studied including 6 nodules with cloudy lipiodol accumulation and 6 nodules with tiny granules of lipiodol accumulation. No enlarged tumor vessel or tumor stain was observed within all 27 nodules on pulmonary arterial DSA. Conclusions: Pulmonary artery supplys only parts of pulmonary metastases, especially those sited at the peripheral region of the lung. Infusion of small volume of lipiodol through pulmonary artery is safe, and the increased density of lung field could return normal after several days. (authors)

  7. Experiment of embolizing hepatocarcinoma with heated lipiodol via hepatic artery in VX2 rabbit model

    International Nuclear Information System (INIS)

    Cao Wei; Wang Zhimin; Zhang Hongxin; Wan Yi

    2006-01-01

    Objective: To evaluate the anti-tumour effect of 60 degree C Lipiodol in the embolization of VX 2 hepatocarcinoma in rabbits. Methods: VX 2 carcinoma cells were surgically implanted into the left liver lobe in 30 male New Zealand white rabbits, which were randomly divided into 3 groups by figure and table method with 10 rabbits in each group. Physiological saline, Lipiodol (37 degree C), and Lipiodol (60 degree C) were injected in each group via hepatic artery and liver cancer was embolized. The volume of tumour and serum level of aspartate aminotransferase (AST) were observed after one week, and the survival period of VX 2 rabbits was also observed. Results: In the group of Lipiodol (60 degree C), the growth rate of tumour (0.92± 0.21) was significantly lower than that of control group (3.48±) and Lipiodol (37 degree C) groups (1.69±0.26), respectively (F=34.95, P 0.05), but was significantly higher than the control group (68.6±6.6) U/L (t=19.24, P<0.05). Conclusion: Lipiodol (60 degree C) greatly decreases the tumour's growth rate and prolongs the survival period. It is a safe method and has stronger inhibitory effect than other groups. (authors)

  8. New labeling and separation methods for in vivo and in vitro diagnostics in Hungary

    International Nuclear Information System (INIS)

    Veres, A.; Toth, G.; Zsinka, L.; Miller, J.

    1986-01-01

    Three methods have been developed: 1. An adsorption chromatographic method for the separation of iodine-125-labeled compounds applied as tracers in the radioimmunoassay; 2. A portable sublimation generator for the separation of technetium-99m from low or medium specific activity molybdenum-99 using titanium molybdate as a new target material; 3. A novel dry distillation method for the production of iodine-131 from melted, pile-irradiated TeO 2 . The method renders possible to get rid of liquid radioactive wastes. 1 reference

  9. New labels for radiation therapy

    Energy Technology Data Exchange (ETDEWEB)

    Kubota, Susumu; Mukai, Minoru; Kato, Hirotoshi (National Inst. of Radiological Sciences, Chiba (Japan))

    1992-12-01

    In simulating radiotherapy, the bone and trachea identified by plain X-P and the other organs, such as the esophagus and bladder, outlined by contrast medium have so far been used as labels. However, irradiation with a high therapeutic ratio is required for an intracorporeal insertion of artificial labels that are identified by X-ray fluoroscopy. For this purpose, metal clips and seed dummies are available, although they cause artifacts in CT scans. Therefore, the authors are using an acupuncture needle and lipiodol for tracing as new artificial labels, since both are identified by X-ray fluoroscopy and CT scan and create few artifacts. (J.P.N.).

  10. New labels for radiation therapy

    International Nuclear Information System (INIS)

    Kubota, Susumu; Mukai, Minoru; Kato, Hirotoshi

    1992-01-01

    In simulating radiotherapy, the bone and trachea identified by plain X-P and the other organs, such as the esophagus and bladder, outlined by contrast medium have so far been used as labels. However, irradiation with a high therapeutic ratio is required for an intracorporeal insertion of artificial labels that are identified by X-ray fluoroscopy. For this purpose, metal clips and seed dummies are available, although they cause artifacts in CT scans. Therefore, the authors are using an acupuncture needle and lipiodol for tracing as new artificial labels, since both are identified by X-ray fluoroscopy and CT scan and create few artifacts. (J.P.N.)

  11. Accidental release of iodine-131 by IRE at Fleurus: back experience of Belgium safety authority; Rejet accidentel d'iode-131 par l'IRE sur le site de Fleurus: retour d'experience de l'autorite de surete belge

    Energy Technology Data Exchange (ETDEWEB)

    Vandecasteele, C.M.; Sonck, M. [AFCN - Agence federale de controle nucleaire, Bruxelles (Belgium); Degueldre, D. [Bel V, Anderlecht (Belgium)

    2011-04-15

    The IRE (National institute for radioelements) produces radionuclides for nuclear medicine from highly enriched uranium irradiated targets. On 22/08/2008, fresh production wastes were transferred into an almost empty decay tank. The mixing of these liquids led to the release of approximately 47 GBq of molecular iodine-131 into the atmosphere. The first conservative assessments of the radiological consequences did not require taking direct protective actions for the population, such as sheltering or stable iodine intake. However, the estimated iodine-131 deposits could locally reach or exceed the derived reference levels for the contamination of milk (4 kBq/m2) and leafy vegetables (10 kBq/m2). For this reason, and because there was a threat of a further release, the federal emergency plan was activated on 28/08 and the population potentially concerned was recommended to avoid consumption of locally produced fruits, vegetables and fresh milk. These protective actions were lifted on 7/09 and the emergency plan was lifted on 12/09. The main lesson learned from this event concerns the paramount importance of the rapid exchange of information that is as accurate and complete as possible between the different stakeholders: from the operator up to the population, through federal and local authorities. (authors)

  12. Iodine-131 treatment of hyperthyroidism in the elderly. Results in 180 patients. Radioprotection and waste management in 131-iodine therapy; Traitement de l'hyperthyroidie du sujet age par l'iode 131. A propos de 180 patients. Problemes de radioprotection et de gestion des dechets lies au traitement par l'iode 131

    Energy Technology Data Exchange (ETDEWEB)

    Dejax, C.; Freitas, D. de; Leroux, M.A.; Aubert, B. [Centre Jean-Perrin, Medecine Nucleaire, 63 - Clermont-Ferrand (France); Vennat, J.C. [Centre Jean-Perrin, Radiopharmacie, 63 - Clermont-Ferrand (France); Kwiatkowski, F. [Centre Jean-Perrin, Biostatistiques, 63 - Clermont-Ferrand (France)

    2005-09-15

    A retrospective study has been performed in patients treated by iodine-131 for hyperthyroidism between April 1999 and February 2004..Among the 270 patients, 180 were more than 65 years old. After 65 years, hyperthyroidism is most often the consequence of a toxic adenoma or multi-nodular goiter while Graves' disease is most frequent in young patients. Iodine-131 is usually proposed as first line treatment in the elderly, at the opposite of young patients. With a mean follow-up of 12 months, return to euthyroidism is observed in 56.5% of the older patients and in 73.6% of the young patients. We explain this results by the lower incidence of Graves' disease in the elderly. Nuclear medicine physicians are legally obliged to provide patients with a proper information about radioprotection. Recommendations should nevertheless not induce overdue nor illegitimate fear. They should not only be written and standardized, but also given orally and adapted to each patient. Urinary incontinence is not specific to the old patients, but it is more frequent after 65. Collection and storage of contaminated waste is sometimes difficult and has often to be solved on a case by case basis. (author)

  13. CT detection of daughter nodules in hepatocellular carcinoma after lipiodol infusion via the hepatic artery

    Energy Technology Data Exchange (ETDEWEB)

    Ohishi, Hajime; Ohgami, Syoichi; Katsuragi, Masami

    1985-02-01

    The detectability of daughter nodules in 80 hepatocellular carcinomas was compared between CT assisted by Lipiodol Ultra Fluid (Lipiodol) infused via the hepatic artery and IHA (Infusion hepatic angiography). Lipiodol infused via the hepatic artery was selectively accumulated in the tumor vessels and the tumors and small daughter nodules appeared as markedly high density areas by CT. 18 cases in which the daughter nodules were detected were identified only by CT. Furthermore, in 38 cases CT demonstrated superior detectability of the daughthr nodules than IHA. In 15 cases the daughter nodules were newly detected in areas other than the invaded area where the primary tumor existed. This method is very effective in the diagnosis of daughter nodules of hepatocellular carcinoma. (author).

  14. Hepatocellular carcinoma: the correlation between the enhancement in arterial-phase and lipiodol accumulation after the trans-arterial chemoembotherapy

    International Nuclear Information System (INIS)

    Tan Lilian; Li Yangbing; Li Shuxin; Jiang Jindai; Li Zhimin; Liang Tongjie; Zhou Shaoping; Han Minjun

    2005-01-01

    Objective: To investigate the relationship between enhancement in arterial-phase, indicating arterial blood supply of the lesions of hepatocellular carcinoma and lipiodol accumulation after the trans-arterial chemoembotherapy. Methods: CT images of primary hepatocellular carcinoma in 32 cases during the hepatic arterial-phase were retrospectively compared with the CT images of lipiodol distribution within the tumor after the trans-arterial chemoembotherapy. Results: The lipiodol distribution was classified into five types: homogeneous and compact(n=11), inhomogeneous though compact (n=7), scanty(n=5), poorly filled(n=3) and miscellaneous (n=3). The lipiodol has a homogeneous or inhomogeneous but compact distribution when remarkable enhancement of the tumor or dominant neoplastic vascularity was demonstrated during hepatic arterial-phase. The lipiodol distribution was scanty, poorly filled, or miscellaneous distributed in the nidus of the hepatocellular carcinoma with no or poor enhancement, or with hypo-vascularity during hepatic arterial-phase. Where there was abundant vascularity of the tumor, there would be a satisfying accumulation of the lipiodol. Conclusion: The CT assessmant of the arterial-phase vascularity of the hepatocellular provides valuable information of lipiodol accumulation after the trans-arterial chemoembotherapy. (authors)

  15. Adverse events and therapeutic efficacy associated with TACE for hepatocellular carcinoma with a miriplatin-lipiodol suspension in comparison with a cisplatin-lipiodol suspension

    International Nuclear Information System (INIS)

    Araki, Takuji; Okada, Taiki; Kimura, Kazufumi; Sawada, Eiichi; Sano, Katushiro; Araki, Tsutomu

    2012-01-01

    The aim of this study was to evaluate the short-term adverse events and therapeutic efficacy of transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) with a miriplatin-lipiodol suspension in comparison with a cisplatin-lipiodol suspension. Of patients who underwent TACE for unresectable HCCs in 2009 and 2010, twenty-nine and twenty-seven patients underwent TACE using cisplatin-lipiodol suspension (C-LS) and miriplatin-lipiodol suspension (M-LS), respectively. Adverse events of fever, pain, nausea, anorexia, elevation of aspartate aminotransferase (AST), total bilirubin, creatinine and a decrease in platelet count were evaluated by the National Cancer Institute Common Toxicity Criteria Ver.4. to compare the C-LS and M-LS groups. The short-term therapeutic efficacy of both groups was evaluated by the treatment effect (TE) on the CT images three months after TACE according to the General Rules for the Clinical and Pathological Study of Primary Liver Cancer (the 5th edition, Revised Version). With regard to the adverse events, the M-LS group had significantly less fever and anorexia than the C-LS group. No critical adverse events were observed in either group. The therapeutic efficacy was not significantly different between the groups. TACE with M-LS had fewer adverse events than TACE with C-LS, but neither TACE led to any critical adverse events. The short-term therapeutic efficacy of TACE with M-LS was equivalent to that of TACE with C-LS. (author)

  16. Experiment of embolizing hepatocarcinoma with heated lipiodol via hepatic artery in VX{sub 2} rabbit model

    Energy Technology Data Exchange (ETDEWEB)

    Wei, Cao; Zhimin, Wang; Hongxin, Zhang [Department of Interventional Radiology, Tangdu Hospital, The Fourth Military Medical Univ., Xi' an (China); Yi, Wan

    2006-09-15

    Objective: To evaluate the anti-tumour effect of 60 degree C Lipiodol in the embolization of VX{sub 2} hepatocarcinoma in rabbits. Methods: VX{sub 2} carcinoma cells were surgically implanted into the left liver lobe in 30 male New Zealand white rabbits, which were randomly divided into 3 groups by figure and table method with 10 rabbits in each group. Physiological saline, Lipiodol (37 degree C), and Lipiodol (60 degree C) were injected in each group via hepatic artery and liver cancer was embolized. The volume of tumour and serum level of aspartate aminotransferase (AST) were observed after one week, and the survival period of VX{sub 2} rabbits was also observed. Results: In the group of Lipiodol (60 degree C), the growth rate of tumour (0.92{+-} 0.21) was significantly lower than that of control group (3.48{+-}) and Lipiodol (37 degree C) groups (1.69{+-}0.26), respectively (F=34.95, P<0.05). The survival period of Lipiodol (60 degree C) group (41.0{+-}3.0) d was significantly longer than the control group (31.5{+-}3.0) d (t=29.18, P<0.05). Four days after the embolization, the serum level of AST of Lipiodol (60 degree C) (148.2{+-}11.3) U/L was not higher than that of Lipiodol (37 degree C) (139.7{+-}12.3) U/L (t=1.61, P>0.05), but was significantly higher than the control group (68.6{+-}6.6) U/L (t=19.24, P<0.05). Conclusion: Lipiodol (60 degree C) greatly decreases the tumour's growth rate and prolongs the survival period. It is a safe method and has stronger inhibitory effect than other groups. (authors)

  17. Superselective transcather arterial embolization for hepatocellular carcinoma with a mixture of ethanol and lipiodol

    International Nuclear Information System (INIS)

    Park, Jae Hyung; Han, Joon Koon; Choi, Byung Ihn; Han, Man Chung

    1992-01-01

    To evaluate the effectiveness of superselective transcatheter arterial embolization (STAE) for hepatocellular carcinoma (HCC) with a mixture of ethanol and Lipiodol, STAE was done in 12 male patients with HCC. There were diagnosed clinically with angiographic findings and elevated alphafetprotein levels and three were recurrent tumors after surgery. Sono-guided aspiration biopsy proved the diagnosis of hepatocellular carcinoma in another six patients. The tumor was a small single nodule (2-5cm in diameter) in 11 patients. In one patient, two nodules were found. Superselective catheterization was done using 3F Tracker catheter (Target Therapeutics USA) coaxially through 6F catheter into the feeding hepatic artery, usually the third order branch. One to four cc of 75% ethanol mixed with Lipiodol was infused under fluoroscopy immediately after injection of 2% lidocaine. Immediate angiography and CT after 2 weeks were undertaken. Complete segmental or subsegmental devascularization including feeding arteries and tumor vascularities occurred in all patients. Follow-up angiography after 6 to 15 months revealed the tumor opacified by Lipiodol. The tumor decreased in 5 cases and recurrence was found in three patients. CT taken 2 weeks after STAE showed low density halo around the tumor in 5 cases. Subsequent segmentectomy in four patients revealed total or near total necrosis of the tumor and no evidence of damage in surrounding parenchyma. STAE for HCC with a mixture of ethanol and Lipiodol is an effective and safe measure for small HCC

  18. BEHAVIOR OF LIPIODOL MARKERS DURING IMAGE GUIDED RADIOTHERAPY OF BLADDER CANCER

    NARCIS (Netherlands)

    Chai, Xiangfei; van Herk, Marcel; van de Kamer, Jeroen B.; Remeijer, Peter; Bex, Axel; Betgen, Anja; de Reijke, Theo M.; Hulshof, Maarten C. C. M.; Pos, Floris J.; Bel, Arjan

    2010-01-01

    Purpose: To investigate the stability of a novel type of markers used in partial bladder tumor irradiation and tumor deformation as indicated by the markers. Materials and Methods: In 15 patients with solitary bladder cancer, lipiodol was injected in the bladder wall during flexible cystoscopy to

  19. Pulmonary Lipiodol Accumulation after Transarterial Chemoembolization: CT Findings and Its Radiologic Outcomes

    Energy Technology Data Exchange (ETDEWEB)

    Youn, In Young; Chong, Se Min; Kwak, Byung Kook; Shin, Hyung Jin; Seo, Gi Young; Seo, Jae Seung; Kim, Jae Kyun [Dept. of Radiology, Chung Ang University Medical Center, Chung Ang University College of Medicine, Seoul (Korea, Republic of)

    2011-12-15

    To evaluate CT findings and radiologic outcomes of pulmonary lipiodol accumulation (PLA) after transarterial chemoembolization (TACE). This retrospective study involved 488 TACEs for hepatocellular carcinoma (HCC) (n = 160) and hepatic metastasis for non-hepatic malignancies (n = 7) in 167 patients. We reviewed the patient clinicoradiologic findings before and after TACE and calculated the incidence of PLA and PLA resolution time after initial CT and after TACE. Lipiodol accumulation in the lungs was seen under CT after TACE in seven patients (M : F = 6 : 1, mean age 61 years). The incidence of PLA at CT was 4.1% (7/167 patients). In five patients, associated intrathoracic abnormalities including pleural effusion with (n 3) or without consolidation (n = 2) were revealed at CT scans. The CT resolution time and PLA recovery time were 56 {+-} 54 days and 66 {+-} 52 days, respectively. The recovery time for lipiodol accumulation was 66 days. It is believed that the clinical and radiologic outcome of PLA without respiratory failure is promising, and conservative treatment will suffice when lipiodol accumulation in the lungs is seen in CT images after TACE.

  20. Indocyanine green labeled with 123I for dynamic studies of the hepato-biliary system

    International Nuclear Information System (INIS)

    Lambrecht, R.M.; Ansari, A.N.; Wolf, A.P.; Atkins, H.L.

    1975-01-01

    This report summarizes the results to develop an iodine-123 labeled agent for dynamic studies of the hepato-biliary system. Iodine-123 is an ideal nuclide for radiopharmaceuticals, because of its short half-life (T/sub 1 / 2 / = 13.3 hr); its decay with a high abundance (83%) of 159 keV photons; and the reduced patient radiation exposure (a factor of 100 less than iodine-131). Indocyanine green, a tricarbanocyanine dye, was introduced by Heseltine and co-workers in 1956, has several characteristics which suggested that iodine-123 labeled ICG might be potentially useful for hepatic functional evaluation. The plasma clearance and biliary excretion kinetics of 123 I-ICG (in dogs) will be compared to 131 I-rose bengal and bromosulphalein labeled with iodine-125

  1. Transarterial lidocaine-lipiodol emulsion administration for relief of pain during transarterial chemoembolization of malignant tumor

    International Nuclear Information System (INIS)

    Wu Anle; Yan Zhiping; Zhou Kangrong; Wang Jianhua; Cheng Jiemin; Qian Sheng; Luo Jianjun; Chen Yi

    2004-01-01

    Objective: To assess the feasibility and efficacy of transarterial lidocaine-lipiodol emulsion administration for controlling abdominal pain and preventing the arterial spasm resulting from TACE, and to evaluate the optimal amount of lidocaine administration. Methods: In a prospective trial of 120 consecutive patients with malignant tumor who underwent TACE were divided into three groups, those who received lidocaine-lipiodol emulsion administration (group A, n=40), those who received lidocaine bolus intraarterial infusion immediately before TACE (group B, n=40) and those who received no lidocaine injection before TACE, (group C, n=40). The degree of post-procedure pain was evaluated by a subjective method (using visual analogue scales from 0 to 10), and an objective method (amount of post-procedure analgesics). Incidence and degree of arterial spasm were assessed by DSA. Results: The correlative pain incidences between the three groups showed significant difference (P 0.05). Mean dose of intramuscular analgesics for controlling intolerable pain in group A and B was significantly lower than that of group C (P<0.05). There was no difference in the incidence of arterial spasm between group A and B but it was much lower in group C. Lipiodol deposit in malignant mass was densest in group A, especially in the metastatic nodules of the liver. Conclusions: Transarterial administration of lidocaine-lipiodol emulsion can not only reduce the incidence of pain during TACE, but also prevent the arterial spasm. It is much more effective than pre-TACE administration of pethidine and intraarterial infusion of lidocaine. The authors recommond routinely for the administration of lidocaine-lipiodol emulsion. (authors)

  2. Prediction of recurrence after HCC resection. Faint oily deposits in preoperative Lipiodol-CT of remnant liver tissue

    International Nuclear Information System (INIS)

    Yamamoto, M.; Iimuro, Y.; Mogaki, M.; Kachi, K.; Fujii, H.; Matsumoto, Y.

    1994-01-01

    In trying to clarify the high recurrence rate after removal of small hepatocellular carconoma (HCC), we assessed the postoperative evolution of minute hepatic Lipiodol deposits which had been diagnosed as artifacts on the preoperative Lipiodol-CT. Of 27 patients with solitary HCC less than 5 cm in diameter, 14 had such Lipiodol deposits in the preoperative CT and 9 of them (64%) developed recurrent tumors. On the other hand, 6 of the 13 patients without deposits (46%) suffered recurrence, but in 5 of these 6 patients the HCC was metachronous multicentric. The cumulative survival rate of the non-deposit group was better than that of the deposit group (p<0.1). The present study suggested that, even in patients with small HCC, minute concomitant tumors invisible by conventional imaging techniques may exist at the time of surgery. Some of these lesions without sufficient tumor vasculature showing a hypervascular blush on angiography appear to retain small, vague Lipiodol deposits. (orig.)

  3. Preparation of a radioactive boron compound (B-I-131-lipiodol) for neutron capture therapy of hepatoma

    International Nuclear Information System (INIS)

    Chou, F.I.; Chung, H.P.; Chung, R.J.; Wen, H.W.; Wei, Y.Y.; Kai, J.J.; Lui, W.Y.; Chi, C.W.

    2000-01-01

    In our research, a radioactive boron compound, B-I-131-lipiodol, that can be selectively retained in hepatoma cells was prepared. Combining the effect of α particles produced by boron neutron capture reaction with the β particles released by radionuclides in the radioactive boron compounds will produce a synergistic killing effect on cancer cells. Human hepatoma HepG2 cell cultures were used to examine the stability and the intracellular distribution of the radioactive boron drug. Microscopes were used to examine the interaction and retention of B-I-131-lipiodol globules in the individual hepatoma cell. Moreover, ICP-AES and NaI scintillation counter were performed to determine boron concentrations and I-131 radioactivity, respectively. Results showed that B-I-131-lipiodol with a boron concentration and a specific radioactivity ranged from 500-2000 ppm and 0.05-10 mCi/mL respectively was stably retained in serum. The radiochemical purity of B-I-131-lipiodol was 98%. After supplement with a medium containing B-I-131-lipiodol, the HepG2 cells had intracellular B-I-131-lipiodol globules in the cytoplasm as seen by inverted light microscope, the I-131 and boron can be stably retained in HepG2 cells. (author)

  4. Rhenium-188-Lipiodol therapy of liver cancer: Optimization of conjugate-view imaging of 188Re for patient-specific dosimetry

    International Nuclear Information System (INIS)

    Chaudakshetrin, P.; Osorio, M.; Padhy, A.K.; Divgi, C.; Zanzonico, P.

    2004-01-01

    Full text: Intrahepatic artery Lipiodol labeled with generator-produced, β-emitting 188Re (17 hr; Eβ=0.53-0.70 MeV; Range=4 mm) localizes in and may effectively treat inoperable liver tumors. Although 188Re emits an imageable 155-keV γ ray (15%), its 478- and 633-keV β rays (2.3%) complicate imaging. Our objective was to optimize 188Re image quality and conjugate-view accuracy for quantitative imaging-based patient-specific dosimetry for 188Re-Lipiodol. Using an ADAC dual-EpicO-circumflex-detector gamma camera, 188Re intrinsic and extrinsic (with LEGP, MEGP, and HEGP collimation) uniformities using either 99mTc intrinsic or 188Re extrinsic flood corrections were evaluated. 188Re conjugate view count rate vs. activity concentration linearity as a function of scattering/attenuating medium thickness was then evaluated with and without corrections for attenuation (a 188Re transmission image) and for scatter and septal penetration, subtracting a fraction of counts in a lower-energy (109-140 keV)- and a higher-energy (170-201 keV)-window image, respectively, from the 20% (140-171 keV) photopeak image. Our phantom consisted of 5 10-ml vials containing 25 to 400 μCi/ml of 188Re with 0 to 6 cm at different positions (∼5 cm apart) between the detectors (60 cm apart) and with a 0- to 6-cm thickness of non-radioactive water between the vials and each detector. With a 99mTc intrinsic correction, 188Re intrinsic uniformity was excellent ( 10% and 'tubey'), and was poorer the lower the energy rating of the collimation. Uniformity with HEGP collimation and an extrinsic 188Re correction was acceptable ( 0.95) and the slope (cps/pixel/μCi/ml) was constant +25% (vs +10% for 99mTc) for 0- to 6-cm thicknesses of water. Regardless of the fraction of counts subtracted, neither scatter nor septal-penetration correction improved the slope constancy. Conclusion: Downscatter/septal penetration of the 478- and 633-keV 188Re γ-rays complicates imaging of its 155-keV γ-ray. Using HEGP

  5. Iodine-131 Releases from Radioactive Lanthanum Processing at the X-10 Site in Oak Ridge, Tennessee (1944-1956)- An Assessment of Quantities released, Off-Site Radiation Doses, and Potential Excess Risks of Thyroid Cancer- APPENDICES Appendices-Volume 1A

    International Nuclear Information System (INIS)

    Apostoaei, A.I.; Burns, R.E.; Hoffman, F.O.; Ijaz, T.; Lewis, C.J.; Nair, S.K.; Widner, T.E.

    1999-01-01

    This report consists of all the appendices for the report described below: In the early 1990s, concern about the Oak Ridge Reservation's past releases of contaminants to the environment prompted Tennessee's public health officials to pursue an in-depth study of potential off-site health effects at Oak Ridge. This study, the Oak Ridge dose reconstruction, was supported by an agreement between the U.S. Department of Energy (DOE) and the State of Tennessee, and was overseen by a 12-member panel appointed by Tennessee's Commissioner of Health. One of the major contaminants studied in the dose reconstruction was radioactive iodine, which was released to the air by X-10 (now called Oak Ridge National Laboratory) as it processed spent nuclear reactor fuel from 1944 through 1956. The process recovered radioactive lanthanum for use in weapons development. Iodine concentrates in the thyroid gland so health concerns include various diseases of the thyroid, such as thyroid cancer. The large report, ''Iodine-131 Releases from Radioactive Lanthanum Processing at the X-10 Site in Oak Ridge, Tennessee (1944-1956) - An Assessment of Quantities Released, Off-site Radiation Doses, and Potential Excess Risks of Thyroid Cancer,'' is in two volumes. Volume 1 is the main body of the report, and Volume 1A, which has the same title, consists of 22 supporting appendices. Together, these reports serve the following purposes: (1) describe the methodologies used to estimate the amount of iodine-131 (I-131) released; (2) evaluate I-131's pathway from air to vegetation to food to humans; (3) estimate doses received by human thyroids; (4) estimate excess risk of acquiring a thyroid cancer during ones lifetime; and (5) provide equations, examples of historical documents used, and tables of calculated values as appendices. Results indicate that females born in 1952 who consumed milk from a goat pastured a few miles east of X-10 received the highest doses from I-131 and would have had the highest

  6. Iodine-131 Releases from Radioactive Lanthanum Processing at the X-10 Site in Oak Ridge, Tennessee (1944-1956)- An Assessment of Quantities released, Off-Site Radiation Doses, and Potential Excess Risks of Thyroid Cancer- APPENDICES Appendices-Volume 1A

    Energy Technology Data Exchange (ETDEWEB)

    Apostoaei, A.I.; Burns, R.E.; Hoffman, F.O.; Ijaz, T.; Lewis, C.J.; Nair, S.K.; Widner, T.E.

    1999-07-01

    This report consists of all the appendices for the report described below: In the early 1990s, concern about the Oak Ridge Reservation's past releases of contaminants to the environment prompted Tennessee's public health officials to pursue an in-depth study of potential off-site health effects at Oak Ridge. This study, the Oak Ridge dose reconstruction, was supported by an agreement between the U.S. Department of Energy (DOE) and the State of Tennessee, and was overseen by a 12-member panel appointed by Tennessee's Commissioner of Health. One of the major contaminants studied in the dose reconstruction was radioactive iodine, which was released to the air by X-10 (now called Oak Ridge National Laboratory) as it processed spent nuclear reactor fuel from 1944 through 1956. The process recovered radioactive lanthanum for use in weapons development. Iodine concentrates in the thyroid gland so health concerns include various diseases of the thyroid, such as thyroid cancer. The large report, ''Iodine-131 Releases from Radioactive Lanthanum Processing at the X-10 Site in Oak Ridge, Tennessee (1944-1956) - An Assessment of Quantities Released, Off-site Radiation Doses, and Potential Excess Risks of Thyroid Cancer,'' is in two volumes. Volume 1 is the main body of the report, and Volume 1A, which has the same title, consists of 22 supporting appendices. Together, these reports serve the following purposes: (1) describe the methodologies used to estimate the amount of iodine-131 (I-131) released; (2) evaluate I-131's pathway from air to vegetation to food to humans; (3) estimate doses received by human thyroids; (4) estimate excess risk of acquiring a thyroid cancer during ones lifetime; and (5) provide equations, examples of historical documents used, and tables of calculated values as appendices. Results indicate that females born in 1952 who consumed milk from a goat pastured a few miles east of X-10 received the highest doses from

  7. Clinical Analysis of Pulmonary Lipiodol Embolism in Patients with Hepatic Carcinoma after Transcatheter Arterial Chemoembolization

    Directory of Open Access Journals (Sweden)

    Wen-jin JIANG

    2015-03-01

    Full Text Available Objective:To explore the clinical manifestations, therapeutic methods and preventive measures of pulmonary lipiodol embolism (PLE induced by transcatheter arterial chemoembolization (TACE so as to improve the cognition and management of PLE. Methods:A total of 2 613 patients with hepatic cancer without history of pulmonary disease who were treated with TACE in our hospital from Sept., 2004 to Mar., 2013 were selected. The clinical manifestations, therapeutic methods and preventing measures of the 9 patients who were accompanied with PLE were observed to analyze the pre-operative hepatic computed tomography (CT and chest X-ray, intra-operative contrast examination, dosage of lipiodol and chemotherapeutic drugs, clinical manifestation and therapeutic progression as well as the postoperative follow-up.Results: Nine patients accompanied by PLE had different-severity cough, hemoptysis and progressive dyspnea, and chest X-ray and/or CT showed flaky high-density radiography. After treated with oxygen inhalation, bronchus expansion and inflammation alleviation, 8 patients were improved but 1 died. Of the 8 patients, 2 were given ventilator to assist breath, and the clinical symptoms of 8 patients disappeared within 3-15 d. The re-examined chest X-ray showed normal after 20-60 d follow-up observation. Additionally, 6 patients were with nidus diameter ≥10 cm, 6 with hepatic artery-vein fistula and 7 with lipiodol dosage ≥20 mL.Conclusion: PLE often occurs in patients with giant hepatic carcinoma accompanied by hepatic artery-vein fistula, whose lipiodol dosage is ≥20 mL. Accurate and correct management during operation can effectively reduce the development of PLE.

  8. A study of image-guided radiotherapy of bladder cancer based on lipiodol injection in the bladder wall

    International Nuclear Information System (INIS)

    Soendergaard, Jimmi; Muren, Ludvig Paul; Elstroem, Ulrik Vindelev; Grau, Cai; Hoeyer, Morten; Oerding Olsen, Kasper

    2010-01-01

    Purpose. We have tested a procedure of focal injection of the contrast medium Lipiodol as a fiducial marker for image-guided boost of the tumor in bladder cancer radiotherapy (RT). In this study, we have evaluated the feasibility and the safety of the method as well as the inter- and intra-fraction shift of the bladder tumor. Materials and methods. Five patients with muscle invasive urinary bladder cancer were included in the study. Lipiodol was injected during flexible cystoscopy into the submucosa of the bladder wall at the periphery of the tumor or the post resection tumor-bed. Cone-beam CT (CBCT) scans were acquired daily throughout the course of RT. Results. Lipiodol demarcation of the bladder tumor was feasible and safe with only a minimum of side effects related to the procedure. The Lipiodol spots were visible on CT and CBCT scans for the duration of the RT course. More than half of all the treatment fractions required a geometric shift of 5 mm or more to match on the Lipiodol spots. The mean intra-fraction shift (3D) of the tumor was 3 mm, largest in the anterior-posterior and cranial-caudal directions. Conclusion. This study demonstrates that Lipiodol can be injected into the bladder mucosa and subsequently visualized on CT and CBCT as a fiducial marker. The relatively large inter-fraction shifts in the positions of Lipiodol spots compared to the intra-fraction movement indicates that image-guided RT based on radio-opaque markers is important for RT of the bladder cancer tumor.

  9. Dicarbonic acid anilides containing radioactive iodine (iodine 131, 123, 125, or 132) as well as their metal and amine salts; methods for the preparation of these compounds and of radioactive functional diagnostics containing them

    International Nuclear Information System (INIS)

    Buttermann, G.

    1976-01-01

    A method for the preparation of dicarbonic acid anilides containing radioactive iodine is described. The initial substances are N,N dimethyl-p-toluene sulfonamide, N,N bis-dimethyl aminosulfon, or dimethyl sulfon, or mixtures of these, which are heated in aqueous solution or in a melt with an alkali or alkaline earth radioiodide as carrier-free as possible. From the water-soluble salts of the obtained iodine-labelled dicarbonic acid anilides aqueous solutions are produced with 1 mg up to 5 g iodine-labelled dicarbonic acid anilide per 10 ml and an activity of 0.025 and 25 mCi per ml with physiologically compatible bases as radioactive functional diagnostics. (RB) [de

  10. Radioiodine therapy of differentiated thyroid cancer: radiologic impact of out-patient treatment with 100 to 150 mCi Iodine-131 activities; Radioiodoterapia do carcinoma diferenciado da tireoide: impacto radiologico da liberacao hospitalar de pacientes com atividades entre 100 e 150 mCi de iodo-131

    Energy Technology Data Exchange (ETDEWEB)

    Sapienza, Marcelo Tatit; Willegaignon, Jose; Ono, Carla Rachel; Watanabe, Tomoco; Guimaraes, Maria Ines Calil Cury; Buchpiguel, Carlos Alberto [Universidade de Sao Paulo (USP), SP (Brazil). Faculdade de Medicina. Servico de Medicina Nuclear; Gutterres, Ricardo Fraga; Marechal, Maria Helena da Hora [Comissao Nacional de Energia Nuclear (CNEN), Rio de Janeiro, RJ (Brazil)

    2009-07-01

    Purpose: To evaluate exposure and dosimetry to family members and environment due to outpatient radioiodine therapy of differentiated thyroid carcinoma. Methods: Twenty patients were treated with 100-150 mCi of iodine-131 on an out-patient basis. Family members dosimetry (n = 27) and potential doses inside the house were measured with thermoluminescent dosimeters. Surface contamination and radioactive wastes were also monitored. Results: Less than 1.0 mSv doses were found in 26 co-habitants and 2.8 mSv in a single case (inferior to the acceptable value of 5.0 mSv/procedure). Potential doses in the houses were inferior to 0.25 mSv, excluding the patients bedroom (mean value = 0.69 mSv). Surface contamination (mean = 4.2 Bq.cm{sup -2}) were below clearance levels. Radioactive wastes generated had a volume of 2.5 liters and a total activity estimated in 90 {mu}Ci, with a calculated exposure close to the background radiation levels. Conclusions: No radiological impact was detected after iodine therapy with 100-150 mCi on an out-patient basis followed by experienced professionals. (author)

  11. Heated lipiodol as an embolization agent for transhepatic arterial embolization in VX2 rabbit liver cancer model

    Energy Technology Data Exchange (ETDEWEB)

    Cao Wei [Department of Interventional Radiology, Tangdu Hospital, Fourth Military Medical University, No.1 Xinshi Road, Shaanxi Province, Xi' an 710038 (China)], E-mail: zjfurong2008@126.com; Wan Yi [Department of Health Statistics, Fourth Military Medical University, No. 17 West Changle Road, Xi' an 710032 (China); Liang Zhihui [Department of Radiology, Bethune International Peace Hospital, Shijiazhuang, Hebei Province 050082 (China); Duan Yunyou; Liu Xi [Department of Ultrasonography, Tangdu Hospital, Fourth Military Medical University, No. 1 Xinshi Road, Xi' an 710038 (China); Wang Zhimin; Liu Yiyong; Zhu Jia; Liu Xiongtao [Department of Interventional Radiology, Tangdu Hospital, Fourth Military Medical University, No.1 Xinshi Road, Shaanxi Province, Xi' an 710038 (China); Zhang Hongxin [Department of Interventional Radiology, Tangdu Hospital, Fourth Military Medical University, No.1 Xinshi Road, Shaanxi Province, Xi' an 710038 (China)], E-mail: cawe-001@163.com

    2010-02-15

    Purpose: To evaluate the therapeutic effect of heated (60 deg. C) lipiodol via hepatic artery administration in a rabbit model of VX2 liver cancer. Materials and methods: Thirty male New Zealand white rabbits were randomly divided into three groups with 10 rabbits assigned to each group. VX2 carcinoma cells were surgically implanted into the left hepatic lobe. The tumors were allowed to grow for 2 weeks, and studies were performed until the diameter of the tumors detected by ultrasonograph reached 2-3 cm. Under anesthesia, trans-catheter hepatic arterial embolization was performed and doxorubicin-lipiodol (37 deg. C) (1 mL), lipiodol (60 deg. C) (1 mL) or control (physiological saline (37 deg. C) (1 mL)) solution was injected into the hepatic arteries of animals in the three groups. One week later, the volume of the tumor was measured by ultrasonograph again. The serum of all rabbits was collected before injection and at 4 and 7 days after injection, and the level of aspartate aminotransferase (AST) was checked. The survival period of the three groups of rabbits after treatment was also recorded. During the last course of their disease, the rabbits were given analgesics to relieve suffering. Results: The tumor growth rate in the lipiodol (60 deg. C) group (0.92 {+-} 0.21, tumor volume from 1811 {+-} 435 to 1670 {+-} 564 mm{sup 3}) was significantly lower than that in the control group (3.48 {+-} 1.17, tumor volume from 1808 {+-} 756 to 5747 {+-} 1341 mm{sup 3}) (P < 0.05) and in the doxorubicin-lipiodol (37 deg. C) group (1.69 {+-} 0.26, tumor volume from 1881 {+-} 641 to 2428 {+-} 752 mm{sup 3}) (P < 0.05). Consequently, the survival period of the animals in the lipiodol (60 deg. C) group (41.0 {+-} 3.0 days) was significantly greater than that in the doxorubicin-lipiodol (37 deg. C) group (38.0 {+-} 2.5 days) (P < 0.05). On the other hand, there was no statistically significant difference in serum AST levels between the lipiodol (60 deg. C) group (148.2 {+-} 11

  12. Heated lipiodol as an embolization agent for transhepatic arterial embolization in VX2 rabbit liver cancer model

    International Nuclear Information System (INIS)

    Cao Wei; Wan Yi; Liang Zhihui; Duan Yunyou; Liu Xi; Wang Zhimin; Liu Yiyong; Zhu Jia; Liu Xiongtao; Zhang Hongxin

    2010-01-01

    Purpose: To evaluate the therapeutic effect of heated (60 deg. C) lipiodol via hepatic artery administration in a rabbit model of VX2 liver cancer. Materials and methods: Thirty male New Zealand white rabbits were randomly divided into three groups with 10 rabbits assigned to each group. VX2 carcinoma cells were surgically implanted into the left hepatic lobe. The tumors were allowed to grow for 2 weeks, and studies were performed until the diameter of the tumors detected by ultrasonograph reached 2-3 cm. Under anesthesia, trans-catheter hepatic arterial embolization was performed and doxorubicin-lipiodol (37 deg. C) (1 mL), lipiodol (60 deg. C) (1 mL) or control (physiological saline (37 deg. C) (1 mL)) solution was injected into the hepatic arteries of animals in the three groups. One week later, the volume of the tumor was measured by ultrasonograph again. The serum of all rabbits was collected before injection and at 4 and 7 days after injection, and the level of aspartate aminotransferase (AST) was checked. The survival period of the three groups of rabbits after treatment was also recorded. During the last course of their disease, the rabbits were given analgesics to relieve suffering. Results: The tumor growth rate in the lipiodol (60 deg. C) group (0.92 ± 0.21, tumor volume from 1811 ± 435 to 1670 ± 564 mm 3 ) was significantly lower than that in the control group (3.48 ± 1.17, tumor volume from 1808 ± 756 to 5747 ± 1341 mm 3 ) (P 3 ) (P -1 ) and the doxorubicin-lipiodol (37 deg. C) group (139.7 ± 12.3 U L -1 ) (P > 0.05). However, the serum AST level in the lipiodol (60 deg. C) group was significantly higher at 4 days after injection (P -1 ). Conclusions: Treatment with lipiodol (60 deg. C) resulted in an effect on serum AST levels similar to that caused by treatment with doxorubicin-lipiodol (37 deg. C). Thus, lipiodol (60 deg. C) treatment could greatly prolong the survival period of rabbits with VX2 cancer by inhibiting tumor growth.

  13. Indocyanine green labeled with /sup 123/I for dynamic studies of the hepato-biliary system. [/sup 131/I, /sup 125/I

    Energy Technology Data Exchange (ETDEWEB)

    Lambrecht, R.M.; Ansari, A.N.; Wolf, A.P.; Atkins, H.L.

    1975-01-01

    This report summarizes the results to develop an iodine-123 labeled agent for dynamic studies of the hepato-biliary system. Iodine-123 is an ideal nuclide for radiopharmaceuticals, because of its short half-life (T/sub /sup 1///sub 2// = 13.3 hr); its decay with a high abundance (83%) of 159 keV photons; and the reduced patient radiation exposure (a factor of 100 less than iodine-131). Indocyanine green, a tricarbanocyanine dye, was introduced by Heseltine and co-workers in 1956, has several characteristics which suggested that iodine-123 labeled ICG might be potentially useful for hepatic functional evaluation. The plasma clearance and biliary excretion kinetics of /sup 123/I-ICG (in dogs) will be compared to /sup 131/I-rose bengal and bromosulphalein labeled with iodine-125.

  14. {sup 188}Re-HDD/lipiodol therapy for hepatocellular carcinoma: an activity escalation study

    Energy Technology Data Exchange (ETDEWEB)

    Lambert, Bieke; Vos, Filip de; Wiele, Christophe van de [Ghent University Hospital, Nuclear Medicine Division, Gent (Belgium); Bacher, Klaus; Thierens, Hubert [Ghent University, Department of Medical Physics, Gent (Belgium); Defreyne, Luc [Ghent University Hospital, Division of Interventional Radiology, Gent (Belgium); Vlierberghe, Hans van [Ghent University Hospital, Division of Gastroenterology, Gent (Belgium); Jeong, Jae Min [Seoul National University College of Medicine, Department of Nuclear Medicine, Cancer Research Institute, Seoul (Korea); Wang, Rong Fu [Beijing University, Department of Nuclear Medicine, Beijing (China); Meerbeeck, Jan van [Ghent University Hospital, Department of Respiratory Diseases, Gent (Belgium); Smeets, Peter [Ghent University Hospital, Department of Radiology, Gent (Belgium); Troisi, Roberto [Ghent University Hospital, Division of Abdominal Surgery and Liver Transplantation, Gent (Belgium)

    2006-03-15

    The aim of this study was to investigate the feasibility of administering increasing activities of {sup 188}Re-4-hexadecyl-1-2,9,9-tetramethyl-4,7-diaza-1,10-decanethiol/lipiodol ({sup 188}Re-HDD/lipiodol) for the treatment of hepatocellular carcinoma (HCC) in patients with well-compensated cirrhosis. The activity levels were increased by 1.1 GBq/step after a 6-week interval without unacceptable adverse events in at least five consecutive patients. Absorbed doses to the various organs were calculated according to the MIRD formalism, based on three gamma-scintigraphic studies. Response was assessed by means of MRI and alpha-fetoprotein (AFP) monitoring. Thirty-five treatments were carried out in 28 patients. Activities from 4.8 to 7.0 GBq {sup 188}Re-HDD/lipiodol were administered via a transfemoral catheter. The mean absorbed dose to the liver (including tumour) was 7.6{+-}2.2, 9.8{+-}4.9 and 15.2{+-}4.9 Gy for the 4.8-, 5.9- and 7.0-GBq groups, respectively. Treatment was well tolerated at all activity levels. Further escalation of the administered activity was not feasible owing to limitations related to the radiolabelling procedure. Response assessment on MRI showed partial response, stable disease and disease progression in 1, 28 and 2 assessable treatments, respectively. In 8 of 17 treatment sessions with an initially elevated AFP, a reduction ranging from 19% to 97% was observed 6 weeks later. (orig.)

  15. Behavior of Lipiodol Markers During Image Guided Radiotherapy of Bladder Cancer

    International Nuclear Information System (INIS)

    Chai Xiangfei; Herk, Marcel van; Kamer, Jeroen B. van de; Remeijer, Peter; Bex, Axel; Betgen, Anja; De Reijke, Theo M.; Hulshof, Maarten C.C.M.; Pos, Floris J.; Bel, Arjan

    2010-01-01

    Purpose: To investigate the stability of a novel type of markers used in partial bladder tumor irradiation and tumor deformation as indicated by the markers. Materials and Methods: In 15 patients with solitary bladder cancer, lipiodol was injected in the bladder wall during flexible cystoscopy to identify the tumor. A planning CT scan was made, followed by daily cone-beam CT (CBCT) scans during treatment. To study the accuracy of using these markers for image guidance, uncertainties U1 and U2 were calculated, which were defined as the difference between submask registration (covering single marker) and the average of all submask registrations and the difference between the submask registration and the general mask registration (including all markers), respectively. Finally, to study tumor deformation, the relative movement of each marker pair was correlated with the relative bladder volume (RBV). Results: The analyzed patients had 2.3 marker injections on average. The lipiodol spot size was 0.72 ± 1.1 cm 3 . The intensity of spots in both CT and CBCT was significantly higher than the surrounding bladder tissue. The uncertainties U1 and U2 were comparable, and the uncertainties in left-right direction (0.14-0.19 cm) were smaller than those in cranial-caudal and anterior-posterior directions (0.19-0.32 cm). The relative marker movement of within-zone marker pairs was much smaller (and has less dependence on the RBV) than across-zones marker pairs. Conclusions: Lipiodol markers are a feasible method to track bladder tumor by using online CBCT. Tumor deformation is observed, especially for tumors that cross the defined bladder zones.

  16. Behavior of Lipiodol Markers During Image Guided Radiotherapy of Bladder Cancer

    Energy Technology Data Exchange (ETDEWEB)

    Chai Xiangfei, E-mail: x.chai@amc.uva.n [Department of Radiation Oncology, Academic Medical Center, University of Amsterdam, Amsterdam (Netherlands); Herk, Marcel van [Department of Radiation Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam (Netherlands); Kamer, Jeroen B. van de [Department of Radiation Oncology, Academic Medical Center, University of Amsterdam, Amsterdam (Netherlands); Remeijer, Peter [Department of Radiation Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam (Netherlands); Bex, Axel [Department of Urology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam (Netherlands); Betgen, Anja [Department of Radiation Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam (Netherlands); De Reijke, Theo M [Department of Urology, Academic Medical Center, University of Amsterdam, Amsterdam (Netherlands); Hulshof, Maarten C.C.M. [Department of Radiation Oncology, Academic Medical Center, University of Amsterdam, Amsterdam (Netherlands); Pos, Floris J [Department of Radiation Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam (Netherlands); Bel, Arjan [Department of Radiation Oncology, Academic Medical Center, University of Amsterdam, Amsterdam (Netherlands)

    2010-05-01

    Purpose: To investigate the stability of a novel type of markers used in partial bladder tumor irradiation and tumor deformation as indicated by the markers. Materials and Methods: In 15 patients with solitary bladder cancer, lipiodol was injected in the bladder wall during flexible cystoscopy to identify the tumor. A planning CT scan was made, followed by daily cone-beam CT (CBCT) scans during treatment. To study the accuracy of using these markers for image guidance, uncertainties U1 and U2 were calculated, which were defined as the difference between submask registration (covering single marker) and the average of all submask registrations and the difference between the submask registration and the general mask registration (including all markers), respectively. Finally, to study tumor deformation, the relative movement of each marker pair was correlated with the relative bladder volume (RBV). Results: The analyzed patients had 2.3 marker injections on average. The lipiodol spot size was 0.72 +- 1.1 cm{sup 3}. The intensity of spots in both CT and CBCT was significantly higher than the surrounding bladder tissue. The uncertainties U1 and U2 were comparable, and the uncertainties in left-right direction (0.14-0.19 cm) were smaller than those in cranial-caudal and anterior-posterior directions (0.19-0.32 cm). The relative marker movement of within-zone marker pairs was much smaller (and has less dependence on the RBV) than across-zones marker pairs. Conclusions: Lipiodol markers are a feasible method to track bladder tumor by using online CBCT. Tumor deformation is observed, especially for tumors that cross the defined bladder zones.

  17. Clinical application of transcatheter arterial thermo-chemotherapy and thermo-lipiodol embolization in treatment of hepatocellular carcinoma

    International Nuclear Information System (INIS)

    Wang Xuan; Chen Xiaofei; Dong Weihua

    2007-01-01

    Objective: To evaluate the clinical efficacy of thermo-chemotherapy and thermo-lipiodol embolization in treatment of primary hepatocellular carcinoma(PHC). Methods: One hundred and sixteen cases of PHC were divided into three groups. Group A (38 cases)was treated with normal temperature chemotherapy and normal temperature lipiodol, Group B(40 cases)with thermo-chemotherapy and normal temperature lipiodol and group C (38 cases)with thermo-chemotherapy and thermo-lipiodol. Group B and group C were called the thermotherapy group. Results: In the thermotherapy groups, the rates of tumor size reduction were significantly greater than those in the normal group. There were no significant different in the hepatic function tests among the three groups. The 6-, 12-, 18-, and 24- month survival rates of the normal group and thermotherapy groups were 97%, 58%, 39% and 18%, versus 99%, 79%, 57% and 36%, respectively. No significant differences were found in the rates of reduction of tumor size and survival rates between group B and group C. Conclusion: Thermo-chemotherapy and thermo-embolization possess significant effect on PHC but without conspicuous damage to liver function. (authors)

  18. Transcatheter hepatic arterial thermo-chemotherapy and thermo-lipiodol embolization for the treatment of hepatic metastases from colorectal carcinoma

    International Nuclear Information System (INIS)

    Wang Xuan; Chen Xiaofei

    2009-01-01

    Objective: To evaluate the clinical efficacy of transcatheter hepatic arterial thermo-chemotherapy and thermo-lipiodol embolization in the treatment of hepatic metastases from colorectal carcinoma. Methods: Sixty-eight cases with hepatic metastases from colorectal carcinoma were equally and randomly divided into two groups. The patients in study group were treated with transcatheter hepatic arterial thermo-chemotherapy and thermo-lipiodol embolization, while the patients in control group were treated with conventional (normal temperature) transcatheter hepatic arterial chemotherapy lipiodol embolization. Results: The effective rate of study group and control group was 65%(22/34) and 32%(11/34) respectively, the difference between two groups was statistically significant (P<0.05). No significant difference in the postoperative changes of hepatic function tests was found between the two groups. The survival rate at 6,12,18 and 24 months after the treatment was 100%, 82%, 44% and 18% respectively in study group, while it was 91%, 47%, 15% and 6% respectively in control group. Conclusion: Transcatheter hepatic arterial thermo-chemotherapy and thermo-lipiodol embolization is an effective and safe treatment for the hepatic metastases from colorectal carcinoma and has no obvious damage to the hepatic function. (authors)

  19. Preliminary results of transarterial Rhenium-188 HDD Lipiodol in treatment of inoperable primary hepatocellular carcinoma

    International Nuclear Information System (INIS)

    Sundram, Felix

    2004-01-01

    Full text: In this paper we present our early experience with a new radio-conjugate, namely rhenium-188 HDD Lipiodol (Re-188 lipiodol). Imported radiopharmaceuticals are generally expensive, particularly for developing countries. A Tungsten (W-188-Re 188) generator obtained from ORNL (Oak Ridge National Laboratory, Tennessee, USA) allows us on-site production of a beta emitting therapeutic isotope (Re-188) for up to 6 months from a single generator. The objectives of this study were to establish the safety of trans-arterial Re-188 lipiodol in patients with inoperable HCC, and determine the adverse effects and efficacy for this radio-conjugate treatment in a multi-center study of patients with advanced HCC. A multi-center study was sponsored by the International Atomic Energy Agency (Vienna) to assess the safety and efficacy of trans-arterial Re-188 HDD conjugated lipiodol (radio-conjugate) in the treatment of patients with inoperable hepatocellular carcinoma (HCC), The radio-conjugate was prepared by using a HDD (4-hexadecyl 1-2, 9, 9-tetramethyl-4, 7-diaza-1, 10-decanethiol) kit developed in Korea, and lipiodol. Over a period of eighteen months seventy patients received at least one treatment of radio-conjugate. Some patients were re-treated if there was no evidence of disease progression. The level of radio-conjugate administered was based on radiation-absorbed dose to critical normal organs, calculated following a 'scout' dose of radio-conjugate. The organs at greatest risk for radiation toxicity are the normal liver, the lung and the bone marrow. A specially designed spreadsheet was used to determine maximum tolerated activity (MTA), defined as the amount of radioactivity calculated to deliver no more than 12 Gray (Gy) to lungs, or 30 Gy to liver, or 1.5 Gy to bone marrow. These doses have been found to be safe in multiple trials using external beam therapy and systemically administered radiopharmaceuticals. Patients were followed for at least twelve weeks

  20. Rhenium-188 Lipiodol Therapy of Hepatocellular Carcinoma: Results of a multicentre-multinational study

    International Nuclear Information System (INIS)

    Padhy, A.K.; Bernal, P.; Buscombe, R.J.

    2007-01-01

    Full text: A multi-centre study was sponsored by the IAEA to assess the safety and efficacy of trans-arterial Rhenium-188 HDD Lipiodol in the treatment of inoperable Hepatocellular Carcinoma. The radioconjugate was prepared by using an HDD kit and Lipiodol. Over three years, 185 patients received at least one treatment. The dose administered was based on radiation absorbed dose to critical normal organs, calculated following a ''scout'' dose (approximately 4 mCi) of radioconjugate. The organs at greatest risk for radiation toxicity are the liver, the lung and the bone marrow. An Excel spreadsheet was used to determine maximum tolerated activity, defined as the amount of radioactivity calculated to deliver no more than 12 Gy to lungs, 30 Gy to liver, or 1.5 Gy to bone marrow. A single treatment was given to 134 patients, 42 patients received two doses, 8 received three and one patient received four treatments. The total injected activity including the scout dose during the first treatment ranged from 21 to 364 mCi (average 108 mCi). Patients were followed for at least l2 weeks after therapy. The clinical parameters evaluated included toxicity, response as determined objectively by contrast enhanced computed tomography, palliation of symptoms, overall survival, performance status (Karnofsky), and hepatic function (Child's classification). Liver function tests, serum alpha-fetoprotein (AFP) levels and complete blood counts were done at each follow-up visit. Side effects were minimal and usually presented as loss of appetite, right hypochondrial discomfort and low-grade fever. Liver function tests at 24 and 72 hours showed no significant changes and complete blood counts at 1 week, 4 weeks and 12 weeks showed no changes (no bone marrow suppression). Data on largest tumour diameter after therapy and/or tumour response as evaluated from CT scans are available for 88 patients. Complete disappearance of tumour was recorded in 3 (3%), partial response in 19 (22%), stable

  1. SU-F-T-630: Energy Spectral Study On Lipiodol After Trans-Arterial Chemoembolization Using the Flattened and Unflattened Photon Beams

    Energy Technology Data Exchange (ETDEWEB)

    Kawahara, D [Radiation Therapy Section, Department of Clinical Support, Hiroshima University Hospital, Hiroshima (Japan); Medical and Dental Sciences Course, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima (Japan); Ozawa, S; Nagata, Y [Department of Radiation Oncology, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima (Japan); Hiroshima High-Precision Radiotherapy Cancer Center, Hiroshima (Japan); Saito, A; Nishio, T; Suzuki, T [Department of Radiation Oncology, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima (Japan); Hioki, K; Masuda, H; Okumura, T; Ochi, Y; Nakashima, T; Ohno, Y [Radiation Therapy Section, Department of Clinical Support, Hiroshima University Hospital, Hiroshima (Japan); Tanaka, S [Department of Nuclear Engineering and Management, School of Engineering, University of Tokyo, Tokyo (Japan)

    2016-06-15

    Purpose: SBRT combining transarterial chemoembolization with Lipiodol is expected to improve local control. Our showed that the dose enhancement effect in the Lipiodol with 10X flattening filter free (FFF) was inserted. This study was to investigate the energy fluence variations of electron in the Lipiodol using flattened (FF) and FFF beams. Methods: FF and FFF for 6X and 10X beams by TrueBeam were used in this study. The Lipiodol (3 X 3 X 3 cm{sup 3}) was located at the depth of 5 cm in water, the dose enhancement factor (DEF) and energy fluence were calculated by Monte Carlo (MC) calculations (PHITS). Results: DEFs with FF and FFF of 6X were 17.1% and 24.3% at rebuild-up region in the Lipiodol (5.3cm depth), 7.0% and 17.0% at the center of Lipiodol (6.5cm depth), and −13.2% and −8.2% at behind Lipiodol (8.3cm depth). DEFs with FF and FFF of 10X were 21.7% and 15.3% at rebuild-up region, 8.2% and 10.5% at the center of Lipiodol, and −14.0% and −8.6% at behind Lipiodol. Spectral results showed that the FFF beam contained more low-energy (0–0.3MeV) component of electrons than FF beam, and FF beam contained more high-energy (over 0.3MeV) electrons than FFF beam in Lipiodol. Behind the Lipiodol, build-down effect with FF beam was larger than FFF beam because FF beam contained more high energy electrons. The difference of DEFs between FFF and FF beams for 6X were larger than for 10X. This is because 10X beam contained more high-energy electrons. Conclusion: It was found that the 6XFFF beam gives the largest change of energy fluence and the largest DEF in this study. These phenomena are mainly caused by component of low-energy electrons, and this energy is almost correspond to the boundary of photo electronic dominant and Compton scattering dominant region for photon beams.

  2. Intra-arterial embolization with pingyangmycin-lipiodol emulsion for the treatment of hepatic cavernous hemangioma: an analysis of factors affecting therapeutic results

    International Nuclear Information System (INIS)

    Zeng Qingle; Chen Yong; Zhao Jianbo; Zhang Kewei; Li Yanhao

    2009-01-01

    Objective: To analyze the factors that might affect the therapeutic results of pingyangmycin-lipiodol emulsion intra-arterial sclerosing embolization (PLE-IASE) in treating symptomatic cavernous hemangioma of liver (SCHL). Methods: PLE-IASE was performed in 89 patients with SCHL (32 males and 57 females). Before treatment the mean diameter of the hemangioma was (8.3±3.8) cm. Of 89 patients, 53 experienced anxiety, 35 suffered from right upper abdominal pain and the remaining one developed Kasabach-Merrit syndrome. Before PLE-IASE, the arteriographic classification was conducted based on hepatic arteriographic findings. Then pingyangmycin-lipiodol emulsion (PLE) was injected through the feeding artery. The dosage of pingyangmycin (PYM) was (9.8 ± 4.4) mg and the dosage of lipiodol (LP) was (5.9 ± 2.9) ml. The lipiodol deposition status was judged by the follow-up spot film taken immediately after PLE-IASE. The observations of the occurrence of complications, the relief of symptoms and the minification of SCHL were followed for 6-72 months after PLE-IASE. The linear regression analysis statistics was conducted by taking the minification as dependent variable and taking the arteriographic classification, lipiodol deposition status, the dosage of PYM, the dosage of lipiodol and the preoperative SCHL diameter as independent variable. Results: Of all 89 cases of SCHL, hypervascular type was seen in 51, hypovascular type in 26 and arteriovenous shunt (AVS) type in 12. Good lipiodol deposition status was found in 64 patients and poor deposition in 25 patients after PLE-IASE. After PLE-IASE, the symptom of anxiety in 53 patients was relieved and the right upper abdominal pain was reduced in 33 cases although intermittent pain still remained in 2 patients. The blood platelet count of the patient with Kasabach-Merrit syndrome returned to normal after the treatment. The symptomatic relieve rate was 98.7%. No serious complications occurred in the follow-up period. The linear

  3. Treatment's results of hyperthyroid patients with Iodine-131

    International Nuclear Information System (INIS)

    Bastan-Hagh, M.H.; Larijani, B.; Rahim-Tabrizi, P.; Khalili-Fard, A.R.; Baradar-Jalili, R.; Saghari, M.

    2004-01-01

    Introduction: radioiodine ( 131 I) is an effective and inexpensive alternative to surgery in the treatment of thyroid hyper function. The debate today concerns the maximum and minimum ablative doses, and factors leading to hypothyroidism. Patients and method: 1035 hyperthyroid patients treated with weight-adjusted ablative doses of 131 I were retrospectively assessed for treatment outcome or correlated with sex, age, underlying pathology, and administrated dose of 131 I . Results: Thyroid hyper function was more common in women. The greatest proportions of patients were in the 31-40 years age group and the smallest proportion over -70. The commonest underlying pathology was Grave's disease. Men had a lower response rate to 131 I therapy, with 2.4-fold greater probability of persistent hyperthyroidism (P 131 I hypothyroidism decreased with increasing age (P 131 I therapy was seen in patients with toxic adenoma, (P=0.0001). The incidence of hypothyroidism did not show a positive correction with increased administered dose of 131 I (P 131 I was effective in reducing thyroid nodule size. There were 18 cases of temporary hyperthyroidism, all of which recovered to euthyroid status within 12 months. Conclusion: one dose of radioiodine was effective in treatment of hyperthyroid patients in 91.2 % of cases. Age, sex and underlying pathology were determining factors. In most cases the average time to hypothyroidism was reasonably short, obviating the need for long time follow up in these patients

  4. Decreased uptake after fractionated ablative doses of iodine-131

    Energy Technology Data Exchange (ETDEWEB)

    Wu, Hurng-Sheng [Show Chwan Memorial Hospital, Department of Surgery, Changhua, Taiwan (Taiwan); Hseu, Huey-Herng [Taichung Veterans General Hospital, Department of Medical Education and Research, Taichung (Taiwan); Lin, Wan-Yu; Wang, Shyh-Jen [Taichung Veterans General Hospital, Department of Nuclear Medicine, Taichung, Taiwan (Taiwan); Liu, Yao-Chi [Department of Surgery, General Surgery, National Defense Medical Center, Taipe (Taiwan)

    2005-02-01

    In an attempt to obviate the necessity for hospitalisation, the ablative dose of {sup 131}I in the treatment of thyroid cancer is divided into two or three fractions at weekly intervals in some hospitals with no special bed for {sup 131}I treatment. Thyroid stunning has been observed in patients receiving a {sup 131}I dose between 74 and 370 MBq (2-10 mCi). However, the influence of {sup 131}I uptake after administration of a higher dose, such as 1,110-1,850 MBq of {sup 131}I, has never been reported. In this study, we evaluated the degree of reduction in {sup 131}I uptake after patients received 1,480 MBq of {sup 131}I and evaluated the clinical value of fractionated ablative doses of {sup 131}I. Thirty-five patients with functional thyroid cancer received a total of 4,440 MBq (120 mCi) of {sup 131}I which was divided into three fractions administered at weekly intervals. In all patients two {sup 131}I whole-body scans were performed. The first scan was performed directly prior to the second dose of {sup 131}I (7 days after the first administration of {sup 131}I), and the second scan was performed 7 days after the second administration of {sup 131}I and directly prior to the third administration. Regions of interest including the neck and lungs were drawn to calculate the uptake of {sup 131}I in the thyroid remnant and possible cervical lymph node and lung metastases. The mean uptake of {sup 131}I was 2.73% 7 days after the first administration, and decreased significantly to 0.26% 7 days after the second administration. The mean decrease was as high as 80.7%. The decrease in {sup 131}I uptake was significant in all patients except the two with lung metastases. In the two patients with lung metastases, no definite evidence of decreased uptake was noted; the uptake of {sup 131}I in the lung metastases even increased on the second {sup 131}I image in one of these patients. After administration of 1,480 MBq of {sup 131}I, the decreased uptake was significant in all neck lesions but not in lung metastases. The use of fractionated ablative doses of {sup 131}I is not to be recommended in patients without lung metastases. However, the influence of fractionated ablative doses of {sup 131}I in patients with lung metastases is worthy of further study. (orig.)

  5. Iodine-131 in breast milk following therapy for thyroid carcinoma

    International Nuclear Information System (INIS)

    Robinson, P.S.; Barker, P.; Campbell, A.

    1994-01-01

    This study evaluates breast milk secretion of 131 I following therapeutic adminstration of 4000 MBq of 131 I-iodide during lactation. Breast milk 131 I activity concentration was measured over a 32-day period. Dosimetry calculations were undertaken to estimate the period for discontinuation of breast feeding and the equivalent dose to the breasts. To achieve an infant effective dose 131 I-iodide adminstration is not undertaken during lactation and that breast feeding is discontinued several days prior to administration. 26 refs., 2 figs., 2 tabs

  6. Treatments with radioactive iodine, 131 I. How, when and where?

    International Nuclear Information System (INIS)

    Ruiz J, A.; Gonzalez T, O.

    2006-01-01

    A great variety of approaches exists in the application of the treatments with radioactive materials, as the 131 I, but it is necessary to standardize them for the patient's benefit, because their doctor doesn't always know the principle that it bases this therapy, called metabolic therapy or radioiodine therapy (RYT). In this work the experience that was acquired by more of 50 years of RYT management in the Thyroid and Nuclear Medicine Clinic in patients with thyroid pathologies is informed, so that their management fulfills its function and it was carried out inside the corresponding juridical frame and the physicochemical and endocrinological principles that should take implicit. (Author)

  7. The absorption of iodine-131 on a ceramic matrix

    International Nuclear Information System (INIS)

    Han, H.S.; Park, U.J.; Dash, A.

    2004-01-01

    The retention of 131 I on ceramic rod coated with silver nitrate followed by coating with a polyurethane membrane to be applied in brachytherapy was studied. The concentration of silver nitrate (20 g/l), the volume of 131 I as a sodium iodide solution (100 μl), the pH of the reaction mixture (pH 9) etc., were optimized to get a maximum uptake on the ceramic rod. The concentration of coating solution (5%, polyurethane in tetrahydrofuran) was also optimized to obtain a minimum leaching of 131 I activity in normal saline solution. After coating with a polyurethane membrane, the 131 I absorbed on the ceramic rod exhibited low leachability (0.03%). This method can be applied for the preparation of 125 I interstitial sources to be used in eye and prostate cancer therapy. (author)

  8. Thyroid cancer from occupational exposures to iodine-131

    International Nuclear Information System (INIS)

    Shore, R.E.

    1983-01-01

    Studies of external irradiation, primarily of children, suggest that the thyroid gland is one of the most radiosensitive sites for carcinogenesis. However, it has generally been thought that 131 I confers much less risk (per rad) than external radiation because of its low dose-rate. A review of the epidemiologic literature indicates that age at irradiation is also an important variable in defining thyroid cancer risk, with a lesser risk at older ages. The available human studies are reasonably consistent in affirming that risks following 131 I are small. However, the data on 131 I exposure are too sparse, particularly for childhood exposure, to determine how much of the observed diminution in risk is due to older ages at exposure and how much is attributable to the characteristics of 131 I exposure per se, such as low dose-rate. Since most of the existing studies have inadequacies in design, dose levels, dosimetry or number of subjects, additional studies are needed before the risk assessment of 131 I at lower dose levels in adult workers can be regarded as definitive

  9. Iodine 131 therapy patients: radiation dose to staff

    International Nuclear Information System (INIS)

    Castronovo, F.P. Jr.; Beh, R.A.; Veilleux, N.M.

    1986-01-01

    Metastasis to the skeletal system from follicular thyroid carcinoma may be treated with an oral dose of 131 I-NaI. Radiation exposures to hospital personnel attending these patients were calculated as a function of administered dose, distance from the patient and time after administration. Routine or emergency patient handling tasks would not exceed occupational radiation protection guidelines for up to 30 min immediately after administration. The emergency handling of several patients presents the potential for exceeding these guidelines. (author)

  10. [Prevention of recurrent amiodarone-induced hyperthyroidism by iodine-131].

    Science.gov (United States)

    Hermida, J S; Jarry, G; Tcheng, E; Moullart, V; Arlot, S; Rey, J L; Schvartz, C

    2004-03-01

    Amioradone-induced hyperthyroidism is a common complication of amiodarone therapy. Although definitive interruption of amiodarone is recommended because of the risks of aggravation of the arrhythmias, some patients may require the reintroduction of amiodarone several months after normalisation of thyroid function. The authors undertook a retrospective study of the effects of preventive treatment of recurrences of amiodarone-induced hyperthyroidism with I131. The indication of amiodarone therapy was recurrent, symptomatic, paroxysmal atrial fibrillation in 13 cases and ventricular tachycardia in 5 cases (M = 14, average age 64 +/- 13 years). The underlying cardiac disease was dilated cardiomyopathy (N = 5), ischaemic heart disease (N = 3), hypertensive heart disease (N = 2), arrhythmogenic right ventricular dysplasia (N = 2) or valvular heart disease (N = 2). Two patients had idiopathic atrial fibrillation. An average dose of 576 +/- 184 MBq of I131 was administered 34 +/- 37 months after an episode of amiodarone-induced hyperthyroidism. Amiodarone was reintroduced in 16 of the 18 patients after a treatment-free period of 98 +/- 262 days. Transient post-radioiodine hyperthyroidism was observed in 3 cases (17%). Sixteen patients (89%) developed hypothyroidism requiring replacement therapy with L-thyroxine. There were no recurrences of amiodarone-induced hyperthyroidism. After 24 +/- 17 months follow-up, the arrhythmias were controlled in 13 of the 16 patients (81%) who underwent the whole treatment sequence. The authors conclude that preventive treatment with I131 is an effective alternative to prevent recurrence of amiodarone-induced hyperthyroidism in patients requiring reintroduction of amiodarone to control their arrhythmias.

  11. Iodine-131 therapy for the treatment of multinodular goitre

    International Nuclear Information System (INIS)

    Akerman, R.L.; Howarth, D.M.

    1997-01-01

    Full text: The purpose of this study was to investigate the effectiveness of 131 l therapy for toxic and non-toxic multinodular goitre (MNG)in the patients treated with the standard dose of 4 x 555 MBq (total 2.2 Bq) and therefore give some indication as to the adequacy of this therapy. This was a retrospective study using information from patients' notes. All patients with large multinodular goitres who had radioiodine therapy for treatment of MNG since 1991 were selected. Data obtained included age, gender, pre, peri and post therapy symptoms and serial biochemical thyroid function results. Each patient was followed for a minimum of six months. The subjects were 35 patients (32 female, three male) with an age range of 37 - 87 years. 26 patients had non-toxic MNG, nine patients had toxic MNG, 24 patients had retrosternal or obstructive symptoms and five patients had had previous thyroid therapy. The patients with retrosternal or obstructive symptoms experienced a reduction in those symptoms. 8.6 per cent of the patients experienced no change at all in symptoms. 2.8 per cent of the patients experienced non-transient side effects (sore throat). 32.8 per cent of the patients experienced transient hyperthyroidism during 131 I therapy. In the toxic group, 77.8 per cent became euthyroid. 11.1 per cent became hypothyroid and 11.1 per cent remained hyperthyroid and required additional treatment. In the non-toxic group, 42.3 per cent became hypothyroid and 57.7 per cent remained euthyroid. The overall incidence of hypothyoidism was 34.4 per cent. The results of this study suggests 131 l therapy in the form of 4 x 555 MBq oral doses (one dose per month for four months) is effective, efficient, relatively risk-free, easy and generally well-tolerated treatment for toxic and non-toxic multinodular goitre

  12. Iodine-131 therapy for the treatment of hyperthyroidism

    International Nuclear Information System (INIS)

    Enkhtuya, B.; Tsevelmaa, L.; Erdenechimeg, S.

    2005-01-01

    Full text: Since 1997, radioactive iodine (I-131) has become the most widely used therapy for patients with hyperthyroidism cased by Graves' disease in the Mongolia. Our seven years clinical experience was reviewed to evaluate the efficacy of the therapy. We treated 150 patients (119 female and 31 male) with hyperthyroidism with I-131 (mean dose 8.2 mCi) between 1997 and 2004. The dose calculation was based on 24 hours thyroid uptake, thyroid gland size and degree of toxicity. We determined their thyroid status after 1 year in relation to age, pretreatment with an antithyroid drug, pretreatment thyroid size and whether or not there are thyroid nodules. Out of the 150 patients, 87(58%) were euthyroid, 30 (20%) hypothyroid at 1 year after treatment, and 33 patients (22%) had persistent hyperthyroidism and required second treatment. The patients who had persistent hyperthyroidism were younger in age, had larger thyroid glands, some of them had thyroid nodules and 27 patients (81%) pretreatment with anti-thyroid drugs for more than 6 months. Our results showed that the majority of patients with Graves' hyperthyroidism had a effective treatment. However, 22% of patients with younger age, larger thyroid glands, patients with thyroid nodules and who had anti-thyroid drugs for more than 6 months had undergone repeated treatment. A higher dose of I-131 maybe advisable in such patients. In order to establish correct treatment dose we may need more precise dosimetry study. (author)

  13. Improved monitoring procedure for Iodine -131 in radiochemical process laboratory

    International Nuclear Information System (INIS)

    Singh, Pratap; Yadav, R.K.B.; Anilkumar, S.; Gopalakrishnan, R.K.; Chakraborty, S.

    2016-01-01

    Radiation Hazard Control Unit at Isotope wing provides radiological safety support and advises for safe processing and production of radiopharmaceuticals. Tellurium Oxide (TeO 2 ), irradiated in a nuclear reactor, is processed in a process laboratory for separating 131 I using dry distillation technique. The workplace environment is being assessed for airborne radioactivity using installed Static Air Samplers (SASs). SASs contains two filter media (glass fibre and charcoal impregnated paper) to collect airborne 131 I radioactivity and laboratory air sampled at 50 litres per minutes (lpm). Personal Air Sampler (PAS) consists of three types of filters viz. a glass fibre, charcoal impregnated paper and cartridges containing activated charcoal granules. Three combinations were studied at a sampling rate of 5 lpm

  14. Mortality in patients treated for hyperthyroidism with iodine-131

    Energy Technology Data Exchange (ETDEWEB)

    Hall, P.; Lundell, G.; Holm, L.E. (Karolinska Hospital, Stockholm (Sweden))

    1993-03-01

    Causes of death were studied in 10552 Swedish hyperthyroid patients treated with [sup 131]I diagnosed between 1950 and 1975. The patients were followed for an average of 15 years and were matched with the Swedish cause of death register. A total of 5400 deaths were observed and the overall standardized mortality ratio was 1.47. The standardized mortality ratio for females was 1.50 compared to 1.31 in males. The most common cause of death was from cardiovascular diseases. Significantly elevated risks were also seen for tumours, diseases of the endocrine system, respiratory system, gastro-intenstinal system, and congenital malformations. In all causes of death, except tumours and trauma, decreasing standardized mortality ratios over time were seen. Patients followed for more than 10 years had significantly elevated risks for tumours, diseases of the endocrine, respiratory, and cardiovascular systems. Patients given higher [sup 131]I activity and younger patients had higher standardized mortality ratios than those given lower activity and older patients. The hyperthyroidism per se, rather than the [sup 131]I treatment, appeared to be the major explanation for the elevated mortality. 20 refs., 3 tabs.

  15. Mortality in patients treated for hyperthyroidism with iodine-131

    International Nuclear Information System (INIS)

    Hall, P.; Lundell, G.; Holm, L.E.

    1993-01-01

    Causes of death were studied in 10552 Swedish hyperthyroid patients treated with 131 I diagnosed between 1950 and 1975. The patients were followed for an average of 15 years and were matched with the Swedish cause of death register. A total of 5400 deaths were observed and the overall standardized mortality ratio was 1.47. The standardized mortality ratio for females was 1.50 compared to 1.31 in males. The most common cause of death was from cardiovascular diseases. Significantly elevated risks were also seen for tumours, diseases of the endocrine system, respiratory system, gastro-intenstinal system, and congenital malformations. In all causes of death, except tumours and trauma, decreasing standardized mortality ratios over time were seen. Patients followed for more than 10 years had significantly elevated risks for tumours, diseases of the endocrine, respiratory, and cardiovascular systems. Patients given higher 131 I activity and younger patients had higher standardized mortality ratios than those given lower activity and older patients. The hyperthyroidism per se, rather than the 131 I treatment, appeared to be the major explanation for the elevated mortality. 20 refs., 3 tabs

  16. Cancer risk after iodine-131 therapy for hyperthyroidism

    International Nuclear Information System (INIS)

    Holm, L.E.; Hall, P.; Wiklund, K.; Lundell, G.; Berg, G.; Bjelkengren, G.; Cederquist, E.; Ericsson, U.B.; Hallquist, A.; Larsson, L.G.

    1991-01-01

    Cancer incidence was studied in 10,552 patients (mean age, 57 years) who received 131I therapy (mean dose, 506 MBq) for hyperthyroidism between 1950 and 1975. Follow-up on these patients was continued for an average of 15 years. Record linkage with the Swedish Cancer Register for the period 1958-1985 identified 1543 cancers occurring 1 year or more after 131I treatment, and the standardized incidence ratio (SIR) was 1.06 (95% confidence interval = 1.01-1.11). Significantly increased SIRs were observed for cancers of the lung (SIR = 1.32; n = 105) and kidney (SIR = 1.39; n = 66). Among 10-year survivors, significantly elevated risks were seen for cancers of the stomach (SIR = 1.33; n = 58), kidney (SIR = 1.51; n = 37), and brain (SIR = 1.63; n = 30). Only the risk for stomach cancer, however, increased over time (P less than .05) and with increasing activity administered (P = not significant). The risk for malignant lymphoma was significantly below expectation (SIR = 0.53; n = 11). Overall cancer risk did not increase with administered 131I dose or with time since exposure. The absence of any increase in leukemia adds further support to the view that a radiation dose delivered gradually over time is less carcinogenic than the same total dose received over a short time. Only for stomach cancer was a possible radiogenic excess suggested

  17. Iodine-131 therapy for the treatment of multinodular goitre

    Energy Technology Data Exchange (ETDEWEB)

    Akerman, R.L.; Howarth, D.M. [John Hunter Hospital, Newcastle, NSW, (Australia). Department of Nuclear Medicine

    1997-09-01

    Full text: The purpose of this study was to investigate the effectiveness of {sup 131}l therapy for toxic and non-toxic multinodular goitre (MNG)in the patients treated with the standard dose of 4 x 555 MBq (total 2.2 Bq) and therefore give some indication as to the adequacy of this therapy. This was a retrospective study using information from patients` notes. All patients with large multinodular goitres who had radioiodine therapy for treatment of MNG since 1991 were selected. Data obtained included age, gender, pre, peri and post therapy symptoms and serial biochemical thyroid function results. Each patient was followed for a minimum of six months. The subjects were 35 patients (32 female, three male) with an age range of 37 - 87 years. 26 patients had non-toxic MNG, nine patients had toxic MNG, 24 patients had retrosternal or obstructive symptoms and five patients had had previous thyroid therapy. The patients with retrosternal or obstructive symptoms experienced a reduction in those symptoms. 8.6 per cent of the patients experienced no change at all in symptoms. 2.8 per cent of the patients experienced non-transient side effects (sore throat). 32.8 per cent of the patients experienced transient hyperthyroidism during {sup 131}I therapy. In the toxic group, 77.8 per cent became euthyroid. 11.1 per cent became hypothyroid and 11.1 per cent remained hyperthyroid and required additional treatment. In the non-toxic group, 42.3 per cent became hypothyroid and 57.7 per cent remained euthyroid. The overall incidence of hypothyoidism was 34.4 per cent. The results of this study suggests {sup 131}l therapy in the form of 4 x 555 MBq oral doses (one dose per month for four months) is effective, efficient, relatively risk-free, easy and generally well-tolerated treatment for toxic and non-toxic multinodular goitre.

  18. Low dose iodine-131 therapy in solitary toxic thyroid nodules

    International Nuclear Information System (INIS)

    Prakash, Rajeev

    1999-01-01

    Forty patients with solitary hyperfunctioning thyroid nodules were treated with relatively low dose radioiodine therapy, 131 I doses were calculated taking into account thyroid mass and radioiodine kinetics to deliver 100 μCi/g of estimated nodule weight corrected for uptake. Patients remaining persistently hyperthyroid at four months after the initial therapy were retreated with a similarly calculated dose. Cure of the hyperthyroid state was achieved in all patients, total administered dose in individual cases ranging from 3-17 mCi. 28 of the 40 patients required a single therapy dose. 36 patients were euthyroid after a 4.5 year mean follow-up period. Four cases developed post therapy hypothyroidism requiring replacement therapy. Nodules regressed completely in nine cases following 131 I treatment, with partial regression in size in 19 patients. Control of hyperthyroid state in cases of solitary toxic thyroid nodules can be satisfactorily achieved using relatively low dose radioiodine therapy with low incidence of post therapy hypothyroidism. (author)

  19. Radionuclide therapy of Sipple syndrome using iodine-131 metaiodobenzylguanidine

    International Nuclear Information System (INIS)

    Furusawa, Mitsuhiro; Shimomura, Osamu; Tomiguchi, Seiji; Hirota, Yoshihisa; Takahashi, Mutsumasa; Yamauchi, Jyoji; Iwaoka, Daisuke; Satoh, Tatsuo

    1992-01-01

    A 40-years-old female who had lung and liver metastases from malignant pheochromocytoma was treated with 3.7 GBq 131 I-MIBG (metaiodobenzylguanidine). After the treatment, 131 I-MIBG showed increased uptake in the metastatic lesions of the lung and liver. The size of tumor was no significant change on CT and MRI, but the intensity of liver metastases decreased gradually on MRI. Prior to the treatment, the levels of adrenaline and noradrenaline were high. One to three days after treatment, the level of these laboratory data further increased, but they gradually decreased in 1 to 3 months. These changes may be due to necrosis of tumor tissue. (author)

  20. Study of thyroid function, using iodine 131, in leprosy patients

    International Nuclear Information System (INIS)

    Tatit, E.D.; Carvalho, N.

    1973-01-01

    A study was made in a group of 117 leprosy patients in differents clinical conditions, under treatment, in drug rest or virgins of treatment. They were divided in sub-groups for the following tests: the radioiodine uptake of 2-24 hours; neck-thigh ratio; thyrobinding index; protein-bound radioiodine (PB 131 I) levels of plasma. The results led to the following conclusions: 1) Leprosy patients present a low uptake in conjunction with a decrease in the velocity of thyroid clearance in the majority of the cases. Even the remaining presented values within the low limit of normality; 2) In view of these results, the tests were repeated after thyroid stimulating hormone (TSH) with exogenous TSH, in the sub-group of patients virgin of treatment. With the positive response observed (increase in the uptake, in the neck-thigh ratio and the PB 131 I) the low uptake was considered secondary with regard to a deficit of the endogenous TSH; 3) The TBI and PB 131 I tests were not in sufficient agreement for an appraisal of the phase of organic binding and release of hormone [pt

  1. Klippel-Trenaunay syndrome: the angiographic manifestations and endovascular treatment with pingyangmycin-lipiodol emulsion

    International Nuclear Information System (INIS)

    Kong Weidong; Li Yanhao; He Xiaofeng; Chen Yong; Zeng Qingle; Zhao Jianbo

    2004-01-01

    Objective: To observe the angiographic manifestations of Klippel-Trenaunay syndrome (KTS) and to treat it by intra-arterial injection of pingyangmycin-lipiodol emulsion (PLE). Methods: Seven young patients (age range 12-19 years, mean 15.2 years) with KTS in the single low limb were examined by arteriography. Then, PLE (mixed with pingyangmycin 6-12 mg, lipiodol 4-8 ml) was injected by transcatheter into the femoral artery. The effects, side-effects, and complications of the therapy were observed. Results: The arteriography revealed a few distended small arteries with staining of venous sinus of different size in the soft tissue (5/7), as well as drainage vein enlargement (4/7) and superficial varicose vein (5/7). PLE deposited visibly in the abnormal sinus except one case. During 13-30 months' follow-up, 6 cases had good effects on limb hypertrophy after the treatment, and the limbs with lesions were obviously shrank and the thigh circumference became near to the normal limb. Another case had no obvious change. One had mild recurring around the knee one year later. The major side-effects included medium to extreme swelling of the limbs (7/7), serum transaminase elevation (2/7), and numbness of the distal end of the limb (1/7). The complications included a small piece of skin necrosis (1/7) and the first toe-drop (1/7). Conclusion: The arteriography in KTS can demonstrate a part of vascular malformations. Transcatheter intra-arterial PLE injection was effective in treating the hypertrophy of the limb caused by KTS. Because the therapy could result in some serious side-effects and complications, it should be used carefully

  2. Oleum of brucea javanica-lipiodol used in hepatic arterial embolization to treat hepatocellular carcinoma: a effect analysis

    International Nuclear Information System (INIS)

    Li Wanjun; Deng Li; Ai Lixin; Li Jiaping

    2005-01-01

    Objective: To investigate the effect of the Oleum of Brucea javanica lipiodol compound (BJLC), a anticancerous agent of traditional Chinese medicine, in the treatment of hepatocellular carcinoma (HCC) through transhepatic arterial embolization (TAE). Methods: BJLC was made by the mixed oleum of Brucea javanica and lipiodol was injected through hepatic artery by catheter to treat 56 patients with HCC. Results: After treatment, the tumors were shrunk 33.8% averagely. 1,2,3 year survival rates were 87.5%, 48.2% and 30.4% respectively. No marrow depression caused by the treatment were found. Conclusion: BJLC has a definite effect in treatment of HCC by TAE. As a oily anticancerous agent of traditional Chinese medicine, its conspicuous characteristic include low toxicity, embolizability and remainability in tumor tissue. so, it has a great superiority to become a satisfactory embolic agent for the treatment of HCC. (authors)

  3. Embolization therapy of uterine fibroids by using pingyangmycin lipiodol emulsion or polyvinyl alcohol particles: a clinical comparative study

    International Nuclear Information System (INIS)

    Zhang Dazhong; Yin Jianlin; Liu Hairi; Zhang Fuqiang; Huang Hai; Gu Youmei

    2010-01-01

    Objective: To evaluate the efficacy and safety of embolization of uterine fibroids by using pingyangmycin lipiodol emulsion or polyvinyl alcohol particles as embolismic materials. Methods: Seventy-three patients with uterine fibroids were divided into two groups. Patients in group A (29 cases) were treated with pingyangmycin lipiodol emulsion as embolismic materials, while patients in group B (44 cases) with polyvinyl alcohol particles (with a diameter of 300-700 μm) as embolismic materials. Embolization therapy of uterine fibroids was performed in all patients. The uterus volume, the size of uterine fibroid and sex hormone level both before and after the treatment were estimated and the results were compared between two groups. The occurrence of complications was observed. Results: The technical success of catheterization and embolization was 100% in both groups. After the therapy,both the uterus volume and the uterine fibroid size decreased significantly, but no significant difference in the size reduction existed between the two groups (P>0.05). The clinical symptoms showed a marked improvement in all patients, while the sex hormone level showed no obvious changes. No serious complications occurred. Conclusion: In treating uterine fibroids with embolization technique, both pingyangmycin lipiodol emulsion and polyvinyl alcohol particles are safe and effective embolismic materials. However, use of polyvinyl alcohol particles may be safer than pingyangmycin, as pingyangmycin is a kind of chemotherapeutic drugs, which might potentially cause some short-term or long-term complications. (authors)

  4. Renal damage induced by dosorubicin-lipiodol emulsion infused into rabbit renal artery : comparison with CT and histologic findings

    International Nuclear Information System (INIS)

    Kim, Jin Gyoo; Moon, Tae Young; Lee, Suck Hong; Kim, Byung Soo; Choi, Sang Yul; Park, Choong Hoon

    1998-01-01

    The purpose of this study is to evaluate the utility of renal CT scanning and to histologically correlate renal damage induced by renal arterial infusion of 0.2 ml/kg of doxorubicin-lipiodol emulsion. Renal CT scans of 20 rabbit kidneys were obtained 15 days after transcatheter arterial chemoembolization and were classified into four grades, as follows: grade 0 - no fleck, grade 1 - one to three nodular flecks; grade 2 - four or more nodular flecks, or one semilunar fleck; and grade 3 - two or more semilunar flecks. The percentage of histological section occupied by lesion was determined using squared paper, and compared with the grades determined on the basis of CT. The histologic findings were interstitial inflammatory cell infiltration, intratubular lipiodol droplets, dystrophic calcification, and and cellular necrosis. The mean sizes of grade 0, 1, 2 and 3 histological lesions were 2.2 % (n=5), 4.5 % (n=4), 21.9 % (n=7), and 24% (n=4), respectively. Grades 0 and 1 accounted for nine cases (3.2%), while grades 2 and 3 accounted for 11 (22.6%); this difference was statistically significant (p<0.01). CT findings showing nodular or semilunar flecks 15 days after infusion into the renal artery of doxorubicin-lipiodol emulsion correlate with the size of the damaged kidney, as seen on histological specimens. (author). 19 refs., 3 tabs., 5 figs

  5. Preliminary results of transarterial rhenium-188 HDD lipiodol in the treatment of inoperable primary hepatocellular carcinoma

    Energy Technology Data Exchange (ETDEWEB)

    Sundram, Felix [Nuclear Medicine Department (The PET Centre), Singapore General Hospital, Block 2 Basement 1, Outram Road, 169608 (Singapore); Chau, Tran Chi Minh [Nuclear Medicine Department, Cho Ray Hospital, Ho Chi Minh City (Viet Nam); Onkhuudai, Peljee [Nuclear Medicine Department, First Central University Hospital, Ulaanbatax (Mongolia); Bernal, Patricia [Nuclear Medicine Department, Fundacion Santa Fe, Bogota (Colombia); Padhy, Ajit Kumar [Division of Human Health, International Atomic Energy Agency, Vienna (Austria)

    2004-02-01

    The radioconjugate was prepared by using an HDD (4-hexadecyl 1-2,9,9-tetramethyl-4,7-diaza-1,10-decanethiol) kit, and lipiodol. Over a period of 18 months, 70 patients received at least one treatment of radioconjugate. Some patients were re-treated if there was no evidence of disease progression. The level of radioconjugate administered was based on radiation-absorbed dose to critical normal organs, calculated following a ''scout'' dose of radioconjugate. The organs at greatest risk for radiation toxicity are the normal liver, the lung and the bone marrow. An Excel spreadsheet was used to determine maximum tolerated activity (MTA), defined as the amount of radioactivity calculated to deliver no more than 12 Gy to lungs, or 30 Gy to liver, or 1.5 Gy to bone marrow. Patients were followed for at least 12 weeks after therapy, until recovery from all toxicity. The clinical parameters evaluated included toxicity, response as determined by contrast-enhanced CT, palliation of symptoms, overall survival, performance status (Karnofsky) and hepatic function (Child's classification). Liver function tests, serum {alpha}-fetoprotein (AFP) levels and complete blood counts were done at each follow-up visit. In the majority of patients, the scout dose studies indicated the radiation absorbed dose to normalliver to be the limiting factor to the treatment dose, while in a few patients dose to lung was the limiting factor. Radiation dose to bone marrow was negligible and was thus not a factor for the MTA calculations. Side-effects were minimal and usually presented as loss of appetite, right hypochondrial discomfort and low-grade fever, even at high levels of administered radioactivity. The symptoms resolved with simple supportive therapy within 3 days of onset. Liver function tests at 24 and 72 h showed no significant changes and complete blood counts at 1 week, 4 weeks and 12 weeks showed no changes (no bone marrow suppression). Sixteen patients were

  6. Preliminary results of transarterial rhenium-188 HDD lipiodol in the treatment of inoperable primary hepatocellular carcinoma

    International Nuclear Information System (INIS)

    Sundram, Felix; Chau, Tran Chi Minh; Onkhuudai, Peljee; Bernal, Patricia; Padhy, Ajit Kumar

    2004-01-01

    The radioconjugate was prepared by using an HDD (4-hexadecyl 1-2,9,9-tetramethyl-4,7-diaza-1,10-decanethiol) kit, and lipiodol. Over a period of 18 months, 70 patients received at least one treatment of radioconjugate. Some patients were re-treated if there was no evidence of disease progression. The level of radioconjugate administered was based on radiation-absorbed dose to critical normal organs, calculated following a ''scout'' dose of radioconjugate. The organs at greatest risk for radiation toxicity are the normal liver, the lung and the bone marrow. An Excel spreadsheet was used to determine maximum tolerated activity (MTA), defined as the amount of radioactivity calculated to deliver no more than 12 Gy to lungs, or 30 Gy to liver, or 1.5 Gy to bone marrow. Patients were followed for at least 12 weeks after therapy, until recovery from all toxicity. The clinical parameters evaluated included toxicity, response as determined by contrast-enhanced CT, palliation of symptoms, overall survival, performance status (Karnofsky) and hepatic function (Child's classification). Liver function tests, serum α-fetoprotein (AFP) levels and complete blood counts were done at each follow-up visit. In the majority of patients, the scout dose studies indicated the radiation absorbed dose to normalliver to be the limiting factor to the treatment dose, while in a few patients dose to lung was the limiting factor. Radiation dose to bone marrow was negligible and was thus not a factor for the MTA calculations. Side-effects were minimal and usually presented as loss of appetite, right hypochondrial discomfort and low-grade fever, even at high levels of administered radioactivity. The symptoms resolved with simple supportive therapy within 3 days of onset. Liver function tests at 24 and 72 h showed no significant changes and complete blood counts at 1 week, 4 weeks and 12 weeks showed no changes (no bone marrow suppression). Sixteen patients were treated in the dose escalation phase

  7. Transcatheter lipiodol chemo-embolization of the inferior phrenic artery in hepatocellular carcinoma

    International Nuclear Information System (INIS)

    Chen Fanghong; Luo Zuyan; Yuan Jianhua; Yu Wenqiang; Cai Xuexiang; Hu Tingyang; Liu Zijiang

    2002-01-01

    Objective: To evaluate the efficacy of transcatheter lipiodol chemo-embolization therapy (TOCE) for HCC via inferior phrenic artery (IPA) and to analyse the location of the tumor feeding inferior phrenic artery. Methods: Twenty-five cases of HCC underwent the procedure of TOCE via the IPA, as well as the hepatic artery using Seldinger's method. The patterns of tumor growth included huge type in 12 cases, solitary nodular type in 8 cases and multiple nodular type in 5 cases. Hepatic artery and inferior phrenic artery chemo-embolization were performed in all cases. Results: Inferior phrenic artery originated from celiac trunk in 16 cases (64%); abdomen aorta around celiac trunk in 8(32%). The site-sort tumors supplied by IPA in right lobe (VII, VIII segment) were 23 cases and left lobe (IV segment) 2 cases. The cumulative survival rates of IPA chemo-embolization for hepatocellular carcinoma were 84%(1 year) and 68%(2 years). No severe complications occurred. Conclusions: TOCE of the IPA is a safe and effective method in the management of HCC supplied by IPA. When the tumor site is adjacent to diaphragm, hepatic ligaments or bare area, may arouse the blood supply by IPA, especially in no tumor staining or staining defect in hepatic artery angiography but tumor enhancement on CT, and increase of the level of serum α-fetoprotein

  8. Lymphangiogram of the pelvic limb in normal dogs with Lipiodol Ultra-Fluide

    International Nuclear Information System (INIS)

    Tachibana, F.; Nishikawa, T.; Kudo, T.; Otomo, K.; Koike, T.

    1982-01-01

    Lipiodol Ultra-Fluide (0.2 ml/kg) was injected directly into the lymphatic vessels of the pelvic limbs in 28 healthy adult mongrel dogs. The contrast medium appeared on the roentgenogram in the popliteal, lateral iliac, medial iliac, sacral and lumbar aortic lymph nodes (LN). It was also visible in the iliofemoral, superficial inguinal and cranial mediastinal LN in several dogs. It diffused from the popliteal into the sacral, medial iliac and lateral iliac LN to fill the cisterna chyli and thoracic duct system. The features of the popliteal, lateral iliac and lumbar aortic LN were shown in the lymphangiograms of all the animals. The incidence of the other LN was different. Depending on the incidence of these LN in the lymphangiogram, the pictures of the canine lymphatic system were classified into three types:(1) medial iliac and sacral LN were visible on both sides (16%);(2) one of these LN was not observed (36%);(3) medial iliac and/or sacral lymph node was not observed on both sides (48%). (author)

  9. A novel method of modifying immune responses by vaccination with lipiodol-siRNA mixtures

    Directory of Open Access Journals (Sweden)

    Yijian Li

    2006-01-01

    Full Text Available Abstract The dendritic cell (DC possesses the ability to stimulate both T helper 1 (Th1 and Th2 responses depending on activation stimuli. Although it is known that chemically or genetically modified DC can be used therapeutically to steer immune responses towards either Th1 or Th2, cellular therapy with ex vivo manipulated DC is clinically difficult. Here we demonstrate a novel method of switching immune responses from Th1 to Th2 through in vivo immune modulation by administration of siRNA. We demonstrate that siRNA targeting of the IL-12p35 gene leads to a Th2 bias in vitro through an IL-10 dependent mechanism. In vivo administration of siRNA admixed with the oil-based contrast agent lipiodol in the presence of antigen and adjuvant induced a deviation in recall response to reduced production of IFN-γ and augmented IL-4 response using either KLH or ovalbumin. This simple method of in vivo modification of immune response possesses therapeutic potential in Th1-mediated diseases such as multiple sclerosis and autoimmune diabetes.

  10. Uterine artery embolization with Pingyangmycin lipiodol emulsion for treatment of symptomatic uterine fibroids

    International Nuclear Information System (INIS)

    Li Yanhao; Liu Biao; Zeng Qingle; Jiang Zhongpu; Chen Yong; Huang Weilang; Shen Qi; Zhao Zhongqing

    2000-01-01

    Objective: To evaluate the effectiveness and side effects of uterine arterial embolization with Pingyangmycin(a homogenous bleomycin) lipiodol emulsion(PLE) for symptomatic uterine fibroids. Methods: Uterine arterial embolization with PLE was performed in 25 patients. The improvement of symptoms and uterine size changes were followed up in 3-18 months(mean 6 months) after the procedure. Results: All but 2 cases were successfully treated bilaterally. Super-selective angiography showed enlargement of uterine artery, accompanied by tortuous branches. The uterine size was increased. The uterus itself was significantly stained and emptied slowly. Coagulation necrosis was found in resected fibroids after embolization in 3 patients. One month after the procedure, a mean 40% reduction of uterine volume was obtained in 18 followed-up cases. The clinical symptoms were relieved significantly. The main side effects were hypogastric pain(13/25),which was intense in 6 cases. Conclusion: Uterine arterial embolization with PLE is a good non-surgical therapy in symptomatic uterine fibroids with mild side effects

  11. Superselective renal artery embolization with lipiodol and absolute alcohol emulsion for renal tumor

    International Nuclear Information System (INIS)

    Yu Miao; Li Jiakai; Sun Minglu; Wang Huixian

    2008-01-01

    Objective: To evaluate the efficacy of the renal arterial embolization with lipidol and absolute alcohol emulsion in the treatment of renal tumors. Methods: The superselective renal arterial embolization by using coaxial-cathaterization with infusion of lipiodol and absolute alcohol (in proportion of 2 :1) emulsion was performed in twenty patients with malignant and benign kidney tumors. 4 weeks later, the renal arteriography was taken routinely and repeated embolization was performed in case of necessary; and follow up was carried out periodically. Results: The imaging findings showed thorough tumor necrosis and feeding vessel abruption in 18 cases after one session of treatment. The volume of tumors decreased more than a half in 13 patients (82.25%, 13/18) associated with a well-distributed lipidol inside the tumors. The second session of treatment was performed in other 2 patients and the clinical symptoms relieved obviously. Conclusions: The superselective renal artery embolization with lipidol and absolute alcohol emulsion can permanently embolize all tumor feeding arteries in capillary vessel level with maximum reservation of renal function, providing definitively efficacy and worthwhile to be recommended widely. (authors)

  12. Fragmentation, labeling and biodistribution studies of KS1/4, a monoclonal antibody

    International Nuclear Information System (INIS)

    Mohd, S.B.

    1987-01-01

    In this study, an IgG2a (KS1/4), a monoclonal antibody (MoAb) specific against a human lung adenocarcinoma (UCLA P-3) was successfully fragmented enzymatically to yield F(ab') 2 and Fab by using pepsin and papain, respectively. The kinetic of fragmentation of the MoAb was compared to that of human immunoglobulin G (IgG). A similar pattern of fragmentation was observed with both antibodies with a higher percentage yield of the F(ab') 2 and Fab obtained upon the fragmentation of the IgG by the enzymes. The KS1/4 and the two fragments were labeled with three different radionuclides, namely iodine-131, indium-111 and selenium-75. The radioiodination of the MoAb and the fragments was carried out by using a modified chloramine-T method. Radiometal labeling of the MoAb and the fragments with indium-111 was performed by using DTPA as a bifunctional chelating agent, while intrinsic labeling of the MoAb was done by culturing the hybridoma in the presence of 75 Se-methionine. The biodistribution of the radiolabeled MoAb, F(ab') 2 and Fab fragments were performed by injecting the preparations intravenously into nude mice bearing human lung adenocarcinoma

  13. Lipiodol injections for optimization of target volume delineation in a patient with a second tumor of the oropharynx. A case report

    Energy Technology Data Exchange (ETDEWEB)

    Haderlein, Marlen; Merten, Ricarda; Stojanovic, Andrea; Speer, Stefan; Fietkau, Rainer; Ott, Oliver J. [University Hospitals of Erlangen, Department of Radiation Oncology, Erlangen (Germany); Scherl, Claudia [University Hospitals of Erlangen, Department of Otorhinolaryngology, Erlangen (Germany)

    2015-08-15

    Lipiodol injections were administered in the head and neck area to improve gross tumor volume (GTV) definition for small-volume re-irradiation of a 63-year-old previously irradiated patient with a second tumor of the oropharynx in the posterior wall with longitudinal ligament infiltration (cT4cN0cM0). The patient had dialysis-depending renal failure. On diagnostic computed tomography (CT), which was performed with intravenous contrast agent, the tumor in the oropharynx was not detectable. Because of dialysis-depending renal failure comorbidity, no contrast agent was applied in the planning CT and in the diagnostic magnetic resonance imaging (MRI) study. In each cross-sectional imaging study performed, the GTV, especially in craniocaudal extensions, was not safely delineable. Therefore, craniocaudal tumor margins were pharyngoscopically marked with Lipiodol injections, an iodine-containing contrast agent. In a second planning CT, the GTV could be defined with the help of the Lipiodol marks and small-volume re-irradiation was performed. No Lipiodol-associated side effects occurred in the patient. In the present case, the use of Lipiodol injections at the tumor margins facilitated the definition of the GTV. (orig.) [German] Anwendung von Lipiodolinjektionen im Kopf-Hals-Bereich zur Verbesserung der GTV-Definition bei einer kleinvolumigen Re-Bestrahlung eines 63-jaehrigen, vorbestrahlten Patienten mit einem Zweitmalignom im Oropharynx mit Infiltration des hinteren Laengsbandes (cT4cN0cM0). Nebenbefundlich bestand bei dem Patienten eine dialysepflichtige Niereninsuffizienz. Im initialen diagnostischen Kontrastmittel-CT der Hals und Thoraxregion war der Tumor nicht abgrenzbar, so dass das Bestrahlungsplanungs-CT in Anbetracht des diagnostischen CTs und der bekannten Niereninsuffizienz ohne intravenoeses Kontrastmittel durchgefuehrt wurde. Das diagnostische MRT (vgl. Abb. 1) wurde ebenfalls ohne intravenoeses Kontrastmittel durchgefuehrt wurden. In allen durchgefuehrten

  14. Cone-Beam Computed Tomography Correlates with Conventional Helical Computed Tomography in Evaluation of Lipiodol Accumulation in HCC after Chemoembolization.

    Directory of Open Access Journals (Sweden)

    Toru Ishikawa

    Full Text Available The amount of drug-loaded lipiodol in an HCC tumor post-transarterial chemoembolization (TACE correlates with the risk of local tumor recurrence. Lipiodol enhancement of a tumor on conventional CT, measured in Hounsfield units (HU, can predict tumor response. Here we investigate whether cone-beam CT (CBCT can also be used to predict tumor response, providing the benefit of being able to optimize the patient's treatment plan intra-procedurally.A total of 82 HCC nodules (82 patients, ≤5 cm in diameter, were treated with balloon-occluded TACE using miriplatin between December 2013 and November 2014. For each patient, both CBCT and conventional CT images were obtained post-TACE. The degree of correlation between CBCT and conventional CT was determined by comparing identical regions of interest for each imaging modality using pixel values.The pixel values from conventional CT and CBCT were highly correlated, with a Pearson correlation coefficient of 0.912 (p<0.001. The location of the nodules within the liver did not affect the results; the correlation coefficient was 0.891 (p<0.001 for the left lobe and 0.926 (p<0.001 for the right lobe. The mean pixel value for conventional CT was 439 ± 279 HU, and the mean pixel value for CBCT was 416 ± 311 HU.CBCT may be used as a substitute for conventional CT to quantitatively evaluate the amount of drug-loaded lipiodol within an HCC nodule and, hence, the efficacy of TACE treatment. The major benefit of using CBCT is the ability to predict the likelihood of local recurrence intra-procedurally, enabling subsequent treatment optimization.

  15. Computed tomography after administration of SMANCS-Lipiodol to liver cancers

    Energy Technology Data Exchange (ETDEWEB)

    Maki, Shojiro; Konno, Toshimitsu; Iwai, Ken; Uchida, Mitsukuni; Tashiro, Seiki; Miyauchi, Yoshimasa; Maeda, Hiroshi [Kumamoto Univ. (Japan). School of Medicine

    1984-08-01

    Sixty-eight cases of liver cancer, 48 cases of hepatocellular carcinoma and 20 cases of metastatic liver cancer, were treated by injection of SMANCS-Lipiodol (S-L) via tumor feeding arteries. Abdominal CT was carried out on the 3 rd day, 1 week, 2 and 4 weeks after the administration. These CT images were compared with those before the administration. Both primary and metastatic liver cancers were visualized as high density area due to the selective stay of S-L. Thus, the method became useful as a diagnostic tool; several tumors were newly visualized after the administration. S-L stayed in primary tumors and metastatic tumors. There were three types of the remaining of S-L in metastatic tumors for a long period: Type A, in which S-L remained in entire tumors; Types B, in which it remained primarily in circumference of tumor and Mixed type of A and B. The anticancer effect of S-L paralleled with the extent of the remaining of S-L in tumors, which was classified from Grade 0 to Grade IV. Grade IV means that S-L was recognized in the entire areas of tumors in the every slice of CT, and in the Grade IV tumors size reduced effectively after several months period. The dosage which was necessary to attain Grade IV was 0.08 ml per square centimeters calculated by the largest slice of every tumor. From Grade 0 to III, they need additional administration of S-L until to attain Grade IV in the tumor for the effective tumor regression.

  16. Transarterial Infusion Chemotherapy Using Cisplatin-Lipiodol Suspension With or Without Embolization for Unresectable Hepatocellular Carcinoma

    International Nuclear Information System (INIS)

    Kawaoka, Tomokazu; Aikata, Hiroshi; Takaki, Shintaro; Katamura, Yoshio; Hiramatsu, Akira; Waki, Koji; Takahashi, Shoichi; Hieda, Masashi; Toyota, Naoyuki; Ito, Katsuhide; Chayama, Kazuaki

    2009-01-01

    We evaluate the long-term prognosis and prognostic factors in patients treated with transarterial infusion chemotherapy using cisplatin-lipiodol (CDDP/LPD) suspension with or without embolization for unresectable hepatocellular carcinoma (HCC). Study subjects were 107 patients with HCC treated with repeated transarterial infusion chemotherapy alone using CDDP/LPD (adjusted as CDDP 10mg/LPD 1ml). The median number of transarterial infusion procedures was two (range, one to nine), the mean dose of CDDP per transarterial infusion chemotherapy session was 30 mg (range, 5.0-67.5 mg), and the median total dose of transarterial infusion chemotherapy per patient was 60 mg (range, 10-390 mg). Survival rates were 86% at 1 year, 40% at 3 years, 20% at 5 years, and 16% at 7 years. For patients with >90% LPD accumulation after the first transarterial infusion chemotherapy, rates were 98% at 1 year, 60% at 3 years, and 22% at 5 years. Multivariate analysis identified >90% LPD accumulation after the first transarterial infusion chemotherapy (p = 0.001), absence of portal vein tumor thrombosis (PVTT; p < 0.001), and Child-Pugh class A (p = 0.012) as independent determinants of survival. Anaphylactic shock was observed in two patients, at the fifth transarterial infusion chemotherapy session in one and the ninth in the other. In conclusion, transarterial infusion chemotherapy with CDDP/LPD appears to be a useful treatment option for patients with unresectable HCC without PVTT and in Child-Pugh class A. LPD accumulation after the first transarterial infusion chemotherapy is an important prognostic factor. Careful consideration should be given to the possibility of anaphylactic shock upon repeat infusion with CDDP/LPD.

  17. Computed tomography after administration of SMANCS-Lipiodol to liver cancers

    International Nuclear Information System (INIS)

    Maki, Shojiro; Konno, Toshimitsu; Iwai, Ken; Uchida, Mitsukuni; Tashiro, Seiki; Miyauchi, Yoshimasa; Maeda, Hiroshi

    1984-01-01

    Sixty-eight cases of liver cancer, 48 cases of hepatocellular carcinoma and 20 cases of metastatic liver cancer, were treated by injection of SMANCS-Lipiodol (S-L) via tumor feeding arteries. Abdominal CT was carried out on the 3 rd day, 1 week, 2 and 4 weeks after the administration. These CT images were compared with those before the administration. Both primary and metastatic liver cancers were visualized as high density area due to the selective stay of S-L. Thus, the method became useful as a diagnostic tool; several tumors were newly visalized after the administration. S-L stayed in primary tumors and metastatic tumors. There were three types of the remaining of S-L in metastatic tumors for a long period: Type A, in which S-L remained in entire tumors; Types B, in which it remained primarily in circumference of tumor and Mixed type of A and B. The anticancer effect of S-L paralleled with the extent of the remaining of S-L in tumors, which was classified from Grade 0 to Grade IV. Grade IV means that S-L was recognized in the entire areas of tumors in the every slice of CT, and in the Grade IV tumors size reduced effectively after several months period. The dosage which was necessary to attain Grade IV was 0.08 ml per square centimeters calculated by the largest slice of every tumor. From Grade 0 to III, they need additional administration of S-L until to attain Grade IV in the tumor for the effective tumor regression. (author)

  18. An experimental study on the effect of mixture of absolute ethanol and lipiodol injected into normal liver of rabbit : CT features and histopathologic changes

    International Nuclear Information System (INIS)

    Lee, Mee Ran; Kim, Yun Hwan; Cha, In Ho; Chung, Kyoo Byung; Suh, Won Hyuk; Um, Soon Ho; Choi, Young Hee

    1999-01-01

    To investigate the safety and usefulness of Lipiodol-percutaneous transhepatic ethanol injection(LPEI) and to determine the appropriate concentration of Lipiodol during L-PEI. This was achieved by evalvating CT findings and histopathologic changes according to the concentration of Lipiodol, amount of ethanol, and the time interval after injection into normal rabbit liver. This experimental study involved 18 New Zealand rabbits under US guidance. They were divided into five groups according to injected materials; two rabbits with 0.4cc of normal saline(group I), six with 0.4cc of ethanol in the left hepatic lobe(group II), and 0.4cc of Lipiodol in the right hepatic lobe(group III), five rabbits with 5% Lipiodol-ethanol(5% vol. of Lipiodol+95% vol. of ethanol), 0.2cc in the right hepatic lobe, and 0.4cc in the left(group IV); and five rabbits with 10% Lipiodol-ethanol as per group IV(group V). CT was performed immediately, one week, two weeks, and three-four weeks after injection, and pathologic specimens were obtained on the third day(acute phase) and during the third or fourth week(chronic phase) after injection. On CT, intrahepatic localization of the L-PEI injection site was well demonstrated as a focal high attenuated area which gradually decreased in attenuation on follow up CT. The opacification of the inferior vena cava by Lipiodol, the linear distribution of Lipiodol along portal veins or fissures, and peritoneal leakage were clearly demonstrated in groups III-V, though the effects gradually disappeared during follow-up CT. There was no remarkable difference in gross CT attenuation between group IV and group V. The main pathologic findings during the acute phase of group II were coagulation necrosis surrounded by macrophage, inflammatory reaction, and early periportal and subcapsular fibrosis. The findings in group IV and V were similar to those in group II and additional fat vacuole accumulations in the necrotic area were also seen. During the chronic phase

  19. The experimental study of VEGF antisense oligodeoxynucleotides with lipiodol in arterial embolization of liver cancer in rats

    International Nuclear Information System (INIS)

    Wu Hanping; Feng Gansheng; Li Xin; Liang Huimin; Zheng Chuansheng

    2003-01-01

    Objective: To study the inhibitory effects of VEGF antisense oligodeoxynucleotides (asODN) on cultured Walker-256 cells' VEGF expression, and to observe the anti-tumor effects of intraarterial infusion of asODN mixed with lipiodol on rat liver cancer. Methods: VEGF asODN and sense ODN were added to the media of non-serum cultured Walker-256 cells, and the VEGF concentrations of the supernatants were detected by using ELISA 48 hours later. Cells of endothelial cell line ECV-304 were cultured in the supernatants. The growth of ECV-304 cells was observed by MTT method. 30 rats with Walker-256 carcinoma cells implanted into left liver lobe were randomly divided into 3 groups. 0.2 ml ultra-fluid lipiodol (UFLP group, n=10), 3OD asODN mixed with 0.2 ml ultra-fluid lipiodol (UFLP + asODN group, n=10), and 0.2 ml normal saline (control group, n=10) were infused into the hepatic artery. The volumes of tumors were measured by using MRI before and 7 days after the treatment. VEGF mRNA in cancerous and peri-cancerous tissues was detected by RT-PCR. The microvessel density (MVD) and VEGF expression were observed by immunohistochemistry. Results: asODN could inhibit Walker-256 cells' VEGF expression. The tumor growth rate was lower in UFLP + asODN group than that in UFLP and control groups [(140.1±33.8)%, (177.9±64.9)%, and (403.9± 69.4)%, respectively, F=60.02, P 0.05). The MVD in UFLP + asODN group (53.1±18.4) was significantly less than that of control group (73.2±20.4) and UFLP group (80.3±18.5) (F=5.44, P<0.05). Conclusion: VEGF asODN could inhibit VEGF expression of Walker-256 cells. It may be an antiangiogenesis therapy drug in malignant tumor. VEGF asODN mixed with UFLP in embolizing liver cancer could decrease liver cancer growth, VEGF expression, and microvessel density better than UFLP alone

  20. Iodine-131 production by a dry method using reactor-irradiated elementary tellurium. Part 1 - Conditions for obtaining iodine emanation and its capture. Part 2 - comparative study of preparation conditions using Pyrex, stainless steel and alumina equipment. Part 3 - production on a semi-industrial scale; Production de l'iode 131 par voie seche a partir de tellure elementaire irradie a la pile. 1ere partie - Etudes des conditions pour obtenir l'emanation de l'iode et le capter. 2eme partie - Etude comparee des conditions pour effectuer cette preparation avec des appareils en Pyrex, en acier inoxydable et en alumine. 3eme partie - production a l'echelle semi-industrielle

    Energy Technology Data Exchange (ETDEWEB)

    Bardy, A; Beydon, J; Murthy, T S; Doyen, J B; Lefrancois, J [Commissariat a l' Energie Atomique, Saclay (France). Centre d' Etudes Nucleaires

    1967-04-15

    A previous report has described how iodine 131 can be prepared from elementary tellurium by a dry method which consists in treating irradiated tellurium at 400 degrees in argon. The possibility of carrying out this treatment in a stainless steel or alumina apparatus has been considered. The behavior of gaseous iodine 131 towards these materials has thus been studied. If the adsorption of iodine on stainless steel is superficial desorption is rapid at 250 degrees in oxygen or 400 degrees in argon. If the adsorption is chemical in nature it becomes necessary to heat to higher temperatures. Adsorption of iodine on alumina is very weak and the iodine can be desorbed rapidly. With these materials tests have been carried out on 300 gms of tellurium containing 41 curies of iodine 131; the yields were very satisfactory ( 98 per cent). (author) [French] La methode de preparation de l iode 131 par voie seche a partir de tellure elementaire decrite dans un precedent rapport consiste a traiter le tellure irradie a 400 degres sous argon. Nous avons examine la possibilite d effectuer ce traitement dans un appareil en acier inoxidable ou en alumine. Le comportement de l iode 131 gazeux vis a vis de ces materiaux a donc ete etudie. Si l adsorption de l iode sur l acier inoxidable est superficielle la desorption est rapide a 250 degres sous oxygene ou 400 degres sous argon. Si la fixation est de nature chimique il est necessaire de chauffer a des temperatures plus elevees. L adsorption de l iode sur l alumine est res faible et l iode peut etre desorbe rapideemnt. En employant ces materiaux des essais ont ete obtenus sur 300 g de tellure contenant 41 curies d iode 131 avec un bon rendement (98 pour cent). (auteur00.

  1. Target localization of 3D versus 4D cone beam computed tomography in lipiodol-guided stereotactic radiotherapy of hepatocellular carcinomas.

    Science.gov (United States)

    Chan, Mark; Chiang, Chi Leung; Lee, Venus; Cheung, Steven; Leung, Ronnie; Wong, Matthew; Lee, Frankle; Blanck, Oliver

    2017-01-01

    Aim of this study was to comparatively evaluate the accuracy of respiration-correlated (4D) and uncorrelated (3D) cone beam computed tomography (CBCT) in localizing lipiodolized hepatocellular carcinomas during stereotactic body radiotherapy (SBRT). 4D-CBCT scans of eighteen HCCs were acquired during free-breathing SBRT following trans-arterial chemo-embolization (TACE) with lipiodol. Approximately 1320 x-ray projections per 4D-CBCT were collected and phase-sorted into ten bins. A 4D registration workflow was followed to register the reconstructed time-weighted average CBCT with the planning mid-ventilation (MidV) CT by an initial bone registration of the vertebrae and then tissue registration of the lipiodol. For comparison, projections of each 4D-CBCT were combined to synthesize 3D-CBCT without phase-sorting. Using the lipiodolized tumor, uncertainties of the treatment setup estimated from the absolute and relative lipiodol position to bone were analyzed separately for 4D- and 3D-CBCT. Qualitatively, 3D-CBCT showed better lipiodol contrast than 4D-CBCT primarily because of a tenfold increase of projections used for reconstruction. Motion artifact was observed to subside in 4D-CBCT compared to 3D-CBCT. Group mean, systematic and random errors estimated from 4D- and 3D-CBCT agreed to within 1 mm in the cranio-caudal (CC) and 0.5 mm in the anterior-posterior (AP) and left-right (LR) directions. Systematic and random errors are largest in the CC direction, amounting to 4.7 mm and 3.7 mm from 3D-CBCT and 5.6 mm and 3.8 mm from 4D-CBCT, respectively. Safety margin calculated from 3D-CBCT and 4D-CBCT differed by 2.1, 0.1 and 0.0 mm in the CC, AP, and LR directions. 3D-CBCT is an adequate alternative to 4D-CBCT when lipoid is used for localizing HCC during free-breathing SBRT. Similar margins are anticipated with 3D- and 4D-CBCT.

  2. Labeling suspended aerosol particles with short-lived radionuclides for determination of particle deposition

    International Nuclear Information System (INIS)

    Smith, M.F.; Bryant, S.; Welch, S.; Digenis, G.A.

    1984-01-01

    Radiotracer techniques were developed to examine parameters that characterize pressurized aerosols designed to deliver insoluble particles suspended in the aerosol formulation. Microaggregated bovine serum albumin microspheres that were to be suspended were labeled with iodine-131 (t1/2 . 8 d). This iodination procedure (greater than 80% effective) is also applicable to iodine-123, which possesses superior characteristics for external imaging and further in vivo studies. This report shows that for pressurized aerosols containing suspended particles, each metered dose is approximately equal (not including the priming doses and the emptying doses). Increase in the delivery of the albumin particles out of the canister was best achieved by pretreating the valve assembly with a solution of 2% (w/v) bovine serum albumin in phosphate buffer. Use of a cascade impactor delineated the particle size distribution of the micropheres, with the majority of particles ranging in size from 2 to 8 microns. The data disclosed here indicate that the techniques developed with short-lived radionuclides can be used to quantitate each metered dose, characterize the particle size distribution profile of the aerosol contents, and determine the extent of deposition of the particles in the aerosol canister and all of its components

  3. Biodistribution of Yttrium-90-Labeled Anti-CD45 Antibody in a Nonhuman Primate Model

    International Nuclear Information System (INIS)

    Nemecek, Eneida; Hamlin, Donald K.; Fisher, Darrell R.; Krohn, Kenneth A.; Pagel, John M.; Applebaum, F. R.; Press, Oliver W.; Matthews, Dana C.

    2005-01-01

    Radioimmunotherapy may improve the outcome of hematopoietic cell transplantation for hematologic malignancies by delivering targeted radiation to hematopoietic organs while relatively sparing nontarget organs. We evaluated the organ localization of yttrium-90-labeled anti-CD45 (90Y-anti-CD45) antibody in macaques, a model that had previously predicted iodine-131-labeled anti-CD-45 (131I-anti-CD45) antibody biodistribution in humans. Experimental Design: Twelve Macaca nemestrina primates received anti-CD45 antibody labeled with 1 to 2 mCi of 90Y followed by serial blood sampling and marrow and lymph node biopsies, and necropsy. The content of 90Y per gram of tissue was determined by liquid scintillation spectrometry. Time-activity curves were constructed using average isotope concentrations in each tissue at measured time points to yield the fractional residence time and estimate radiation absorbed doses for each organ per unit of administered activity. The biodistribution of 90Y-anti-CD45 antibody was then compared with that previously obtained with 131I-anti-CD45 antibody in macaques. Results: The spleen received 2,120, marrow 1,060, and lymph nodes 315 cGy/mCi of 90Y injected. The liver and lungs were the nontarget organs receiving the highest radiation absorbed doses (440 and 285 cGy/mCi, respectively). Ytrrium-90-labeled anti-CD45 antibody delivered 2.5- and 3.7-fold more radiation to marrow than to liver and lungs, respectively. The ratios previously observed with 131I-antiCD45 antibody were 2.5-and 2.2-fold more radiation to marrow than to liver and lungs, respectively. Conclusions: This study shows that 90Y-anti-CD45 antibody can deliver relatively selective radiation to hematopoietic tissues, with similar ratios of radiation delivered to target versus nontarget organs, as compared with the 131I immunoconjugate in the same animal model

  4. The use of indocyanine green lymphography for the treatment of postoperative chylothorax with lipiodol lymphangiography in a 2-year-old child

    Directory of Open Access Journals (Sweden)

    Motoi Kato

    2017-08-01

    Full Text Available Postoperative chylothorax in infants prolongs hospital stay and possibly causes developmental delay because of its conservative treatment including inanition. Several medical and surgical treatments may be applied, but none constitute the absolute solution. Treatment with lipiodol during lymphangiography for postoperative chylothorax has been reported to be highly effective and less invasive in adults. On the other hand, few cases have been reported in infants. We demonstrate successful blockage of chyle leakage with lipiodol injection through the inguinal lymph node in a 2-year-old infant. The patient had undergone on-pump coarctectomy and chylothorax developed soon after surgery. Several medical treatments were partially effective, but the chest tube could not be removed because sequential aspiration was required to maintain a normal respiratory status. With the patient under general anesthesia, lipiodol injection combined with indocyanine green (ICG lymphography was performed. Lymphography combined with ICG significantly contributed not only to intraoperative detection of the inguinal lymph nodes but also to postoperative early detection of lymphedema caused by this procedure. This procedure required a simple maneuver and is probably applicable to other cases of traumatic chylothorax, such as after surgeries on the esophagus, trachea, or other components of the posterior mediastinum.

  5. High precision bladder cancer irradiation by integrating a library planning procedure of 6 prospectively generated SIB IMRT plans with image guidance using lipiodol markers

    International Nuclear Information System (INIS)

    Meijer, Gert Johan; Toorn, Peter-Paul van der; Bal, Matthieu; Schuring, Danny; Weterings, Jan; Wildt, Michel de

    2012-01-01

    Purpose: To increase local control and decrease side effects for urinary bladder cancer patients by integrating a library planning procedure with image guidance using lipiodol markers. Methods and materials: Twenty patients with T2-T4N0M0 grade 2–3 invasive bladder carcinoma were treated according to an online adaptive protocol. Initially, the gross tumour volume (GTV) was demarcated during cystoscopy by injecting several drops of lipiodol in the submucosa around the tumour. Subsequently two CT scans were acquired with a full bladder and a voided bladder. On both scans, the boost volume (GTV) and the low-risk bladder volume were delineated. Using an interpolation tool, six concomitant boost IMRT plans with increasing bladder volumes were generated. For each fraction the procedure at the treatment unit was as follows: Firstly, a ConeBeam-CT was acquired and based on the amount of bladder filling the best fitting bladder contours and corresponding GTV and IMRT plans were selected. Secondly, the lipiodol markers were registered using the corresponding GTV contours and it was verified that the corresponding 95%-isodose surface covered the entire bladder. Finally, an online setup correction was applied based on this registration and the corresponding treatment plan was irradiated. Results: The lipiodol markers were very useful in outlining the GTV at the planning CT and for daily setup correction. While the patients strived for a full bladder filling at time of the treatment, this was seldom accomplished. Due to our protocol an appropriate plan with adequate coverage of the PTV and without excessive dose to healthy tissue was delivered every day. The treatment was very well tolerated by all patients. At the end of the treatment no grade 3 urinary or gastro-intestinal toxicity was observed. After a median follow-up of 28 months two local relapses occurred. Conclusion: Using the library planning approach combined with online image guidance using lipiodol markers, we

  6. High precision bladder cancer irradiation by integrating a library planning procedure of 6 prospectively generated SIB IMRT plans with image guidance using lipiodol markers.

    Science.gov (United States)

    Meijer, Gert Johan; van der Toorn, Peter-Paul; Bal, Matthieu; Schuring, Danny; Weterings, Jan; de Wildt, Michel

    2012-11-01

    To increase local control and decrease side effects for urinary bladder cancer patients by integrating a library planning procedure with image guidance using lipiodol markers. Twenty patients with T2-T4N0M0 grade 2-3 invasive bladder carcinoma were treated according to an online adaptive protocol. Initially, the gross tumour volume (GTV) was demarcated during cystoscopy by injecting several drops of lipiodol in the submucosa around the tumour. Subsequently two CT scans were acquired with a full bladder and a voided bladder. On both scans, the boost volume (GTV) and the low-risk bladder volume were delineated. Using an interpolation tool, six concomitant boost IMRT plans with increasing bladder volumes were generated. For each fraction the procedure at the treatment unit was as follows: Firstly, a ConeBeam-CT was acquired and based on the amount of bladder filling the best fitting bladder contours and corresponding GTV and IMRT plans were selected. Secondly, the lipiodol markers were registered using the corresponding GTV contours and it was verified that the corresponding 95%-isodose surface covered the entire bladder. Finally, an online setup correction was applied based on this registration and the corresponding treatment plan was irradiated. The lipiodol markers were very useful in outlining the GTV at the planning CT and for daily setup correction. While the patients strived for a full bladder filling at time of the treatment, this was seldom accomplished. Due to our protocol an appropriate plan with adequate coverage of the PTV and without excessive dose to healthy tissue was delivered every day. The treatment was very well tolerated by all patients. At the end of the treatment no grade 3 urinary or gastro-intestinal toxicity was observed. After a median follow-up of 28 months two local relapses occurred. Using the library planning approach combined with online image guidance using lipiodol markers, we were able to deliver a highly conformal dose distribution

  7. Sodium alginate microsphere combined with pingyangmycin lipiodol emulsion for clinical treatment of cavernous hemangioma of the liver

    International Nuclear Information System (INIS)

    Yu Miao; Zhang Jinshan; Deng Liping

    2010-01-01

    Objective: To further reduce the adverse reactions of vascular embolization therapy for cavernous hemangioma of the liver (CHL) in order to find better embolizing agents. Methods: Sixty CHL patients were randomly and evenly divided into three groups: embolization therapy with sodium alginate microsphere(SAM) + pingyangmycin lipiodol emulsion (PLE) (group SAM + PLE), PLE (group PLE) and SAM (group SAM). The routine postoperative symptomatic treatments were conducted, including odynolysis, liver-protection and antiinflammatory therapy. The liver function and the intraoperative or postoperative discomfort symptoms before and 7 days after operation, and the changes in tumors were examined with CT scan. Clinical symptoms 3 months after operation were respectively compared. Results: The greatest impact on liver function was seen in group PLE among the three groups. The maximum intraoperative or postoperative discomfort symptoms were seen in group SAM, but the therapeutic effectiveness of the three groups had no significant difference. Conclusion: SAM + PLE is a safe and effective embolizing agent, being user-friendly, minor in the effect on liver function and light in the intraoperative and postoperative reaction. It is recommended that SAM + PLE be widely used for cavernous hemangioma of the liver. (authors)

  8. Significance of Lipiodol-CT in the evaluation of therapeutic effects of Lp-TAE for hepatocellular carcinoma

    International Nuclear Information System (INIS)

    Jinno, Kenji; Tokuyama, Katuyuki; Yumoto, Yasuhiro

    1988-01-01

    In 20 lesions of 17 patients treated with arterial infusion of SMANCS dissolved in lipiodol (Lp) and transcatheter arterial embolization (TAE) for hepatocellular carcinoma (HCC), Lp deposition within the tumor were depicted on CT (Lp-CT). The findings of Lp-CT were compared with those of macroscopic, soft X-ray, and histologic examinations for resected specimens. Lp-CT appearance of HCC fell into four types: (I) complete type - round and homogeneous high density area (HDA) - in which Lp was deposited over the whole area; (II) defective type - inhomogeneous HDA - in which Lp was deposited in part of the tumor; (III) aggregated type - aggregation of small HDA; (IV) deficient type - no HDA - in which little or no Lp was deposited. Type I was found in 20 % of the lesions, type II in 25 %, type III in 20 %, and type IV in 35 %. In type I, HCC was of macroscopically nodular form with expansive growth and pseudocapsule and of histologically trabecular form with broad blood spaces and inviable cancer cells. In the other types, similar findings were seen in the necrotic area in which Lp was deposited, whereas scirrhous or compact type of HCC was histologically seen in the area containing viable cancer cells in which no Lp was deposited. The presence or not of Lp deposition, as depicted on CT, was closely correlated with histologic findings, which has significant implications for the evaluation of therapeutic efficacy of TAE with Lp. (Namekawa, K.)

  9. Food Labels

    Science.gov (United States)

    ... Staying Safe Videos for Educators Search English Español Food Labels KidsHealth / For Teens / Food Labels What's in ... to have at least 95% organic ingredients. Making Food Labels Work for You The first step in ...

  10. Radiochemical study on preparation and quality control of 1-125/1-131 labelled some organic compounds for medical uses

    International Nuclear Information System (INIS)

    El-azoney, K.M.S.E.

    1997-01-01

    The main objective of this thesis is to investigate the optimum condition for the radioiodination of some organic compounds which find wide applications in nuclear medicine. Iodine-131 (T 1 /2= 8.04 d) which is of great importance in the field, are used for this purpose. long chain fatty acids such as 16-Bromo-hexadecanoic (16-brHDA) and -phenyl -fatty acids such as 15-p-iodophenyl pentadecanoic acid (p-IPPA) will be used as model substrates. 1- Labelling of 16-Br-HDA with Na 131 I. Labelling of 16-BrHDA will be investigated via the non-isotopic exchange between 16-Br HDA and Na 131 I to give 16- 131 IHDA. In order to obtain a high radiochemical yield with high radiochemical purity for the product 16- 131 IHDA, simple and fast methods will be followed. The influence of reagents concentrations, time, temperature, solvents and four quaternary ammonium salts as phase transfer catalysts with only one crown ether will be studied. The determination of reaction velocities and activation energies of catalysed systems was effected and compared with results on the dry state system. 2- Labelling of p-Ipa with Na 131 I. Radioiodination of 15-p-iodophenyl pentadecanoic acid is investigated by the nucleophilic substitution reaction via the isotopic exchange between p-Ipa and Na 131 I. As with 16-BrHDA, factors affecting the labelling yield such as reagent concentrations, solvents, reaction time, temperature and catalyst, is examine. The effect of different temperatures on the radiochemical yield of P- 131 Ipa is studied to determine the activation energy of the exchange reaction. Because of the necessity to separate the iodinated products from the starting materials, high performance liquid chromatographic techniques were applied for this purpose. 3.15 figs., 3.2 tabs., 179 refs

  11. Transarterial chemoembolization using gelatin sponges or microspheres plus lipiodol-doxorubicin versus doxorubicin-loaded beads for the treatment of hepatocellular carcinoma

    International Nuclear Information System (INIS)

    Liu, Yi Sheng; Ou, Ming Ching; Tsai, Yi Shan; Lin, Xi Zhang; Wang, Chien Kuo; Tsai, Hong Ming; Chuang, Ming Tsung

    2015-01-01

    To retrospectively compare treatment of hepatocellular carcinoma (HCC) with transarterial chemoembolization (TACE) using gelatin sponges or microspheres plus lipiodol-doxorubicin vs. doxorubicin-loaded drug-eluting beads (DEB). A total of 158 patients with HCC received TACE from November 2010 to November 2011 were enrolled in this study, including 64 (40.5%) received TACE with lipiodol-doxorubicin and gelatin sponges (group A), 41 (25.9%) received TACE with lipiodol-doxorubicin and microspheres (group B), and 53 (33.5%) received TACE with doxorubicin-loaded DEB (group C). Tumor response and adverse events (AEs) were evaluated. No significant difference was found at baseline among the three groups. The doxorubicin dosage in group C was significantly (p < 0.001) higher compared to the dose used in groups A or B (median, 50 mg vs. 31 mg or 25 mg). Significantly (p < 0.001) more patients in group C achieved complete response compared to those in groups A or B (32.1% vs. 6.3% or 2.4%). Significantly (p < 0.001) less patients in group C had progressive disease compared to those in groups A or B (34.0% vs. 57.8% or 68.3%). Minor AEs were more common in groups A and B compared to group C, with rates of 54.7%, 34.1%, and 5.7%, respectively. In patients with HCC, TACE with DEB offers better safety and efficacy profiles compared to either TACE with gelatin sponges or TACE with microspheres.

  12. Stabilization Improves Theranostic Properties of Lipiodol{sup ®}-Based Emulsion During Liver Trans-arterial Chemo-embolization in a VX2 Rabbit Model

    Energy Technology Data Exchange (ETDEWEB)

    Deschamps, F., E-mail: frederic.deschamps@gustaveroussy.fr; Farouil, G. [Université Paris-Saclay, Département de radiologie Interventionnelle, Gustave Roussy (France); Gonzalez, W.; Robic, C. [Guerbet France, Guerbet (France); Paci, A.; Mir, L. M. [Université Paris-Saclay, UMR 8203 (France); Tselikas, L.; Baère, T. de [Université Paris-Saclay, Département de radiologie Interventionnelle, Gustave Roussy (France)

    2017-06-15

    PurposeTo demonstrate that stability is a crucial parameter for theranostic properties of Lipiodol{sup ®}-based emulsions during liver trans-arterial chemo-embolization.Materials and MethodsWe compared the theranostic properties of two emulsions made of Lipiodol{sup ®} and doxorubicin in two successive animal experiments (One VX2 tumour implanted in the left liver lobe of 30 rabbits). Emulsion-1 reproduced one of the most common way of preparation (ratio of oil/water: 1/1), and emulsion-2 was designed to obtain a water-in-oil emulsion with enhanced stability (ratio of oil/water: 3/1, plus an emulsifier). The first animal experiment compared the tumour selectivity of the two emulsions: seven rabbits received left hepatic arterial infusion (HAI) of emulsion-1 and eight received HAI of emulsion-2. 3D-CBCT acquisitions were acquired after HAI of every 0.1 mL to measure the densities’ ratios between the tumours and the left liver lobes. The second animal experiment compared the plasmatic and tumour doxorubicin concentrations after HAI of 1.5 mg of doxorubicin administered either alone (n = 3) or in emulsion-1 (n = 6) or in emulsion-2 (n = 6).ResultsEmulsion-2 resulted in densities’ ratios between the tumours and the left liver lobes that were significantly higher compared to emulsion-1 (up to 0.4 mL infused). Plasmatic doxorubicin concentrations (at 5 min) were significantly lower after HAI of emulsion-2 (19.0 μg/L) than emulsion-1 (275.3 μg/L, p < 0.01) and doxorubicin alone (412.0 μg/L, p < 0.001), and tumour doxorubicin concentration (day-1) was significantly higher after HAI of emulsion-2 (20,957 ng/g) than in emulsion-1 (8093 ng/g, p < 0.05) and doxorubicin alone (2221 ng/g, p < 0.01).ConclusionStabilization of doxorubicin in a water-in-oil Lipiodol{sup ®}-based emulsion results in better theranostic properties.

  13. Scintigraphies after renal transplant: study of transplant function and of sup(99m)Tc labelled lymphocytes transit

    Energy Technology Data Exchange (ETDEWEB)

    Guey, A; Touraine, J L; Collard, M; Traeger, J [Institut National de la Sante et de la Recherche Medicale (INSERM), Hopital Edouard-Herriot, 69 - Lyon (France)

    1977-01-01

    In a first series of scintigraphic investigations in patients with a renal transplant, 'conventional' tracers, were used (sup(99m)Tc pertechnetate and sodium iodohippurate iodine-131) and they gave insight on alteration of the function of the transplanted kidney. Precisions on scintigraphic criteria of diagnosis of vascular complications and urinary fistulae were obtained but no clear cut discrimination between ischemic acute tubular necrosis and early rejection was apparent. Despite the use of a data acquisition and processing system (SCINTI-16) and despite improved functional characterization of the transplant, such methods do not appear to provide definite criteria for an early diagnosis of acute rejection. A different approach, using lymphocytes as a vector, was investigated. A method for lymphocyte labelling with sup(99m)Tc was developed. Labelled autologous lymphocytes were injected to normal volunteers and to patients, then the body distribution was determined and followed over a period of 24 hours. The activity was more precisely quantified at the site of the transplant, repeatedly for 24 hours following injection, and the resulting curves were altered in phases of preclinical rejection. The lymphocyte transit in the kidney would be slower during acute rejection crises of the transplanted kidney and this might be responsible for the different aspect of the curve, especially at 3 to 5 hours. This working hypothesis, will be analysed and documented, using more precise quantifications (close selection of the studied area), evaluating the intrarenal transit of each lymphocyte subpopulation and accurately measuring isotope release. It will then perhaps be possible to define very precise and precocious criteria of rejection.

  14. Nutrition Labeling

    DEFF Research Database (Denmark)

    Grunert, Klaus G

    2013-01-01

    because consumers will avoid products that the label shows to be nutritionally deficient, but also because food producers will try to avoid marketing products that appear, according to the label, as nutritionally problematic, for example, because of a high content of saturated fat or salt. Nutrition......Nutrition labeling refers to the provision of information on a food product’s nutritional content on the package label. It can serve both public health and commercial purposes. From a public health perspective, the aim of nutrition labeling is to provide information that can enable consumers...... to make healthier choices when choosing food products. Nutrition labeling is thus closely linked to the notion of the informed consumer, that chooses products according to their aims, on the basis of the information at their disposal. Because many consumers are assumed to be interested in making healthy...

  15. Private Labels

    OpenAIRE

    Kolmačková, Zuzana

    2013-01-01

    This Bachelor Thesis titled Private labels deals with distribution strategy based on the introduction of private labels especially in retail chains. At the beginning it is focused on the general concept of private label offered by retailers, where is mentioned basic characteristics, history and structuring of distribution brands. Subsequently this thesis informs readers about the introduction of new special distribution brands, which focus primarily on the new consumption habits of customers....

  16. Long-term efficiency and safety of trans-catheter uterine artery embolization by lipiodol-pingyingmycin emulsion for uterine fibroids

    International Nuclear Information System (INIS)

    Du Juan; Zuo Yuewei; Hong Nanhua; Chen Xiaoming; Li Yong

    2009-01-01

    Objective: To investigate the long-term efficiency and safety of trans-catheter uterine artery embolization using lipiodol-pingyingmycin emulsion (LPE-TUAE) for uterine fibroids. Methods: Two hundred and forty-three patients with uterine fibroids were treated by LPE-TUAE. Fourteen of them underwent hysterectomy or myomectomy 3 days to 6 months after LPE-TUAE. The specimens were studied pathologically. Another 229 patients were followed up for 1 to 4 years to observe the long-term outcomes. Results: Menorrhagia became normal or improved markedly in 96.0% (193/201). Lumbago and lower abdominal pain disappeared or relieved markedly in 949% (94/99). Bulk-related symptoms disappeared or lessened markedly in 96.0% (48/50). Ultrasound revealed that the average decreased rate in the largest fibroid volume were 60.7% at 1 year, 63.3% at 2 year, 65.6% at 3 year and 67.4% at 4 year after embolization, and the average decreased rate in the largest uterine volume were 49.6% at 1 year, 54.3% at 2 year, 55.2% at 3 year and 57.1% at 4 year after embolization. Reoccurrence rate of myoma was 10.8% 3-4 year after embolization. No significant difference was found in hormone level between pre- and post-embolization. Pathological studies of specimens showed that lipiodol was only accumulated in fibroids and was not seen in myometrium. Spotty necrosis 2 weeks after embolization and extensive patchy necrosis 3 weeks after embolization were occurred in fibroids. Necrosis was not showed in myometrium. No serious complications occurred. Conclusion: LPE-TUAE possesses a good long-term effectiveness for uterine fibroids, which doesn't cause the damage on ovarian function and normal myometrium or serious complications. (authors)

  17. Iodine-131 saliva secretion in ablation treatment for thyroid cancer patients

    International Nuclear Information System (INIS)

    Nascimento, Ana C.H.; Brandao, Luis E.; Candeiro, Ricardo E.; Rebelo, Ana M.O.; Corbo, Rossana; Dutra, Janaina

    2008-01-01

    In general, well-differentiated thyroid cancer treatment consists in Na 131 I administration following total or a near total thyroidectomy. The activity of a single administration in the majority of nuclear centers ranges from 1 to 4 GBq for residual thyroid tissue elimination and ranges from 4 to 8 GBq for residual thyroid tissue as well as metastases elimination. The high magnitude of 131 I activities administered for thyroid cancer treatment can lead to side effects, where salivary gland dysfunctions are the most common observed. In the absence of thyroid gland, secondary tissues - iodide specific uptake, mainly the salivary glands, rise at the element body retention process. In addition, among nuclear medicine professionals, there is no consensus about suitable restrictions that must be observed by the hospital released patient to avoid 131 I contamination by saliva. The aim of this study is to evaluate qualitatively the secretion of 131 I by salivary glands after the administration of the radionuclide to thyroid cancer patients for ablation purposes. Well-differentiated thyroid cancer patients from Clementino Fraga Filho University Hospital (HUCFF) of Federal University of Rio de Janeiro (UFRJ) followed-up in the present study are female, adult and without additional health diseases detected. After 131 I administration for ablation purposes, saliva samples were collected systematically and counting rate was assessed using a NaI(Tl) scintillator detector. As the study is at an early stage, the preliminary results concern the possibility of conducting an evaluation of 131 I secreted in saliva using the proposed protocol. It can be seen that many factors have potential to influence the behaviour of 1 31 I secretion in saliva, for example the use of Na 131 I in solution or in capsules. It was observed two standards that can be defined according to these variables. (author)

  18. Comparison of two spreadsheets for calculation of radiation exposure following hyperthyroidism treatment with iodine-131

    Energy Technology Data Exchange (ETDEWEB)

    Vrigneaud, J.M. [CHU Bichat, nuclear medicine department, 75 - Paris (France); Carlier, T. [CHU Hotel Dieu, nuclear medicine department, 44 - Nantes (France)

    2006-07-01

    Comparison of the two spreadsheets did not show any significant differences provided that proper biological models were used to follow 131 iodine clearance. This means that even simple assumptions can be used to give reasonable radiation safety recommendations. Nevertheless, a complete understanding of the formalism is required to use correctly these spreadsheets. Initial parameters must be chosen carefully and validation of the computed results must be done. Published guidelines are found to be in accordance with those issued from these spreadsheets. Furthermore, both programs make it possible to collect biological data from each patient and use it as input to calculate individual tailored radiation safety advices. Also, measured exposure rate may be entered into the spreadsheets to calculate patient-specific close contact delays required to reduce the dose to specified limits. These spreadsheets may be used to compute restriction times for any given radiopharmaceutical, provided that input parameters are chosen correctly. They can be of great help to physicians to provide patients with guidance on how to maintain doses to other individuals as low as reasonably achievable. (authors)

  19. Radiation exposure to family members of patients with thyrotoxicosis treated with iodine-131

    International Nuclear Information System (INIS)

    Cappelen, Tone; Amundsen, Anne Lise; Kravdal, Gunnhild; Unhjem, Jan Frede; Foelling, Ivar

    2006-01-01

    The purpose of this study was twofold: (1) to measure the radiation exposure to family members of out-patients with thyrotoxicosis treated with radioiodine, 131 I, using the recommendations from the European Commission (EC) guidance and age-specific periods for behaviour restrictions; (2) to use the results to identify necessary restrictions to ensure recommended dose constraints. The study population comprised 76 family members (46 adults and 30 children below the age of 18) of 42 patients. The patients were treated with an average activity of 417 MBq (range 260-600 MBq). They received oral and written EC recommendations about behaviour restrictions (translated into Norwegian). On the day of treatment we repeated the oral instructions to the patient and an adult family member. The time periods for restrictions were 14 days for children aged 0-10 years, 7 days for persons aged 11-59 years and 3 days for persons aged 60 years and older. Family members wore a thermoluminescent dosimeter (TLD) on each wrist day and night for 2 weeks. The doses received were adjusted to give an estimate of the expected values if the TLDs had been worn indefinitely. Radiation doses well below the recommended dose constraints were measured for all adult family members and children, except one 2-year-old child; in the latter case the mother probably did not comply with the instructions given. The radiation dose to family members of thyrotoxic patients treated with up to 600 MBq of radioiodine is well below recommended dose constraints if EC instructions are given and compliance is adequate. The duration of restrictions for various age groups used in this study may be considered when establishing guidelines in Norway. (orig.)

  20. Iodine-131 metaiodobenzylguanidine intra- and extravesicular accumulation in the rat heart

    International Nuclear Information System (INIS)

    Nakajo, M.; Shimabukuro, K.; Yoshimura, H.; Yonekura, R.; Nakabeppu, Y.; Tanoue, P.; Shinohara, S.

    1986-01-01

    In order to establish the appropriate time for [ 123 I]MIBG human myocardial imaging to assess the adrenergic nerve activity, the time courses of metaiodobenzylguanidine (MIBG) intra- and extravesicular accumulation in the rat heart were estimated by using [ 131 I]MIBG and reserpine. In the heart, the intravesicular accumulation was relatively constant, while the extravesicular accumulation decreased rapidly from 5 min to 6 hr. The intravesicular percentage of the total cardiac tissue concentration reached a plateau value of 50% at 4 hr after i.v. injection of [ 131 I]MIBG. In the spleen, similar time courses were observed as those in the heart, both of these organs being richly innervated by adrenergic nerves. Along with the time activity difference previously observed in the human hearts, these results suggest that at 4 hr post i.v. injection, [ 123 I]MIBG myocardial imaging will best express the neuronal accumulation of the tracer and may be useful for the assessment of adrenergic function in various pathological conditions of the human heart

  1. Iodine-131 in milk 1961-62 and in thyroid glands of cattle and sheep 1962

    International Nuclear Information System (INIS)

    Hvinden, T.; Lillegraven, A.

    1976-03-01

    Cases of late effects from radioactive iodine uptake in children have renewed interest in this contaminant. I-131 data collected in Norway during periods following the nuclear weapons test series in 1961 and 1962 have been re-examined and collated with more recent data on natural iodine in the milk and thyroid glands from domestic animals. Some of the measured values may be interpreted as indications of an inverse relationship between the level of natural iodine and the uptake of I-131, but the material is too small and inconsistent to draw any conclusions. Obviously the uptake and concentration of I-131 in animal milk and thyroid glands are influenced by many factors besides the fallout amounts; at present it is not possible to determine their relative importance and set up a satisfactory model for the I-131 uptake. (Auth.)

  2. Biological dosimetry in patients with differenced thyroid carcinoma treated with Iodine-131

    International Nuclear Information System (INIS)

    Vallerga, M.; Taja, Maria R.; Radl, A.; Rojo, Ana M.; Deluca, G.; Di Giogio, Marina; Fadel, A.; Chebel, G.; Oneto, A.; Cabrejas, Mariana

    2007-01-01

    The differentiated thyroid carcinoma (DTC), constitutes the 90 % of the thyroid gland cancers. 80% of patients are cured after the initial therapy and 12% remained disease-free after successive treatments. The 24 patients included in this study represent a sample of the aforementioned 12% and 8%, with recurrence in the first decade post-treatment (local disease and/or recurrence at distance). The internal radiotherapy with 131 I in patients with DTC is used within the therapeutic schema as a step post-thyroidectomy. The success of the therapy is to get a lethal dose in the tumor tissue, which depends on the therapeutic activity and the retention of 131 I, without exceeding the dose of tolerance in healthy tissues. The most widespread way of administration is the empirical prescription which considers the clinical and laboratory parameters for its determination. In this work, the treatment protocol applied incorporates assessment by biological (DB) and internal (DI) dosimetry for estimating absorbed dose to the whole body and bone marrow to manage a personalized therapeutic dose for each patient. The biological dose estimation is based on the quantification of chromosomal aberrations, which is often referred to a dose-response curve in which lymphocytes are irradiated in vitro with 131 I, allowing to determine the dose in vivo of circulating lymphocytes patients [es

  3. Iodine-131 uptake in a patient with thyroid cancer and rheumatoid arthritis during acupuncture treatment

    International Nuclear Information System (INIS)

    Otsuka, N.; Fukunaga, M.; Morita, K.; Ono, S.; Nagai, K.; Katagiri, M.; Harada, T.; Morita, R.

    1990-01-01

    A patient with thyroid carcinoma had abnormal accumulation of I-131 in the areas of both feet and hands on whole body scan. The sites of abnormal accumulation of I-131 were similar to those on bone scintigraphy. The radiographic examination of the lesions showed characteristic findings of rheumatoid arthritis, and the presence of small gold needles for acupuncture treatment was demonstrated. There were no findings of bone metastases. Although the mechanism of accumulation of I-131 in this patient is unknown, interpreters of I-131 whole body scintigraphs should keep this case in mind when acupuncture treatment has been done. The authors can only speculate on a common blood flow mechanism for enhanced HMDP and I-131 uptake in this arthritic patient who had been treated by acupuncture

  4. Occupational and public radiation protection in the treatment with iodine 131

    International Nuclear Information System (INIS)

    Di Trano, Jose L.; Rojo, Ana M.; Kunst, Juan J.

    2004-01-01

    A common radionuclide therapy carried out by nuclear medicine departments is the administration of 131 I for thyroid ablation and for hyperthyroid treatment. The administration of 140 a 600 MBq for hyperthyroid treatment and 3700 a 7400 MBq for carcinoma diseases is made after surgery to ablate thyroid tissues and metastasis. The revision of radiological protection was done on the occupational exposure of workers, members of the public and relatives of patients treated with 131 I. This paper presents the results of area and individual dosimetry to external exposure, surface activity and air concentration of 131 I carried out during the practice in the nuclear medicine department. An area survey in the isolation room allowed to determine exposure rate from surface activity and air concentration of 131 I. The patient clothes activity was determined as well as the activity excreted in urine and sweat. On the basis of this analysis, can be concluded that the annual effective dose for workers due to external and internal exposure, considering 40 iodine practice per year, reach values from 4 up to 30 mSv per year. The patients with cancer therapy treatment must be hospitalized during the first 48 hrs after iodine administration, in an isolated room taking into account the radioprotection of the staff, others patients and public during the isolation. The patients with hyperthyroid treatment do not need hospitalization but they must to follow the instructions given by the physician, which will take into account socioeconomic conditions. (author)

  5. Optimizing a single fixed dose of Iodine-131 in Graves' Disease (An Experience)

    International Nuclear Information System (INIS)

    Khan, S.H.

    2007-01-01

    Full text: Kashmir is a Himalayan mountain state of India enclosed by high snow capped ridges of Pir Panjal Mountains at an average height of 4000-5000 meters above the sea level. For most of the 4 million inhabitants in this land locked valley, agriculture horticulture and handcrafts are the main source of income. Due to long and severe winters the terraced farming on the mountain slopes yield just a single crop of rice which is barely sufficient to meet the local needs of this staple diet. People are relatively poor with low annual per capita income. Goiter is endemic in the Valley of Kashmir. In a published report the overall prevalence of goiter among the school going children in Kashmir between the ages of 5 years is 45.2% (+ SEM) with urinary iodine excretion of 49 + 3.55 μg per gram of creatinine. The extremely shy people of Kashmir are casual towards the aesthetic aspects of their goiters but nevertheless seek medical advice when associated with physical symptoms. In a published study of 203 patients of thyrotoxicosis from Kashmir, Graves' disease was the commonest cause, accounting for 63% of patients. One hundred and twentyone patients of Graves' disease were prospectively studied for their response to a single fixed dose of I-131. Patients were randomly treated with two different fixed doses of I- 131. Sixty four patients belonging to Group-I received a fixed dose of 185 MBq (Low Dose) and 57 patients belonging to Group -2 received 370 MBq (High Dose) of I- 131. Following therapy all patients were evaluated at 3 months. Patients with normal or reduced thyroid hormone levels were termed as responders and those with persistently elevated levels of thyroid hormone were termed as non responders. The response rates among the two groups were analyzed for their statistical significance. Patients treated with the high fixed dose of 370 MBq revealed good response to therapy achieving a rate of 91.22%, while the response rate in the group of patients treated with low fixed dose of 185 MBq of I-131 was found to be significantly lower at 59.37%. On further analysis it was observed that the higher single fixed dose yielded a significantly higher cure rates irrespective of age, sex, thyroidal radioactive iodine uptake and pre-treatment hormonal status. There was no significant difference in the overall incidence of post-131 hypothyroidism at the end of 1 and 5 yeas following I-131 low or high single fixed dose of I-131. A steady rise in the percentage of patients becoming hypothyroid was noted between the 1 and 5 year period. The overall incidence of hypothyroidism at one and five years following I-131 therapy was found to be 48.76% and 82.64% respectively. The incidence of hypothyroidism appears to be higher in the present study, in comparison to several results reported in literature. This could be attributed to increased avidity of radioiodine to the available body iodine pool in the people living in the endemic area of iodine deficiency. Based on the results of this study we conclude that in an endemic area of iodine deficiency, a high single fixed dose of I-131 yields a higher cure rate as in non- endemic areas but the incidence of post I-131 hypothyroidism appears to be higher. However, this should not discourage physicians from choosing-I-131 as the first line of therapy for hyperthyroidism, considering the fact that hypothyroidism is easily managed by thyroid hormone supplementation, is cost effective and lastly, it (hypothyroidism) is part of the natural history of Graves' disease. (author)

  6. Plant iodine-131 uptake in relation to root concentration as measured in minirhizotron by video camera:

    International Nuclear Information System (INIS)

    Moss, K.J.

    1990-09-01

    Glass viewing tubes (minirhizotrons) were placed in the soil beneath native perennial bunchgrass (Agropyron spicatum). The tubes provided access for observing and quantifying plant roots with a miniature video camera and soil moisture estimates by neutron hydroprobe. The radiotracer I-131 was delivered to the root zone at three depths with differing root concentrations. The plant was subsequently sampled and analyzed for I-131. Plant uptake was greater when I-131 was applied at soil depths with higher root concentrations. When I-131 was applied at soil depths with lower root concentrations, plant uptake was less. However, the relationship between root concentration and plant uptake was not a direct one. When I-131 was delivered to deeper soil depths with low root concentrations, the quantity of roots there appeared to be less effective in uptake than the same quantity of roots at shallow soil depths with high root concentration. 29 refs., 6 figs., 11 tabs

  7. Determination of intake and internal radiation dose for occupationally exposed workers to iodine 131

    International Nuclear Information System (INIS)

    Kharita, M. H.; Maghrabi, M.; Sadyya, A.

    2004-12-01

    Workers who prepare and inject radioactive Iodine I 131 doses at the medical centers in Syria are potentially exposed to the radioactive intake by ingestion or inhalation during preparation or injection processes. The received amount of the radioactive intake differs according to the amount of the I 131 that released during the preparation or injection processes, and to the work conditions and the applying ways of the radiation protection principles. Because of this radioactive intake, the thyroid gland may expose to amounts of I 131 which may negatively affect the health of the workers, so it is necessary to make routine monitoring for all workers who receive an intake of more than 10% of the annual intake limit which is (2*10 6 Bq/y) for I 131 . To make this monitoring process, it is necessary to use either the thyroid gland counter in order to know the concentrated amount of the radioactivity in the gland, or the analysis of a 24 hours urine sample of the exposed workers to determine the eliminated amount of the radioactivity using gamma spectrometry, also the two processes can be applied at the same time. Since the thyroid gland counter is not available, the analysis of urine sample was done to determine the concentrated amount of the radioactivity in urine, then to estimate the radioactive intake and the internal radioactive dose. The results of applying this method dictated that some workers work in safe conditions according to the radiation protection and there is no need for them to make routine monitoring . But the other workers receive a radioactive intake of about 10% yearly of the annual intake limit and that requires a routine periodical monitoring for those workers in addition to the necessity of applying the principles of the radiation protection during the work with I 131 . These principles and systems should indicate the basic requirement of radiation protection that must be available in the laboratory that deal with I 131 either for therapy or for diagnosis. (Authors)

  8. Changing annual incidence of hypothyroidism after iodine-131 therapy for hyperthyroidism, 1951-1975

    International Nuclear Information System (INIS)

    Holm, L.E.

    1982-01-01

    The incidence of hypothyroidism was analyzed in 4,553 hyperthyroid patients treated with I-131 between 1951 and 1975. The average annual rate of hypothyroidism during the first 7 yr after therapy increased continuously for each 5-yr period of treatment, from 3.6% for patients treated between 1951 and 1955 to 7.7% for patients treated during the period from 1971 through 1975 (p<0.001). The increase in the incidence of hypothyroidism was seen before the introduction of TSH assays and when allowance was made for thyroid gland size, the age of the patient, and the experience of the radiotherapist. The use of TSH assays has probably resulted in an earlier recognition of hypothyroidism, which may explain why the most marked rise in the incidence of hypothyroidism was observed after the introduction of TSH assays

  9. Radiological accident with Iodine-131 in the Radioisotope Division at IPEN-CNEN/SP (Brazil)

    International Nuclear Information System (INIS)

    Sanches, Matias Puga; Rodrigues, Demerval Leonidas

    1997-01-01

    The accident occurred in the first week of May 1995, in the Radioisotope Division-TPI, involving two tubes containing a total volume of 3 ml, aqueous solution of N Al 1 31, with 370 MBq and 1480 MBq activity is reported. Part of installation and six workers involved in the distribution process were contaminated with 131 I, but there were no contamination outside the building. The workers were decontaminated and the received radiation doses were evaluated by the Radiotoxicological Laboratory of IPEN-CNEN/SP together with IRD-CNEN/RJ. The building involved was closed and the activities stopped until the complete decontamination by the Radioprotection experts of IPEN-CNEN/SP. (author)

  10. Evaluation of biological analysis program for iodine 131; Avaliacao do programa de bioanalise para Iodo-131

    Energy Technology Data Exchange (ETDEWEB)

    Gaburo, J.C.; Todo, A.S.; Potiens Junior, A.; Oliveira, E.M.; Sordi, G.M.A.A. [Instituto de Pesquisas Energeticas e Nucleares (IPEN), Sao Paulo, SP (Brazil)

    1997-12-31

    A program for the occupational control of internal contamination for the Radioisotopes Division workers of the IPEN-CNEN/SP has been performed by in vitro and in vivo bioassay techniques, every two weeks. From the assessment of the monitoring program, two groups of workers were identified in accordance with their activities and handling frequency {sup 131} I. The groups A and B are exposed five and three days respectively every week. In this program, urinalysis methods, thyroid and whole body measurements have been evaluated over the year. The sampling scheme, performed every two week, was altered for weekly, in order to minimize the interpretation errors and to get a better estimative of the intake. This study also provides and evaluation of the cost for the weekly urinalysis sampling method. (author) 6 refs., 1 fig.; e-mail: janetegc at net.ipen.br

  11. Changing annual incidence of hypothyroidism after iodine-131 therapy for hyperthyroidism, 1951-1975

    International Nuclear Information System (INIS)

    Holm, L.E.

    1982-01-01

    The incidence of hypothyroidism was analyzed in 4,553 hyperthyroid patients treated with I-131 between 1951 and 1975. The average annual rate of hypothyroidism during the first 7 yr after therapy increased continuously for each 5-yr period of treatment, from 3.6% for patients treated between 1951 and 1955 to 7.7% for patients treated during the period from 1971 though 1975 (p less than 0.001). The increase in the incidence of hypothyroidism was seen before the introduction of TSH assays and when allowance was made for thyroid gland size, the age of the patient, and the experience of the radiotherapist. The use of TSH assays has probably resulted in an earlier recognition of hypothyroidism, which may explain why the most marked rise in the incidence of hypothyroidism was observed after the introduction of TSH assays

  12. Permanent Hypothyroidism after Radioactive Iodine(131I) Treatment in Diffuse Toxic Goiter

    International Nuclear Information System (INIS)

    Park, Soon Yang; Lee, Jung Sang; Lee, Hong Kyu; Koh, Chang Soon; Lee, Mun Ho

    1977-01-01

    Radioactive iodine (RAI), principally 131 I, effectively controls hyperthyroidism in the majority of patients. The subsequent development of hypothyroidism, however, has been of increasing concern since it was first pointed out by Chapman and Maloof in 1955. And the steady increase of late hypothyroidism during the passage of time was known with its relation with dosage of RAI. The authors have investigated the development of hypothyroidism in 935 patients with diffuse toxic goiter (DTG) who were treated with RAI ( 131 I) at the Seoul National University Hospital from 1960 to 1977 to reveal its relation with the number of RAI treatments, dosage of RAI, age of patients and exophthalmos with the following results. 1) The incidence of hypothyroidism by year after RAI therapy among 631 patients with DTG who were treated with single RAI regimen was 7.4% (1 year), 11.8% (2 year), 16.2% (3 year), 22.1% (4 year) and 25.5% (5 year), and that among 163 patients given multiple RAI treatments was 8.6% (1 year), 10.4% (2 year), 13.3% (3 year), 29.1% (4 year), and 54.1% (5 year) respectively showing much higher yearly increments from 4 years after RAI treatment in comparison with the former. 2) Among 550 patients in the lower dose group treated with single RAI regimen less than 5.0 mCi (Mean±S.D.: 4.3±0.6 mCi), the incidence of hypothyroidism by year after RAI treatment was 6.8% (1 year), 11.4% (2 year), 15.4% (3 year), while among 81 patients in the higher dose group given single RAI treatment not less than 5.5 mCi (Mean±S.D.: 6.3±0.5 mCi) it was 12.0% (1 year), 15.4% (2 year) and 20.4% (3 year) respectively. However, the duration till euthyroid state after RAI therapy in the two groups was 5.1±3.6 months and 4.8±2.8 months respectively showing no statistically significant difference (p>0.1). 4) The incidence of hypothyroidism after RAI treatment in patients younger than 30 years of age was 4.3% (1 year) and 7.7% (2 year); in patients from 30 years to 49 years of age, 5.8% (1 year) and 11.1% (2 year); and in those older than 50 years, 11.0% (1 year) and 14.4% (2 year). The data revealed rising incidence of hypothyroidism with increase of patients' age. 5) Among 116 patients with exophthalmos the incidence of hypothyroidism by year after RAI treatment was 7.1% (1 year) and 12.15 (2 year) while that among 184 patients without exophthalmos was 7.3% (1 year) and 12.2% (2 year) respectively. With the above data the authors could conclude that the hypothyroidism in patients with DTG who were treated by RAI developed more frequently than reported by others in Korea till now, and increased with the passage of time, the yearly increments from 4 years after RAI treatment increasing markedly in the multiple dose group, and the incidence could be reduced by decreasing the administered RAI dose not increasing the duration till euthyroid state after RAI therapy.

  13. Proposal of a methodology for individualized iodine-131 therapy for Graves' disease in patients with hyperthyroidism

    International Nuclear Information System (INIS)

    Araujo, Francisco de; Melo, Rossana Corbo de; Rebelo, Ana Maria de Oliveira; Dantas, Bernardo Maranhao; Dantas, Ana Leticia A.; Lucena, Eder Augusto de

    2007-01-01

    Objective: Several methods are utilized for determining the radioiodine activity in the treatment of Graves' disease (hyperthyroidism). Some of this methods do not take into consideration the thyroid absorbed dose or the necessary parameters for this estimation. The association between absorbed dose and administered activity depends on effective half-life, iodine uptake and thyroid mass of each patient. The present study was aimed at developing a methodology for individualized 131 I therapy for Graves' disease in patients with hyperthyroidism of the Graves' disease. Materials and methods: A neck-thyroid phantom developed at Instituto de Radioprotecao e Dosimetria, containing a standard solution of 131 I, was utilized for calibrating the scintillation gamma camera and uptake probe installed in the Department of Nuclear Medicine of the Hospital Universitario Clementino Fraga Filho da Universidade Federal do Rio de Janeiro. Results: The view angle of the collimator/detector assembly presented values compatible with the thyroid gland size for distances of 25 cm (uptake probe) and 45.8 cm (scintillation gamma camera). Calibration factors were 39.3 ± 0.78 and 4.3 ± 0.17 cpm/kBq, respectively. The 14-30-hour interval in the retention curve allows the estimation of activity between two points for determining the effective iodine half-life in the thyroid. Conclusion: The utilization of equipment usually available in nuclear medicine clinics is feasible, so this is a simple, effective and low cost methodology. (author)

  14. Lutetium-177 and iodine-131 loaded chelating polymer microparticles intended for radioembolization of liver malignancies

    Czech Academy of Sciences Publication Activity Database

    Hrubý, Martin; Škodová, Michaela; Macková, Hana; Skopal, Jan; Tomeš, Marek; Kropáček, Martin; Zimová, Jana; Kučka, Jan

    2011-01-01

    Roč. 71, č. 12 (2011), s. 1155-1159 ISSN 1381-5148 R&D Projects: GA ČR GPP207/10/P054; GA MŠk 1M0505 Institutional research plan: CEZ:AV0Z40500505; CEZ:AV0Z10480505 Keywords : macroporous chelating beads * radioembolization * quinoline-8-ol Subject RIV: CD - Macromolecular Chemistry Impact factor: 2.479, year: 2011

  15. Numerical simulations of atmospheric dispersion of iodine-131 by different models.

    Directory of Open Access Journals (Sweden)

    Ádám Leelőssy

    Full Text Available Nowadays, several dispersion models are available to simulate the transport processes of air pollutants and toxic substances including radionuclides in the atmosphere. Reliability of atmospheric transport models has been demonstrated in several recent cases from local to global scale; however, very few actual emission data are available to evaluate model results in real-life cases. In this study, the atmospheric dispersion of 131I emitted to the atmosphere during an industrial process was simulated with different models, namely the WRF-Chem Eulerian online coupled model and the HYSPLIT and the RAPTOR Lagrangian models. Although only limited data of 131I detections has been available, the accuracy of modeled plume direction could be evaluated in complex late autumn weather situations. For the studied cases, the general reliability of models has been demonstrated. However, serious uncertainties arise related to low level inversions, above all in case of an emission event on 4 November 2011, when an important wind shear caused a significant difference between simulated and real transport directions. Results underline the importance of prudent interpretation of dispersion model results and the identification of weather conditions with a potential to cause large model errors.

  16. Radiation Exposure to Relatives of Patients Treated with Iodine-131 for Thyroid Cancer at Siriraj Hospital

    International Nuclear Information System (INIS)

    Tonnonchiang, S.; Sritongkul, N.; Chaudakshetrin, P.; Tuntawiroon, M.

    2012-01-01

    Thyroid carcinoma patients treated with I-131 are potential source of high radiation exposure to relatives who are knowingly and willingly exposed to ionizing radiation as a result of providing support and comfort to patients undergoing radionuclide therapy. The purpose of this study is to present the results of measurements of radiation doses to relatives who designated to care fornon self-supporting patients treated with radioiodine at Radionuclide Therapy Ward, Siriraj Hospital. Twenty caregivers of 20 patients underwent radioiodine therapy for thyroid cancers with a standard protocol were given specific instructions with regard to radiation safety and provided with electronic digital dosimeter (PDM 112) to continuously measure radiation dose received on the daily basis, during three days in the hospital. On the day of patients' release, in vivo bioassays were performed on caregivers to determine the thyroid uptake estimates. The 3-day accumulative doses to caregivers to patients receiving 5.55 GBq (n=11) and 7.4 GBq (n=9) of I-131 ranged from 37 to 333 μSv and 176 to 1920 μSv respectively depending on the extent and level of supports required. The thyroid uptake estimates in all caregivers were undetectable. Electronic dosimeters indicated a maximum whole-body effective dose of 1920 μSv was more than the public dose limit of 1 mSv but within the general dose constraint of 5 mSv. Radiation dose to caregivers of a non self-supporting hospitalized patient undergoing radioiodine therapy were well below the limits recommended by the ICRP and the IAEA. The patients can be comforted with confidence that dose to caregivers will be below the 5- mSv limit. This study provides guidance for medical practitioners to obtain practical radiation safety concerns associated with hospitalized patients receiving I-131 therapy especially when patients are comforted in the hospital ward by caregivers. (author)

  17. Side effects of rational dose iodine-131 therapy for metastatic well-differentiated thyroid carcinoma

    International Nuclear Information System (INIS)

    Van Nostrand, D.; Neutze, J.; Atkins, F.

    1986-01-01

    Benua, Leeper, and others (BEL) have advocated the estimation of radiation exposure to the blood to select a more rational maximum safe dose of radioiodine (dosimetry) to treat metastatic functioning well-differentiated thyroid carcinoma. After adopting the BEL dosimetry approach, we reviewed the immediate (during hospitalization) and intermediate (from discharge up to 3 mo) side effects after our initial 15 therapies in ten patients. The doses ranged from 51 mCi (1887 MBq) to 450 mCi (16.65 GBq). Immediate side effects were observed in 12/15 (80%), are described in detail, and were as follows: gastrointestinal 10/15, salivary 9/15, nonsalivary neck pain, swelling, etc. 2/15, pulmonary 0/15. Intermediate side effects were observed in 10/15 (67%), are described in detail, and were as follows: gastrointestinal 0/15, salivary 3/15, nonsalivary neck pain, swelling, etc. 3/15, nasal complaints 2/15, transient bone marrow suppression 9/10, pulmonary 0/15. No patient required blood transfusions or had complications secondary to reduced blood counts. All patient complaints resolved; however, several patients may have reduced baseline blood counts one year after therapy. No other long-term side effect has been noted but the mean follow-up has been only 15 mo. In our opinion, we have not observed any side effect to date which would contraindicate the continued use and evaluation of the BEL dosimetry approach

  18. Side effects of rational dose iodine-131 therapy for metastatic well-differentiated thyroid carcinoma

    Energy Technology Data Exchange (ETDEWEB)

    Van Nostrand, D.; Neutze, J.; Atkins, F.

    1986-10-01

    Benua, Leeper, and others (BEL) have advocated the estimation of radiation exposure to the blood to select a more rational maximum safe dose of radioiodine (dosimetry) to treat metastatic functioning well-differentiated thyroid carcinoma. After adopting the BEL dosimetry approach, we reviewed the immediate (during hospitalization) and intermediate (from discharge up to 3 mo) side effects after our initial 15 therapies in ten patients. The doses ranged from 51 mCi (1887 MBq) to 450 mCi (16.65 GBq). Immediate side effects were observed in 12/15 (80%), are described in detail, and were as follows: gastrointestinal 10/15, salivary 9/15, nonsalivary neck pain, swelling, etc. 2/15, pulmonary 0/15. Intermediate side effects were observed in 10/15 (67%), are described in detail, and were as follows: gastrointestinal 0/15, salivary 3/15, nonsalivary neck pain, swelling, etc. 3/15, nasal complaints 2/15, transient bone marrow suppression 9/10, pulmonary 0/15. No patient required blood transfusions or had complications secondary to reduced blood counts. All patient complaints resolved; however, several patients may have reduced baseline blood counts one year after therapy. No other long-term side effect has been noted but the mean follow-up has been only 15 mo. In our opinion, we have not observed any side effect to date which would contraindicate the continued use and evaluation of the BEL dosimetry approach.

  19. Clinical Investigation and Treatment of Thyroid Disease with Radioactive Iodine (131I)

    International Nuclear Information System (INIS)

    Lee, Mun Ho; Koh, Chang Soon; Ro, Heung Kyu; Koo, In Seu; Suh, Whan Jo; Lee, Kyung Ja; Lee, Hong Kyu; Lee, Chung Sang

    1970-01-01

    A summary of the clinical data of the 131 I-thyroid function tests and the therapeutic results of 131 I among the 2,658 patients of various thyroid diseases treated over the past 10 years from May 1960 to Oct. 1969 at the Radioisotope Clinic and Laboratory, SNUH were presented and discussed. 1) The patients examined consisted of 929 cases (34.9%) of diffuse toxic goiter, 762 cases (28.7%) of diffuse nontoxic goiter, 699 cases (26.3%) of nodular nontoxic goiter, 58 cases (2.2%) of nodular toxic goiter and 210 cases (7.9%) of hypothyroidism. 2) There were 300 (11.4%) male and 2358 (88.6%) female, showing a ratio of 1 : 8. 3) The majority of patients (79.1%) were in the 3rd-5th decade of their lives. 3) The normal ranges, diagnostic values of 131 I uptake test, 48 hrs serum activity, BMR and main subjective symptoms of various thyroid diseases were discussed. 5) In the 579 patients among 867 cases with hyperthyroidism treated with 131 I, 47.8% were confirmed to be cured completely after single therapeutic doses. 6) The complications of 131 I therapy were discussed and myxedema had developed in 6.75% of our patients. 7) The results of 131 I thyroid function tests were analysed among the 160 cases of thyroid diseases which were confirmed the diagnosis with histopathological measures.

  20. Recommendations for waste disposal of phosphorus-32 and iodine-131 for medical users. Handbook 49

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    1951-11-02

    With the increasing use of radioactive isotopes by industry, the medical profession, and research laboratories, it is essential that certain minimal precautions be taken to protect the users and the public. The recommendations contained in this Handbook represent what is believed to be the best available opinions on the subject as of this date. As our experience with radioisotopes broadens, we will undoubtedly be able to improve and strengthen the recommendations for their safe handling, utilization, and disposal of wastes. Comments on those recommendations will be welcomed by the committee. One of the greatest difficulties encountered in the preparation of this Handbook lay in the uncertainty regarding permissible radiation exposure levels, particularly for ingested radioactive materials. The establishment of sound figures for such exposure still remains a problem of high priority for many conditions and radioactive substances. Such figures as are used in this report represent the best available information today. If, in the future, these can be improved upon, appropriate corrections will be issued. The subject will be under continuous study by the subcommittees mentioned above. The best available information on permissible radiation levels and permissible quantities of ingested radioactive material may be found in the Recommendations of the International Commission on Radiological Protection and the Supplement to these recommendations in NBS Handbook 47. It should be borne in mind, however, that even the values given in that Handbook may be subject to change. As the problem of the disposal of radioactive wastes varies over such wide limits, depending upon the usage to which the isotopes are put, the committee has decided that it will not be feasible to incorporate in one volume broad recommendations covering all situations and materials. This is the first of a series of such reports. The present Handbook has been prepared by the Subcommittee on Waste Disposal and decontamination.

  1. Comparison of two spreadsheets for calculation of radiation exposure following hyperthyroidism treatment with iodine-131

    International Nuclear Information System (INIS)

    Vrigneaud, J.M.; Carlier, T.

    2006-01-01

    Comparison of the two spreadsheets did not show any significant differences provided that proper biological models were used to follow 131 iodine clearance. This means that even simple assumptions can be used to give reasonable radiation safety recommendations. Nevertheless, a complete understanding of the formalism is required to use correctly these spreadsheets. Initial parameters must be chosen carefully and validation of the computed results must be done. Published guidelines are found to be in accordance with those issued from these spreadsheets. Furthermore, both programs make it possible to collect biological data from each patient and use it as input to calculate individual tailored radiation safety advices. Also, measured exposure rate may be entered into the spreadsheets to calculate patient-specific close contact delays required to reduce the dose to specified limits. These spreadsheets may be used to compute restriction times for any given radiopharmaceutical, provided that input parameters are chosen correctly. They can be of great help to physicians to provide patients with guidance on how to maintain doses to other individuals as low as reasonably achievable. (authors)

  2. Iodine-131 uptake in a patient with thyroid cancer and rheumatoid arthritis during acupuncture treatment

    Energy Technology Data Exchange (ETDEWEB)

    Otsuka, N.; Fukunaga, M.; Morita, K.; Ono, S.; Nagai, K.; Katagiri, M.; Harada, T.; Morita, R. (Kawasaki Medical School, Okayama (Japan))

    1990-01-01

    A patient with thyroid carcinoma had abnormal accumulation of I-131 in the areas of both feet and hands on whole body scan. The sites of abnormal accumulation of I-131 were similar to those on bone scintigraphy. The radiographic examination of the lesions showed characteristic findings of rheumatoid arthritis, and the presence of small gold needles for acupuncture treatment was demonstrated. There were no findings of bone metastases. Although the mechanism of accumulation of I-131 in this patient is unknown, interpreters of I-131 whole body scintigraphs should keep this case in mind when acupuncture treatment has been done. The authors can only speculate on a common blood flow mechanism for enhanced HMDP and I-131 uptake in this arthritic patient who had been treated by acupuncture.

  3. Diagnosis and treatment of a carcinoid tumor using iodine-131 meta-iodobenzylguanidine

    International Nuclear Information System (INIS)

    Hoefnagel, C.A.; Den Hartog Jager, F.C.; Van Gennip, A.H.; Marcuse, H.R.; Taal, B.G.

    1986-01-01

    Scintigraphy using I-131 meta-iodobenzylguanidine has been introduced as an effective method to detect pheochromocytomas and neuroblastomas, and the radiopharmaceutical also is applied in therapy of these tumors. The authors present a case of a metastatic gastric carcinoid tumor, another neural crest tumor, concentrating I-131 MIBG, which was documented by conventional scintigraphy and SPECT in correlation with CT scans and colloid scintigrams of the liver. Two therapeutic attempts in this patient, using I-131 MIBG, are described. The metabolic basis of this phenomenon is discussed, and the importance of I-131 MIBG imaging in the detection of neural crest tumors is underlined

  4. Thyroid cancer incidence among Swedish patients exposed to diagnostic doses of iodine-131: A preliminary report

    International Nuclear Information System (INIS)

    Hall, P.E.

    1996-01-01

    The level of risk associated with I-131 is not well defined but appears lower than equivalent doses of x-rays. To provide quantitative data on the risk of thyroid cancer following I-131 exposure, 34,104 patients surviving ≅ 5 years after I-131 administration between 1950-69 for diagnostic purposes were studied. The mean thyroid dose was estimated to be 1.1 Gy (range 0-40.5). A significantly increased risk of a subsequent thyroid cancer was found, however, the excess rates were based entirely on patients referred because of a suspicion of a thyroid tumor. There was no suggestion of an increasing risk with increasing dose or time since exposure. No significant excess risk was found among those less than 20 years of age at exposure. The absence of a risk among those over age 20 is consistent with studies of A-bomb survivors and implies that any type of exposure to ionizing radiation later in life is associated with a minimal cancer risk. (author). 23 refs, 4 tabs

  5. Effect of technetium-99m on iodine-131 thyroid uptake measurements

    International Nuclear Information System (INIS)

    Wasserman, H.J.; Klopper, J.F.; Erlank, P.

    1985-01-01

    Following administration of 2.5-5.0 mCi[/sup 99m/Tc]pertechnetate, several hundred microcuries may be present in the necks of hyperthyroid patients after 6 hr. Coincidence summing of Tc-99m photons may disturb I-131 uptake measurements in such patients if an oral diagnostic dose of I-131 is administered immediately after completion of a [/sup 99m/Tc]pertechnetate scintigram. Using a lower discriminator level of 300 keV, false increases of 10%-50% may occur at 6 hr. The 24-hr uptake is also affected if an I-131 predose measurement is performed after administration of the Tc-99m dose. The authors have shown that these errors may be prevented by using a 1-mm lead filter in front of the scintillation detector. The attenuation of Tc-99m photons by the filter effectively eliminates summation pulses while it reduces the I-131 count rate by approximately 28%

  6. Clinical application of SPECT in adrenal imaging with iodine-131 6 beta-iodomethyl-19-norcholesterol

    International Nuclear Information System (INIS)

    Ishimura, J.; Kawanaka, M.; Fukuchi, M.

    1989-01-01

    Forty-one patients with or without adrenocortical disorders were studied to evaluate the clinical usefulness of SPECT in adrenal imaging with I-131 Adosterol. In the SPECT images from this study, all glands with either normally functioning or hyperfunctioning adrenal cortices could be detected, while those glands with hypofunctioning adrenal cortices could not be detected. Particularly in transaxial and sagittal slices, the adrenal gland was identified posteriorly and was clearly distinguished from the gallbladder. In preliminary results using SPECT by a standard method, uptake in 68 detectable glands ranged from 1.7% to 4.9% in four glands with Cushing's syndrome, from 1.1% to 1.3% in seven glands with primary aldosteronism, and were distributed below 1.0% in the remaining glands with normally functioning adrenal cortices. These data show that it is possible to evaluate the adrenocortical functioning status simply by analyzing the SPECT images of the adrenal

  7. Clinical application of SPECT in adrenal imaging with iodine-131 6 beta-iodomethyl-19-norcholesterol

    Energy Technology Data Exchange (ETDEWEB)

    Ishimura, J.; Kawanaka, M.; Fukuchi, M.

    1989-04-01

    Forty-one patients with or without adrenocortical disorders were studied to evaluate the clinical usefulness of SPECT in adrenal imaging with I-131 Adosterol. In the SPECT images from this study, all glands with either normally functioning or hyperfunctioning adrenal cortices could be detected, while those glands with hypofunctioning adrenal cortices could not be detected. Particularly in transaxial and sagittal slices, the adrenal gland was identified posteriorly and was clearly distinguished from the gallbladder. In preliminary results using SPECT by a standard method, uptake in 68 detectable glands ranged from 1.7% to 4.9% in four glands with Cushing's syndrome, from 1.1% to 1.3% in seven glands with primary aldosteronism, and were distributed below 1.0% in the remaining glands with normally functioning adrenal cortices. These data show that it is possible to evaluate the adrenocortical functioning status simply by analyzing the SPECT images of the adrenal.

  8. Recommendations for waste disposal of phosphorus-32 and iodine-131 for medical users. Handbook 49

    International Nuclear Information System (INIS)

    1951-01-01

    With the increasing use of radioactive isotopes by industry, the medical profession, and research laboratories, it is essential that certain minimal precautions be taken to protect the users and the public. The recommendations contained in this Handbook represent what is believed to be the best available opinions on the subject as of this date. As our experience with radioisotopes broadens, we will undoubtedly be able to improve and strengthen the recommendations for their safe handling, utilization, and disposal of wastes. Comments on those recommendations will be welcomed by the committee. One of the greatest difficulties encountered in the preparation of this Handbook lay in the uncertainty regarding permissible radiation exposure levels, particularly for ingested radioactive materials. The establishment of sound figures for such exposure still remains a problem of high priority for many conditions and radioactive substances. Such figures as are used in this report represent the best available information today. If, in the future, these can be improved upon, appropriate corrections will be issued. The subject will be under continuous study by the subcommittees mentioned above. The best available information on permissible radiation levels and permissible quantities of ingested radioactive material may be found in the Recommendations of the International Commission on Radiological Protection and the Supplement to these recommendations in NBS Handbook 47. It should be borne in mind, however, that even the values given in that Handbook may be subject to change. As the problem of the disposal of radioactive wastes varies over such wide limits, depending upon the usage to which the isotopes are put, the committee has decided that it will not be feasible to incorporate in one volume broad recommendations covering all situations and materials. This is the first of a series of such reports. The present Handbook has been prepared by the Subcommittee on Waste Disposal and decontamination

  9. Influence of surgical or propylthiouracil pretreatment on the efficacy of iodine-131 therapy in hyperthyroidism

    International Nuclear Information System (INIS)

    Shi Genming; Xu Qin; Yang Yili; Ye Anfang; Zhu Chengyi

    2006-01-01

    Objective: To investigate the influence of surgical or propylthiouracil(PTU) pretreatment on the efficacy of radioactive iodine therapy in hyperthyroidism. Methods: A group (group 1) of 41 hyperthyroidism patients relapsed after surgery were treated with 131 I in our department from 2003 through 2004. During that period, another group (group 2) of 41 cases were selected randomly from patients untreated either surgically or chemically before oral administration of 131 I, and a third group (group 3) of 41 cases were selected randomly from those pretreated only with PTU. We analysed the results of these three groups of patients after followed-up for 3 and 6 months separately after 131 I therapy. Results: Approximately 90.24% (37/41 cases) and 92.68% (38/ 41 cases) of patients in group 2 without any pretreatment were cured 3 months and 6 months after 131 I treatment, respectively, and 9.76% (4/41 cases) and 7.32% (3/41 cases) of them did not respond to 131 I treatment. About 43.90% (18/41 cases) and 53.66 % (22/41 cases) of patients pretreated with PTU (group 3) were cured at 3 and 6 months, respectively, and approximately 56.10% (23/41 cases) and 46.34% (19/41 cases) of this group patients did not respond to 131 I treatment at 3 and 6 months, respectively (P 131 I treatment, respectively, and 31.71% (13/41) and 29.27% (12/ 41) of them did not respond to 131 I treatment (P 131 I treatment can affect the efficacy of 131 I therapy, resulting in reduction of the cure rate. (authors)

  10. Endobronchial administration of iodine-131 B72.3 monoclonal antibody in patients with lung cancer

    International Nuclear Information System (INIS)

    Del Vecchio, S.; Mansi, L.; Petrillo, A.; Camera, L.; Salvatore, M.; Sofia, M.; Marra, A.; Carratu, L.

    1991-01-01

    We tested the feasibility of endobronchial administration of radiolabelled monoclonal antibodies (MoAbs) and the biodistribution of the radiotracer. Ten patients with histological confirmed adenocarcinoma or squamous cell carcinoma were studied. Nine received 470 μCi (103 μg) of 131 I-B72.3, a monoclonal antibody reacting against TAG 72 antigen, while one patient received 502 μCi (291 μg) of 131 I-4C4, an indifferent antibody used for comparison in a negative control study. The radiolabelled antibody was administered through a flexible fiberoptic bronchoscope and placed on the tumour mass under visual monitoring. Scans with a large field-of-view gamma-camera showed retention of 131 I-B72.3 at the tumour site up to 6-9 days in six of eight patients. No other organs were visualized with the exception of faint activity in the gastrointestinal tract, bladder and thyroid. On the contrary, the indifferent antibody 131 I-4C4 was not retained at the tumour site 6 days after MoAbs administration, and more prominent activity was found in the gastrointestinal tract. In one patient the study was not technically adequate because of failure of the delivery system. The vascular compartment contained less than 3% of the administered dose. We conclude that endobronchial administration is a feasible technique and allows stable and specific targetting of bronchial tumours. Furthermore, the low activity found in the plasma and other organs suggests that this approach may be used to deliver therapeutic doses of MoAbs to lung cancers. (orig.)

  11. Uncertainty of inhalation dose coefficients for representative physical and chemical forms of iodine-131

    Science.gov (United States)

    Harvey, Richard Paul, III

    Releases of radioactive material have occurred at various Department of Energy (DOE) weapons facilities and facilities associated with the nuclear fuel cycle in the generation of electricity. Many different radionuclides have been released to the environment with resulting exposure of the population to these various sources of radioactivity. Radioiodine has been released from a number of these facilities and is a potential public health concern due to its physical and biological characteristics. Iodine exists as various isotopes, but our focus is on 131I due to its relatively long half-life, its prevalence in atmospheric releases and its contribution to offsite dose. The assumption of physical and chemical form is speculated to have a profound impact on the deposition of radioactive material within the respiratory tract. In the case of iodine, it has been shown that more than one type of physical and chemical form may be released to, or exist in, the environment; iodine can exist as a particle or as a gas. The gaseous species can be further segregated based on chemical form: elemental, inorganic, and organic iodides. Chemical compounds in each class are assumed to behave similarly with respect to biochemistry. Studies at Oak Ridge National Laboratories have demonstrated that 131I is released as a particulate, as well as in elemental, inorganic and organic chemical form. The internal dose estimate from 131I may be very different depending on the effect that chemical form has on fractional deposition, gas uptake, and clearance in the respiratory tract. There are many sources of uncertainty in the estimation of environmental dose including source term, airborne transport of radionuclides, and internal dosimetry. Knowledge of uncertainty in internal dosimetry is essential for estimating dose to members of the public and for determining total uncertainty in dose estimation. Important calculational steps in any lung model is regional estimation of deposition fractions and gas uptake of radionuclides in various regions of the lung. Variability in regional radionuclide deposition within lung compartments may significantly contribute to the overall uncertainty of the lung model. The uncertainty of lung deposition and biological clearance is dependent upon physiological and anatomical parameters of individuals as well as characteristic parameters of the particulate material. These parameters introduce uncertainty into internal dose estimates due to their inherent variability. Anatomical and physiological input parameters are age and gender dependent. This work has determined the uncertainty in internal dose estimates and the sensitive parameters involved in modeling particulate deposition and gas uptake of different physical and chemical forms of 131I with age and gender dependencies.

  12. Thyroid cancer incidence among Swedish patients exposed to diagnostic doses of iodine-131: A preliminary report

    Energy Technology Data Exchange (ETDEWEB)

    Hall, P E [Karolinska Hospital, Stockhom (Sweden). Dept. of General Oncology; Holm, L E [National Inst. of Public Health, Stockholm (Sweden)

    1996-08-01

    The level of risk associated with I-131 is not well defined but appears lower than equivalent doses of x-rays. To provide quantitative data on the risk of thyroid cancer following I-131 exposure, 34,104 patients surviving {approx_equal} 5 years after I-131 administration between 1950-69 for diagnostic purposes were studied. The mean thyroid dose was estimated to be 1.1 Gy (range 0-40.5). A significantly increased risk of a subsequent thyroid cancer was found, however, the excess rates were based entirely on patients referred because of a suspicion of a thyroid tumor. There was no suggestion of an increasing risk with increasing dose or time since exposure. No significant excess risk was found among those less than 20 years of age at exposure. The absence of a risk among those over age 20 is consistent with studies of A-bomb survivors and implies that any type of exposure to ionizing radiation later in life is associated with a minimal cancer risk. (author). 23 refs, 4 tabs.

  13. Transfer of iodine-131 from deposition-to-milk : estimation of pasture intake

    International Nuclear Information System (INIS)

    Dreicer, M.; Bouville, A.; Wachholz, B.W.

    1988-01-01

    In assessments of radiological transport of I-131 from fallout deposition to cow's milk, knowledge of the fraction of the dairy cow's diet that is due to fresh pasture is essential because it is the only portion of the feed that may be contaminated to a substantial extent. For studies involving past fallout events covering large geographic areas, such as the current effort by the National Cancer Institute to assess the exposure to I-131 received by the American people during the Nevada Test Site atmospheric weapons tests conducted during the 1950's, it is necessary to derive this estimate of pasture consumption from past records

  14. Normal values of iodine - 131 uptake in 24 hours, in Rio Grande do Norte, Brazil

    International Nuclear Information System (INIS)

    Oliveira Filho, T.F. de; Oliveira, C.F.F. de

    Thorough clinical exams on all patients come to the radioisotope Laboratory at UFRN, where carried out attempting to select those patients with thyroids considered to be clinically normal. After wayne tests for hypo and hyperthyroidism were carried out, 100 patients were considered to be fit for the research. All of them had an impalpable and asympitomatic thyroid. Waynes clinical indices were precisely revealed in 93% of cases. It was concluded that the normal values of uptake of 131 I during the 24 hours in RGN varied between 14% and 44% [pt

  15. Leak detection on underground fuel oil transfer line using radio tracer iodine-131

    International Nuclear Information System (INIS)

    Wickramanayake, D.G.L.; Ranjith, H.L.A.

    1998-01-01

    Leak detection study was carried out on the fuel oil transfer line of the Ceylon Petroleum Corporation using 131 I tracer. The study was carried out to determine whether the technique developed can be used in the field and to monitor the condition of the pipeline. Radiation safety assessment was made prior to the test. The dynamic pressurization technique was used. Any detectable leak was not shown at the detecting sensitivity of 0.40 mm 2 under the test conditions. The method reported is considered to be successful and economically viable. (author)

  16. Age and its influence on effects of iodine-131 in guinea pig thyroid glands

    International Nuclear Information System (INIS)

    Book, S.A.; McNeill, D.A.; Spangler, W.L.

    1980-01-01

    To identify the differences in age-related radiosensitivity of the thyroid gland to radioiodine exposure, we exposed fetal, neonatal, weanling, and adult guinea pigs to single graded doses of 131 I. Injected quantities ranged from 1 to 100 μCi 131 I, depending on the age group, and resulted in thyroid doses ranging from hundreds to tens of thousands of rad. At approximately 100 days of age (or 100 days after dosing for adults), a single microcurie of 131 I was given and animals were killed 1 day later to provide data on thyroid weight and percentage 131 I uptake. Analysis of these data and information on pathology suggested that the fetal and weanling guinea pig thyroid glands were more radiosensitive than the adult thyroid; the neonatal thyroid appeared less radiosensitive than that of the adult. The increase in radiosensitivity of the young thyroid glands over the adults, however, did not appear to be greater than twofold. Nevertheless, the demonstration of age-related radiosensitivity requires that it be considered by those who assess radiologic risks to human populations

  17. Optimization of SPECT calibration for quantification of images applied to dosimetry with iodine-131

    International Nuclear Information System (INIS)

    Carvalho, Samira Marques de

    2018-01-01

    SPECT systems calibration plays an essential role in the accuracy of the quantification of images. In this work, in its first stage, an optimized SPECT calibration method was proposed for 131 I studies, considering the partial volume effect (PVE) and the position of the calibration source. In the second stage, the study aimed to investigate the impact of count density and reconstruction parameters on the determination of the calibration factor and the quantification of the image in dosimetry studies, considering the reality of clinical practice in Brazil. In the final step, the study aimed evaluating the influence of several factors in the calibration for absorbed dose calculation using Monte Carlo simulations (MC) GATE code. Calibration was performed by determining a calibration curve (sensitivity versus volume) obtained by applying different thresholds. Then, the calibration factors were determined with an exponential function adjustment. Images were performed with high and low counts densities for several source positions within the simulator. To validate the calibration method, the calibration factors were used for absolute quantification of the total reference activities. The images were reconstructed adopting two approaches of different parameters, usually used in patient images. The methodology developed for the calibration of the tomographic system was easier and faster to implement than other procedures suggested to improve the accuracy of the results. The study also revealed the influence of the location of the calibration source, demonstrating better precision in the absolute quantification considering the location of the target region during the calibration of the system. The study applied in the Brazilian thyroid protocol suggests the revision of the calibration of the SPECT system, including different positions for the reference source, besides acquisitions considering the Signal to Noise Ratio (SNR) of the images. Finally, the doses obtained with the simulations presented significant differences between the doses calculated according to their location and calibration factor used, also showing a tendency to overestimate the dose calculation with the use of standard central calibration. The results obtained will contribute to the optimization and better accuracy of therapeutic procedures in nuclear medicine. (author)

  18. Thyroid γ ray measurement after iodine-131 therapy for Graves' disease

    International Nuclear Information System (INIS)

    Liu Jianfeng; Guo Qingling; Ye Genyao; Li Xin; Wang Anyu; Wang Ying; Zhu Hui; He Ling; Yuan Chao

    2004-01-01

    Objective: To study the thyroid 131 I uptake within 24 hours following 131 I therapy for Graves' disease. Methods: Eighteen hyperthyroidism patients were divided into two groups according to thyroid weight and radiotherapy dosage. Low-dose group and high-dose group received the mean dose 162.8 MBq (4.4 mCi) and 255.3 MBq (6.9 mCi), respectively. The γ ray dose rates from thyroids were measured in all patients at 1, 2, 4, 8,12 and 24 h after 131 I therapy. Results: γ ray dose rates were elevated rapidly at 1 hour and continued at high level between 2-12 h and slowly fell in 24 h after 131 I therapy. γ Rat curve of low-dose group was lower than that of high-dose group. Conclusion: There was a rapid absorption and concentration period in 1 h and slow metabolism and release period after 12 h in thyroid following radioiodine therapy of Graves' disease. The thyroids of hyperthyroidism patients displayed different γ ray curves. (author)

  19. Incidence of hypothyroidism occurring long after iodine-131 therapy for hyperthyroidism

    International Nuclear Information System (INIS)

    Holm, L.E.; Lundell, G.; Israelsson, A.; Dahlgvist, I.

    1982-01-01

    We have studied the long-term incidence of hypothyroidism in 4,473 formerly hyperthyroid patients given I-131 therapy between 1951 and 1975. The mean age at the first I-131 treatment was 56 yr. Six percent developed hypothyroidism within one year of therapy, and 72% within 26 yr. Prior antithyroid medication did not affect the incidence of hypothyroidism. Patients cured with one dose of I-131 had a lower cumulative long-term incidence of hypothyroidism than those requiring more than one dose

  20. Radioiodine uptake following iodine-131 therapy for Graves' disease: an early indicator of need for retreatment

    International Nuclear Information System (INIS)

    Carpentier, W.R.; Gilliland, P.F.; Piziak, V.K.; Petty, F.C.; McConnell, B.G.; Verdonk, C.A.; Ibarra, J.D.; Thompson, J.Q.

    1989-01-01

    Forty-five patients with Graves' disease were studied prospectively to determine if 24-hour I-131 uptake measurements alone or in combination with serum thyroid hormone levels at six weeks would determine the necessity for retreatment of the thyrotoxicosis. All patients with an I-131 uptake greater than 30% at six weeks required retreatment. No patient with an I-131 uptake of less than 15% required retreatment. Patients with uptakes between 15% and 30% were variable. An elevated free thyroxin index at 6 weeks is not helpful to determine which patients will remain thyrotoxic. Patients with a free thyroxin index within the normal range at six weeks can be predicted to be euthyroid by 12 weeks if their 24-hour I-131 uptake is between 15% and 30% and to be hypothyroid if their 24-hour I-131 uptake is below 15%. There was no difference between patient groups treated initially with antithyroid medication and those who were not

  1. Late effects of iodine-131 in utero exposure: Toxicological effects in first generation of rats

    International Nuclear Information System (INIS)

    Liu, P.T.; Stevens, R.H.; Cole, D.A.; Lindholm, P.A.; Cheng, H.F.

    1984-01-01

    The authors have initiated studies to evaluate the possible immunotoxic effects to both the mother and offspring following an in utero exposure to /sup 131/I, and initial observations suggest induction of antitumor immunity as measured by cell-mediated immune (CMI) and antibody-dependent cell-mediated cytotoxicity (ADCC). The animal model selected for these studies was the Fischer F344 female rat intraperitoneally exposed to concentrations ranging from 4 to 3700 kBq of Na/sup 131/I during the gestation period of 16 to 18 days. The CMI results suggested the male offspring were 1.7 times more immunologically responsive than their sisters with a threshold detection level in the range of 9.25 kBq being observed. The parents of F/sub 1/ generation exposed to the /sup 131/I are now being evaluated for possible immunotoxicity according to: host resistance to E. coli endotoxin and blastogenenic responses to phytohemagglutin, concanavalin A, and lipopolysaccharide. The results of these studies suggest that perinatal /sup 131/I exposure exerts an immunotoxic effect upon the first generation

  2. Iodine-131 thyroid uptake results in travelers returning from Europe after the Chernobyl accident

    International Nuclear Information System (INIS)

    Castronovo, F.P. Jr.

    1987-01-01

    Thyroid screening measurements for 131 I were performed on 58 travelers returning from Eastern and Western Europe to Boston after the Chernobyl reactor accident on April 26, 1986. The travelers consisted of both Americans arriving home after business or vacation and European nationals visiting relatives in the Boston area. For purposes of dosimetry the population was divided into three subpopulations--adult (greater than 18 yr old), children (less than or equal to 18 yr old), and two individuals, 17 and 26 wk pregnant. Seventy-four percent of the population had detectable quantities of 131 I thyroid burdens, ranging from 1 nCi (37 Bq) to 900 nCi (33,300 Bq). The highest adult radiation dose equivalent was 5.18 mrem (51.8 mSv). The children, however, had considerably higher dose equivalents with one infant receiving 37 rem (370 mSv). Several other children were above 1 rem (10 mSv). The fetal dose equivalents were less than 14 mrem (140 mu Sv). The presence of rain dominated those testing positive for 131 I. Radioactive fallout from the Chernobyl accident contaminated a wide range of Europe and a large population subsequently ingested radioactivity. The children exhibited the highest thyroid radiation dose equivalents of the individuals monitored in the present study. The significance of this is presently unknown

  3. Separation of iodine-131 from water using isotopic exchange with iodine-starch compound

    International Nuclear Information System (INIS)

    Ignatov, V.P.; Kolomejtseva, I.V.

    1990-01-01

    Conditions of iodine isotopic exchange with iodine-starch compound (ISC) were studied with the aim of compound utilizatoin for radioactive iodine separation from solution. It is shown that in pH range from 2 to 7 the degree of iodine extraction and coefficient of its distribution practically do not depend on pH, at pH>7 ISC destruction (decolorizing) starts and iodine extraction decreases. Rapid method of iodine separation from solution is suggested. The method can be used in radiochemical techniques. The degree of extraction equals 80 %, a higher degree of extraction can not be achieved owing to ISC formation peculiarities

  4. Biological dosimetry of patients with differenced carcinoma of thyroid treated with Iodine-131

    International Nuclear Information System (INIS)

    Vallerga, M. B.; Rojo, A.M.; Taja, M.R.; Deluca, G.; Di Giorgio, M.; Fadel, A.; Cabrejas, M.; Valdivieso, C.

    2006-01-01

    The administration of I-131 to patient with Differentiated Thyroid Carcinoma (CaDiT) it is used inside the therapeutic outline as later step to the thyroidectomy. However, the good activity to give is of difficult determination due to factors such as, the variability in the capacity of tumoral reception of the I-131, distribution of the pharmaceutical, physiologic status, other associate pathologies, grade of advance of the illness, and previous treatments. Additionally, the activity to administer is dependent of the dose of tolerance in the healthy tissues; superior dose to 2 Gy in bone marrow, its could drive to myelotoxicity. At the moment, the form more extended of administration it is the empiric prescription that considers clinical parameters and of laboratory for their determination. Presently work, the protocol of applied treatment incorporates the evaluation for internal dosimetry and biological dosimetry to estimate absorbed dose in bone marrow. The biological estimate of the dose of these patients is based on the quantification of chromosomal aberrations whose frequency is referred to a curve-dose response in which the lymphocytes is irradiated in vitro with I-131, allowing to determine the in vivo dose to the patient's circulating lymphocytes. The objective of the present work is to determine the applicability of different cytogenetic essays in the estimate of the absorbed dose to the whole body or specific organs. Three patients were evaluated with CaDiT. Their treatment protocol consisted on a tracer administration of radioactive iodine of 74 - 111 MBq (2 - 3 mCi) and a therapy 7,4 - 11,1 GBq (200 - 300 mCi). Previous to the tracer administration and 8 days post-therapeutic administration took samples of veined blood that were evaluated by biological dosimetry by means of the application of the techniques: conventional cytogenetic Micronucleus and FISH (Hybridization in situ by Fluorescence). Starting from the frequencies of observed chromosomal aberrations it was considered absorbed dose to whole body. The obtained doses were compared by the different biological methods used. The evaluation by internal dosimetry of the data obtained tracer post-activity allowed to personalize the activity of I-131 to administer, starting from physical-mathematical models that consider the particular biokinetics of each patient (MIRD methodology). The doses estimated by the used biological dosemeters were consistent among them. It was discussed its scopes and limitations to be applied in the validation of the dosimetric estimation based on models, in order to administer a therapeutic dose protecting the patient of the adverse effects of the internal radiotherapy in organs that are not target of the same one. The acquired experience is considered of utility to give answer in cases of radioiodine incorporation in occupationally exposed personnel. (Author)

  5. Sustainability Labeling

    NARCIS (Netherlands)

    Dam, van Y.K.

    2017-01-01

    Sustainability labeling originated from a need to protect the identity of alternative systems of food production and to increase market transparency. From the 1980s onwards sustainability labeling has changed into a policy instrument replacing direct government regulation of the food market, and a

  6. Pesticide Labels

    Science.gov (United States)

    Pesticide labels translate results of our extensive evaluations of pesticide products into conditions, directions and precautions that define parameters for use of a pesticide with the goal of ensuring protection of human health and the environment.

  7. Labelling patients

    International Nuclear Information System (INIS)

    Strudwick, R.M.

    2016-01-01

    This article looks at how diagnostic radiographers label their patients. An ethnographic study of the workplace culture in one diagnostic imaging department was undertaken using participant observation for four months and semi-structured interviews with ten key informants. One of the key themes; the way in which radiographers label their patients, is explored in this article. It was found from the study that within the department studied the diagnostic radiographers labelled or categorised their patients based on the information that they had. This information is used to form judgements and these judgements were used to assist the radiographers in dealing with the many different people that they encountered in their work. This categorisation and labelling of the patient appears to assist the radiographer in their decision-making processes about the examination to be carried out and the patient they are to image. This is an important aspect of the role of the diagnostic radiographer. - Highlights: • I have studied the culture in one imaging department. • Radiographers label or categorise their patients. • These labels/categories are used to manage the patient. • This is an important aspect of the way in which radiographers work.

  8. Synthesis of PBAD-lipiodol nanoparticles for combination treatment with boric acid in boron neutron capture therapy for hepatoma in-vitro

    International Nuclear Information System (INIS)

    Chou, F.I.; Chung, H.P.; Liu, H.M.; Wen, H.W.; Chi, C.W.; Lin, Shanyang; Lui, W.Y.; Kai, J.J.

    2006-01-01

    This study attempted to increase BNCT efficiency for hepatoma by a combined treatment of phenylboric acid derivative entrapped lipiodol nanoparticles (PBAD-L nanoparticles) with boric acid. The size of PBAD-L nanoparticles were 400-750 nm at the boron concentrations of 0.3-2.7 mg/ml. After 24 hours the boron concentration in PBAD-L nanoparticles treated human hepatoma HepG2 cells was 112 ppm, while that in rat liver Clone 9 cells was 52 ppm. With the use of 25 μg B/ml boric acid, after 6 hours the boron concentration in HepG2 and Clone 9 cells were 75 ppm and 40 ppm, respectively. In a combined treatment, boron concentration in HepG2 cells which were treated with PBAD-L nanoparticles for 18 hours and then combined with boric acid for 6 hours was 158 ppm. After neutron irradiation, the surviving fraction of HepG2 cells treated with PBAD-L nanoparticles was 12.6%, while that in the ones with a combined treatment was 1.3%. In conclusion, the combined treatment provided a higher boron concentration in HepG2 cells than treatments with either PBAD-L nanoparticles or boric acid, resulting in a higher therapeutic efficacy of BNCT in hepatoma cells. (author)

  9. An intravenously injectable emulsified iodinated oil contrast agent for liver CT. Experimental study of lipiodol emulsion emulsified by lecithin (LEL38) in rabbits

    International Nuclear Information System (INIS)

    Kamei, Tsuyoshi

    1994-01-01

    LEL38 (lipiodol emulsion emulsified by lecithin 38 mgI/ml, mean diameter 200 nm) is a new intravenously injectable oil contrast agent for liver CT. The aim of this report was to evaluate its ability to enhance contrast in the liver of 46 rabbits with regard to the correlation of density with time at an injected dose of 76 mgI/kg (before to 120 minutes after), the correlation of density with dose (0-760 mgI/kg) and the detectability of liver mass. The time-density correlation of LEL38 in the liver, that is, peak density, was achieved after 30 minutes, and it was elevated to 20.9 H. U. Thereafter, it decreased slowly. In the blood vessels, it reached a sharp peak after immediately being elevated to 14. 7 H. U. Thereafter detectability decreased quickly. The maximum difference in density between liver and blood vessels was 34 H. U. after 60 minutes. The dose-density correlation in the liver and blood vessels was linear. Tumors were detected as clear areas of low density. The minimal detectability was about 3 mm. LEL38 may be an effective contrast agent for screening CT studies of liver disease. (author)

  10. Selective and persistent deposition and gradual drainage of iodized oil, Lipiodol in the hepatocellular carcinoma after injection into the feeding hepatic artery

    International Nuclear Information System (INIS)

    Okayasu, I.; Hatakeyama, S.; Yoshida, T.; Yoshimatsu, S.; Tsuruta, K.; Miyamoto, H.; Kimula, Y.

    1988-01-01

    The selective and long-term deposition of iodized oil in the hepatocellular carcinoma (HCC) and its gradual drainage were clinicopathologically analyzed in 13 cases. All patients were Japanese and had an intrahepatic arterial injection of Lipiodol (LIP) mixed with Mitomycin C. The comparison among the follow-up computerized tomography (CT) findings, the observation of the soft x-ray radiogram, and histopathologic studies of the surgical or autopsy materials revealed that the selective deposition of LIP in HCC lasted for a long term, particularly in cases treated by LIP combined with transcatheter arterial embolization (TAE). Also revealed was an extremely gradual decrease of LIP from the HCC. It was thus postulated that, mainly, the accumulated macrophages surrounding LIP around the necrotic cancer tissue and, partially, the intrahepatic lymphatic system itself contributed to this drainage. Further, in histologic sections with lipid staining, x-ray microanalysis proved that the lipid droplets in the cancer tissue included highly concentrated iodine, as a deposition of LIP

  11. Gigantic Cavernous Hemangioma of the Liver Treated by Intra-Arterial Embolization with Pingyangmycin-Lipiodol Emulsion: A Multi-Center Study

    International Nuclear Information System (INIS)

    Zeng Qingle; Li Yanhao; Chen Yong; Ouyang Yong; He Xiang; Zhang Heping

    2004-01-01

    Purpose: To evaluate the therapeutic effect and safety of pingyangmycin-lipiodol emulsion (PLE) intra-arterial embolization for treating gigantic cavernous hemangioma of the liver (CHL).Methods: Three hospitals (Nanfang Hospital, Inner Mongolia Autonomous Region's Hospital and Huai He Hospital) participated in the study during 1997-2001. A total of 98 patients with CHL were embolized with PLE via the hepatic artery. The therapeutic effects including changes in tumor diameter, symptomatic improvement and occurrence of complications were evaluated for a period of 12 months after the procedure.Results: The tumor diameters decreased significantly from 9.7 ± 2.3 cm to 5.6 ± 1.6 cm 6 months after the treatment (P < 0.01), and then to 3.0 ± 1.2 cm at 12 months (P < 0.01). Transient impairment of liver function was found in 77 cases after embolization, 69 cases of which returned to normal in 2 weeks, and the other eight cases of which recovered 1 month later. The clinical symptoms were significantly relieved in all 53 symptomatic patients. Persistent pain in the hepatic region was found in two cases, and these two patients resorted to surgery eventually.Conclusion: Intra-arterial PLE embolization proves to be effective and safe in treating patients with CHL

  12. Food labels

    DEFF Research Database (Denmark)

    Selsøe Sørensen, Henrik; Clement, Jesper; Gabrielsen, Gorm

    2012-01-01

    evidence for dividing consumers into two profiles: one relying on general food knowledge and another using knowledge related to signpost labels. In a combined eyetracking and questionnaire survey we analyse the influence of background knowledge and identify different patterns of visual attention......The food industry develops tasty and healthy food but fails to deliver the message to all consumers. The consumers’ background knowledge is essential for how they find and decode relevant elements in the cocktail of signs which fight for attention on food labels. In this exploratory study, we find...... for the two consumer profiles. This underlines the complexity in choosing and designing the ‘right’ elements for a food package that consumers actually look at and are able to make rational use of. In spite of any regulation of food information provided by authorities, consumers will still be confronted...

  13. The value of paradoxical uptake of hepatocellular carcinoma on the hepatobiliary phase of gadoxetic acid-enhanced liver magnetic resonance imaging for the prediction of lipiodol uptake after transcatheter arterial chemoembolization

    Energy Technology Data Exchange (ETDEWEB)

    Kim, Jeong Woo, E-mail: pridebio@naver.com [Department of Radiology, Korea University Guro Hospital, Korea University College of Medicine, Seoul (Korea, Republic of); Lee, Chang Hee, E-mail: chlee86@korea.ac.kr [Department of Radiology, Korea University Guro Hospital, Korea University College of Medicine, Seoul (Korea, Republic of); Park, Yang Shin, E-mail: pys797979@naver.com [Department of Radiology, Korea University Guro Hospital, Korea University College of Medicine, Seoul (Korea, Republic of); Seo, Tae Seok, E-mail: g1q1papa@korea.ac.kr [Department of Radiology, Korea University Guro Hospital, Korea University College of Medicine, Seoul (Korea, Republic of); Song, Myung Gyu, E-mail: acube808@naver.com [Department of Radiology, Korea University Guro Hospital, Korea University College of Medicine, Seoul (Korea, Republic of); Kim, Ji Hoon, E-mail: kjhhepar@naver.com [Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul (Korea, Republic of); Kim, Kyeong Ah, E-mail: kahkim@korea.ac.kr [Department of Radiology, Korea University Guro Hospital, Korea University College of Medicine, Seoul (Korea, Republic of); Park, Cheol Min, E-mail: radpic@hanmail.net [Department of Radiology, Korea University Guro Hospital, Korea University College of Medicine, Seoul (Korea, Republic of)

    2017-04-15

    Highlights: • HCC{sub para} shows more frequent initial compact lipiodol uptake after TACE than HCC{sub def}. • HCC{sub para} demonstrates less frequent early local recurrence after TACE. • HCC{sub para} has larger mean size, lower AER, and more frequent capsule appearance. - Abstract: Purpose: To compare the response to transcatheter arterial chemoembolization (TACE) between hepatocellular carcinoma (HCC) with paradoxical uptake on the hepatobiliary phase (HBP) (HCC{sub para}) and HCC with defect on the HBP (HCC{sub def}), and to identify some imaging features that can differentiate between two groups. Materials and methods: Ninety-three HCCs from 54 patients who underwent gadoxetic acid-enhanced liver magnetic resonance imaging (MRI) prior to TACE were included. HCCs were classified into two groups according to the signal intensity (SI) on the HBP: HCC{sub para} and HCC{sub def}. Using post-TACE computed tomography (CT) as a reference standard, initial compact lipiodol uptake was assessed and compared between groups. The arterial enhancement ratio (AER), SI ratios of the arterial phase and HBP, and presence of the capsule appearance were compared between groups. After initial response, local tumor recurrence within 6 and 18 months was evaluated based on follow-up CT or MRI. Results: Fifteen HCC{sub para} and 78 HCC{sub def} were included. Compared to HCC{sub def}, HCC{sub para} showed more frequent initial compact lipiodol uptake (p = 0.009), larger mean size (p = 0.019), lower AER (p = 0.005), higher SI ratio of the HBP (p < 0.0001), and more frequent capsule appearance (p < 0.0001). Local tumor recurrence rate within 6 months was also significantly lower in HCC{sub para} than in HCC{sub def} (p = 0.008). Conclusion: Despite larger size and lower AER, HCC{sub para} showed more frequent initial compact lipiodol uptake and lower early local recurrence rate after TACE than did HCC{sub def}.

  14. Label triangulation

    International Nuclear Information System (INIS)

    May, R.P.

    1983-01-01

    Label Triangulation (LT) with neutrons allows the investigation of the quaternary structure of biological multicomponent complexes under native conditions. Provided that the complex can be fully separated into and reconstituted from its single - protonated and deuterated - components, small angle neutron scattering (SANS) can give selective information on shapes and pair distances of these components. Following basic geometrical rules, the spatial arrangement of the components can be reconstructed from these data. LT has so far been successfully applied to the small and large ribosomal subunits and the transcriptase of E. coli. (author)

  15. Evaluation of long-term effect of hepatic arterial embolization with pingyangmycin-lipiodol emulsion in patients with hepatic cavernous hemangiomas

    International Nuclear Information System (INIS)

    Zhang Xuejun; Ouyang Yong; Ma Heping; Chao Lumeng; Zhen Yanli; Gu Subin; Zhou Qunhui; Liu Pengzhi; Wang Hong

    2010-01-01

    Objective: To evaluate the long-term effect of hepatic arterial embolization with pingyanmycin-lipiodol emulsion (PLE) in patients with cavernous hemangiomas of the liver (CHL) and its influence factors. Methods: One hundred and fifty-six hemangiomas that were diagnosed by imaging examinations or confirmed pathologically by surgery in 105 patients with integral follow-up data were analyzed retrospectively in this paper. All hemangiomas were divided into 4 groups according to their size (the largest size of hemangioma) by the authors as follows: A group (≤3 cm, n=25); B group (>3 cm and 2 test respectively. And the influence factors, included of the variant size of hemangiomas, abundant or sparse of abnormal sinusoids and the number of treatment procedures, were also analyzed respectively. Results: The total effective rate of the 156 hemangiomas in 105 patients was 92.95% (145/156). After single procedure of hepatic arterial embolization with PLE, the total effective rate of A and B groups were 100% (57/57), that of C and D groups were 85.86% (85/99), and the difference reach significant (X 2 =8.8553, P 2 =5.2642, P<0.05) than those of group with single procedure (72.73%, 8/11). Conclusions: A best long-term curative effect (complete cure) is usually obtained in the small hemangiomas with abundant abnormal sinusoids, and a satisfactory long-term curative effect can also be achieved in the larger or multiple hemangiomas, particularly in those hemangiomas with abundant abnormal sinusoids by using the repeat procedures of hepatic arterial embolization with PLE. (authors)

  16. Understanding Food Labels

    Science.gov (United States)

    ... Healthy eating for girls Understanding food labels Understanding food labels There is lots of info on food ... need to avoid because of food allergies. Other food label terms top In addition to the Nutrition ...

  17. Issues in Data Labelling

    NARCIS (Netherlands)

    Cowie, Roddy; Cox, Cate; Martin, Jeam-Claude; Batliner, Anton; Heylen, Dirk K.J.; Karpouzis, Kostas; Cowie, Roddy; Pelachaud, Catherine; Petta, Paolo

    2011-01-01

    Labelling emotion databases is not a purely technical matter. It is bound up with theoretical issues. Different issues affect labelling of emotional content, labelling of the signs that convey emotion, and labelling of the relevant context. Linked to these are representational issues, involving time

  18. Mixed Map Labeling

    Directory of Open Access Journals (Sweden)

    Maarten Löffler

    2016-12-01

    Full Text Available Point feature map labeling is a geometric visualization problem, in which a set of input points must be labeled with a set of disjoint rectangles (the bounding boxes of the label texts. It is predominantly motivated by label placement in maps but it also has other visualization applications. Typically, labeling models either use internal labels, which must touch their feature point, or external (boundary labels, which are placed outside the input image and which are connected to their feature points by crossing-free leader lines. In this paper we study polynomial-time algorithms for maximizing the number of internal labels in a mixed labeling model that combines internal and external labels. The model requires that all leaders are parallel to a given orientation θ ∈ [0, 2π, the value of which influences the geometric properties and hence the running times of our algorithms.

  19. Age- and sex-specific estimation of dose to a normal thyroid from clinical administration of iodine-131

    International Nuclear Information System (INIS)

    Killough, G.G.; Eckerman, K.F.

    1986-09-01

    This report describes the derivation of an age- and sex-dependent model of radioiodine dosimetry in the thyroid and the application of the model to estimating the thyroid dose for each of 4215 patients who were exposed to 131 I in diagnostic and therapeutic procedures. In most cases, the data available consisted of the patient's age at the time of administration, the patient's sex, the quantity of activity administered, the clinically determined uptake of radioiodine by the thyroid, and the time after administration at which the uptake was determined. The model was made to conform to these data requirements by the use of age-specific estimates of the biological half-time of iodine in the thyroid and an age- and sex-dependent representation of the mass of the thyroid. Also, it was assumed that the thyroid burden was maximum at 24 hours after administration (the 131 I dose is not critically sensitive to this assumption). The metabolic model is of the form A(t) = K x (exp(-μ 1 t) - exp(-μ 2 t)) μCi where μ/sub i/ = λ/sub r/ + λ/sub i//sup b/ (i = 1, 2), λ/sub r/ is the radiological decay-rate coefficient, and the λ/sub i//sup b/ are biological removal-rate coefficients. The values of λ/sub i//sup b/ are determined by solving a nonlinear equation that depends on assumptions about the time of maximum uptake and the eventual biological loss rate (through which age dependence enters). An addendum (Appendix C) extends the method to other radioiodines and gives age- and sex-dependent dose conversion factors for most isotopes

  20. Biological (DB) and internal dosimetry (DI) in patients with differentiated thyroid carcinoma (CaDT) treated with iodine 131

    International Nuclear Information System (INIS)

    Fadel, Ana M.; Chebel, G.; Oneto, A.; Di Giorgio, Marina; Vallerga, Maria B.; Taja, Maria R.; Radl, A.; Rojo, Ana M.; Deluca, G.; Levi de Cabrejas, Mariana; Cabrejas, Raul C.

    2009-01-01

    The internal 131 I radiotherapy in patients with CaDT is used within the therapeutic scheme as a step post-thyroidectomy. The success of therapy is to achieve a lethal dose in the tumor tissue without exceeding the dose of tolerance in healthy tissues (doses greater than 2 Gy in bone marrow could lead to myelotoxicity). In this work, the treatment protocol applied incorporates assessment by biological (DB) and internal dosimetry (DI) for estimating doses to the whole body and bone marrow to administer a therapeutic personalized for each patient. The estimate biological dose is based in the quantification of chromosomal aberrations, which is referred to a dose-response curve. Objectives: 1) To estimate the absorbed dose to the whole body and bone marrow due to the administration of 131 I therapy in patients with CaDT, by applying three different cytogenetic tests: conventional cytogenetics, micronuclei (MN) and fluorescence in situ hybridization (FISH); 2) Assess the correlation of the results obtained by DB and DI for personalization of treatment. Materials and methods: We evaluated 24 patients with CaDiT by applying the cytogenetic tests mentioned and internal dosimetry (methodology Mird-Olinda). Internal dosimetry: We administered a tracer dose 74 to 111 MBq. Measurements were made of activity in whole body and blood. By adjusting the scheme was estimated MIRD dose in bone marrow and the maximum therapeutic activity to manage and secure. Through software Olinda was determined absorbed dose to the whole body for each patient. We considered patient-specific data (physical frame size, weight, hematocrit) to adjust the methodology in each particular case. It is assumed that the tracer activity administered has a kinetic in the body similar to the 131 I to be administered in therapeutic amounts. Biology Dosimetry : We performed for each patient taking 2 sequential venous blood samples to estimate the dose due to therapeutic activity in review: the first shows, pre-dose tracers (to assess the contribution of therapeutic doses above) and the second shows, 8 days post-therapeutic dose (in this period most of the energy of 131 I is deposited in the body and it is possible to assess the biological effect that this produces absorbed dose). These samples were applied techniques cytogenetics, MN and FISH. It assumes: 1) uniform distribution of 131 I in the body, because the total thyroidectomy; 2) that in the absence of bone metastases that compromise bone marrow estimated average dose to the whole body can be considered an approximation appropriate dosage bone marrow. The technique FISH estimated equivalent dose active in bone marrow. Results: A comparison of the doses received by 3 cytogenetic tests applied indicates that these methods are consistent with each other. The absorbed dose to the whole body estimated by DB correlate with those estimated by DI, p 131 I to administer in patients with CaDiT. These results support the advantage of applying quantitative methods of DI, who consider the patient's own parameters, in order to customize their therapy, with respect to the empirical method. In this context, the DB provides evidence for the validation of the DI. Also, from a clinical point of view, the DB conducted on samples from patients with previous treatments, before a new therapeutic administration, would assess the status cytogenetic (radiation damage and repair capacity). The dosimetry presented clinical importance in reducing potential complications hematologic. In cases with cumulative doses higher than 1000 mCi, it would be useful to indicate the need to consider other schemes therapeutic alternative to the administration of 131 I, such as chemotherapy or radiotherapy, reducing morbidity. (author)

  1. Radioactive iodine (131I) therapy for differentiated thyroid cancer in Japan. Current issues with historical review and future perspective

    International Nuclear Information System (INIS)

    Higashi, Tatsuya; Kudo, Takashi; Kinuya, Seigo

    2012-01-01

    Radioactive iodine (RAI, 131 I) has been used as a therapeutic agent for differentiated thyroid cancer (DTC) with over 50 years of history. Recently, it is now attracting attention in medical fields as one of the molecular targeting therapies, which is known as targeted radionuclide therapy. Radioactive iodine therapy (RIT) for DTC, however, is now at stake in Japan, because Japan is confronting several problems, including the recent occurrence of the Great East Japan Disaster (GEJD) in March 2011. RIT for DTC is strictly limited in Japan and requires hospitalization. Because of strict regulations, severe lack of medical facilities for RIT has become one of the most important medical problems, which results in prolonged waiting time for Japanese patients with DTC, including those with distant metastasis, who wish to receive RIT immediately. This situation is also due to various other factors, such as prolonged economic recession, super-aging society, and subsequent rapidly changing medical environment. In addition, due to the experience of atomic bombings in Hiroshima and Nagasaki, Japanese people have strong feeling of ''radiophobia ''. There is fear that GEJD and related radiation contamination may worsen this feeling, which might be reflected in more severe regulation of RIT. To overcome these difficulties, it is essential to collect and disclose all information about the circumstances around this therapy in Japan. In this review, we would like to look at this therapy through several lenses, including historical, cultural, medical, and socio-economic points of view. We believe that clarifying the problems is sure to lead to the resolution of this complicated situation. We have also included several recommendations for future improvements. (author)

  2. Evaluation of radiotherapy of patients with Graves' disease treated with fixed activities of 555 MBq of Iodine-131

    Energy Technology Data Exchange (ETDEWEB)

    Silva, Jose M.F. da; Filho, Joao A.; Junior, Manoel R. de S.; Mendonca, Keyla M.C., E-mail: josemarcosfs@yahoo.com.br, E-mail: jaf@ufpe.br, E-mail: manoel@de.ufpe.br, E-mail: keylamcm@yahoo.com.br [Universidade Federal de Pernambuco (UFPE), e-mail: Recife, PE (Brazil)

    2013-07-01

    Graves' disease treatment is done by radioiodine therapy (RIT), which destroys cells of the thyroid and reduces the synthesis of T{sub 3} and T{sub 4}; and surgery. In Brazil, applies RIT with fixed activities. Studies show that RIT should be based on individual biokinetics. There is controversy regarding the use of fixed activities or calculated. This study was conducted at the HC-UFPE in the period 2006-2010. Of the overall sample of 132 patients that entered the study, twenty-five of them formed a group chosen to estimate the maximum uptake of {sup 131}I and thyroid mass, to calculate the activity to be administered and the absorbed dose. All the patients were treated with fixed activities of 555 MBq {sup 131}I. Observed that 28% of patients received radioactivities above, 72% received radioactivities below, and nobody received no radioactivity as a real need. The group obtained an average rate of cure of (76 ± 5) % at 24 months of follow up, less than those obtained under the same conditions biokinetics and mean follow-up interval, among many, who have used doses of 250 Gy and 350 Gy and achieved cure rates approximately 90%. Doses received totaled 9,166 Gy, and 6,698 Gy were necessary, therefore were wasted 2,468 Gy. Were risk factors observed: extrapolation of interval of the thyroid function tests of three to six months to one to three years; economic difficulties, interfamily, socio emotional and to perform the tests requested and great distances between homes and hospital; among others; may be limitations that led to the contraposition that higher activities of {sup 131}I promote greater cure rate of GD. Results of univariate analysis - were statistically significant risk factors: female, thyroid mass between 31 g and 60 g and duration of the GD before of RIT > five years (p < 0.05). The factors sex and thyroid mass are consistent with other studies. The results suggest the use of optimized activities based on individual dosimetric parameters and the implementation of more effective public policies for the patient accompaniments, so that be decreased the radiological risks, detriments and unnecessary expenses. (author)

  3. Detriments of radioactive Iodine 131 in managing thyroid carcinoma - a retrospective study with review of the current scenario

    International Nuclear Information System (INIS)

    Mohan, Shaweta; Agnihotri, Gaurav

    2016-01-01

    Radioactive iodine (RAI) ablation following thyroidectomy is recommended for most patients diagnosed with papillary and follicular thyroid carcinoma. We performed a literature search on MEDLlNE and EMBASE, using keywords, such as, differentiated thyroid carcinoma, radioiodine therapy, "1"3"1I complications, adverse effects and side effects, and chose the most relevant studies till date to prepare this work on the side effects of RAIT (Radioactive Iodine Therapy) for thyroid cancer. We contacted authors of published studies where appropriate for further information. Also, the percentage incidence of the hazards was determined for North Indian population accessing data from Govt. Medical Colleges of Punjab, Haryana, and Postgraduate Institute of Medical Education and Research, Chandigarh. The most prominent side effect came out to be xerostomia with an incidence of 47%, followed by local neck pain and swelling (39%). The incidence of gastritis was also common (34%). Radioactive iodine therapy complications have been divided into early and late effects. Early complications include gastrointestinal symptoms, radiation thyroiditis, sialadenitis/xerostomia, bone marrow suppression, gonadal damage, dry eye, and nasolacrimal duct obstruction. Late complications include secondary cancers, pulmonary fibrosis, permanent bone marrow suppression, and genetic effects. As "1"3"1I is an efficacious form of treatment that can significantly decrease the rate of mortality, recurrence and metastasis, and as the side effects are often minor and well-tolerated, radio iodine therapy remains the principal mode of treatment for patients. (author)

  4. The optimization of treatment with radioactive iodine (131I) of the hypersecretive ''hot'' tumors of the thyroid

    International Nuclear Information System (INIS)

    Gorowski, T.; Zgliczynski, S.

    1987-01-01

    The studies have been carried out in 50 patients with hyperthyroidism associated with the presence of ''hot'' thyroid tumor. The effectiveness of treatment with a standard dose of radioactive iodine, a dose which after 48 hours following the administration caused an appearance of 5.55 MBq (150 μCi) of 131 I in 1 cubic centimeter of the tumor, has been determined. In each case the condition of the patient was evaluated several times before and after the treatment, basing on clinical examination, scintigraphy of the thyroid, the determinations of T 3 , T 4 and TSH concentrations and, when needed, also the determination of TSH after stimulation with TRH. The period of observation after the administration of the first therapeutic dose of radioactive iodine was between 2 and 19 years (mean 6.5 years). The results obtained indicated that in 40 among 50 patients (80%) hyperthyroidism disappeared after administration of a single dose of radioactive iodine calculated as specified above. In two of these patients (4%) hypothyroidism resulted. In the remaining 10 patients (20%) the treatment with radioactive iodine had to be repeated. This resulted in disappearance of hyperthyroidism also in these 10 patients, bringing the total amount of cured patients to 50 (100%), and increasing the amount of patients with hypothyroidism to barely 3 cases (6%). 23 refs., 2 tabs. (author)

  5. Sub-stoichiometric isotope dilution analysis method for the determination of iodine in common salts using iodine-131 tracer

    International Nuclear Information System (INIS)

    Singh, Vivek; Garg, A.N.

    1994-01-01

    A sub-stoichiometric isotope dilution analysis (SIDA) method was developed for the determination of iodine in different brands of common salts. An aqueous salt solution containing 131 I tracer and NaI as carrier is oxidized by tartaric acid and KIO 3 and the liberated iodine is extracted with CCl 4 . To the extract an aqueous solution of AgNO 3 is added in substoichiometric amount to obtain a colloidal solution of AgI. On adding sodium thiosulfate solution, the NaI so formed passes into aqueous solution, which is then counted. Several different brands of salt were analysed. The method is especially suitable for the determination of microgram amounts of iodide in the presence of excess of chloride. (Author)

  6. Evaluation of local hospital discharge for thyroid cancer patients treated with Iodine-131; comparison with internationally accepted release criteria

    International Nuclear Information System (INIS)

    Stylianou-Markidou, E.; Peraticou, A.; Constantinou, C.; Giannos, A.; Aritkan, A.V.; Dimitriadou, D.; Frangos, S.

    2007-01-01

    Full text: Aim: Patients with Thyroid Cancer treated with I-131 in our institution, stay in a shielded room for two days, or until they emit less than 40 μSv/hr at 1m, based on the Cyprus legislation for radiation protection. Other countries have different regulations and public dose limits, and their hospital discharge guidelines vary accordingly. The purpose of this study is to evaluate local hospital discharge regulations, make a comparison with other countries' accepted release criteria, and find where improvements can be made. Methods: 267 patients were treated with I-131 (activity 1.8-8.9GBq) from September 2001 to April 2007. The dose equivalent rate (DER) was measured within 30 min of the administration at a distance of 1 m from the patient. Measurements at 1m were also obtained before the release of the patient. For a group of these patients, measurements were also carried out a week after the treatment with I-131. The doses given to members of the public, from each of the above patients, were calculated using the Total Effective Dose Equivalent (TEDE) concept, which is based on the line source model. For 10% of these patients, measurements of the dose emitted to surroundings were taken, using two different methods. (a) Doses were measured with TLD dosimeters placed at specific points of the room during the two day restriction of the patient in the shielded room. These points were at bedside, at 1 m from the patient's bed, at 3m from the patient's bed, in the shower area, and at the side of the toilet. (b) On the day of release, personal dosimeters were given to a member of the immediate family (carer) of the patient for a minimum of five days. The skin dose and dose at approximately 10cm depth were measured by the National personnel monitoring for radiation protection authority of Cyprus. Results: Our calculation of the TEDE values indicated that, had the patients been released just after the administration of the radiopharmaceutical, members of the public within 1 m of the patient, would have received a dose varying between 1.11mSv-5.46mSV, with 96% of the cases resulting in a dose greater than 2mSv to members of the public. The measurements carried out on 10% of the patients showed that during the first 2 days after administration, with the patient restricted in the specially shielded room, the dose received by TLD dosimeters ranged as follows: (a) At bedside, from 2.1mSv to 4mSv (b) At 1m from the patient, from 1.0mSv to 2.5mSv (c) At 3m from the patient, from 0.5mSv to 0.9mSv (d) In the shower area, from 0.7mSv to 1.7mSv (e) At the side of the toilet, from 0.7mSv to 8.7mSv. The doses measured from the personal dosimeters given to these patients' relatives, after a minimum of 5 days from the hospital discharge, ranged between 0.05mSv to 0.62mSv for skin, and from 0.03mSv to 0.59mSv at 10cm depth. Discussion and Conclusions: The E.U. directive on 'Radiation protection following I-131 therapy' separates the members of the family and possible carers into three different categories based on age, and sets different dose limits per treatment for each of them. It also goes a step further and sets a limit 0.3mSv as the upper limit for this type of exposure to third parties. In some States of the U.S.A, patients treated I-131 are released to go home after the administration of the radiopharmaceutical, with written behavioral instructions, but under the dose constraint that the effective dose to any other individual from the discharged patient is not likely to exceed 5mSv. This is considerably less stringent than the public exposure limit of 1mSv adopted in Cyprus and the E.U. In Australia, as in Cyprus and the EU, the patients are admitted to shielded rooms until the dose rate at 1m from the patient in reduced to 25 μSv/hr. The public should again not be exposed to more than 1mSv from these patients. Again, in the case that a patient should require assistance, the dose to the carer should not exceed 5mSv. The conclusion from our study is that the minimum time a patient should spend in the shielded room, in order for the dose limit to the public will not exceed, is two days. This limit in Cyprus and the EU is set to 1mSv/yr. For those Iodine patients who require the assistance of a carer, the dose limit for voluntary carers is set to 5mSv per treatment session, in Cyprus. (author)

  7. Proposal of a methodology for individualized iodine-131 therapy for Graves' disease in patients with hyperthyroidism

    Energy Technology Data Exchange (ETDEWEB)

    Araujo, Francisco de [Instituto de Radioprotecao e Dosimetria (IRD), Rio de Janeiro, RJ (Brazil)]. E-mail: faraujo@ird.gov.br; Melo, Rossana Corbo de [Universidade Federal do Rio de Janeiro (UFRJ), RJ (Brazil); Rebelo, Ana Maria de Oliveira [Universidade Federal, Rio de Janeiro, RJ (Brazil). Coordenacao dos Programas de Pos-graduacao de Engenharia (COPPE); Dantas, Bernardo Maranhao; Dantas, Ana Leticia A.; Lucena, Eder Augusto de [Universidade do Estado do Rio de Janeiro (UERJ), RJ (Brazil)

    2007-11-15

    Objective: Several methods are utilized for determining the radioiodine activity in the treatment of Graves' disease (hyperthyroidism). Some of this methods do not take into consideration the thyroid absorbed dose or the necessary parameters for this estimation. The association between absorbed dose and administered activity depends on effective half-life, iodine uptake and thyroid mass of each patient. The present study was aimed at developing a methodology for individualized {sup 131}I therapy for Graves' disease in patients with hyperthyroidism of the Graves' disease. Materials and methods: A neck-thyroid phantom developed at Instituto de Radioprotecao e Dosimetria, containing a standard solution of {sup 131}I, was utilized for calibrating the scintillation gamma camera and uptake probe installed in the Department of Nuclear Medicine of the Hospital Universitario Clementino Fraga Filho da Universidade Federal do Rio de Janeiro. Results: The view angle of the collimator/detector assembly presented values compatible with the thyroid gland size for distances of 25 cm (uptake probe) and 45.8 cm (scintillation gamma camera). Calibration factors were 39.3 {+-} 0.78 and 4.3 {+-} 0.17 cpm/kBq, respectively. The 14-30-hour interval in the retention curve allows the estimation of activity between two points for determining the effective iodine half-life in the thyroid. Conclusion: The utilization of equipment usually available in nuclear medicine clinics is feasible, so this is a simple, effective and low cost methodology. (author)

  8. How frequently is the thymus seen on whole-body iodine-131 diagnostic and post-treatment scans?

    Energy Technology Data Exchange (ETDEWEB)

    Davidson, J. [Departments of Medicine and Nuclear Medicine, Glasgow Royal Infirmary, Glasgow (United Kingdom); McDougall, I.R. [Division of Nuclear Medicine, Stanford University School of Medicine, Stanford, CA (United States)

    2000-04-01

    The purpose of the study was to determine how often the thymus is visualized on whole-body radioiodine scans. One hundred and seventy-five patients had 325 diagnostic scans and 200 post-treatment scans. Activity in the mediastinum possibly consistent with the thymus was seen on seven scans in six patients. Four of these were diagnostic scans (three were second follow-up scans, and the fourth, a third follow-up scan). Three post-treatment scans demonstrated mediastinal uptake. Only one patient had persistent mediastinal uptake on both a post-treatment scan and a subsequent follow-up diagnostic scan. None of these six patients were treated as a result of this finding and none has clinical or biochemical evidence of metastatic disease. (orig.)

  9. How frequently is the thymus seen on whole-body iodine-131 diagnostic and post-treatment scans?

    International Nuclear Information System (INIS)

    Davidson, J.; McDougall, I.R.

    2000-01-01

    The purpose of the study was to determine how often the thymus is visualized on whole-body radioiodine scans. One hundred and seventy-five patients had 325 diagnostic scans and 200 post-treatment scans. Activity in the mediastinum possibly consistent with the thymus was seen on seven scans in six patients. Four of these were diagnostic scans (three were second follow-up scans, and the fourth, a third follow-up scan). Three post-treatment scans demonstrated mediastinal uptake. Only one patient had persistent mediastinal uptake on both a post-treatment scan and a subsequent follow-up diagnostic scan. None of these six patients were treated as a result of this finding and none has clinical or biochemical evidence of metastatic disease. (orig.)

  10. Rhenium-188 as an alternative to Iodine-131 for treatment of breast tumors expressing the sodium/iodide symporter (NIS)

    International Nuclear Information System (INIS)

    Dadachova, E.; Bouzahzah, B.; Zuckier, L.S.; Pestell, R.G.

    2002-01-01

    The sodium-iodide symporter (NIS), which transports iodine into the cell, is expressed in thyroid tissue and was recently found to be expressed in approximately 80% of human breast cancers but not in healthy breast tissue. These findings raised the possibility that therapeutics targeting uptake by NIS may be used for breast cancer treatment. To increase the efficacy of such therapy it would be ideal to identify a radioactive therapy with enhanced local emission. The feasibility of using the powerful beta-emitting radiometal 188 Re in the form of 188 Re-perrhenate was therefore compared with 131 I for treatment of NIS-expressing mammary tumors. In the current studies, using a xenografted breast cancer model induced by the ErbB2 oncogene in nude mice, 188 Re-perrhenate exhibited NIS-dependent uptake into the mammary tumor. Dosimetry calculations in the mammary tumor demonstrate that 188 Re-perrhenate is able to deliver a dose 4.5 times higher than 131 I suggesting it may provide enhanced therapeutic efficacy

  11. Evaluation of radiotherapy of patients with Graves' disease treated with fixed activities of 555 MBq of Iodine-131

    International Nuclear Information System (INIS)

    Silva, Jose M.F. da; Filho, Joao A.; Junior, Manoel R. de S.; Mendonca, Keyla M.C.

    2013-01-01

    Graves' disease treatment is done by radioiodine therapy (RIT), which destroys cells of the thyroid and reduces the synthesis of T 3 and T 4 ; and surgery. In Brazil, applies RIT with fixed activities. Studies show that RIT should be based on individual biokinetics. There is controversy regarding the use of fixed activities or calculated. This study was conducted at the HC-UFPE in the period 2006-2010. Of the overall sample of 132 patients that entered the study, twenty-five of them formed a group chosen to estimate the maximum uptake of 131 I and thyroid mass, to calculate the activity to be administered and the absorbed dose. All the patients were treated with fixed activities of 555 MBq 131 I. Observed that 28% of patients received radioactivities above, 72% received radioactivities below, and nobody received no radioactivity as a real need. The group obtained an average rate of cure of (76 ± 5) % at 24 months of follow up, less than those obtained under the same conditions biokinetics and mean follow-up interval, among many, who have used doses of 250 Gy and 350 Gy and achieved cure rates approximately 90%. Doses received totaled 9,166 Gy, and 6,698 Gy were necessary, therefore were wasted 2,468 Gy. Were risk factors observed: extrapolation of interval of the thyroid function tests of three to six months to one to three years; economic difficulties, interfamily, socio emotional and to perform the tests requested and great distances between homes and hospital; among others; may be limitations that led to the contraposition that higher activities of 131 I promote greater cure rate of GD. Results of univariate analysis - were statistically significant risk factors: female, thyroid mass between 31 g and 60 g and duration of the GD before of RIT > five years (p < 0.05). The factors sex and thyroid mass are consistent with other studies. The results suggest the use of optimized activities based on individual dosimetric parameters and the implementation of more effective public policies for the patient accompaniments, so that be decreased the radiological risks, detriments and unnecessary expenses. (author)

  12. Long-term follow-up results in children and adolescents treated with radioactive iodine (131I) for hyperthyroidism

    International Nuclear Information System (INIS)

    Safa, A.M.; Schumacher, O.P.; Rodriguez-Antunez, A.

    1975-01-01

    To evaluate the long-term results of 131 I therapy for children, the course of 87 patients (three to 18 years old, 24 boys and 63 girls) treated from 1949 through 1968, for hyperthyroidism due to Graves's disease was studied. Dose of 131 I per patient ranged from 2.9 to 31 mCi (mean +- S. D., 9.75 +- 6.5). Patients were followed for five to 24 years (mean, 12.3 +- 3.5). Hyperthyroidism was controlled in 85 within one to 14 months (mean, 3.3 +- 2.6). Recurrence of thyrotoxicosis due to toxic diffuse goiter, observed in only one case after 11 years, was successfully re-treated with 131 I. Reproductive history and health status of the progeny of 131 I-treated patients were not different from those of the general population. No deaths and no cancer or leukemia were observed in patients or their offspring. The major cause of goiter regrowth was Hashimoto's thyroiditis. Hypothyroidism developed in 35 of 76 patients (46 percent). 131 I deserves further use in treatment of hyperthyroid children with Graves's disease

  13. Clinical application and observation of curative effect in the near future of iodine-131 therapy in juvenile patients with hyperthyroidism

    International Nuclear Information System (INIS)

    Chen Huilin; Liang Jun; Liang Fengyun

    2004-01-01

    Objective: To assess clinical application of 131 I therapy and observation of curative effect in the near future after treatment in juvenile patients with hyperthyroidism Methods: 44 juvenile patients with hyperthyroidism were divided two subgroups of that children and early youths .The dosage of 131 I were respectively 135.1±34.0(3.65±0.92), 200.2±64.0 MBq(5.41±1.73 mCi). The curative effect belonged in four kinds being to fully recovered, quite a lot, fail to respond to medical and hypothyroidism at six month slater or from then. Results: 46 times treatment were gave and therapy effect was same in every subgroups. The effective rate of total was 89.1% and rater on clinical hypothyroidism was 4.3%. Conclusions: It had an obvious effect that 131 I therapy for juvenile patients with hyperthyroidism. 131 I therapy was also a firmly good select because a well ratio effect/cost. (authors)

  14. Does remnant from differentiated thyroid micro-carcinoma patients really not be treated with Iodine-131 ablation?

    International Nuclear Information System (INIS)

    D'Antuono, F.; Gallicchio, R.; Venetucci, A.; Giacomobono, S.; Tempone, A.; Di Leo, A.; Storto, G.; Nardelli, A.; Pellegrino, T.; Gattozzi, D.

    2015-01-01

    Full text of publication follows. Aim: Remnant ablation by radioiodine is generally not recommended in patients presenting uni- or multifocal cancer <1 cm, without other higher risk features. We retrospectively studied low-risk patients (pts) with differentiated thyroid cancer (DTC) less than 1 cm recruited for radioiodine therapy (RAI). Methods: 91 pts (79 women, age 49.4 ± 10 years) with DTC were recruited for RAI. Pts underwent pre-therapy ultrasonography (US), those with suspected/ambiguous lymph-nodes were excluded and proposed for cytology. Treated pts underwent post-therapeutic whole body scan (WBSt) completed by neck/chest SPECT-CT, when necessary (e.g. evidence of uptake outside of thyroid bed). A target lesion on SPECT-CT was defined as an identifiable lymph-nodal site presenting a matched significant iodine uptake. Patients were followed up for 13 ± 2 months thereafter. Results: All pts/cancers were pT1. Mean histological diameter was (0.66 ± 0.25) cm. Six patients were excluded because of clear nodal involvement at US. Thirty (35%) out of 85 pts had suspicious WBSt as per lymph-nodal involvement which was confirmed at the following SPECT-CT acquisition in most part of pts (25/30; 83 %). Overall detected target lesions was 34, ten (29%) had interim positive fine needle cytology. Conclusions: a significant part of low risk DTC patients, for whom RAI is not recommended, presents an incidental evidence of lymph-nodal involvement at WBSt confirmed by SPECT-CT, when performed. Such setting would have not been treated by I-131. Indications for RAI in DTC low risk patients could be revised at least considering a different dimensional cut-off for the primary lesion. (authors)

  15. Radioiodine uptake following iodine-131 therapy for Graves' disease: an early indicator of need for retreatment

    Energy Technology Data Exchange (ETDEWEB)

    Carpentier, W.R.; Gilliland, P.F.; Piziak, V.K.; Petty, F.C.; McConnell, B.G.; Verdonk, C.A.; Ibarra, J.D.; Thompson, J.Q.

    1989-01-01

    Forty-five patients with Graves' disease were studied prospectively to determine if 24-hour I-131 uptake measurements alone or in combination with serum thyroid hormone levels at six weeks would determine the necessity for retreatment of the thyrotoxicosis. All patients with an I-131 uptake greater than 30% at six weeks required retreatment. No patient with an I-131 uptake of less than 15% required retreatment. Patients with uptakes between 15% and 30% were variable. An elevated free thyroxin index at 6 weeks is not helpful to determine which patients will remain thyrotoxic. Patients with a free thyroxin index within the normal range at six weeks can be predicted to be euthyroid by 12 weeks if their 24-hour I-131 uptake is between 15% and 30% and to be hypothyroid if their 24-hour I-131 uptake is below 15%. There was no difference between patient groups treated initially with antithyroid medication and those who were not.

  16. Transient hypothyroidism in iodine-131 treated thyrotoxicosis - a review of cases from 1970-1984 at JRRMMC

    International Nuclear Information System (INIS)

    Reyes, E.B.; de la Cruz, C.; Gonzales, V.L.

    1988-01-01

    This review was conducted to determine the minimum dose of radioactive iodine necessary to show signs and symptoms of thyrotoxicosis among Filipinos, to determine the incidence of hypothyroidism secondary to radioactive treatment and to determine if some cases of hypothyroidism following radioactive iodine treatment are only transient and replacement therapy could be withheld or not. A total of 212 patients who had I-131 therapy was evaluated (177 female and 35 male). Of this number 19 or 8.9% developed hypothyroidism. After three years, 14 or 74% of the hypothyroids were noted. Easy fatigability ranked first of the patients complaints, followed by dry skin, sleepiness, numbness of extremities, and joint pains. Results of this study indicate that there is a definite, although low incidence of hypothyroidism following I-131 therapy (8.9%). (ELC). 6 refs.; 6 tabs

  17. Comparative dual-tracer studies of carbon-14 tryptophan and iodine-131 HIPDM in animal models of pancreatic diseases

    International Nuclear Information System (INIS)

    Kubota, K.; Som, P.; Brill, A.B.; Sacker, D.F.; Meinken, G.E.; Srivastava, S.C.; Atkins, H.L.

    1989-01-01

    Our previous studies have shown that a significant amount of the diamine derivative 131 I-N,N,N'-trimethyl-N'-(2-hydroxy-3-methyl-5-iodobenzyl)-1,3- propanediamine (HIPDM) is taken up and retained by the normal pancreas. Therefore, we studied the uptake of [ 13 1I]HIPDM in various pathophysiological models in mice (chronic alcoholism, diabetes with beta-cell atrophy and obesity with beta-cell hypertrophy) and compared to 14 C-L-Tryptophan (TRY) distribution in order to determine the factors influencing their pancreatic uptake. In normal animals, the pancreas uptake of TRY was generally higher than HIPDM. In diabetes, the relative concentration of both compounds was higher over the controls; however, in obesity, TRY showed lower accumulation than in controls while HIPDM showed no significant difference. Chronic ethanol (20%) ingestion increased TRY uptake in the pancreas compared to controls (36.88 ± 3.21 vs. 30.03 ± 4.17% ID/g; p less than 0.01) after 5 wk study period, but it decreased by 10 wk (22.36 ± 0.95% ID/g; p less than 0.005). There were no significant changes in [ 131 I]HIPDM distribution in alcoholics as compared to the controls. Radioiodinated HIPDM has potential advantages over [ 11 C]TRY for pancreatic imaging since conventional imaging techniques can be employed. Our data, however, suggest that 11 C-L-TRY is a more sensitive indicator of various pancreatic disorders

  18. [Complete hormonal and metabolic response after iodine-131 metaiodobenzylguanidine treatment in a patient diagnosed of malignant pheochromocytoma].

    Science.gov (United States)

    García Alonso, M P; Balsa Bretón, M A; Paniagua Correa, C; Castillejos Rodríguez, L; Rodríguez Pelayo, E; Mendoza Paulini, A; Ortega Valle, A; Penín González, J

    2013-01-01

    Radiolabeled metaiodobenzylguanidine is an analogue of norepinephrine used to localize tumors that express the neurohormone transporters, specifically those derived from the neural crest having a neuroendocrine origin. It is also used to treat non-surgical metastases derived from them. A review of the literature revealed symptomatic improvements associated to a decrease in hormone levels in a significant percentage of patients after (131)I-MIBG treatment. However, complete tumor remission has been described only in very few cases and hardly ever when bone metastases exist. We present a case of a patient diagnosed of malignant pheochromocytoma who achieved complete hormonal and metabolic response after (131)I-MIBG treatment (600 mCi) in spite of the presence of bone metastases. Copyright © 2012 Elsevier España, S.L. and SEMNIM. All rights reserved.

  19. Succesful labelling schemes

    DEFF Research Database (Denmark)

    Juhl, Hans Jørn; Stacey, Julia

    2001-01-01

    . In the spring of 2001 MAPP carried out an extensive consumer study with special emphasis on the Nordic environmentally friendly label 'the swan'. The purpose was to find out how much consumers actually know and use various labelling schemes. 869 households were contacted and asked to fill in a questionnaire...... it into consideration when I go shopping. The respondent was asked to pick the most suitable answer, which described her use of each label. 29% - also called 'the labelling blind' - responded that they basically only knew the recycling label and the Government controlled organic label 'Ø-mærket'. Another segment of 6...

  20. Synthesizing labeled compounds

    International Nuclear Information System (INIS)

    London, R.E.; Matwiyoff, N.A.; Unkefer, C.J.; Walker, T.E.

    1983-01-01

    A metabolic study is presented of the chemical reactions provided by isotopic labeling and NMR spectroscopy. Synthesis of 13 C-labeled D-glucose, a 6-carbon sugar, involves adding a labeled nitrile group to the 5-carbon sugar D-arabinose by reaction with labeled hydrogen cyanide. The product of this reaction is then reduced and hydrolyzed to a mixture of the labeled sugars. The two sugars are separated by absorption chromotography. The synthesis of 13 C-labeled L-tyrosine, an amino acid, is also presented

  1. Electronic Submission of Labels

    Science.gov (United States)

    Pesticide registrants can provide draft and final labels to EPA electronically for our review as part of the pesticide registration process. The electronic submission of labels by registrants is voluntary but strongly encouraged.

  2. Robust Active Label Correction

    DEFF Research Database (Denmark)

    Kremer, Jan; Sha, Fei; Igel, Christian

    2018-01-01

    for the noisy data lead to different active label correction algorithms. If loss functions consider the label noise rates, these rates are estimated during learning, where importance weighting compensates for the sampling bias. We show empirically that viewing the true label as a latent variable and computing......Active label correction addresses the problem of learning from input data for which noisy labels are available (e.g., from imprecise measurements or crowd-sourcing) and each true label can be obtained at a significant cost (e.g., through additional measurements or human experts). To minimize......). To select labels for correction, we adopt the active learning strategy of maximizing the expected model change. We consider the change in regularized empirical risk functionals that use different pointwise loss functions for patterns with noisy and true labels, respectively. Different loss functions...

  3. Pesticide Product Label System

    Data.gov (United States)

    U.S. Environmental Protection Agency — The Pesticide Product Label System (PPLS) provides a collection of pesticide product labels (Adobe PDF format) that have been approved by EPA under Section 3 of the...

  4. Semiotic labelled deductive systems

    Energy Technology Data Exchange (ETDEWEB)

    Nossum, R.T. [Imperial College of Science, Technology and Medicine, London (United Kingdom)

    1996-12-31

    We review the class of Semiotic Models put forward by Pospelov, as well as the Labelled Deductive Systems developed by Gabbay, and construct an embedding of Semiotic Models into Labelled Deductive Systems.

  5. Mental Labels and Tattoos

    Science.gov (United States)

    Hyatt, I. Ralph

    1977-01-01

    Discusses the ease with which mental labels become imprinted in our system, six basic axioms for maintaining negative mental tattoos, and psychological processes for eliminating mental tattoos and labels. (RK)

  6. Soil Fumigant Labels - Dazomet

    Science.gov (United States)

    Updated labels include new safety requirements for buffer zones and related measures. Find information from the Pesticide Product Labeling System (PPLS) for products such as Basamid G, manufactured by Amvac.

  7. Soil Fumigant Labels - Chloropicrin

    Science.gov (United States)

    Search by EPA registration number, product name, or company name, and follow the link to the Pesticide Product Label System (PPLS) for details on each fumigant. Updated labels include new safety requirements for buffer zones and related measures.

  8. A Label to Regulate

    DEFF Research Database (Denmark)

    Tricoire, Aurélie; Boxenbaum, Eva; Laurent, Brice

    This paper examines the role labelling plays in the government of the contemporary economy.1Drawing on a detailed study of BBC-Effinergy, a French label for sustainable construction, we showhow the adoption and evolution of voluntary labels can be seen as emblematic of a governmentthrough experim...

  9. Labelling subway lines

    NARCIS (Netherlands)

    Garrido, M.A.; Iturriaga, C.; Márquez, A.; Portillo, J.R.; Reyes, P.; Wolff, A.; Eades, P.; Takaoka, T.

    2001-01-01

    Graphical features on map, charts, diagrams and graph drawings usually must be annotated with text labels in order to convey their meaning. In this paper we focus on a problem that arises when labeling schematized maps, e.g. for subway networks. We present algorithms for labeling points on a line

  10. Label Review Training: Module 1: Label Basics, Page 15

    Science.gov (United States)

    This module of the pesticide label review training provides basic information about pesticides, their labeling and regulation, and the core principles of pesticide label review. Learn about the consequences of improper labeling.

  11. Label Review Training: Module 1: Label Basics, Page 23

    Science.gov (United States)

    This module of the pesticide label review training provides basic information about pesticides, their labeling and regulation, and the core principles of pesticide label review. Lists types of labels that do not require review.

  12. Label Review Training: Module 1: Label Basics, Page 16

    Science.gov (United States)

    This module of the pesticide label review training provides basic information about pesticides, their labeling and regulation, and the core principles of pesticide label review. Learn about the importance of labels and the role in enforcement.

  13. Label Review Training: Module 1: Label Basics, Page 14

    Science.gov (United States)

    This module of the pesticide label review training provides basic information about pesticides, their labeling and regulation, and the core principles of pesticide label review. Learn about positive effects from proper labeling.

  14. Label Review Training: Module 1: Label Basics, Page 21

    Science.gov (United States)

    This module of the pesticide label review training provides basic information about pesticides, their labeling and regulation, and the core principles of pesticide label review. Learn about types of labels.

  15. Label Review Training: Module 1: Label Basics, Page 22

    Science.gov (United States)

    This module of the pesticide label review training provides basic information about pesticides, their labeling and regulation, and the core principles of pesticide label review. Learn about what labels require review.

  16. Label Review Training: Module 1: Label Basics, Page 18

    Science.gov (United States)

    This module of the pesticide label review training provides basic information about pesticides, their labeling and regulation, and the core principles of pesticide label review. This section discusses the types of labels.

  17. Label Review Training: Module 1: Label Basics, Page 26

    Science.gov (United States)

    This module of the pesticide label review training provides basic information about pesticides, their labeling and regulation, and the core principles of pesticide label review. Learn about mandatory and advisory label statements.

  18. Label Review Training: Module 1: Label Basics, Page 24

    Science.gov (United States)

    This module of the pesticide label review training provides basic information about pesticides, their labeling and regulation, and the core principles of pesticide label review. This page is about which labels require review.

  19. Label Review Training: Module 1: Label Basics, Page 27

    Science.gov (United States)

    This module of the pesticide label review training provides basic information about pesticides, their labeling and regulation, and the core principles of pesticide label review. See examples of mandatory and advisory label statements.

  20. Label Review Training: Module 1: Label Basics, Page 19

    Science.gov (United States)

    This module of the pesticide label review training provides basic information about pesticides, their labeling and regulation, and the core principles of pesticide label review. This section covers supplemental distributor labeling.

  1. Label Review Training: Module 1: Label Basics, Page 17

    Science.gov (United States)

    This module of the pesticide label review training provides basic information about pesticides, their labeling and regulation, and the core principles of pesticide label review. See an overview of the importance of labels.

  2. Labelling of equipment dispensers.

    Science.gov (United States)

    Gray, D C

    1993-01-01

    A new labelling system for use on medical equipment dispensers is tested. This system uses one of the objects stored in each unit of the dispenser as the 'label', by attaching it to the front of the dispenser with tape. The new system was compared to conventional written labelling by timing subjects asked to select items from two dispensers. The new system was 27% quicker than the conventional system. Images Fig. 1 PMID:8110335

  3. Deuterium labeled cannabinoids

    International Nuclear Information System (INIS)

    Driessen, R.A.

    1979-01-01

    Complex reactions involving ring opening, ring closure and rearrangements hamper complete understanding of the fragmentation processes in the mass spectrometric fragmentation patterns of cannabinoids. Specifically labelled compounds are very powerful tools for obtaining more insight into fragmentation mechanisms and ion structures and therefore the synthesis of specifically deuterated cannabinoids was undertaken. For this, it was necessary to investigate the preparation of cannabinoids, appropriately functionalized for specific introduction of deuterium atom labels. The results of mass spectrometry with these labelled cannabinoids are described. (Auth.)

  4. Effective sample labeling

    International Nuclear Information System (INIS)

    Rieger, J.T.; Bryce, R.W.

    1990-01-01

    Ground-water samples collected for hazardous-waste and radiological monitoring have come under strict regulatory and quality assurance requirements as a result of laws such as the Resource Conservation and Recovery Act. To comply with these laws, the labeling system used to identify environmental samples had to be upgraded to ensure proper handling and to protect collection personnel from exposure to sample contaminants and sample preservatives. The sample label now used as the Pacific Northwest Laboratory is a complete sample document. In the event other paperwork on a labeled sample were lost, the necessary information could be found on the label

  5. Dynamic map labeling.

    Science.gov (United States)

    Been, Ken; Daiches, Eli; Yap, Chee

    2006-01-01

    We address the problem of filtering, selecting and placing labels on a dynamic map, which is characterized by continuous zooming and panning capabilities. This consists of two interrelated issues. The first is to avoid label popping and other artifacts that cause confusion and interrupt navigation, and the second is to label at interactive speed. In most formulations the static map labeling problem is NP-hard, and a fast approximation might have O(nlogn) complexity. Even this is too slow during interaction, when the number of labels shown can be several orders of magnitude less than the number in the map. In this paper we introduce a set of desiderata for "consistent" dynamic map labeling, which has qualities desirable for navigation. We develop a new framework for dynamic labeling that achieves the desiderata and allows for fast interactive display by moving all of the selection and placement decisions into the preprocessing phase. This framework is general enough to accommodate a variety of selection and placement algorithms. It does not appear possible to achieve our desiderata using previous frameworks. Prior to this paper, there were no formal models of dynamic maps or of dynamic labels; our paper introduces both. We formulate a general optimization problem for dynamic map labeling and give a solution to a simple version of the problem. The simple version is based on label priorities and a versatile and intuitive class of dynamic label placements we call "invariant point placements". Despite these restrictions, our approach gives a useful and practical solution. Our implementation is incorporated into the G-Vis system which is a full-detail dynamic map of the continental USA. This demo is available through any browser.

  6. Stable isotopes labelled compounds

    International Nuclear Information System (INIS)

    1982-09-01

    The catalogue on stable isotopes labelled compounds offers deuterium, nitrogen-15, and multiply labelled compounds. It includes: (1) conditions of sale and delivery, (2) the application of stable isotopes, (3) technical information, (4) product specifications, and (5) the complete delivery programme

  7. Edge colouring by total labellings

    DEFF Research Database (Denmark)

    Brandt, Stephan; Rautenbach, D.; Stiebitz, M.

    2010-01-01

    We introduce the concept of an edge-colouring total k-labelling. This is a labelling of the vertices and the edges of a graph G with labels 1, 2, ..., k such that the weights of the edges define a proper edge colouring of G. Here the weight of an edge is the sum of its label and the labels of its...

  8. Radioiodine and its labelled compounds

    International Nuclear Information System (INIS)

    Robles, Ana Maria

    1994-01-01

    Chemical characteristics and their nuclear characteristics, types of labelled molecules,labelling procedures, direct labelling with various oxidizing agents, indirect labelling with various conjugates attached to protein molecules, purification and quality control. Iodination damage.Safe handling of labelling procedures with iodine radioisotopes.Bibliography

  9. 'Naturemade' -- a new label

    International Nuclear Information System (INIS)

    Niederhaeusern, A.

    2001-01-01

    This short article discusses the introduction of the 'Naturemade' two-level labelling scheme in the Swiss electricity market, which is to help provide transparency in the market for green power and promote the building of facilities for its production. In the form of an interview with the CEO of Swissolar and the president of Greenpeace Switzerland, the pros and contras of these labels are discussed. In particular, the interview partners' opinions on the possible misuse of the less stringent label and the influence of the labels on the construction of new installations for the generation of electricity from renewable sources are presented. The basic principles of the promotional model behind the labels are listed

  10. Label Review Training: Module 1: Label Basics, Page 25

    Science.gov (United States)

    This module of the pesticide label review training provides basic information about pesticides, their labeling and regulation, and the core principles of pesticide label review: clarity, accuracy, consistency with EPA policy, and enforceability.

  11. Label Review Training: Module 1: Label Basics, Page 29

    Science.gov (United States)

    This module of the pesticide label review training provides basic information about pesticides, their labeling and regulation, and the core principles of pesticide label review. This page is a quiz on Module 1.

  12. Soil Fumigant Labels - Methyl Bromide

    Science.gov (United States)

    Search soil fumigant pesticide labels by EPA registration number, product name, or company, and follow the link to The Pesticide Product Label System (PPLS) for details. Updated labels include new safety requirements for buffer zones and related measures.

  13. Radioactive labelled orgotein

    International Nuclear Information System (INIS)

    1980-01-01

    The preparation and use of radioactively labelled orgotein, i.e. water-soluble protein congeners in pure, injectable form, is described. This radiopharmaceutical is useful in scintigraphy, especially for visualization of the kidneys where the orgotein is rapidly concentrated. Details of the processes for labelling bovine orgotein with sup(99m)Tc, 60 Co, 125 I or 131 I are specified. The pharmaceutical preparation of the labelled orgotein for intravenous and parenteral administration is also described. Examples using either sup(99m)TC or 125 I-orgotein in scintiscanning dogs' kidneys are given. (UK)

  14. The clearance of liposomes administered by the intramuscular route

    International Nuclear Information System (INIS)

    Arrowsmith, M.; Mills, S.N.

    1982-01-01

    Iodine 131-labelled lecithin was used to label liposomes entrapping cortisone-21-palmitate. The lecithin was injected into the fascia latae muscles of rabbits and the percentage of the initial dose remaining at certain time intervals was calculated from gamma camera image data. Release from the intramuscular site occurs by diffusion from intact liposomes. (U.K.)

  15. A comparison of targeting of neuroblastoma with mIBG and anti L1-CAM antibody mAb chCE7: therapeutic efficacy in a neuroblastoma xenograft model and imaging of neuroblastoma patients

    NARCIS (Netherlands)

    Hoefnagel, C. A.; Rutgers, M.; Buitenhuis, C. K.; Smets, L. A.; de Kraker, J.; Meli, M.; Carrel, F.; Amstutz, H.; Schubiger, P. A.; Novak-Hofer, I.

    2001-01-01

    Iodine-131 labelled anti L1-CAM antibody mAb chCE7 was compared with the effective neuroblastoma-seeking agent 131I-labelled metaiodobenzylguanidine (MIBG) with regard to (a) its therapeutic efficacy in treating nude mice with neuroblastoma xenografts and (b) its tumour targeting ability in

  16. On Online Labeling with Polynomially Many Labels

    DEFF Research Database (Denmark)

    Babka, Martin; Bulánek, Jan; Cunat, Vladimír

    2012-01-01

    be necessary to change the labels of some items; such changes may be done at any time at unit cost for each change. The goal is to minimize the total cost. An alternative formulation of this problem is the file maintenance problem, in which the items, instead of being labeled, are maintained in sorted order...... in an array of length m, and we pay unit cost for moving an item. For the case m = cn for constant c > 1, there are known algorithms that use at most O(n log(n)2) relabelings in total [9], and it was shown recently that this is asymptotically optimal [1]. For the case of m = θ(nC) for C > 1, algorithms...

  17. Clinical applications of cells labelling

    International Nuclear Information System (INIS)

    Gonzalez, B.M.

    1994-01-01

    Blood cells labelled with radionuclides are reviewed and main applications are described. Red blood cell labelling by both random and specific principle. A table with most important clinical uses, 99mTc labelling of RBC are described pre tinning and in vivo reduction of Tc, in vitro labelling and administration of labelled RBC and in vivo modified technique. Labelled leucocytes with several 99mTc-complex radiopharmaceuticals by in vitro technique and specific monoclonal s for white cells(neutrofiles). Labelled platelets for clinical use and research by in vitro technique and in vivo labelling

  18. Labeling of vasoactive intestinal peptide (VIP) and VIP 10-28 fragment with radioiodine by direct method. Comparative study of the kinetics biodistribution and affinity for neuroendocrine tumor cells

    International Nuclear Information System (INIS)

    Colturato, Maria Tereza

    2005-01-01

    mixture (simple purification) and to produce the radiopharmaceutical with high specific activity (complex purification and HPLC), were both efficient in the separation of the species in the reaction mixtures, as demonstrated by quality control procedures. Biological distribution studies were accomplished by venous administration of the radiopharmaceuticals in laboratory animals: biodistribution study of [ 131 I]VIP and [ 131 I]VIP 10-28 in normal Swiss mice, [ 131 I]VIP not purified and purified in Swiss mice with tumor and [ 131 I]VIP and [ 131 I]VIP 10-28 in Nude mice with tumor, scintigraphic images of [ 131/123 I]VIP and [ 123 I]VIP 10-28 in Swiss and Nude mice and Wistar rats with tumor. In vitro studies were accomplished to determine the percentage of [ 131 I]VIP and [ 131 I]VIP 10-28 bound to plasmatic proteins, stability study of [ 131 I]VIP and [ 131 I]VIP 10-28 in human plasma and the affinity and internalization of [ 131 I]VIP and [ 131 I]VIP 10-28 by tumour adenocarcinoma cells of human rectal colon (HT-29). All biological distribution studies demonstrated that both [ 131/123 I]VIP and [ 131/123 I]VIP 10-28 showed fast blood clearance, low renal and liver uptake, relative uptake in thyroid, showing in vivo dehalogenation and good uptake in tumour. Comparative biological distribution of the radiopharmaceuticals showed high uptake in the stomach for both peptides. The blood clearance of the fragment was slower, and influences the visualization of the tumour mass. The radiopharmaceuticals, [ 123 I]VIP and [ 123 I]VIP 10-28, were obtained with high radiochemical purity, but with low radiochemical yield when comparing with labeling procedures using iodine-131. Quality control assays of [ 123 I]Na indicated that the presence of radiochemical and radionuclide impurities influenced on labeling results. (author)

  19. FDA Online Label Repository

    Data.gov (United States)

    U.S. Department of Health & Human Services — The drug labels and other drug-specific information on this Web site represent the most recent drug listing information companies have submitted to the Food and Drug...

  20. Figuring Out Food Labels

    Science.gov (United States)

    ... It's also displayed in grocery stores near fresh foods, like fruits, vegetables, and fish. The nutrition facts label includes: a ... found in citrus fruits, other fruits, and some vegetables. Food companies might also list the amounts of other ...

  1. Energy efficiency labelling

    Energy Technology Data Exchange (ETDEWEB)

    1978-04-01

    This research assesses the likely effects on UK consumers of the proposed EEC energy-efficiency labeling scheme. Unless (or until) an energy-labeling scheme is introduced, it is impossible to do more than postulate its likely effects on consumer behavior. This report shows that there are indeed significant differences in energy consumption between different brands and models of the same appliance of which consumers are unaware. Further, the report suggests that, if a readily intelligible energy-labeling scheme were introduced, it would provide useful information that consumers currently lack; and that, if this information were successfully presented, it would be used and could have substantial effects in reducing domestic fuel consumption. Therefore, it is recommended that an energy labeling scheme be introduced.

  2. Like your labels?

    Science.gov (United States)

    Field, Michele

    2010-01-01

    The descriptive “conventions” used on food labels are always evolving. Today, however, the changes are so complicated (partly driven by legislation requiring disclosures about environmental impacts, health issues, and geographical provenance) that these labels more often baffle buyers than enlighten them. In a light-handed manner, the article points to how sometimes reading label language can be like deciphering runes—and how if we are familiar with the technical terms, we can find a literal meaning, but still not see the implications. The article could be ten times longer because food labels vary according to cultures—but all food-exporting cultures now take advantage of our short attention-span when faced with these texts. The question is whether less is more—and if so, in this contest for our attention, what “contestant” is voted off.

  3. Labelling of electricity

    International Nuclear Information System (INIS)

    Dettli, R.; Markard, J.

    2001-01-01

    This comprehensive report for the Swiss Federal Office of Energy (SFOE) presents a possible course of action to be taken to provide a means of declaring the sources of electrical power, as is foreseen in the draft of new Swiss electricity market legislation. The report presents the basic ideas behind the idea and defines the terms used such as labelling, certificates and declarations. Also, the legal situation in the European Union and in Switzerland is examined and a quantitative overview of electricity production and consumption is presented. Suggestions for a labelling scheme are made and some of the problems to be expected are looked at. The report also presents a series of examples of labelling schemes already implemented in other countries, such as Austria, Great Britain, Sweden and Germany. Tradable certificates and tracking systems are discussed as are initial quality labels like the Swiss 'Naturemade' label for green power. A concrete recommendation for the declaration and labelling of electricity in Switzerland is presented and various factors to be considered such as import/export, pumped storage, distribution losses, small-scale producers as well as the time-scales for introduction are discussed

  4. 78 FR 66826 - Prior Label Approval System: Generic Label Approval

    Science.gov (United States)

    2013-11-07

    ... raising of animals, such as ``no antibiotics administered'' or ``vegetarian fed''; (4) instructional or... Standards and Labeling Policy Book includes animal production claims; omega fatty acid guidance; allergen... inclusion of Country of Origin Labeling on all labels; the production and sale of labels by USDA; developing...

  5. European consumers and nutrition labelling

    DEFF Research Database (Denmark)

    Wills, Josephine M.; Grunert, Klaus G.; Celemín, Laura Fernández

    2009-01-01

    Nutrition labelling of food in Europe is not compulsory, unless a nutrition or health claim is made for the product. The European Commission is proposing mandatory nutrition labelling, even front of pack labelling with nutrition information. Yet, how widespread is nutrition labelling in the EU...

  6. Genetic algorithms for map labeling

    NARCIS (Netherlands)

    Dijk, Steven Ferdinand van

    2001-01-01

    Map labeling is the cartographic problem of placing the names of features (for example cities or rivers) on the map. A good labeling has no intersections between labels. Even basic versions of the problem are NP-hard. In addition, realistic map-labeling problems deal with many cartographic

  7. Radioactive labelling of peptidic hormones

    International Nuclear Information System (INIS)

    Fromageot, P.; Pradelles, P.; Morgat, J.L.; Levine, H.

    1976-01-01

    The labelling of peptidic hormones requires stability, specificity and sensitivity of the label. Introduction of a radioactive atome is one way to satisfy these criteria. Several processes have been described to prepare radioactive TRF: synthesis of the peptide with labelled aminoacids or introduction of the label into the hormone. In that approach, tritium can be substituted in the imidazole ring, via precursors activating the proper carbon. Monoiodo TRF leads essentially to tritium labelling of the 5 positions whereas monoazo TRF allows the preparation of 3 H TRF labelled in the 2 positions. Di-substituted TRF leads to labelling into the 2 and 5 carbons. Labelled analogs of TRF can be prepared with labelled iodine; further developments of peptide labelling, will be presented. In particular, the homolytic scission of the C-iodine, bond by photochemical activation. The nascent carbon radical can be stabilized by a tritiated scavenger. This approach eliminates the use of heavy metal catalysts

  8. Radiopharmaceutical labeling research

    International Nuclear Information System (INIS)

    Anon.

    1985-01-01

    The objective of this research is to develop methods of attaching radionuclides to monoclonal antibodies and antibody fragments for use in tumor imaging and internal radiation therapy. Monoclonal antibodies and their fragments are of interest because they enable the selective targeting of tumors. The labeled antibodies could be employed as carriers to transport radioisotopes to tumors, thus minimizing total-body radiation dose and radiation damage to normal tissue. Because the time required for labeled antibodies to find the tumor antigen and deliver the dose to the tumor is estimated to be about 1-3 days, radionuclides with a l- to 3-day half-life would be optimum for this purpose. Two of the radionuclides produced at LAMPF, 67 Cu and 77 Br, have the suitable half-life and nuclear-decay properties for use in tumor imaging or therapy with radiolabeled antibodies. These radionuclides and the efforts to prepare radiolabeled antibodies with them are described. We have used three different approaches to meet this objective of labeling antibodies: (1) labeling chelating agents with metal radionuclides, then conjugating the labeled chelating agents to antibodies; (2) conjugating activated chelating agents to antibodies, followed by metalation with metal radionuclides; and (3) radiobrominating small molecules that can be conjugated to antibodies

  9. Fluorine-18 labelled compounds

    International Nuclear Information System (INIS)

    Kleijn, J.P. de

    1978-01-01

    The work presented in this thesis deals with the problems involved in the adaption of reactor-produced fluorine-18 to the synthesis of 18 F-labelled organic fluorine compounds. Several 18 F-labelling reagents were prepared and successfully applied. The limitations to the synthetic possibilities of reactor-produced fluoride- 18 become manifest in the last part of the thesis. An application to the synthesis of labelled aliphatic fluoro amino acids has appeared to be unsuccessful as yet, although some other synthetic approaches can be indicated. Seven journal articles (for which see the availability note) are used to compose the four chapters and three appendices. The connecting text gives a survey of known 18 F-compounds and methods for preparing such compounds. (Auth.)

  10. Synthesis of labeled compounds

    International Nuclear Information System (INIS)

    Whaley, T.W.

    1977-01-01

    Intermediate compounds labeled with 13 C included methane, sodium cyanide, methanol, ethanol, and acetonitrile. A new method for synthesizing 15 N-labeled 4-ethylsulfonyl-1-naphthalene-sulfonamide was developed. Studies were conducted on pathways to oleic-1- 13 C acid and a second pathway investigated was based on carbonation of 8-heptadecynylmagnesium bromide with CO 2 to prepare sterolic acid. Biosynthetic preparations included glucose- 13 C from starch isolated from tobacco leaves following photosynthetic incubation with 13 CO 2 and galactose- 13 C from galactosylglycerol- 13 C from kelp. Research on growth of organisms emphasized photosynthetic growth of algae in which all cellular carbon is labeled. Preliminary experiments were performed to optimize the growth of Escherichia coli on sodium acetate- 13 C

  11. Environmental Labels and Declarations

    DEFF Research Database (Denmark)

    Frydendal, Jeppe; Hansen, Lisbeth; Bonou, Alexandra

    2018-01-01

    Based on the terminology and structure developed by the International Organization for Standardization, a description is given on the types of ecolabels that build on life cycle assessments. Focus is on type I labels that point out products and services with an overall environmental preferability...... of labelling, the use of ecolabels in marketing, and the way ecolabels help build a market for “greener products”. Type III labels—or Environmental Product Declarations—are also briefly described with indicative examples from the building sector, a declaration for office furniture, and an introduction is given...... to the European Commission’s programme for product—and organisational environmental footprints ....

  12. Semantic Role Labeling

    CERN Document Server

    Palmer, Martha; Xue, Nianwen

    2011-01-01

    This book is aimed at providing an overview of several aspects of semantic role labeling. Chapter 1 begins with linguistic background on the definition of semantic roles and the controversies surrounding them. Chapter 2 describes how the theories have led to structured lexicons such as FrameNet, VerbNet and the PropBank Frame Files that in turn provide the basis for large scale semantic annotation of corpora. This data has facilitated the development of automatic semantic role labeling systems based on supervised machine learning techniques. Chapter 3 presents the general principles of applyin

  13. Competing Environmental Labels

    NARCIS (Netherlands)

    Fischer, Carolyn; Lyon, Thomas P.

    2014-01-01

    We study markets in which consumers prefer green products but cannot determine the environmental quality of any given firm's product on their own. A nongovernmental organization (NGO) can establish a voluntary standard and label products that comply with it. Alternatively, industry can create its

  14. The Language of Labels

    Science.gov (United States)

    Markham, Darcy

    2005-01-01

    The author describes how the language of labels and her own cultural biases affect how she approaches teaching her students with disabilities. The author examines how the mythopoetic narratives of our past force us to examine the underlying assumptions of our culture that are expressed within our language and how understanding our own linguistic…

  15. Labeling of Cosmetic Products

    Directory of Open Access Journals (Sweden)

    Nicola Lionetti

    2018-03-01

    Full Text Available The labeling of cosmetic products provides a set of obligations, as reported in the Regulation 1223/2009, which came into force in Europe in July 2013. The indications reported on the label are intended to enable the clear identification of the functionality and proper use of cosmetics, ensure the protection of the consumer from the commercial aspects and, above all, from the safety point of view. Moreover, it should allow quick tracing of the product details and all info of toxicological relevance. However, the misuse of this tool often leads, on one side, to confusion among cosmetics, pharmaceuticals, medical devices, and biocides. On the other side, it gives rise to fanciful interpretations by a huge number of web users, who pretend to be able to judge the quality of a cosmetic product just by reading the ingredients list. This article points out the concrete purpose of cosmetic labels, in order to shed light on the use of certain categories of ‘controversial’ ingredients and on the real quality concepts of cosmetic products. Indeed, when properly interpreted, cosmetic labels represent a good tool for the professional investigation of adverse reactions to cosmetics.

  16. Label Review Training: Module 1: Label Basics, Page 7

    Science.gov (United States)

    Page 7, Label Training, Pesticide labels translate results of our extensive evaluations of pesticide products into conditions, directions and precautions that define parameters for use of a pesticide with the goal of ensuring protection of human he

  17. Spin labels. Applications in biology

    International Nuclear Information System (INIS)

    Frangopol, T.P.; Frangopol, M.; Ionescu, S.M.; Pop, I.V.; Benga, G.

    1980-11-01

    The main applications of spin labels in the study of biomembranes, enzymes, nucleic acids, in pharmacology, spin immunoassay are reviewed along with the fundamentals of the spin label method. 137 references. (author)

  18. Modeling the effects of labeling

    DEFF Research Database (Denmark)

    Juhl, Hans Jørn; Fjord, Thomas Ahle; Poulsen, Carsten Stig

    A new approach to evaluate the consequences of labeling is presented and applied to test the potential effect of a label on fresh fish. Labeling effects on quality perceptions and overall quality are studied. The empirical study is based on an experimental design and nearly 500 respondents...

  19. Isotopically labelled benzodiazepines

    International Nuclear Information System (INIS)

    Liebman, A.A.

    1987-01-01

    This paper reports on the benzodiazepines which are a class of therapeutic agents. Improvements in the analytical methodology in the areas of biochemistry and pharmacology were significant, particularly in the application of chromatographic and spectroscopic techniques. In addition, the discovery and subsequent development of tritium and carbon-14 as an analytical tool in the biological sciences were essentially post-world war II phenomena. Thus, as these new chemical entities were found to be biologically active, they could be prepared in labeled form for metabolic study, biological half-life determination (pharmacokinetics), tissue distribution study, etc. This use of tracer methodology has been liberally applied to the benzodiazepines and also more recently to the study of receptor-ligand interactions, in which tritium, carbon-11 or fluorine-18 isotopes have been used. The history of benzodiazepines as medicinal agents is indeed an interesting one; an integral part of that history is their use in just about every conceivable labeled form

  20. Labeling of vasoactive intestinal peptide (VIP) and VIP 10-28 fragment with radioiodine by direct method. Comparative study of the kinetics biodistribution and affinity for neuroendocrine tumor cells; Marcacao do peptideo intestinal vasoativo (VIP) e do fragmento VIP10-28 com radioiodo por metodo direto. Estudo comparativo da cinetica de biodistribuicao e da afinidade por celulas de tumor neuroendocrino

    Energy Technology Data Exchange (ETDEWEB)

    Colturato, Maria Tereza

    2005-07-01

    labeling mixture (simple purification) and to produce the radiopharmaceutical with high specific activity (complex purification and HPLC), were both efficient in the separation of the species in the reaction mixtures, as demonstrated by quality control procedures. Biological distribution studies were accomplished by venous administration of the radiopharmaceuticals in laboratory animals: biodistribution study of [{sup 131}I]VIP and [{sup 131}I]VIP 10-28 in normal Swiss mice, [{sup 131}I]VIP not purified and purified in Swiss mice with tumor and [{sup 131}I]VIP and [{sup 131}I]VIP 10-28 in Nude mice with tumor, scintigraphic images of [{sup 131/123}I]VIP and [{sup 123}I]VIP 10-28 in Swiss and Nude mice and Wistar rats with tumor. In vitro studies were accomplished to determine the percentage of [{sup 131}I]VIP and [{sup 131}I]VIP 10-28 bound to plasmatic proteins, stability study of [{sup 131}I]VIP and [{sup 131}I]VIP 10-28 in human plasma and the affinity and internalization of [{sup 131}I]VIP and [{sup 131}I]VIP 10-28 by tumour adenocarcinoma cells of human rectal colon (HT-29). All biological distribution studies demonstrated that both [{sup 131/123}I]VIP and [{sup 131/123}I]VIP 10-28 showed fast blood clearance, low renal and liver uptake, relative uptake in thyroid, showing in vivo dehalogenation and good uptake in tumour. Comparative biological distribution of the radiopharmaceuticals showed high uptake in the stomach for both peptides. The blood clearance of the fragment was slower, and influences the visualization of the tumour mass. The radiopharmaceuticals, [{sup 123}I]VIP and [{sup 123}I]VIP 10-28, were obtained with high radiochemical purity, but with low radiochemical yield when comparing with labeling procedures using iodine-131. Quality control assays of [{sup 123}I]Na indicated that the presence of radiochemical and radionuclide impurities influenced on labeling results. (author)

  1. Review of nutrition labeling formats.

    Science.gov (United States)

    Geiger, C J; Wyse, B W; Parent, C R; Hansen, R G

    1991-07-01

    This article examines nutrition labeling history as well as the findings of nine research studies of nutrition labeling formats. Nutrition labeling regulations were announced in 1973 and have been periodically amended since then. In response to requests from consumers and health care professionals for revision of the labeling system, the Food and Drug Administration initiated a three-phase plan for reform of nutrition labeling in 1990. President Bush signed the Nutrition Labeling and Education Act in November 1990. Literature analysis revealed that only nine studies with an experimental design have focused on nutrition labeling since 1971. Four were conducted before 1975, which was the year that nutrition labeling was officially implemented, two were conducted in 1980, and three were conducted after 1986. Only two of the nine studies supported the traditional label format mandated by the Code of Federal Regulations, and one study partially supported it. Four of the nine studies that evaluated graphic presentations of nutrition information found that consumer comprehension of nutrition information was improved with a graphic format for nutrition labeling: three studies supported the use of bar graphs and one study supported the use of a pie chart. Full disclosure (ie, complete nutrient and ingredient labeling) was preferred by consumers in two of the three studies that examined this variable. The third study supported three types of information disclosure dependent upon socioeconomic class. In those studies that tested graphics, a bar graph format was significantly preferred and showed better consumer comprehension than the traditional format.

  2. Linerless label device and method

    KAUST Repository

    Binladen, Abdulkari

    2016-01-14

    This apparatus and method for applying a linerless label to an end user product includes a device with a printer for printing on a face surface of a linerless label, and a release coat applicator for applying a release coat to the face surface of the label; another device including an unwinder unit (103) to unwind a roll of printed linerless label; a belt (108); a glue applicator (102) for applying glue to the belt; a nip roller (106) for contacting and applying pressure to the face surface of the linerless label such that the glue on the belt transfers to the back surface of the linerless label; at least one slitting knife 105) positioned downstream the belt and a rewinder unit (104) positioned downstream the slitting knife; and a third device which die cuts and applies the linerless label to an end user object.

  3. Labelled compounds. (Pt. B)

    International Nuclear Information System (INIS)

    Buncel, E.; Jones, J.R.

    1991-01-01

    Since the end of World War II there has been a tremendous increase in the number of compounds that have been synthesized with radioactive or stable isotopes. They have found application in many diverse fields, so much so, that hardly a single area in pure and applied science has not benefited. Not surprisingly it has been reflected in appearance of related publications. The early proceedings of the Symposia on Advances in Trace Methodology were soon followed by various Euratom sponsored meetings in which methods of preparing and storing labelled compounds featured prominently. In due course a resurgence of interest in stable isotopes, brought about by their greater availability (also lower cost) and partly by development of new techniques such as gas chromatography - mass spectrometry (gc-ms), led to the publication of proceedings of several successful conferences. More recently conferences dealing with the synthesis and applications of isotopes and isotopically labelled compounds have been established on a regular basis. In addition to the proceedings of conferences and journal publications individuals left their mark by producing definitive texts, usually on specific nuclides. Only the classic two volume publication of Murray and Williams (Organic syntheses with isotopes, New York 1985), now over 30 years old and out of print, attempted to do justice to several nuclides. With the large amount of work that has been undertaken since then it seems unlikely that an updated edition could be produced. The alternative strategy was to ask scientists currently active to review specific areas and this is the approach adopted in the present series of monographs. In this way it is intended to cover the broad advances that have been made in the synthesis and applications of isotopes and isotopically labelled compounds in the physical and biomedical sciences. (author). refs.; figs.; tabs

  4. From Label to Practice

    DEFF Research Database (Denmark)

    Byrkjeflot, Haldor; Strandgaard, Jesper; Svejenova, Silviya

    2013-01-01

    because NNC was conceived as an identity movement, triggered by active involvement of entrepreneurial leaders from the culinary profession, high-profile political supporters, legitimating scientists, disseminating media, and interpreting audiences. It was facilitated by three mechanisms: First, the use......This article examines the process of creation of new Nordic cuisine (NNC) as a culinary innovation, focusing on the main stages, actors, and mechanisms that shaped the new label and its practices and facilitated its diffusion in the region and internationally. Fast-paced diffusion was possible...

  5. Label and Label-Free Detection Techniques for Protein Microarrays

    Directory of Open Access Journals (Sweden)

    Amir Syahir

    2015-04-01

    Full Text Available Protein microarray technology has gone through numerous innovative developments in recent decades. In this review, we focus on the development of protein detection methods embedded in the technology. Early microarrays utilized useful chromophores and versatile biochemical techniques dominated by high-throughput illumination. Recently, the realization of label-free techniques has been greatly advanced by the combination of knowledge in material sciences, computational design and nanofabrication. These rapidly advancing techniques aim to provide data without the intervention of label molecules. Here, we present a brief overview of this remarkable innovation from the perspectives of label and label-free techniques in transducing nano‑biological events.

  6. Distance labeling schemes for trees

    DEFF Research Database (Denmark)

    Alstrup, Stephen; Gørtz, Inge Li; Bistrup Halvorsen, Esben

    2016-01-01

    We consider distance labeling schemes for trees: given a tree with n nodes, label the nodes with binary strings such that, given the labels of any two nodes, one can determine, by looking only at the labels, the distance in the tree between the two nodes. A lower bound by Gavoille et al. [Gavoille...... variants such as, for example, small distances in trees [Alstrup et al., SODA, 2003]. We improve the known upper and lower bounds of exact distance labeling by showing that 1/4 log2(n) bits are needed and that 1/2 log2(n) bits are sufficient. We also give (1 + ε)-stretch labeling schemes using Theta...

  7. Co-Labeling for Multi-View Weakly Labeled Learning.

    Science.gov (United States)

    Xu, Xinxing; Li, Wen; Xu, Dong; Tsang, Ivor W

    2016-06-01

    It is often expensive and time consuming to collect labeled training samples in many real-world applications. To reduce human effort on annotating training samples, many machine learning techniques (e.g., semi-supervised learning (SSL), multi-instance learning (MIL), etc.) have been studied to exploit weakly labeled training samples. Meanwhile, when the training data is represented with multiple types of features, many multi-view learning methods have shown that classifiers trained on different views can help each other to better utilize the unlabeled training samples for the SSL task. In this paper, we study a new learning problem called multi-view weakly labeled learning, in which we aim to develop a unified approach to learn robust classifiers by effectively utilizing different types of weakly labeled multi-view data from a broad range of tasks including SSL, MIL and relative outlier detection (ROD). We propose an effective approach called co-labeling to solve the multi-view weakly labeled learning problem. Specifically, we model the learning problem on each view as a weakly labeled learning problem, which aims to learn an optimal classifier from a set of pseudo-label vectors generated by using the classifiers trained from other views. Unlike traditional co-training approaches using a single pseudo-label vector for training each classifier, our co-labeling approach explores different strategies to utilize the predictions from different views, biases and iterations for generating the pseudo-label vectors, making our approach more robust for real-world applications. Moreover, to further improve the weakly labeled learning on each view, we also exploit the inherent group structure in the pseudo-label vectors generated from different strategies, which leads to a new multi-layer multiple kernel learning problem. Promising results for text-based image retrieval on the NUS-WIDE dataset as well as news classification and text categorization on several real-world multi

  8. The radioactive labeling of monocytes

    International Nuclear Information System (INIS)

    Ensing, G.J.

    1985-01-01

    With the aim of studying a possible relationship between circulating monocytes and Sternberg-Reed cells investigations were started on the specific labeling of monocytes. In this thesis the literature on the pertinent data has been reviewed and a series of experiments on the monocyte labeling procedure has been described. The principles of cell labeling with radioactive compounds were discussed. 1. Total separation of the particular cell population to be labeled and subsequent labeling with a non-specific radiopharmaceutical. 2. Specific cell labeling in a mixture of cell types based on a well defined affinity of the cell under study for the radiopharmaceutical used. Next the radionuclides that can be used for cell labeling purposes were discussed with special attention for 111 In and its chelates. The principles of radiodosimetry were also discussed shortly. This section was focussed on the radiation dose the labeled cells receive because of the intracellular localized radioactivity. The radiation burden is high in comparison to amounts of radiation known to affect cell viability. A newly developed method for labeling monocytes specifically by phagocytosis of 111 In-Fe-colloid without apparent loss of cells was described in detail. (Auth.)

  9. Labelled molecules, modern research implements

    International Nuclear Information System (INIS)

    Pichat, L.; Langourieux, Y.

    1974-01-01

    Details of the synthesis of carbon 14- and tritium-labelled molecules are examined. Although the methods used are those of classical organic chemistry the preparation of carbon 14-labelled molecules differs in some respects, most noticeably in the use of 14 CO 2 which requires very special handling techniques. For the tritium labelling of organic molecules the methods are somewhat different, very often involving exchange reactions. The following are described in turn: the so-called Wilzbach exchange method; exchange by catalysis in solution; catalytic hydrogenation with tritium; reductions with borotritides. Some applications of labelled molecules in organic chemistry, biochemistry and pharmacology are listed [fr

  10. Relative value of thallium-201 and iodine-131 scans in the detection of recurrence or distant metastasis of well differentiated thyroid carcinoma

    Energy Technology Data Exchange (ETDEWEB)

    Lin Jen-Der; Weng Hsiao-Fen; Lu Wen-Tsoung [Division of Endocrinology and Metabolism, Chang Gung Memorial Hospital (Taiwan, Province of China); Kao Pan-Fu; Huang Miau-Ju [Department of Nuclear Medicine, Chang Gung Memorial Hospital, Taiwan (Taiwan, Province of China)

    1998-07-01

    Radioactive iodine ({sup 131}I) has been found to be more sensitive and more specific than thallium-201 for the detection of distant metastases and thyroid remnants in the neck in cases of well-differentiated thyroid carcinoma. {sup 201}Tl has been deemed particularly useful in localizing metastases or recurrence in patients with a negative {sup 131}I scan and abnormal levels of serum thyroglobulin (Tg). This study aimed to: (1) determine the value of {sup 201}Tl imaging in localizing metastases or recurrence in patients with well-differentiated thyroid carcinoma, and (2) evaluate the false-positive and false-negative results of {sup 131}I and {sup 201}Tl scintigraphy. Sixty-two thyroid remnant ablated patients who underwent simultaneous postoperative {sup 201}Tl and {sup 131}I scans and and serum Tg determinations were evaluated. Fifty patients had papillary thyroid carcinomas and 12 had follicular thyroid carcinomas. {sup 201}Tl imaging was performed before the {sup 131}I studies. Of the 62 patients who underwent {sup 201}Tl imaging studies, 24 were found to have positive results, with local recurrence or distant metastases. Patients with positive results in the {sup 201}Tl imaging studies tended to be older, were mor often male, had higher Tg levels and had a higher recurrence rate. Of these 24 patients, ten had negative diagnostic or therapeutic {sup 131}I scans. Concurrently, serum Tg levels were less than 5 ng/ml in five of these ten patients. Three patients were deemed false positive by {sup 201}Tl scans; one had a parotid tumour, one a periodontal abscess and one lung metastasis. Among the 38 patients with negative {sup 201}Tl scans, 11 had positive findings on {sup 131}I scans. Three had distant metastases: two with lung metastases and one with bone metastases. Patients with false-positive results on {sup 131}I scans included those with biliary tract stones, ovarian cysts, and breast secretion. Of the 27 patients with negative {sup 201}Tl and {sup 131}I scans, 15 had elevated serum Tg levels. Among these, local recurrence followed by lung metastases was manifested in a 49-year-old male with papillary thyroid carcinoma. In conclusion, both {sup 131}I and {sup 201}Tl scans are useful in the detection of recurrence or distant metastasis of well differentiated thyroid cancers. {sup 201}Tl scan could in particular be used in patients with a negative {sup 131}I scan in conjunction with an elevated Tg level. (orig.) With 8 figs., 3 tabs., 27 refs.

  11. Management of low-risk patients with thyroid carcinoma and detectable thyroglobulin on T4 after thyroidectomy and ablation with iodine-131

    Energy Technology Data Exchange (ETDEWEB)

    Rosario, Pedro Weslley Souza [Clinica de Endocrinologia e Metabologia (CEPCEM), Belo Horizonte, MG (Brazil). Centro de Estudos e Pesquisa]. E-mail: pedrorosario@globo.com; Borges, Michelle A.R.; Costa, Graciela B.C.; Resende, Leonardo L.; Padrao, Eduardo L.; Barroso, Alvaro L.; Purish, Saulo [Santa Casa de Belo Horizonte, MG (Brazil). Dept. de Tireoide. Servico de Endocrinologia; Santa Casa de Belo Horizonte, MG (Brazil). Servico de Medicina Nuclear

    2007-01-15

    Objective: To evaluate the positive predictive value of detectable Tg during T4 therapy (Tg on T4) in patients with thyroid cancer after total thyroidectomy and remnant ablation, discussing the work-up in this situation and the empirical indication of {sup 131}I. Patients and methods: Initially, 234 low-risk patients [tumor {<=} 5 cm, completely resected, no extensive extrathyroid invasion (pT4)] submitted to total thyroidectomy and ablation with {sup 131}I (3.7-5.5 GBq) who presented no ectopic uptake on RxWBS were studied. Of these, 23 patients with detectable Tg on T4 (> 1 ng/ml) during the first year after initial therapy were selected. Results: Metastases were detected by neck US in 7 patients, by chest CT in 2 and by US and CT in 3. Four of five patients with lung metastases upon CT had a positive RxWBS. Eleven patients with negative US and CT received a new {sup 131}I dose (without DxWBS), and RxWBS showed ectopic uptake in 3 patients. Among the patients with negative RxWBS, 7 remained free of apparent disease and Tg was declining (5 with undetectable Tg on T4 at the end of the study). One patient presented an increase in Tg and FDG-PET was positive for lymph node and bone metastases. Conclusions: All patients with Tg on T4 > 5 ng/ml presented apparent disease. In these cases, even when US and CT are negative, the administration of a therapeutic dose of {sup 131}I (without DxWBS) and FDG-PET are recommended. Among patients with detectable Tg on T4 {<=} 5 ng/ml and negative US and CT, only 12% presented ectopic uptake on RxWBS. These cases could be followed up by monitoring Tg on T4, and RxWBS and FDG-PET should only be performed if this marker does not decrease after 1-2 years. (author)

  12. Age dependency in the absorption of radioactive Iodine (131I) in the thyroid and total body of newborn, pubertal and adult fischer 344 rats

    International Nuclear Information System (INIS)

    Nitta, Yumiko; Endo, Satoru; Fujimoto, Nariaki; Kamiya, Kenji; Ohtaki, Megu; Hayakawa, Norihiko; Takada, Jun; Hoshi, Masaharu

    1998-01-01

    In this study, activities of 131 I in the thyroid, total body and blood were measured for rats of three different ages to estimate the movement of 131 I in the body, the absorbed doses were calculated in the thyroid and total body under the exposed condition of iodine deficiency and sufficiency, and the standard curves for the determination of absorbed doses in the thyroid and total body were obtained for rats of newborn, pubertal and adult. Authors used female rats of Fisher 344 strain in this experiment and set up twelve experimental group of different ages (1, 4 and 9 weeks old), and divided each age group into one standard diet (SD) group and three iodine deficient diet (IDD) groups. Rats were intravenously injected once with 131 I in 0.9% saline with the activity of 0.38, 1.03 and 9.42 kBq per g weight. In the thyroid and total body, the absorbed dose values increased in an injected activity-dependent manner, and those of 1-week-old rats were significantly higher than those of 4- and 9-weeks old rats. The absorbed dose values in IDD-treated groups were higher than those in the SD-treated groups. The speed of 131 I accumulation into the thyroid and that of 131 I excretion from the body was slow in 1-week-old groups. The data also showed that most of injected 131 I distributed in the thyroid and blood in 4- and 9-week-old groups but not in the 1-week-old group, indicating that 131 I is pooled in certain tissues or organs except the thyroid in rats of the 1-week-old group at which the development of the thyroid has not been completed. Standard curves were obtained for the estimation of absorbed doses in the thyroid and total body on the bases of injected activity of 131 I for each age group of rats. These standard curves are to be used in the carcinogenesis experiment which compare the effectiveness of internal with external irradiation under the condition of iodine deficiency or sufficiency in the rats of different ages. (K.H.)

  13. Comparison of oral iodine-131-cellulose and indium-111-DTPA as tracers for colon transit scintigraphy: Analysis by colon activity profiles

    International Nuclear Information System (INIS)

    Smart, R.C.; McLean, R.G.; Gaston-Parry, D.; Barbagallo, S.; Bruck, C.E.; King, D.W.; Lubowski, D.Z.; Talley, N.A.

    1991-01-01

    In 11 normal subjects and 11 patients with a clinical diagnosis of constipation, oral 131I-cellulose and 111In-DTPA were compared simultaneously as tracers for radionuclide colon transit scintigraphy. Visual assessment of the images revealed no differences between tracers. Quantitation was performed using total and segmental percent retention and the derived value of clearance half-time. In addition, profiles of the activity distribution along the length of the colon were generated and the mean position of the activity in the colon calculated. For all indices, the results were similar in both normal subjects and constipated patients when comparing tracers, although marked differences were present between normal subjects and constipated patients for each tracer. Indium-111-DTPA was easy to administer and dosimetry was more acceptable than for 131I-cellulose, especially in constipated patients. It is concluded that 111In-DTPA is the preferred tracer for oral colon transit scintigraphy

  14. Clinical comparison of technetium-99m-EC, technetium-99-m-MAG3 and Iodine-131-OIH in renal disorders

    International Nuclear Information System (INIS)

    Kabasakal, L.; Turoglu, T.; Oensel, C.

    1995-01-01

    Technetium-99m-ethylenedicysteine has recently been developed for renal function studies. The pharmacokinetics of 99m Tc-EC were studied by constant infusion technique and compared with 99m Tc-MAG3 and 131 I-OIH in 11 patients with various renal disorders. After giving a 7.4 MBq 131 I-OIH and 90-110 MBq 99m Tc-EC or 99m Tc-MAG3 bolus, a constant infusion (MBq/ml) 99m Tc--agent and 0.07 MBq/m 131 I-OIH was started. Sixteen blood and five urine samples were obtained over three hr. The renal clearance of 99m Tc-EC was higher than than of 99m Tc-MAG3. The 99m Tc-EC/OIH and 99m Tc-MAG3/OIH ratios were 0.75 ± 0.05 and 0.55 ± 0.10 (p=0.00087), respectively. The distribution volume of 99m Tc-EC was also higher than that of 99m Tc-MAG3 (15722 ± 4644 and 9509 ± 2788 ml/1.73m 2 , respectively; p=0.072). The 99m Tc-EC/OIH and 99m Tc-MAG/OIH distribution volume ratios were 1.03 ± 0.14 and 0.55 ± 0.10, respectively (p = 0.0003). The 60-min excretion values of 99m Tc-EC and 99m Tc-MAG3 were compared to that of OIH. The 99m Tc-EC/OIH and 99m Tc-MAG3/OIH excretion ratios were 0.96 ± 0.06 and 1.07 ± 0.10, respectively (p=0.162). The protein binding of 99m -EC and OIH were found to be 34% ±4 and 66% ±5, respectively (p 99m Tc-EC was negligible (3% ±1.2) in comparison to OIH (27% ±3; p 99m Tc-EC. This agent has good potential for renal function evaluation. 32 refs., 5 tabs

  15. Long-term follow-up studies on iodine-131 treatment of hyperthyroid Graves' disease based on the measurement of thyroid volume by ultrasonography

    International Nuclear Information System (INIS)

    Tsuruta, Masako; Nagayama, Yuji; Yokoyama, Naokata; Izumi, Motomori; Nagataki, Shigenobu

    1993-01-01

    In the present series of studies, the long-term (four year) effect of 80 Gy of 131 I treatment was evaluated in patients with hyperthyroid Graves' disease whose thyroid volumes have been accurately estimated with a high resolution ultrasound scanner. One year after 131 I treatment, 23.1% (3 out of 13 patients) remained hyperthyroid, 69.2% (9 out of 13) became euthyroid, and 7.7% (1 out of 13) were in a hypothyroid state. Since three patients in a hyperthyroid state one year after treatment were subsequently treated with either antithyroid drugs or additional 131 I treatment, the remaining ten patients (9 euthyroid and 1 hypothyroid patients) have been followed up for three more years. Two patients developed a hypothyroid state three years after treatment and one patient four years after treatment. Overall, 60% (6 out of 10 patients) were in a euthyroid state and 40% (4 out of 10) in a hypothyroid state, four years after 80 Gy 131 I treatment. There was no significant difference between eu- and hypo-thyroid groups in the sex ratio, age, radiation doses, therapeutic dose, thyroid gland volume, 24-hr 131 I uptake, the effective half-life of 131 I in the thyroid or the duration of hyperthyroidism. In our preliminary studies, the incidence of late hypothyroidism in our 131 I treatment is similar to those previously reported. These suggest that uncertain factor(s), such as inhomogeneity of iodine distribution in the thyroid, unequal sensitivity of the thyroid cells to the radiation, and/or persistent destructive effects of the autoimmune process may influence the long-term effect of 131 I treatment of Graves' disease. (author)

  16. Contribution of radio-iodine 131 in the treatment of Grave's Basedow disease in the department of nuclear medicine of Ibn Sina Hospital in Rabat

    International Nuclear Information System (INIS)

    Mbodj, M.; Amjad, I.; Guerrouj, H.; Ben Rais, N.A.

    2009-01-01

    One hundred and twenty-nine Grave's Basedow diseases in any gender and variable age patients, coming from several cities of Morocco, were randomized in a study of radio-iodine treatment who took place at the nuclear medicine department of Ibn Sina Hospital (Rabat, Morocco) during the period (from January 2001 to December 2008). The radio-iodine treatment was a first, second or third option and radio-iodine activities delivered varied (from 222 to 555 MBq 6 to 15 mCi) according to the age, the thyroid volume, the degree of hyperthyroidism and socio-economical situation. The high amounts of 131 I were reserved especially to the patients who live far and whose socio-economic level is low with an aim of quickly obtaining an easily controllable state of hypothyroidism by a substitute treatment. The results showed that: (1) 57.36% of patients reverted to euthyroidism (n = 74) with a patient having received two 131 I cures. The second cure was justified by recurrence of hyperthyroidism after the first cure; (2) 34.88% passed in hypothyroidism (n = 45) with three patients having received two cures of 131 I, the second cure was justified by recurrence of hyperthyroidism after the first cure in two patients and by the persistence of the hyperthyroidism after the first cure for the third patient. The average time of passage in hypothyroidism was 4.5 months; (3) 7.76% had remained in hyperthyroidism after the radioactive iodine treatment. Finally, 92.24% of our patients treated by radioactive iodine had passed in euthyroidism or hypothyroidism against 7.76% whose hyperthyroidism had persisted or occurred. (authors)

  17. The role of FDG-PET/CT in differentiated thyroid cancer patients with negative iodine-131 whole-body scan and elevated anti-Tg level.

    Science.gov (United States)

    Asa, Sertac; Aksoy, Sabire Yılmaz; Vatankulu, Betül; Aliyev, Anar; Uslu, Lebriz; Ozhan, Meftune; Sager, Sait; Halac, Metin; Sonmezoglu, Kerim

    2014-12-01

    In the follow-up of differentiated thyroid cancer (DTC) after a successful total-near total thyroidectomy and I-131 ablation therapy, anti-thyroglobulin antibodies (anti-Tg) may be persistently or progressively increased in the patients with an undetectable serum thyroglobulin (Tg) level. In these cases, further investigation was performed to search for recurrence/metastases. The aim of our study was clarifying the role of FDG-PET/CT in detecting recurrence/metastasis in patients with DTC with negative serum Tg and elevated anti-Tg level. A total of 40 patients (32 female, 8 male; mean age: 43.15 years (22-65); mean age at diagnosis: 39.08 (16-64)) with DTC who had undetectable serum Tg and elevated anti-Tg level after a successful initial therapy were included in the study. All of the patients had serum anti-Tg of >40 IU/ml and underwent FDG-PET/CT to search for recurrence/metastasis. Twenty patients (50 %) had recurrence/metastasis on FDG-PET/CT while the other 20 had no pathologic findings. Of the 20 patients who had positive FDG-PET/CT, 12 had a histopathological final diagnosis of which 11 were true positive (TP) and 1 was false positive (FP). On the other hand, 16 of the 40 patients had a histopathological final diagnosis of which 11/16 had TP, 1/16 FP, 3/16 false negative (FN) and 1/16 true negative (TN) findings by PET/CT. The final diagnosis was made by clinical follow-up in the remaining 24 patients. Of these, 8 patients were PET positive, and in 1 (12.5 %) of 8 patients a decrease in serum anti-Tg level, in 2 (25 %) patients a saw-toothed pattern and in 5 (62.5 %) a progressive increase in the serum anti-Tg level were noted during the follow-up. Of the 16 of 24 patients who were diagnosed by clinical follow-up, in 8 a (50 %) decrease in serum anti-Tg level, in 6 (37.5 %) a saw-toothed pattern, and in 2 (12.5 %) a progressively increased anti-Tg level was seen. Of the 40 patients, 14 (35 %) had a diagnosis of recurrence/metastasis finally, with PET/CT detecting 11 (78.6 %) of them. The value of a persistently or progressively increased serum anti-Tg level in the follow-up of DTC in the prediction of recurrence/metastasis is controversial. However, it is reported that FDG-PET can be useful in the detection of recurrence/metastasis. We conclude from the available data that PET/CT can be effectively used in the detection of recurrence/metastasis in the follow-up of patients with DTC and negative serum Tg and a persistently/progressively increased anti-Tg level. Besides, one half of the patients were FDG negative, meaning that further studies are needed to assess the prognostic-clinical value of PET negativity.

  18. Biological dosimetry of patients with differenced carcinoma of thyroid treated with Iodine-131; Dosimetria biologica de pacientes con carcinoma diferenciado de tiroides tratados con Iodo-131

    Energy Technology Data Exchange (ETDEWEB)

    Vallerga, M. B.; Rojo, A.M.; Taja, M.R.; Deluca, G.; Di Giorgio, M. [Autoridad Regulatoria Nuclear Av. Del Libertador 8250 (C1429BNP). Buenos Aires (Argentina); Fadel, A. [Hospital General de Agudos Dr. Carlos Durand Av. Diaz Velez 5044. Buenos Aires (Argentina); Cabrejas, M.; Valdivieso, C. [Hospital de Clfnicas Jose de San Martin Av. Cordoba 2351 (CP1120). Buenos Aires (Argentina)]. e-mail: mvallerg@cae.arn.gov.ar

    2006-07-01

    The administration of I-131 to patient with Differentiated Thyroid Carcinoma (CaDiT) it is used inside the therapeutic outline as later step to the thyroidectomy. However, the good activity to give is of difficult determination due to factors such as, the variability in the capacity of tumoral reception of the I-131, distribution of the pharmaceutical, physiologic status, other associate pathologies, grade of advance of the illness, and previous treatments. Additionally, the activity to administer is dependent of the dose of tolerance in the healthy tissues; superior dose to 2 Gy in bone marrow, its could drive to myelotoxicity. At the moment, the form more extended of administration it is the empiric prescription that considers clinical parameters and of laboratory for their determination. Presently work, the protocol of applied treatment incorporates the evaluation for internal dosimetry and biological dosimetry to estimate absorbed dose in bone marrow. The biological estimate of the dose of these patients is based on the quantification of chromosomal aberrations whose frequency is referred to a curve-dose response in which the lymphocytes is irradiated in vitro with I-131, allowing to determine the in vivo dose to the patient's circulating lymphocytes. The objective of the present work is to determine the applicability of different cytogenetic essays in the estimate of the absorbed dose to the whole body or specific organs. Three patients were evaluated with CaDiT. Their treatment protocol consisted on a tracer administration of radioactive iodine of 74 - 111 MBq (2 - 3 mCi) and a therapy 7,4 - 11,1 GBq (200 - 300 mCi). Previous to the tracer administration and 8 days post-therapeutic administration took samples of veined blood that were evaluated by biological dosimetry by means of the application of the techniques: conventional cytogenetic Micronucleus and FISH (Hybridization in situ by Fluorescence). Starting from the frequencies of observed chromosomal aberrations it was considered absorbed dose to whole body. The obtained doses were compared by the different biological methods used. The evaluation by internal dosimetry of the data obtained tracer post-activity allowed to personalize the activity of I-131 to administer, starting from physical-mathematical models that consider the particular biokinetics of each patient (MIRD methodology). The doses estimated by the used biological dosemeters were consistent among them. It was discussed its scopes and limitations to be applied in the validation of the dosimetric estimation based on models, in order to administer a therapeutic dose protecting the patient of the adverse effects of the internal radiotherapy in organs that are not target of the same one. The acquired experience is considered of utility to give answer in cases of radioiodine incorporation in occupationally exposed personnel. (Author)

  19. Treatment with rhenium-188-perrhenate and iodine-131 of NIS-expressing mammary cancer in a mouse model remarkably inhibited tumor growth

    Energy Technology Data Exchange (ETDEWEB)

    Dadachova, Ekaterina [Department of Nuclear Medicine, Albert Einstein College of Medicine, Bronx, NY 10461 (United States)]. E-mail: edadacho@aecom.yu.edu; Nguyen, Andrew [Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461 (United States); Lin, Elaine Y. [Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY 10461 (United States); Gnatovskiy, Leo [Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY 10461 (United States); Lu, Ping [Department of Nuclear Medicine, Albert Einstein College of Medicine, Bronx, NY 10461 (United States); Pollard, Jeffrey W. [Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY 10461 (United States)

    2005-10-01

    Introduction: Novel therapeutic modalities are needed for breast cancer patients in whom standard treatments are not effective. Mammary gland sodium/iodide symporter has been identified as a molecular target in breast cancers in humans and in some transgenic mouse models. We report the results of a therapy study with {sup 131}I{sup -} and {sup 188}ReO{sub 4} {sup -} of breast cancer in polyoma middle T oncoprotein (PyMT) transgenic mice endogenously expressing the Na{sup +}/I{sup -} symporter (NIS). Methods: PyMT mice (12-13 weeks old) with one palpable tumor of 0.5-0.8 cm in diameter were used. For the therapy studies, PyMT mice were (1) treated with two intraperitoneal injections of 1.5 mCi of {sup 188}ReO{sub 4} {sup -} 1 week apart, (2) pretreated for 1 week with 5 {mu}g of triiodothyronine (T3) followed by two intraperitoneal injections of 1.5 mCi of {sup 131}I{sup -} 1 week apart or (3) left untreated. The tumor and normal organ uptakes were assessed by scintigraphic imaging. The thyroid function of treated and control animals was evaluated at the completion of the study by measuring the T3/thyroxine (T4) ratio in their blood. Results: There was significant uptake of {sup 131}I{sup -} and {sup 188}ReO{sub 4} {sup -} in the primary palpable tumors as well as in nonpalpable tumors, stomachs and thyroids. The tumor uptake after the second injection was 10 times lower in comparison with the first injection. Tumor growth was significantly inhibited in both the {sup 131}I{sup -} and {sup 188}ReO{sub 4} {sup -} groups in comparison with the control group, and tumors in the {sup 188}ReO{sub 4} {sup -} group increased in size significantly less than in the {sup 131}I{sup -} group. The T3/T4 ratios were calculated to be 27 and 25 for the control group and the {sup 188}ReO{sub 4} {sup -} group, respectively; for {sup 131}I{sup -}, both the T3 and T4 levels were below detection limit, demonstrating much less effect on the thyroids of treatment with {sup 188}ReO{sub 4} {sup -} than with {sup 131}I{sup -}. Conclusions: These results prove that NIS expression in breast tumors in animal models allows specific, efficient and safe treatment with a variety of radionuclides transported by NIS.

  20. Preliminary study of the distribution of dose in patients with Graves' disease undergoing examination of uptake of iodine-131 using Monte Carlo simulation

    International Nuclear Information System (INIS)

    Schwarcke, Marcelo; Marques, Tatiana; Nicolucci, Patricia; Baffa, Oswaldo; Bornemann, Clarissa

    2010-01-01

    Patients with Graves disease have a high hormonal disorder, which causes behavioral changes. One way to treat this disease is the use of high doses of 131 Iodine, requiring that the patient carries out the examination of 131 I uptake to estimate the activity to be administered. Using these data capture and compared with the simulated data using the Monte Carlo code PENELOPE is possible to determine a distribution of dose to the region surrounding the thyroid. As noted the difference between the simulated values and the experimentally obtained were 10.36%, thus showing the code of simulation for accurate determination of absorbed dose in tissue near the thyroid. (author)

  1. Management of low-risk patients with thyroid carcinoma and detectable thyroglobulin on T4 after thyroidectomy and ablation with iodine-131

    International Nuclear Information System (INIS)

    Rosario, Pedro Weslley Souza; Borges, Michelle A.R.; Costa, Graciela B.C.; Resende, Leonardo L.; Padrao, Eduardo L.; Barroso, Alvaro L.; Purish, Saulo; Santa Casa de Belo Horizonte, MG

    2007-01-01

    Objective: To evaluate the positive predictive value of detectable Tg during T4 therapy (Tg on T4) in patients with thyroid cancer after total thyroidectomy and remnant ablation, discussing the work-up in this situation and the empirical indication of 131 I. Patients and methods: Initially, 234 low-risk patients [tumor ≤ 5 cm, completely resected, no extensive extrathyroid invasion (pT4)] submitted to total thyroidectomy and ablation with 131 I (3.7-5.5 GBq) who presented no ectopic uptake on RxWBS were studied. Of these, 23 patients with detectable Tg on T4 (> 1 ng/ml) during the first year after initial therapy were selected. Results: Metastases were detected by neck US in 7 patients, by chest CT in 2 and by US and CT in 3. Four of five patients with lung metastases upon CT had a positive RxWBS. Eleven patients with negative US and CT received a new 131 I dose (without DxWBS), and RxWBS showed ectopic uptake in 3 patients. Among the patients with negative RxWBS, 7 remained free of apparent disease and Tg was declining (5 with undetectable Tg on T4 at the end of the study). One patient presented an increase in Tg and FDG-PET was positive for lymph node and bone metastases. Conclusions: All patients with Tg on T4 > 5 ng/ml presented apparent disease. In these cases, even when US and CT are negative, the administration of a therapeutic dose of 131 I (without DxWBS) and FDG-PET are recommended. Among patients with detectable Tg on T4 ≤ 5 ng/ml and negative US and CT, only 12% presented ectopic uptake on RxWBS. These cases could be followed up by monitoring Tg on T4, and RxWBS and FDG-PET should only be performed if this marker does not decrease after 1-2 years. (author)

  2. Is radioactive iodine-131 treatment related to the occurrence of non-synchronous second primary malignancy in patients with differentiated thyroid cancer?

    International Nuclear Information System (INIS)

    Souza, Marcelo Cruzick de; Momesso, Denise P.; Vieira Neto, Leonardo; Vaisman, Mario; Vaisman, Fernanda; Corbo, Rossana; Martins, Rosangela Aparecida Gomes

    2016-01-01

    Objective: Much controversy relates to the risk of non-synchronous second primary malignancies (NSSPM) after radioactive iodine treatment (RAI-131) in differentiated thyroid cancer (DTC) patients. This study evaluated the relationship between RAI-131 and NSSPM in DTC survivors with long-term follow-up. Materials and methods: Retrospective analysis of 413 DTC cases was performed; 252 received RAI-131 and 161 were treated with thyroidectomy alone. Exclusion criteria were: prior or synchronous non-thyroidal malignancies (within the first year), familial syndromes associated to multiple neoplasms, ionizing radiation exposure or second tumors with unknown histopathology. Results: During a mean follow-up of 11.0 ± 7.5 years, 17 (4.1%) patients developed solid NSSPM. Patients with NSSPM were older than those without (p = 0.02). RAI-131 and I-131 cumulative activity were similar in patients with and without NSSPM (p = 0.18 and p = 0.78, respectively). Incidence of NSSPM was 5.2% in patients with RAI-131 treatment and 2.5% in those without RAI-131 (p = 0.18). Using multivariate analysis, RAI-131 was not significantly associated with NSSPM occurrence (p = 0.35); age was the only independent predictor (p = 0.04). Under log rank statistical analysis, after 10 years of follow-up, it was observed a tendency of lower NSSPM-free survival among patients that received RAI-131 treatment (0.96 vs. 0.87; p = 0.06), what was not affected by age at DTC diagnosis. Conclusion: In our cohort of DTC survivors, with a long-term follow-up period, RAI-131 treatment and I-131 cumulative dose were not significantly associated with NSSPM occurrence. A tendency of premature NSSPM occurrence among patients treated with RAI-131 was observed, suggesting an anticipating oncogenic effect by interaction with other risk factors. (author)

  3. Evaluation of Iodine-131 dispersion after accident in Nuclear Angra Power Plant using the model of aquatic dispersion, SisBahia

    International Nuclear Information System (INIS)

    Aguiar, Andre Silva de; Alvim, Antonio Carlos Marques

    2014-01-01

    It was inserted, in the cooling system of the nucleus, a LOCA, where 431 m 3 of coolant was lost. Such an inventory contained 3,04 x 10 10 Bq / m 3 and iodine was released near the beach Itaorna, Angra dos Reis - RJ. Applying the model in the proposed scenario (Angra 1 and Angra 2 in operation and 3 in with varying capture and discharge with the discharge gradually reduced after the accident), the dilution of the specific activity of radionuclides reached lower values after 22 hours, the reference levels for seawater 131 I (7,40 x 10 2 Bq / m 3 ). After 54 hours, levels of the radionuclide, in the area of indirect influence, are already below minimum activity values detected by the laboratory for environmental monitoring of the CNAAA (5,0 x 10 1 Bq / m 3

  4. Representation of a model of radionuclide transfer in food chains following deposition of strontium-90, cesium-137 and iodine-131 on areas for agricultural use

    International Nuclear Information System (INIS)

    Proehl, G.

    1990-09-01

    The 'SINK' model (contaminants in food chains - FORTRAN 77) was used in an attempt to predict the amounts of radioactivity building up in animal and vegetable foods after one single deposition of Sr-90, Cs-137 and I-131. The model is described in detail. The input quantities include such factors as time-integrated concentration of activity in the air just above the ground, physicochemical form of the radionuclides, activity deposited with precipitation and amount of rain to fall in any particular case. The model was so designed as to take account of 18 different plants, 11 animal products and 14 kinds of processed nutrients. The radionuclide contents of vegetable foods were calculated with reference to the season of the year, at which deposition took place. The estimations of the activity concentrations in animal foods were in each case based on different fudder rations. (orig./HP) [de

  5. Stimulation with 0.3-mg recombinant human thyrotropin prior to iodine 131 therapy to improve the size reduction of benign nontoxic nodular goiter

    DEFF Research Database (Denmark)

    Nielsen, Viveque Egsgaard; Bonnema, Steen Joop; Boel-Jørgensen, Henrik

    2006-01-01

    measurements of thyroid size and function and patient satisfaction. RESULTS: Baseline median goiter volume was 51 mL (range, 20-99 mL) in the placebo group and 59 mL (range, 25-92 mL) in the thyrotropin group (P = .75). At 12 months, the mean +/- SEM relative goiter reduction was 46.1% +/- 4.0% in the placebo...

  6. Application of computational models to estimate organ radiation dose in rainbow trout from uptake of molybdenum-99 with comparison to iodine-131

    International Nuclear Information System (INIS)

    Martinez, N.E.; Johnson, T.E.; Pinder, J.E.

    2016-01-01

    This study compares three anatomical phantoms for rainbow trout (Oncorhynchus mykiss) for the purpose of estimating organ radiation dose and dose rates from molybdenum-99 ( 99 Mo) uptake in the liver and GI tract. Model comparison and refinement is important to the process of determining accurate doses and dose rates to the whole body and the various organs. Accurate and consistent dosimetry is crucial to the determination of appropriate dose-effect relationships for use in environmental risk assessment. The computational phantoms considered are (1) a geometrically defined model employing anatomically relevant organ size and location, (2) voxel reconstruction of internal anatomy obtained from CT imaging, and (3) a new model utilizing NURBS surfaces to refine the model in (2). Dose Conversion Factors (DCFs) for whole body as well as selected organs of O. mykiss were computed using Monte Carlo modeling and combined with empirical models for predicting activity concentration to estimate dose rates and ultimately determine cumulative radiation dose (μGy) to selected organs after several half-lives of 99 Mo. The computational models provided similar results, especially for organs that were both the source and target of radiation (less than 30% difference between all models). Values in the empirical model as well as the 14 day cumulative organ doses determined from 99 Mo uptake are compared to similar models developed previously for 131 I. Finally, consideration is given to treating the GI tract as a solid organ compared to partitioning it into gut contents and GI wall, which resulted in an order of magnitude difference in estimated dose for most organs. - Highlights: • Existing computational models for the internal dosimetry of trout are applied to 99 Mo uptake. • Consideration is given to the effect of alternate source distribution in the gut. • A hybrid computational phantom is developed. • At 14 days post-release, 99 Mo and 131 I provide similar contributions to organ dose. • Pros and cons of the main types of computational phantoms are discussed.

  7. Development and comparison of computational models for estimation of absorbed organ radiation dose in rainbow trout (Oncorhynchus mykiss) from uptake of iodine-131

    International Nuclear Information System (INIS)

    Martinez, N.E.; Johnson, T.E.; Capello, K.; Pinder, J.E.

    2014-01-01

    This study develops and compares different, increasingly detailed anatomical phantoms for rainbow trout (Oncorhynchus mykiss) for the purpose of estimating organ absorbed radiation dose and dose rates from 131 I uptake in multiple organs. The models considered are: a simplistic geometry considering a single organ, a more specific geometry employing additional organs with anatomically relevant size and location, and voxel reconstruction of internal anatomy obtained from CT imaging (referred to as CSUTROUT). Dose Conversion Factors (DCFs) for whole body as well as selected organs of O. mykiss were computed using Monte Carlo modeling, and combined with estimated activity concentrations, to approximate dose rates and ultimately determine cumulative radiation dose (μGy) to selected organs after several half-lives of 131 I. The different computational models provided similar results, especially for source organs (less than 30% difference between estimated doses), and whole body DCFs for each model (∼3 × 10 −3 μGy d −1 per Bq kg −1 ) were comparable to DCFs listed in ICRP 108 for 131 I. The main benefit provided by the computational models developed here is the ability to accurately determine organ dose. A conservative mass-ratio approach may provide reasonable results for sufficiently large organs, but is only applicable to individual source organs. Although CSUTROUT is the more anatomically realistic phantom, it required much more resource dedication to develop and is less flexible than the stylized phantom for similar results. There may be instances where a detailed phantom such as CSUTROUT is appropriate, but generally the stylized phantom appears to be the best choice for an ideal balance between accuracy and resource requirements. - Highlights: • Computational models (phantoms) are developed for rainbow trout internal dosimetry. • Phantoms are combined with empirical models for 131 I uptake to estimate dose. • Voxel and stylized phantoms predict similar organ radiation doses from 131 I uptake. • Direct and indirect approaches to calculating organ dose are compared. • The voxel phantom is more accurate, but requires more resource dedication to develop

  8. Correction of count losses due to deadtime on a DST-XLi (SMVi-GE) camera during dosimetric studies in patients injected with iodine-131

    International Nuclear Information System (INIS)

    Delpon, G.; Ferrer, L.; Lisbona, A.; Bardies, M.

    2002-01-01

    In dosimetric studies performed after therapeutic injection, it is essential to correct count losses due to deadtime on the gamma camera. This note describes four deadtime correction methods, one based on the use of a standard source without preliminary calibration, and three requiring specific calibration and based on the count rate observed in different spectrometric windows (20%, 20% plus a lower energy window and the full spectrum of 50-750 keV). Experiments were conducted on a phantom at increasingly higher count rates to check correction accuracy with the different methods. The error was less than +7% with a standard source, whereas count-rate-based methods gave more accurate results. On the assumption that the model was paralysable, preliminary calibration allowed an observed count rate curve to be plotted as a function of the real count rate. The use of the full spectrum led to a 3.0% underestimation for the highest activity imaged. As count losses depend on photon flux independent of energy, the use of the full spectrum during measurement allowed scatter conditions to be taken into account. A protocol was developed to apply this correction method to whole-body acquisitions. (author)

  9. Radiation protection of people in contact with patient treated with metabolic radiotherapy using iodine-131 in nuclear medicine - case of the Laboratoire des Radio-Isotopes(LRI) Anpandrianomby

    International Nuclear Information System (INIS)

    RAMAROJAONA, H.

    2008-01-01

    In the aim to propose recommendations for radiation protection of those in contact with patients, simulations were performed for restricting the radiation hazards to the family and the members of the public coming into contact with a patient treated with 131 Iode for a thyroid pathology. The simulated dose constraint was 0,3 mSv for the family. According to the regulation in radiation protection in Madagascar, annual dose limit for the public is 1mSv and 20 mSv for the workers. Several contact patterns were tested: contact to the workers, daily visits, public transports, return to work, sleeping with partner and close contact with children. The recommendations duration was evaluated both as a function of the administered activity (out-patient) or the residual activity (discharged inpatient) by measuring the dose rate at 1 m distance from the patient. [fr